(6523,2,'2020-07-10 13:02:42','2020-07-10 13:02:42','This molecular atlas is\"a previously unachieved degree of cellular resolution for cocaine-mediated receptor regulation in this area,\" said Day, an associate professor in the UAB Department of Neurobiology.\r\n\r\nThe atlas was only the launch of a significant study, published in the journal Science Advances, which utilized multiple cutting-edge technologies to spell out a more dopamine-induced gene expression signature which regulates the brain\'s response to cocaine.\r\n\r\n\"They also show new details regarding how transcriptional mechanisms regulate activity-dependent processes inside the central nervous system.\"\r\n\r\nThe procedures used in this analysis, \'\' states, may also help dissect the role of similar receptor applications that mediate other types of behavior, memory formation, or neuropsychiatric disorders.\r\n\r\nThe NAc is intensely involved with drug dependence, along with a comprehensive understanding of how drugs change its neurological circuitry to initiate addictive behavior can suggest new therapeutic interventions.\r\n\r\nThe NAc is a central integrator of their mind\'s reward circuit, also most of addictive drugs greatly increase the amount of the neurotransmitter dopamine in the NAc.\r\n\r\nDopamine signaling during recurrent drug use contributes to widespread changes in gene expression, initiating alterations in neural synaptic circuitry, and changes in behaviour associated with drug dependence.\r\n\r\nPrevious studies of fluctuations within NAc gene expression were just able to look at bulk tissue -- a mixture of many different cell types. After the Day laboratory looked in single-cell varies by RNA-sequencing 15,631 human rat NAc nuclei, they found a surprise.\r\n\r\nThe researchers comprehensively defined the core gene structure that is activated when dopamine is inserted to a striatal neuron culture system. Like the reactions from the rat NAc after cocaine treatment, transcriptional activation mostly happened in Drd1-receptor-medium spiny neurons.\r\n\r\nDay and colleagues identified a core group of approximately 100 genes altered by dopamine, and which also associated with essential genes triggered in the NAc of rats .\r\n\r\nIt\'s been hypothesized that gene expression programs in the mind function in concert to make downstream effects on cognitive functioning and behaviour. However, until recently researchers have lacked a way to analyze key gene expression applications, which requires inducing numerous genes at the exact same moment.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://advances.sciencemag.org/content/6/26/eaba4221\">Day and colleagues engineered an multiplexed CRISPR guide-RNA range to target 16 of the greatest candidate genes changed by dopamine.</a></span>\r\n\r\nWhen paired with a neuron-optimized CRISPR/dead-Cas9 activation system, they were able to simultaneously upregulate the 16 genes in neuronal cultures or in the NAc of live rats.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://advances.sciencemag.org/content/6/26/eaba4221\">This program significantly increased neuron burst fire frequency. In live rodents, induction of the gene signature generated sensitization to repeated cocaine administration. These changes have been observed in the adrenal culture and live rats are similar to the Cardiovascular and behavioral alterations initiated by drugs of misuse.</a></span>\r\n\r\nDay says his team\'s study is the first proof-of-principle evidence that CRISPR activation can be used for simultaneous and selective regulation of a gene expression signature in vivo.\r\n\r\n\"Critically,\" Day explained,\"these results reflect the first demonstration -- to our knowledge of multiplexed gene regulation at virtually any neuropsychiatric model, providing a roadmap for future studies to investigate the connection between altered gene applications and adrenal disease conditions.\r\n\r\n\"While the present work offers insight into how cellular diversity results in transcriptional responses after an initial alcoholic encounter,\" Day explained,\"continuing exposure to drugs of misuse boosts neurophysiological adaptations which are considered to drive compulsive drug-seeking long after cessation of use.\r\n\r\nTherefore, it is going to be critical for future studies to expand on this work by analyzing the transcriptional outcome of repeated or self-administered drug use in the single-cell level, as well as understanding how these changes are maintained within distinct cell populations over longer periods of time and as a result of the volitional drug experience.\"\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.uab.edu/news/research/item/11424-a-complex-gene-program-initiates-brain-changes-in-response-to-cocaine\" target=\"_blank\" rel=\"noopener noreferrer\">University of Alabama at Birmingham</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nSavell, K. E.,<em> et al</em>. (2020) A dopamine-induced gene expression signature regulates the neuronal function and cocaine response. <em>Science Advances</em>. <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://dx.doi.org/10.1126/sciadv.aba4221\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1126/sciadv.aba4221.</a></span>\r\n\r\n</div>','Study reveals new insight into neurobiological procedures that control medicate related adjustments','','publish','open','open','','study-reveals-new-insight-into-neurobiological-procedures-that-control-medicate-related-adjustments','','','2020-07-10 13:02:42','2020-07-10 13:02:42','',0,'https://microbiozindia.com/?p=6523',0,'post','',0),(6524,2,'2020-07-10 13:01:59','2020-07-10 13:01:59','','neurology-1024x665','','inherit','open','closed','','neurology-1024x665','','','2020-07-10 13:01:59','2020-07-10 13:01:59','',6523,'https://microbiozindia.com/wp-content/uploads/2020/07/neurology-1024x665-1.jpg',0,'attachment','image/jpeg',0),(6525,2,'2020-07-10 13:02:42','2020-07-10 13:02:42','This molecular atlas is\"a previously unachieved degree of cellular resolution for cocaine-mediated receptor regulation in this area,\" said Day, an associate professor in the UAB Department of Neurobiology.\r\n\r\nThe atlas was only the launch of a significant study, published in the journal Science Advances, which utilized multiple cutting-edge technologies to spell out a more dopamine-induced gene expression signature which regulates the brain\'s response to cocaine.\r\n\r\n\"They also show new details regarding how transcriptional mechanisms regulate activity-dependent processes inside the central nervous system.\"\r\n\r\nThe procedures used in this analysis, \'\' states, may also help dissect the role of similar receptor applications that mediate other types of behavior, memory formation, or neuropsychiatric disorders.\r\n\r\nThe NAc is intensely involved with drug dependence, along with a comprehensive understanding of how drugs change its neurological circuitry to initiate addictive behavior can suggest new therapeutic interventions.\r\n\r\nThe NAc is a central integrator of their mind\'s reward circuit, also most of addictive drugs greatly increase the amount of the neurotransmitter dopamine in the NAc.\r\n\r\nDopamine signaling during recurrent drug use contributes to widespread changes in gene expression, initiating alterations in neural synaptic circuitry, and changes in behaviour associated with drug dependence.\r\n\r\nPrevious studies of fluctuations within NAc gene expression were just able to look at bulk tissue -- a mixture of many different cell types. After the Day laboratory looked in single-cell varies by RNA-sequencing 15,631 human rat NAc nuclei, they found a surprise.\r\n\r\nThe researchers comprehensively defined the core gene structure that is activated when dopamine is inserted to a striatal neuron culture system. Like the reactions from the rat NAc after cocaine treatment, transcriptional activation mostly happened in Drd1-receptor-medium spiny neurons.\r\n\r\nDay and colleagues identified a core group of approximately 100 genes altered by dopamine, and which also associated with essential genes triggered in the NAc of rats .\r\n\r\nIt\'s been hypothesized that gene expression programs in the mind function in concert to make downstream effects on cognitive functioning and behaviour. However, until recently researchers have lacked a way to analyze key gene expression applications, which requires inducing numerous genes at the exact same moment.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://advances.sciencemag.org/content/6/26/eaba4221\">Day and colleagues engineered an multiplexed CRISPR guide-RNA range to target 16 of the greatest candidate genes changed by dopamine.</a></span>\r\n\r\nWhen paired with a neuron-optimized CRISPR/dead-Cas9 activation system, they were able to simultaneously upregulate the 16 genes in neuronal cultures or in the NAc of live rats.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://advances.sciencemag.org/content/6/26/eaba4221\">This program significantly increased neuron burst fire frequency. In live rodents, induction of the gene signature generated sensitization to repeated cocaine administration. These changes have been observed in the adrenal culture and live rats are similar to the Cardiovascular and behavioral alterations initiated by drugs of misuse.</a></span>\r\n\r\nDay says his team\'s study is the first proof-of-principle evidence that CRISPR activation can be used for simultaneous and selective regulation of a gene expression signature in vivo.\r\n\r\n\"Critically,\" Day explained,\"these results reflect the first demonstration -- to our knowledge of multiplexed gene regulation at virtually any neuropsychiatric model, providing a roadmap for future studies to investigate the connection between altered gene applications and adrenal disease conditions.\r\n\r\n\"While the present work offers insight into how cellular diversity results in transcriptional responses after an initial alcoholic encounter,\" Day explained,\"continuing exposure to drugs of misuse boosts neurophysiological adaptations which are considered to drive compulsive drug-seeking long after cessation of use.\r\n\r\nTherefore, it is going to be critical for future studies to expand on this work by analyzing the transcriptional outcome of repeated or self-administered drug use in the single-cell level, as well as understanding how these changes are maintained within distinct cell populations over longer periods of time and as a result of the volitional drug experience.\"\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.uab.edu/news/research/item/11424-a-complex-gene-program-initiates-brain-changes-in-response-to-cocaine\" target=\"_blank\" rel=\"noopener noreferrer\">University of Alabama at Birmingham</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nSavell, K. E.,<em> et al</em>. (2020) A dopamine-induced gene expression signature regulates the neuronal function and cocaine response. <em>Science Advances</em>. <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://dx.doi.org/10.1126/sciadv.aba4221\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1126/sciadv.aba4221.</a></span>\r\n\r\n</div>','Study reveals new insight into neurobiological procedures that control medicate related adjustments','','inherit','closed','closed','','6523-revision-v1','','','2020-07-10 13:02:42','2020-07-10 13:02:42','',6523,'https://microbiozindia.com/uncategorized/6523-revision-v1/',0,'revision','',0),(6526,2,'2020-07-10 15:52:11','2020-07-10 15:52:11','Mundipharma today announced that lab testing at the Duke NUS Medical School at Singapore, has confirmed the potency of its BETADINE® antiseptic services and products against the publication coronavirus (SARS-CoV-2) that causes COVID-19 disease.\r\n\r\nTesting has demonstrated BETADINE\'s® strong in vitro virucidal exercise, killing 99.99% of the SARS-CoV-2 virus in 30 seconds.\r\n\r\nThe investigation was published in the prestigious Infectious Disease and Therapy Journal on 08 July 2020.\r\n<blockquote>These results confirm our view that BETADINE® antiseptic products, used appropriately and in conjunction with other preventative treatment options including PPE, can play a role in limiting the spread of infections, including COVID-19. It also provides the medical community as well as consumers with a science-based assurance that they are using a product that is a proven defense against COVID-19.”<em>Raman Singh, CEO Mundipharma</em></blockquote>\r\nThe analysis conducted in Duke-NUS is directed by Laboratory testing performed in the Royal Infectious Diseases Research and Education Center (TIDREC) at the University of Malaya, Malaysia, that additionally attested strong in vitro virucidal exercise, with the analyzed product BETADINE® Gargle and also Mouthwash (1.0percent PVP-I) murdering 99.99% of those SARS-CoV-2 virus at 15 seconds. The journal is published by Springer Nature for the British Dental Association.\r\n\r\nPreviously, BETADINE® anti-septic products containing povidone iodine (PVP-I) have been demonstrated effective in vitro against a wide array of viruses, for example coronaviruses who have generated major outbreaks like Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS). The BETADINE® anti-septic range includes Povidone-iodine (PVP-I), that will be remarkably effective against a wide assortment of germs, such as viruses, bacteria and fungi and is typically utilised in hospitals.','Research center testing affirms adequacy of BETADINE germicide items against SARS-CoV-2','','publish','open','open','','research-center-testing-affirms-adequacy-of-betadine-germicide-items-against-sars-cov-2','','','2020-07-10 15:52:11','2020-07-10 15:52:11','',0,'https://microbiozindia.com/?p=6526',0,'post','',0),(6527,2,'2020-07-10 15:52:00','2020-07-10 15:52:00','','581_main','','inherit','open','closed','','581_main','','','2020-07-10 15:52:00','2020-07-10 15:52:00','',6526,'https://microbiozindia.com/wp-content/uploads/2020/07/581_main.jpg',0,'attachment','image/jpeg',0),(6528,2,'2020-07-10 15:52:11','2020-07-10 15:52:11','Mundipharma today announced that lab testing at the Duke NUS Medical School at Singapore, has confirmed the potency of its BETADINE® antiseptic services and products against the publication coronavirus (SARS-CoV-2) that causes COVID-19 disease.\r\n\r\nTesting has demonstrated BETADINE\'s® strong in vitro virucidal exercise, killing 99.99% of the SARS-CoV-2 virus in 30 seconds.\r\n\r\nThe investigation was published in the prestigious Infectious Disease and Therapy Journal on 08 July 2020.\r\n<blockquote>These results confirm our view that BETADINE® antiseptic products, used appropriately and in conjunction with other preventative treatment options including PPE, can play a role in limiting the spread of infections, including COVID-19. It also provides the medical community as well as consumers with a science-based assurance that they are using a product that is a proven defense against COVID-19.”<em>Raman Singh, CEO Mundipharma</em></blockquote>\r\nThe analysis conducted in Duke-NUS is directed by Laboratory testing performed in the Royal Infectious Diseases Research and Education Center (TIDREC) at the University of Malaya, Malaysia, that additionally attested strong in vitro virucidal exercise, with the analyzed product BETADINE® Gargle and also Mouthwash (1.0percent PVP-I) murdering 99.99% of those SARS-CoV-2 virus at 15 seconds. The journal is published by Springer Nature for the British Dental Association.\r\n\r\nPreviously, BETADINE® anti-septic products containing povidone iodine (PVP-I) have been demonstrated effective in vitro against a wide array of viruses, for example coronaviruses who have generated major outbreaks like Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS). The BETADINE® anti-septic range includes Povidone-iodine (PVP-I), that will be remarkably effective against a wide assortment of germs, such as viruses, bacteria and fungi and is typically utilised in hospitals.','Research center testing affirms adequacy of BETADINE germicide items against SARS-CoV-2','','inherit','closed','closed','','6526-revision-v1','','','2020-07-10 15:52:11','2020-07-10 15:52:11','',6526,'https://microbiozindia.com/uncategorized/6526-revision-v1/',0,'revision','',0),(6530,2,'2020-07-10 17:03:14','2020-07-10 17:03:14','Gilead Sciences Inc said on Friday additional data from a late-stage study revealed its antibacterial remdesivir significantly enhanced clinical recovery from seriously ill COVID-19 patients.\r\n\r\nFindings from a study of its late-stage study revealed that 74.4 percent of remdesivir-treated patients recovered by Day 14 versus 59.0 percentage of individuals receiving standard of care, the business said.\r\n\r\nGilead shares were up almost 2 percent 76.14 prior to the bell.','Gilead says Extra data on remdesivir Reveals improved clinical Retrieval','','publish','open','open','','gilead-says-extra-data-on-remdesivir-reveals-improved-clinical-retrieval','','','2020-07-10 17:03:14','2020-07-10 17:03:14','',0,'https://microbiozindia.com/?p=6530',0,'post','',0),(6531,2,'2020-07-10 17:03:14','2020-07-10 17:03:14','Gilead Sciences Inc said on Friday additional data from a late-stage study revealed its antibacterial remdesivir significantly enhanced clinical recovery from seriously ill COVID-19 patients.\r\n\r\nFindings from a study of its late-stage study revealed that 74.4 percent of remdesivir-treated patients recovered by Day 14 versus 59.0 percentage of individuals receiving standard of care, the business said.\r\n\r\nGilead shares were up almost 2 percent 76.14 prior to the bell.','Gilead says Extra data on remdesivir Reveals improved clinical Retrieval','','inherit','closed','closed','','6530-revision-v1','','','2020-07-10 17:03:14','2020-07-10 17:03:14','',6530,'https://microbiozindia.com/uncategorized/6530-revision-v1/',0,'revision','',0),(6532,2,'2020-07-11 17:11:10','2020-07-11 17:11:10','Researchers at the University of Houston are suffering from a air filter which will trap and trap the book coronavirus immediately.\r\n\r\nThe atmosphere filter, also Made from nickel foam, has been created by the Manager at Texas Center of Superconductivity Doctor Zhifeng Ren in cooperation with Medistar CEO Monzer Hourani.\r\n\r\nThe first concept was the brain child of all Hourani, that directs medical property development company Medistar. Medistar had approached the Texas Center for Superconductivity to help to develop the virus-trapping air-filter March 3 1, at some period that the pandemic had started spreading rapidly across states.\r\n\r\nLater, tests were conducted in the Galveston National Laboratory, to figure out the effectiveness of this heated atmosphere filter. Researchers discovered that 99.8 percentage COVID-19 inducing publication coronavirus were murdered immediately since it passed through the filter, so reported that the Houston Chronicle.\r\n\r\nIts capacity to control the spread of this herpes virus can possibly be helpful for society\"\r\n\r\nMedistar has aims to come up with a background version which are going to find a way to purify the atmosphere in a workplace goers\' prompt surroundings.\r\n\r\nDoctor Garrett Peel of all Medistar has implied a phased roll out of this heated atmosphere filter, so handing it out into hospitals, schools, healthcare centers, planes as well as other public transportation methods. They intend to set up the\"high heeled COVID-19 killer\" at another 60 days.','US scientists create warmed air filter that can trap and slaughter novel coronavirus','','publish','open','open','','us-scientists-create-warmed-air-filter-that-can-trap-and-slaughter-novel-coronavirus','','','2020-07-11 17:11:10','2020-07-11 17:11:10','',0,'https://microbiozindia.com/?p=6532',0,'post','',0),(6533,2,'2020-07-11 17:10:11','2020-07-11 17:10:11','','3349c493-4f46-4dfb-86e8-38166226b022_1920x1080','','inherit','open','closed','','3349c493-4f46-4dfb-86e8-38166226b022_1920x1080','','','2020-07-11 17:10:11','2020-07-11 17:10:11','',6532,'https://microbiozindia.com/wp-content/uploads/2020/07/3349c493-4f46-4dfb-86e8-38166226b022_1920x1080.jpg',0,'attachment','image/jpeg',0),(6534,2,'2020-07-11 17:11:10','2020-07-11 17:11:10','Researchers at the University of Houston are suffering from a air filter which will trap and trap the book coronavirus immediately.\r\n\r\nThe atmosphere filter, also Made from nickel foam, has been created by the Manager at Texas Center of Superconductivity Doctor Zhifeng Ren in cooperation with Medistar CEO Monzer Hourani.\r\n\r\nThe first concept was the brain child of all Hourani, that directs medical property development company Medistar. Medistar had approached the Texas Center for Superconductivity to help to develop the virus-trapping air-filter March 3 1, at some period that the pandemic had started spreading rapidly across states.\r\n\r\nLater, tests were conducted in the Galveston National Laboratory, to figure out the effectiveness of this heated atmosphere filter. Researchers discovered that 99.8 percentage COVID-19 inducing publication coronavirus were murdered immediately since it passed through the filter, so reported that the Houston Chronicle.\r\n\r\nIts capacity to control the spread of this herpes virus can possibly be helpful for society\"\r\n\r\nMedistar has aims to come up with a background version which are going to find a way to purify the atmosphere in a workplace goers\' prompt surroundings.\r\n\r\nDoctor Garrett Peel of all Medistar has implied a phased roll out of this heated atmosphere filter, so handing it out into hospitals, schools, healthcare centers, planes as well as other public transportation methods. They intend to set up the\"high heeled COVID-19 killer\" at another 60 days.','US scientists create warmed air filter that can trap and slaughter novel coronavirus','','inherit','closed','closed','','6532-revision-v1','','','2020-07-11 17:11:10','2020-07-11 17:11:10','',6532,'https://microbiozindia.com/uncategorized/6532-revision-v1/',0,'revision','',0),(6535,2,'2020-07-11 17:13:21','2020-07-11 17:13:21','DCGI has vowed to market Itolizumab (ALZUMAb) injection 25mg and 5mL solution for emergency usage within India for the cure of cytokine release syndrome (CRS) at moderate to severe ARDS (acute respiratory distress syndrome) patients thanks to COVID-19, Biocon said in a release.\r\n\r\nIt said Itolizumab is your first publication biologic therapy to become approved around the globe for treating patients having mild to severe COVID-19 complications.\r\n\r\nBiocon has repurposed Itolizumab, an anti-CD6 IgG1 monoclonal antibody launched in India at 2013 as ALZUMAb for curing chronic plaque psoriasis, for the treatment of CRS in moderate to severe ARDS patients due to COVID-19, it included.\r\n\r\nItolizumab will be fabricated and formulated as a intravenous injection at Biocon\'s bio-manufacturing centre at Biocon Park here.\r\n\r\n\"I\'m proud of this successful outcome of this critical study we ran together with our book immuno-modulating anti-CD6 monoclonal antibody,\'\' Itolizumab, that has been shown to be an efficacious intervention in treating the significant hyper-immune response seen by COVID-19. The data remains compelling and I am convinced that this first-in-class biologic helps you to save lives and help reduce the mortality rate in our country,\" Biocon Executive Chair Person Kiran Mazumdar Shaw said.\r\n\r\nNoting this positions India one of the top worldwide innovators within their attempt to over come the COVID-19 pandemic, she said, the randomized control trial signaled that most the patients treated using Itolizumab (ALZUMAb) reacted favorably and recovered.\r\n\r\nItolizumab has become qualified for the treatment of CRS in patients who have moderate to severe ARDS on account of COVID-19. We plan to take this therapy to all other sections of the world affected by the pandemic, \'\' she added.\r\n\r\nBiocon reported the endorsement of Itolizumab from the DCGI is based on the outcomes from the successful completion of a randomized, controlled clinical trial in multiple hospitals at Mumbai and New Delhi.\r\n\r\nThe study focussed on the efficacy and safety of Itolizumab in preventing CRS at moderate to severe ARDS patients due to COVID-19, he said adding that the principal endpoints for lowering of mortality rate were fulfilled along with other key secondary endpoints for efficiency and biomarkers have been likewise achieved.','Biocon tranquilize gets DCGI gesture for use in moderate to extreme COVID-19 patients','','publish','open','open','','biocon-tranquilize-gets-dcgi-gesture-for-use-in-moderate-to-extreme-covid-19-patients','','','2020-07-11 17:13:21','2020-07-11 17:13:21','',0,'https://microbiozindia.com/?p=6535',0,'post','',0),(6536,2,'2020-07-11 17:13:21','2020-07-11 17:13:21','DCGI has vowed to market Itolizumab (ALZUMAb) injection 25mg and 5mL solution for emergency usage within India for the cure of cytokine release syndrome (CRS) at moderate to severe ARDS (acute respiratory distress syndrome) patients thanks to COVID-19, Biocon said in a release.\r\n\r\nIt said Itolizumab is your first publication biologic therapy to become approved around the globe for treating patients having mild to severe COVID-19 complications.\r\n\r\nBiocon has repurposed Itolizumab, an anti-CD6 IgG1 monoclonal antibody launched in India at 2013 as ALZUMAb for curing chronic plaque psoriasis, for the treatment of CRS in moderate to severe ARDS patients due to COVID-19, it included.\r\n\r\nItolizumab will be fabricated and formulated as a intravenous injection at Biocon\'s bio-manufacturing centre at Biocon Park here.\r\n\r\n\"I\'m proud of this successful outcome of this critical study we ran together with our book immuno-modulating anti-CD6 monoclonal antibody,\'\' Itolizumab, that has been shown to be an efficacious intervention in treating the significant hyper-immune response seen by COVID-19. The data remains compelling and I am convinced that this first-in-class biologic helps you to save lives and help reduce the mortality rate in our country,\" Biocon Executive Chair Person Kiran Mazumdar Shaw said.\r\n\r\nNoting this positions India one of the top worldwide innovators within their attempt to over come the COVID-19 pandemic, she said, the randomized control trial signaled that most the patients treated using Itolizumab (ALZUMAb) reacted favorably and recovered.\r\n\r\nItolizumab has become qualified for the treatment of CRS in patients who have moderate to severe ARDS on account of COVID-19. We plan to take this therapy to all other sections of the world affected by the pandemic, \'\' she added.\r\n\r\nBiocon reported the endorsement of Itolizumab from the DCGI is based on the outcomes from the successful completion of a randomized, controlled clinical trial in multiple hospitals at Mumbai and New Delhi.\r\n\r\nThe study focussed on the efficacy and safety of Itolizumab in preventing CRS at moderate to severe ARDS patients due to COVID-19, he said adding that the principal endpoints for lowering of mortality rate were fulfilled along with other key secondary endpoints for efficiency and biomarkers have been likewise achieved.','Biocon tranquilize gets DCGI gesture for use in moderate to extreme COVID-19 patients','','inherit','closed','closed','','6535-revision-v1','','','2020-07-11 17:13:21','2020-07-11 17:13:21','',6535,'https://microbiozindia.com/uncategorized/6535-revision-v1/',0,'revision','',0),(6537,2,'2020-07-11 17:29:08','2020-07-11 17:29:08','Researchers regularly study the genomes of human organisms to attempt and tease out the association between genes and behaviour.\r\n\r\nA brand new study of Africanized honeybees shows, but that the genetic inheritance of human bees has little effect in the propensity for aggression.\r\n\r\nAs an alternative, the genomic faculties of this hive for a whole are closely correlated with just how its soldiers strike.\r\n\r\n\"That really is an indication that there may possibly be to the genetics of behaviour as a complete than we are considering\"\r\n\r\n<em>We wanted to know which parts of the genome are responsible for gentle behavior versus aggressive behavior. And because there\'s quite a bit of variation in aggression among these bees, they are an ideal population to study.\"<strong>-</strong></em><strong>Matthew Hudson,</strong><em> Study Lead and Urbana-Champaign Professor of Bioinformatics, Department of Crop Sciences, University of Illinois</em>\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://doi.org/10.1073/pnas.1922927117\">The researchers dedicated to a exceptional population of tender Africanized honeybees at Puerto Rico, that were evolved to be pliable compared to Africanized bees somewhere else on the planet.</a></span>\r\n\r\nAfricanized bees are somewhat increasingly more resistant to infection compared to their European allies in the island, therefore scientists are happy to find out more about the genetic underpinnings of their Puerto Rican bees\' tender nature.\r\n\r\nAs soon as a honeybee hive is upset, shield bees emit a compound signal that dissipates soldier bees to actions. The answer is dependent upon the character of the hazard and the aggressiveness of this hive.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://doi.org/10.1073/pnas.1922927117\">When the soldiers bite their target would be just another step of aggression, even as soldiers who sting will probably perish as a outcome.</a></span>\r\n\r\nGenerally, foragers don\'t shield the hive.\r\n\r\nAdditionally they analyzed how sharply the soldier bees reacted to an attack within the hive.\r\n\r\nWith their surprise, that the scientists detected no genome-sequence differences between your soldiers and foragers that constantly clarified different answers.\r\n\r\nNevertheless as soon as the researchers ran a genomewide institution study comparing the most-aggressive along with least-aggressive hives, they saw a solid correlation between wolves genomics and aggression.\r\n\r\nThe investigations revealed this certain region of the genome did actually play an essential function in the hives\' comparative gentleness or aggression.\r\n\r\n\"There clearly was clearly one chunk of DNA at which the frequency of this chunk from the hive appears to dictate gentle that hive will be on a big extent,\" Hudson explained.\r\n\r\n\"However, the hereditary makeup of this society which the bees reside in - that the colony - includes an extremely strong effect on how competitive the bees at that colony are\"\r\n\r\n\"Many behavioral faculties from humans and animals are considered to be closely influenced by inherited influences in genome arrangement, however for most behaviours, the way the individual behaves is influenced by the way the others round it are behaving - nature and nurture, respectively,\" Robinson stated.\r\n\r\n\"We see in the beehive, cultivate also can have a sturdy genomic signature\"\r\n\r\nSuch behavioral genomic influences might be specially conspicuous in honeybees, which are now living within a exceedingly combined society at which every person has a specified societal and operational role, \'\' he said.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://aces.illinois.edu/news/group-genomics-drive-aggression-honey-bees#:~:text=A%20new%20study%20of%20Africanized,from%20the%20Illinois%20News%20Bureau.\" target=\"_blank\" rel=\"noopener noreferrer\">​ University of Illinois at Urbana-Champaign, News Bureau</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nAvalos, A., <em>et al. </em>(2020) Genomic regions influencing aggressive behavior in honey bees are defined by colony allele frequencies. <em>Proceedings of the National Academy of Sciences</em>. <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://doi.org/10.1073/pnas.1922927117\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1073/pnas.1922927117</a><em>.</em></span>\r\n\r\n</div>','Study: Group genomics are liable for animosity in Africanized bumble bees','','publish','open','open','','study-group-genomics-are-liable-for-animosity-in-africanized-bumble-bees','','','2020-07-11 17:29:08','2020-07-11 17:29:08','',0,'https://microbiozindia.com/?p=6537',0,'post','',0),(6538,2,'2020-07-11 17:28:14','2020-07-11 17:28:14','','F8A9780F-2278-4CB6-9BED5269B0FE0F51_source','','inherit','open','closed','','f8a9780f-2278-4cb6-9bed5269b0fe0f51_source','','','2020-07-11 17:28:14','2020-07-11 17:28:14','',6537,'https://microbiozindia.com/wp-content/uploads/2020/07/F8A9780F-2278-4CB6-9BED5269B0FE0F51_source.jpg',0,'attachment','image/jpeg',0),(6539,2,'2020-07-11 17:28:15','2020-07-11 17:28:15','','SCIEX_LOGO_RGB','','inherit','open','closed','','sciex_logo_rgb','','','2020-07-11 17:28:15','2020-07-11 17:28:15','',6537,'https://microbiozindia.com/wp-content/uploads/2020/07/SCIEX_LOGO_RGB.jpg',0,'attachment','image/jpeg',0),(6540,2,'2020-07-11 17:29:08','2020-07-11 17:29:08','Researchers regularly study the genomes of human organisms to attempt and tease out the association between genes and behaviour.\r\n\r\nA brand new study of Africanized honeybees shows, but that the genetic inheritance of human bees has little effect in the propensity for aggression.\r\n\r\nAs an alternative, the genomic faculties of this hive for a whole are closely correlated with just how its soldiers strike.\r\n\r\n\"That really is an indication that there may possibly be to the genetics of behaviour as a complete than we are considering\"\r\n\r\n<em>We wanted to know which parts of the genome are responsible for gentle behavior versus aggressive behavior. And because there\'s quite a bit of variation in aggression among these bees, they are an ideal population to study.\"<strong>-</strong></em><strong>Matthew Hudson,</strong><em> Study Lead and Urbana-Champaign Professor of Bioinformatics, Department of Crop Sciences, University of Illinois</em>\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://doi.org/10.1073/pnas.1922927117\">The researchers dedicated to a exceptional population of tender Africanized honeybees at Puerto Rico, that were evolved to be pliable compared to Africanized bees somewhere else on the planet.</a></span>\r\n\r\nAfricanized bees are somewhat increasingly more resistant to infection compared to their European allies in the island, therefore scientists are happy to find out more about the genetic underpinnings of their Puerto Rican bees\' tender nature.\r\n\r\nAs soon as a honeybee hive is upset, shield bees emit a compound signal that dissipates soldier bees to actions. The answer is dependent upon the character of the hazard and the aggressiveness of this hive.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://doi.org/10.1073/pnas.1922927117\">When the soldiers bite their target would be just another step of aggression, even as soldiers who sting will probably perish as a outcome.</a></span>\r\n\r\nGenerally, foragers don\'t shield the hive.\r\n\r\nAdditionally they analyzed how sharply the soldier bees reacted to an attack within the hive.\r\n\r\nWith their surprise, that the scientists detected no genome-sequence differences between your soldiers and foragers that constantly clarified different answers.\r\n\r\nNevertheless as soon as the researchers ran a genomewide institution study comparing the most-aggressive along with least-aggressive hives, they saw a solid correlation between wolves genomics and aggression.\r\n\r\nThe investigations revealed this certain region of the genome did actually play an essential function in the hives\' comparative gentleness or aggression.\r\n\r\n\"There clearly was clearly one chunk of DNA at which the frequency of this chunk from the hive appears to dictate gentle that hive will be on a big extent,\" Hudson explained.\r\n\r\n\"However, the hereditary makeup of this society which the bees reside in - that the colony - includes an extremely strong effect on how competitive the bees at that colony are\"\r\n\r\n\"Many behavioral faculties from humans and animals are considered to be closely influenced by inherited influences in genome arrangement, however for most behaviours, the way the individual behaves is influenced by the way the others round it are behaving - nature and nurture, respectively,\" Robinson stated.\r\n\r\n\"We see in the beehive, cultivate also can have a sturdy genomic signature\"\r\n\r\nSuch behavioral genomic influences might be specially conspicuous in honeybees, which are now living within a exceedingly combined society at which every person has a specified societal and operational role, \'\' he said.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://aces.illinois.edu/news/group-genomics-drive-aggression-honey-bees#:~:text=A%20new%20study%20of%20Africanized,from%20the%20Illinois%20News%20Bureau.\" target=\"_blank\" rel=\"noopener noreferrer\">​ University of Illinois at Urbana-Champaign, News Bureau</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nAvalos, A., <em>et al. </em>(2020) Genomic regions influencing aggressive behavior in honey bees are defined by colony allele frequencies. <em>Proceedings of the National Academy of Sciences</em>. <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://doi.org/10.1073/pnas.1922927117\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1073/pnas.1922927117</a><em>.</em></span>\r\n\r\n</div>','Study: Group genomics are liable for animosity in Africanized bumble bees','','inherit','closed','closed','','6537-revision-v1','','','2020-07-11 17:29:08','2020-07-11 17:29:08','',6537,'https://microbiozindia.com/uncategorized/6537-revision-v1/',0,'revision','',0),(6541,2,'2020-07-11 17:36:35','2020-07-11 17:36:35','SCIEX, a worldwide leader in life engineering analytic technologies, launches another generation of its flagship nominal mass spectrometer, the SCIEX Triple Quad&#x2122; 7500 LC-MS/MS System -- QTRAP® Ready. This technique delivers the maximum level of sensitivity in the SCIEX portfolio also empowers clients to go beyond previous constraints.\r\n\r\n<em>The 7500 System is going to absolutely improve the productivity and efficiency in the laboratory. What I am happily surprised and shocked about is usually we see incremental improvements. 20 years ago it was easy to gain an order of magnitude in sensitivity but that has not been the case over the last 10 years. Now with this new 7500 System, we have gone to another level of sensitivity. SCIEX has again set the bar for sensitivity.”<strong>-</strong></em><strong>Shane R. Needham, Co-Founder at Alturas Analytics</strong>\r\n\r\n<strong>Key features of the SCIEX 7500 System include:</strong>\r\n\r\n1.Work-flows become simplified with a linear dynamic assortment of up to six orders of magnitude, exceeding existing sensitivity parameters to better assess lower levels together with accuracy.\r\n2.New Steel Jet&#x2122; Ion Guide allows users to clarify analytes which were once previously undetectable. The special design also captures more ions from the spray plume.\r\n3.New OptiFlow® Pro Ion Source improves productivity and reduces the demand for extensive sample preparation, allowing users to quantify more follow analytes at lower rates.\r\nIntegral E Lens&#x2122; Technology increases ion sampling.\r\n4.Powered by SCIEX OS computer software, this method may restrain, acquire, analyze, interrogate and record, on a single intuitive stage.\r\n5.Straightforward upgrade course enables additional QTRAP functionality scan classes to enhance confidence. MRM3 work flows can push quantification levels through matrix interferences.\r\n\r\n\"The most substantial effect of faster and more sensitive tools is twofold, you are able to more reliably get lower results in quantification, also you\'ll be able to combine several runs. For the food and environmental distance, the impact is a lot more profound. For labs such as ourswe need to constantly innovate our methods, our approaches to fulfill these conditions. Faster and more sensitive instruments help with this \"\r\n\r\n<em>The SCIEX 7500 System is a culmination of everything we’ve learned about our customers, about our own ambition, and the absolute limits of what can be achieved. By reaching parts per quadrillion in sensitivity, our customers’ research can touch each of us on a very personal level and have a lasting effect on a whole generation.”-</em><strong>Inese Lowenstein, President of SCIEX</strong>','Nex gen SCIEX 7500 System dispatches at virtual product experience','','publish','open','open','','nex-gen-sciex-7500-system-dispatches-at-virtual-product-experience','','','2020-07-11 17:36:35','2020-07-11 17:36:35','',0,'https://microbiozindia.com/?p=6541',0,'post','',0),(6542,2,'2020-07-11 17:36:35','2020-07-11 17:36:35','SCIEX, a worldwide leader in life engineering analytic technologies, launches another generation of its flagship nominal mass spectrometer, the SCIEX Triple Quad&#x2122; 7500 LC-MS/MS System -- QTRAP® Ready. This technique delivers the maximum level of sensitivity in the SCIEX portfolio also empowers clients to go beyond previous constraints.\r\n\r\n<em>The 7500 System is going to absolutely improve the productivity and efficiency in the laboratory. What I am happily surprised and shocked about is usually we see incremental improvements. 20 years ago it was easy to gain an order of magnitude in sensitivity but that has not been the case over the last 10 years. Now with this new 7500 System, we have gone to another level of sensitivity. SCIEX has again set the bar for sensitivity.”<strong>-</strong></em><strong>Shane R. Needham, Co-Founder at Alturas Analytics</strong>\r\n\r\n<strong>Key features of the SCIEX 7500 System include:</strong>\r\n\r\n1.Work-flows become simplified with a linear dynamic assortment of up to six orders of magnitude, exceeding existing sensitivity parameters to better assess lower levels together with accuracy.\r\n2.New Steel Jet&#x2122; Ion Guide allows users to clarify analytes which were once previously undetectable. The special design also captures more ions from the spray plume.\r\n3.New OptiFlow® Pro Ion Source improves productivity and reduces the demand for extensive sample preparation, allowing users to quantify more follow analytes at lower rates.\r\nIntegral E Lens&#x2122; Technology increases ion sampling.\r\n4.Powered by SCIEX OS computer software, this method may restrain, acquire, analyze, interrogate and record, on a single intuitive stage.\r\n5.Straightforward upgrade course enables additional QTRAP functionality scan classes to enhance confidence. MRM3 work flows can push quantification levels through matrix interferences.\r\n\r\n\"The most substantial effect of faster and more sensitive tools is twofold, you are able to more reliably get lower results in quantification, also you\'ll be able to combine several runs. For the food and environmental distance, the impact is a lot more profound. For labs such as ourswe need to constantly innovate our methods, our approaches to fulfill these conditions. Faster and more sensitive instruments help with this \"\r\n\r\n<em>The SCIEX 7500 System is a culmination of everything we’ve learned about our customers, about our own ambition, and the absolute limits of what can be achieved. By reaching parts per quadrillion in sensitivity, our customers’ research can touch each of us on a very personal level and have a lasting effect on a whole generation.”-</em><strong>Inese Lowenstein, President of SCIEX</strong>','Nex gen SCIEX 7500 System dispatches at virtual product experience','','inherit','closed','closed','','6541-revision-v1','','','2020-07-11 17:36:35','2020-07-11 17:36:35','',6541,'https://microbiozindia.com/uncategorized/6541-revision-v1/',0,'revision','',0),(6543,2,'2020-06-25 07:19:20','2020-06-25 07:19:20','It is usually easier to clean glassware should you do it straight away. When detergent is used, it is normally one designed for lab glassware, such as Liquinox or Alconox. These detergents are preferable to some other dishwashing detergent you might use on meals at home. A lot of the time, detergent and tap water will be neither required nor desired.You can rinse the glassware using the proper solvent, and then end up with two or three rinses with distilled water, followed by final rinses with deionized water. As the main story of this present month comprised Everything You Need to Know about Cleaning Laboratory Glassware covered by our editorial staff.','Everything You Need to Know about Cleaning Laboratory Glassware','','publish','closed','closed','','everything-you-need-to-know-about-cleaning-laboratory-glassware','','','2020-07-12 07:41:25','2020-07-12 07:41:25','',0,'https://microbiozindia.com/?post_type=magazines&#038;p=6543',0,'magazines','',0),(6544,2,'2020-07-12 07:31:33','2020-07-12 07:31:33','','JUNE CVR','','inherit','open','closed','','june-cvr','','','2020-07-12 07:31:33','2020-07-12 07:31:33','',6543,'https://microbiozindia.com/wp-content/uploads/2020/07/JUNE-CVR.png',0,'attachment','image/png',0),(6545,2,'2020-07-12 07:32:41','2020-07-12 07:32:41','','Untitled design (1)','','inherit','open','closed','','untitled-design-1-9','','','2020-07-12 07:32:41','2020-07-12 07:32:41','',6543,'https://microbiozindia.com/wp-content/uploads/2020/07/Untitled-design-1.png',0,'attachment','image/png',0),(6546,2,'2020-07-12 07:32:42','2020-07-12 07:32:42','','Untitled design (2)','','inherit','open','closed','','untitled-design-2','','','2020-07-12 07:32:42','2020-07-12 07:32:42','',6543,'https://microbiozindia.com/wp-content/uploads/2020/07/Untitled-design-2.png',0,'attachment','image/png',0),(6547,2,'2020-07-12 07:32:43','2020-07-12 07:32:43','','Untitled design (3)','','inherit','open','closed','','untitled-design-3','','','2020-07-12 07:32:43','2020-07-12 07:32:43','',6543,'https://microbiozindia.com/wp-content/uploads/2020/07/Untitled-design-3.png',0,'attachment','image/png',0),(6548,2,'2020-07-12 07:32:44','2020-07-12 07:32:44','','Untitled design (4)','','inherit','open','closed','','untitled-design-4','','','2020-07-12 07:32:44','2020-07-12 07:32:44','',6543,'https://microbiozindia.com/wp-content/uploads/2020/07/Untitled-design-4.png',0,'attachment','image/png',0),(6549,2,'2020-07-12 07:41:25','2020-07-12 07:41:25','It is usually easier to clean glassware should you do it straight away. When detergent is used, it is normally one designed for lab glassware, such as Liquinox or Alconox. These detergents are preferable to some other dishwashing detergent you might use on meals at home. A lot of the time, detergent and tap water will be neither required nor desired.You can rinse the glassware using the proper solvent, and then end up with two or three rinses with distilled water, followed by final rinses with deionized water. As the main story of this present month comprised Everything You Need to Know about Cleaning Laboratory Glassware covered by our editorial staff.','Everything You Need to Know about Cleaning Laboratory Glassware','','inherit','closed','closed','','6543-revision-v1','','','2020-07-12 07:41:25','2020-07-12 07:41:25','',6543,'https://microbiozindia.com/uncategorized/6543-revision-v1/',0,'revision','',0),(6550,2,'2020-07-12 13:14:15','2020-07-12 13:14:15','Scientists, for example those with Indian-origin, have given the first extensive breakdown of COVID-19\'s effects beyond the lungs, also have advocated that physicians treat this like a multisystem disorder with indicators such as blood clots, kidney failure, and neurological disorders such as delirium. \"I had been on the frontlines directly from the start. I discovered that patients were a whole lot, that they had elevated blood glucose if they didn\'t have diabetesand many were undergoing trauma for their kidneys and hearts,\" explained Aakriti Gupta, also a co author of this analysis from Columbia University at the united states.\r\n\r\nThe researchers urged that doctors treat those illnesses alongside the respiratory disorder.\r\n\r\n\"Physicians should think about COVID-19 for a multisystem illness,\" Gupta explained.\r\n\r\nOne of those non-respiratory complications reported with studies is blood-clotting, according to the researchers.\r\n\r\nThey said that these clotting complications could result from the virus\' attack on cells which line the bloodstream.\r\n\r\nThe scientists also said when herpes strikes arteries, inflammation grows blood begins to make clots, big and small.\r\n\r\nAll these blood clots, based on the analysis, may travel throughout the human body and also wreak havoc in organs, perpetuating a vicious cycle of melancholy.\r\n\r\n\"Researchers all around the planet will work in an unprecedented speed towards focusing on this virus specifically hijacks the protective biological mechanics. We expect this would aid in the evolution of effective treatments for COVID-19 while in the close foreseeable future,\" stated Kartik Sehgal, still another co author of this analysis from Harvard Medical School in the united states.\r\n\r\nBased on the researchers, the creation of clots may result in heart attacks.\r\n\r\nBut they said the specific mechanism of coronary damage in COVID-19 patients is now unsure because the herpes virus have been dispersed by one\'s center tissue at autopsy cases.\r\n\r\nThe researchers believe that the heart muscle can be damaged from systemic inflammation, and also the corresponding discharge of immunity system\'s signalling molecules, cytokines.\r\n\r\nThey also said a flood of this cytokines which normally clean infected cells may spiral out of control within acute COVID-19 cases.\r\n\r\nYet another surprising finding, in accordance with the scientists, may be that the high percentage of COVID-19 patients at the ICU with severe kidney impairment.\r\n\r\nThey said the ACE2 receptor molecule that\'s used by the herpes virus to gain entrance into human cells can be available in elevated concentrations within the gut, and may likely cause the renal impairment.\r\n\r\nAt nyc at the united states, the scientists saidthat renal failure was reported up to 50 percent of patients at the ICU.\r\n\r\n\"Approximately five to 10% of patients had dialysis. That is clearly a really significant number,\" Gupta explained.\r\n\r\nDescribing the neurological signs of COVID-19, the researchers said that these generally include nausea, headache, fatigue, and lack of odor, which might happen in roughly a third of patients.\r\n\r\nThey said fractures brought on by blood clots has been detected up to half a cent of acute scenarios, along with delirium in eight to eight percent of COVID-19 patients.\r\n\r\n\"COVID-19 patients might be intubated for 2 to three weeks: per year require ventilators to get 30 or more days,\" Gupta explained.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.moneycontrol.com/news/world/covid-19-symptoms-outside-lungs-decoded-5537871.html\">\"This virus is so odd and it\'s really difficult to not take back a step not to be impressed how many expressions it\'s on the body,\" said Mahesh Madhavan, still another co author of this analysis from Columbia University.</a></span>\r\n\r\nBut have a better look at this paint all the way down to the nanoscale -- also there is far more likely than you may think.\r\n\r\nThin film coatings do considerably more than simply shake walls up. As an instance, they are sometimes applied as pharmaceutical apparatus in raw films, very similar to people to send medication used to fight with the outbreak. These coatings can transform their possessions, that will be particularly essential for films utilized in medication delivery.\r\n\r\nIn their newspaper,\"Chemical vs. mechanical microstructure development in drying colloid and polymer coatings, so\" that the Lehigh researchers looked at the way that particles encircle themselves throughout drying if their interactions have been tuned. These particles acted being a surrogate for its active pharmaceutical ingredient in a medication shipping film.\r\n\r\nGraduate student Titiporn Kaewpetch looks directly inside those pictures employing highspeed confocal laser scanning microscopy to shoot tens of thousands of graphics that provide nanoscale information of how particles stream and build throughout drying. Gigabytes of data for each picture are left handed to show their 3 d arrangement, giving simulation-like detail around the differently hidden internal procedures that happen.\r\n\r\nThe researchers discovered that if particles attract one another, they produce a scaffold which buckles and fractures through the drying on account of the motion of the highest interface. Their 3 d investigation of this microstructure development shows clear signatures with the technique through the duration of drying compared to people at which contaminants are gruesome.\r\n\r\n\"In real medication delivery systems, you\'ll find lots of ingredients getting together with one another, always changing their interactions all through drying,\" says Gilchrist. \"By lessening this procedure to the critical ingredientswe can observe these customs because they happen. This will allow new insights in to making of these pictures.\"\r\n\r\nKaewpetch is encouraged by the Royal Thai Scholars application.','COVID-19 side effects outside lungs decoded','','publish','open','open','','covid-19-side-effects-outside-lungs-decoded','','','2020-07-12 13:20:08','2020-07-12 13:20:08','',0,'https://microbiozindia.com/?p=6550',0,'post','',0),(6551,2,'2020-07-12 12:19:07','2020-07-12 12:19:07','','5c18fceef3bbb','','inherit','open','closed','','5c18fceef3bbb','','','2020-07-12 12:19:07','2020-07-12 12:19:07','',6550,'https://microbiozindia.com/wp-content/uploads/2020/07/5c18fceef3bbb.jpg',0,'attachment','image/jpeg',0),(6552,2,'2020-07-12 12:19:08','2020-07-12 12:19:08','','caronavirusLungs-125957837-770x533-1','','inherit','open','closed','','caronaviruslungs-125957837-770x533-1','','','2020-07-12 12:19:08','2020-07-12 12:19:08','',6550,'https://microbiozindia.com/wp-content/uploads/2020/07/caronavirusLungs-125957837-770x533-1.jpg',0,'attachment','image/jpeg',0),(6553,2,'2020-07-12 12:19:09','2020-07-12 12:19:09','','fatCellsInBody-625302208-770x553','','inherit','open','closed','','fatcellsinbody-625302208-770x553','','','2020-07-12 12:19:09','2020-07-12 12:19:09','',6550,'https://microbiozindia.com/wp-content/uploads/2020/07/fatCellsInBody-625302208-770x553-1.jpg',0,'attachment','image/jpeg',0),(6554,2,'2020-07-12 13:14:15','2020-07-12 13:14:15','Scientists, for example those with Indian-origin, have given the first extensive breakdown of COVID-19\'s effects beyond the lungs, also have advocated that physicians treat this like a multisystem disorder with indicators such as blood clots, kidney failure, and neurological disorders such as delirium. \"I had been on the frontlines directly from the start. I discovered that patients were a whole lot, that they had elevated blood glucose if they didn\'t have diabetesand many were undergoing trauma for their kidneys and hearts,\" explained Aakriti Gupta, also a co author of this analysis from Columbia University at the united states.\r\n\r\nThe researchers urged that doctors treat those illnesses alongside the respiratory disorder.\r\n\r\n\"Physicians should think about COVID-19 for a multisystem illness,\" Gupta explained.\r\n\r\nOne of those non-respiratory complications reported with studies is blood-clotting, according to the researchers.\r\n\r\nThey said that these clotting complications could result from the virus\' attack on cells which line the bloodstream.\r\n\r\nThe scientists also said when herpes strikes arteries, inflammation grows blood begins to make clots, big and small.\r\n\r\nAll these blood clots, based on the analysis, may travel throughout the human body and also wreak havoc in organs, perpetuating a vicious cycle of melancholy.\r\n\r\n\"Researchers all around the planet will work in an unprecedented speed towards focusing on this virus specifically hijacks the protective biological mechanics. We expect this would aid in the evolution of effective treatments for COVID-19 while in the close foreseeable future,\" stated Kartik Sehgal, still another co author of this analysis from Harvard Medical School in the united states.\r\n\r\nBased on the researchers, the creation of clots may result in heart attacks.\r\n\r\nBut they said the specific mechanism of coronary damage in COVID-19 patients is now unsure because the herpes virus have been dispersed by one\'s center tissue at autopsy cases.\r\n\r\nThe researchers believe that the heart muscle can be damaged from systemic inflammation, and also the corresponding discharge of immunity system\'s signalling molecules, cytokines.\r\n\r\nThey also said a flood of this cytokines which normally clean infected cells may spiral out of control within acute COVID-19 cases.\r\n\r\nYet another surprising finding, in accordance with the scientists, may be that the high percentage of COVID-19 patients at the ICU with severe kidney impairment.\r\n\r\nThey said the ACE2 receptor molecule that\'s used by the herpes virus to gain entrance into human cells can be available in elevated concentrations within the gut, and may likely cause the renal impairment.\r\n\r\nAt nyc at the united states, the scientists saidthat renal failure was reported up to 50 percent of patients at the ICU.\r\n\r\n\"Approximately five to 10% of patients had dialysis. That is clearly a really significant number,\" Gupta explained.\r\n\r\nDescribing the neurological signs of COVID-19, the researchers said that these generally include nausea, headache, fatigue, and lack of odor, which might happen in roughly a third of patients.\r\n\r\nThey said fractures brought on by blood clots has been detected up to half a cent of acute scenarios, along with delirium in eight to eight percent of COVID-19 patients.\r\n\r\n\"COVID-19 patients might be intubated for 2 to three weeks: per year require ventilators to get 30 or more days,\" Gupta explained.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.moneycontrol.com/news/world/covid-19-symptoms-outside-lungs-decoded-5537871.html\">\"This virus is so odd and it\'s really difficult to not take back a step not to be impressed how many expressions it\'s on the body,\" said Mahesh Madhavan, still another co author of this analysis from Columbia University.</a></span>\r\n\r\nBut have a better look at this paint all the way down to the nanoscale -- also there is far more likely than you may think.\r\n\r\nThin film coatings do considerably more than simply shake walls up. As an instance, they are sometimes applied as pharmaceutical apparatus in raw films, very similar to people to send medication used to fight with the outbreak. These coatings can transform their possessions, that will be particularly essential for films utilized in medication delivery.\r\n\r\nIn their newspaper,\"Chemical vs. mechanical microstructure development in drying colloid and polymer coatings, so\" that the Lehigh researchers looked at the way that particles encircle themselves throughout drying if their interactions have been tuned. These particles acted being a surrogate for its active pharmaceutical ingredient in a medication shipping film.\r\n\r\nGraduate student Titiporn Kaewpetch looks directly inside those pictures employing highspeed confocal laser scanning microscopy to shoot tens of thousands of graphics that provide nanoscale information of how particles stream and build throughout drying. Gigabytes of data for each picture are left handed to show their 3 d arrangement, giving simulation-like detail around the differently hidden internal procedures that happen.\r\n\r\nThe researchers discovered that if particles attract one another, they produce a scaffold which buckles and fractures through the drying on account of the motion of the highest interface. Their 3 d investigation of this microstructure development shows clear signatures with the technique through the duration of drying compared to people at which contaminants are gruesome.\r\n\r\n\"In real medication delivery systems, you\'ll find lots of ingredients getting together with one another, always changing their interactions all through drying,\" says Gilchrist. \"By lessening this procedure to the critical ingredientswe can observe these customs because they happen. This will allow new insights in to making of these pictures.\"\r\n\r\nKaewpetch is encouraged by the Royal Thai Scholars application.','COVID-19 side effects outside lungs decoded','','inherit','closed','closed','','6550-revision-v1','','','2020-07-12 13:14:15','2020-07-12 13:14:15','',6550,'https://microbiozindia.com/uncategorized/6550-revision-v1/',0,'revision','',0),(6555,2,'2020-07-12 13:24:12','2020-07-12 13:24:12','Whilst the death toll from the COVID-19 pandemic mounts, the boffins worldwide carry on their push to create effective treatments and a vaccine to its highly infectious respiratory tract.\r\n\r\nThe inhibitors demonstrate potent structural and chemical connections with an viral critical to this herpes virus\'s capacity to proliferate.\r\n\r\nThe very promising drug candidates - like the FDA-approved Hepatitis-C drugs boceprevir and also an investigational veterinary antifungal medication called GC-376 - target that the SARS-CoV-2 main protease (Mpro), a molecule which cuts proteins out form a very long strand which the herpes virus produces as it invades an individual cell.\r\n\r\nThis receptor had been confirmed as an antiviral drug target for its initial SARS and MERS, both genetically much like SARS-CoV-2.\r\n\r\n\"Having a fast emerging infectious illness such as COVID-19, we do not have enough time to create new antiviral medication from scratch,\" explained Yu Chen, Ph.D., USF Health associate professor of molecular medicine and also a co author of this Cell Research newspaper.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.nature.com/articles/s41598-020-66875-0\">Ahead of the outbreak, Dr. Chen implemented his expertise from structure-based medication design to help grow inhibitors (medication compounds) which aim bacterial enzymes inducing immunity to certain widely prescribed antibiotics like penicillin.</a></span>\r\n\r\nHis lab focuses its complex methods, for example xray crystallography and molecular docking, on searching for strategies to halt SARS-CoV-2.\r\n\r\nSince people don\'t need the receptor, drugs targeting this protein tend to be not as prone to induce negative effects, \'\' he clarified.\r\n\r\nThese inhibitors climbed into the very best following viewing over 50 present protease chemicals for possible Re-purposing:\r\n\r\nIts dose that is effective, safety profile, formula, and also the way your human body processes the medication (pharmacokinetics) already are known, which could greatly accelerate the actions required to find boceprevir to clinical trials for COVID-19, Dr. Chen said. This broker was the very powerful inhibitor of this Mpro receptor in Laboratory evaluations, Dr. Chen said, however before human trials may begin it could want to be analyzed in animal models of SARS-CoV-2. Dr. Chen and his doctoral student Michael Sacco ascertained the xray crystal arrangement of GC-376 jumped by Mpro, also characterized molecular connections between your chemical and viral receptor utilizing 3D computer modeling.\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.nature.com/articles/s41598-020-66875-0\">All compounds were more advanced than additional Mpro inhibitors previously defined as convenient to evaluate for curing SARS-CoV-2, Dr. Chen said.</a></span>\r\n\r\nA promising drug candidate one which interrupts or kills herpes without destroying healthy cells fits snugly, in the exceptional shape of their viral receptor\'s\"pocket\" GC-376 worked especially well at adapting to (complementing) the model of targeted Mpro receptor binding websites, Dr. Chen said.\r\n\r\nEmploying a lock (binding pocket, or receptor) and vital (medication ) analogy,\"GC-376 was far the secret with the most useful, or tightestmatch, healthy,\" he further added. \"Our modeling demonstrates the way the inhibitor may mimic the authentic peptide substrate once it binds to the active site onto the top layer of the SARS-CoV-2 main protease.\"\r\n\r\nRather than boosting the experience of the viral receptor, such as the bacterium generally does, that the inhibitor somewhat reduces the action of this enzyme which helps SARS-CoV-2 create copies of it self.\r\n\r\nVisualizing 3 d interactions involving the antibacterial substances and also the viral protein supplies a better knowledge of the way a Mpro complex works and also, at the longterm, may result in the style of fresh COVID-19 drugs, Dr. Chen said.\r\n\r\nMeanwhile, he added, researchers concentrate on getting targeted antifungal treatments into the front lines quicker by tweaking existing coronavirus medication candidates to enhance their stability and operation.\r\n\r\n<strong>Story Source:</strong>\r\n\r\nMaterials provided by Lehigh University and Content may be edited for style and length.\r\n\r\n<strong>Journal Reference:</strong>\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.nature.com/articles/s41598-020-66875-0\">Thitiporn Kaewpetch, James F. Gilchrist. Chemical vs. mechanical microstructure evolution in drying colloid and polymer coatings. Scientific Reports, 2020; 10 (1) DOI: 10.1038/s41598-020-66875-0</a></span>','Microscopy method uncovers nanoscale detail of coatings as they dry','','publish','open','open','','microscopy-method-uncovers-nanoscale-detail-of-coatings-as-they-dry','','','2020-07-12 13:24:37','2020-07-12 13:24:37','',0,'https://microbiozindia.com/?p=6555',0,'post','',0),(6556,2,'2020-07-12 13:23:50','2020-07-12 13:23:50','','unnamed','','inherit','open','closed','','unnamed-4','','','2020-07-12 13:23:50','2020-07-12 13:23:50','',6555,'https://microbiozindia.com/wp-content/uploads/2020/07/unnamed.jpg',0,'attachment','image/jpeg',0),(6557,2,'2020-07-12 13:24:12','2020-07-12 13:24:12','Whilst the death toll from the COVID-19 pandemic mounts, the boffins worldwide carry on their push to create effective treatments and a vaccine to its highly infectious respiratory tract.\r\n\r\nThe inhibitors demonstrate potent structural and chemical connections with an viral critical to this herpes virus\'s capacity to proliferate.\r\n\r\nThe very promising drug candidates - like the FDA-approved Hepatitis-C drugs boceprevir and also an investigational veterinary antifungal medication called GC-376 - target that the SARS-CoV-2 main protease (Mpro), a molecule which cuts proteins out form a very long strand which the herpes virus produces as it invades an individual cell.\r\n\r\nThis receptor had been confirmed as an antiviral drug target for its initial SARS and MERS, both genetically much like SARS-CoV-2.\r\n\r\n\"Having a fast emerging infectious illness such as COVID-19, we do not have enough time to create new antiviral medication from scratch,\" explained Yu Chen, Ph.D., USF Health associate professor of molecular medicine and also a co author of this Cell Research newspaper.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.nature.com/articles/s41598-020-66875-0\">Ahead of the outbreak, Dr. Chen implemented his expertise from structure-based medication design to help grow inhibitors (medication compounds) which aim bacterial enzymes inducing immunity to certain widely prescribed antibiotics like penicillin.</a></span>\r\n\r\nHis lab focuses its complex methods, for example xray crystallography and molecular docking, on searching for strategies to halt SARS-CoV-2.\r\n\r\nSince people don\'t need the receptor, drugs targeting this protein tend to be not as prone to induce negative effects, \'\' he clarified.\r\n\r\nThese inhibitors climbed into the very best following viewing over 50 present protease chemicals for possible Re-purposing:\r\n\r\nIts dose that is effective, safety profile, formula, and also the way your human body processes the medication (pharmacokinetics) already are known, which could greatly accelerate the actions required to find boceprevir to clinical trials for COVID-19, Dr. Chen said. This broker was the very powerful inhibitor of this Mpro receptor in Laboratory evaluations, Dr. Chen said, however before human trials may begin it could want to be analyzed in animal models of SARS-CoV-2. Dr. Chen and his doctoral student Michael Sacco ascertained the xray crystal arrangement of GC-376 jumped by Mpro, also characterized molecular connections between your chemical and viral receptor utilizing 3D computer modeling.\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.nature.com/articles/s41598-020-66875-0\">All compounds were more advanced than additional Mpro inhibitors previously defined as convenient to evaluate for curing SARS-CoV-2, Dr. Chen said.</a></span>\r\n\r\nA promising drug candidate one which interrupts or kills herpes without destroying healthy cells fits snugly, in the exceptional shape of their viral receptor\'s\"pocket\" GC-376 worked especially well at adapting to (complementing) the model of targeted Mpro receptor binding websites, Dr. Chen said.\r\n\r\nEmploying a lock (binding pocket, or receptor) and vital (medication ) analogy,\"GC-376 was far the secret with the most useful, or tightestmatch, healthy,\" he further added. \"Our modeling demonstrates the way the inhibitor may mimic the authentic peptide substrate once it binds to the active site onto the top layer of the SARS-CoV-2 main protease.\"\r\n\r\nRather than boosting the experience of the viral receptor, such as the bacterium generally does, that the inhibitor somewhat reduces the action of this enzyme which helps SARS-CoV-2 create copies of it self.\r\n\r\nVisualizing 3 d interactions involving the antibacterial substances and also the viral protein supplies a better knowledge of the way a Mpro complex works and also, at the longterm, may result in the style of fresh COVID-19 drugs, Dr. Chen said.\r\n\r\nMeanwhile, he added, researchers concentrate on getting targeted antifungal treatments into the front lines quicker by tweaking existing coronavirus medication candidates to enhance their stability and operation.\r\n\r\n<strong>Story Source:</strong>\r\n\r\nMaterials provided by Lehigh University and Content may be edited for style and length.\r\n\r\n<strong>Journal Reference:</strong>\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.nature.com/articles/s41598-020-66875-0\">Thitiporn Kaewpetch, James F. Gilchrist. Chemical vs. mechanical microstructure evolution in drying colloid and polymer coatings. Scientific Reports, 2020; 10 (1) DOI: 10.1038/s41598-020-66875-0</a></span>','Microscopy method uncovers nanoscale detail of coatings as they dry','','inherit','closed','closed','','6555-revision-v1','','','2020-07-12 13:24:12','2020-07-12 13:24:12','',6555,'https://microbiozindia.com/uncategorized/6555-revision-v1/',0,'revision','',0),(6558,2,'2020-07-12 13:24:37','2020-07-12 13:24:37','Whilst the death toll from the COVID-19 pandemic mounts, the boffins worldwide carry on their push to create effective treatments and a vaccine to its highly infectious respiratory tract.\r\n\r\nThe inhibitors demonstrate potent structural and chemical connections with an viral critical to this herpes virus\'s capacity to proliferate.\r\n\r\nThe very promising drug candidates - like the FDA-approved Hepatitis-C drugs boceprevir and also an investigational veterinary antifungal medication called GC-376 - target that the SARS-CoV-2 main protease (Mpro), a molecule which cuts proteins out form a very long strand which the herpes virus produces as it invades an individual cell.\r\n\r\nThis receptor had been confirmed as an antiviral drug target for its initial SARS and MERS, both genetically much like SARS-CoV-2.\r\n\r\n\"Having a fast emerging infectious illness such as COVID-19, we do not have enough time to create new antiviral medication from scratch,\" explained Yu Chen, Ph.D., USF Health associate professor of molecular medicine and also a co author of this Cell Research newspaper.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.nature.com/articles/s41598-020-66875-0\">Ahead of the outbreak, Dr. Chen implemented his expertise from structure-based medication design to help grow inhibitors (medication compounds) which aim bacterial enzymes inducing immunity to certain widely prescribed antibiotics like penicillin.</a></span>\r\n\r\nHis lab focuses its complex methods, for example xray crystallography and molecular docking, on searching for strategies to halt SARS-CoV-2.\r\n\r\nSince people don\'t need the receptor, drugs targeting this protein tend to be not as prone to induce negative effects, \'\' he clarified.\r\n\r\nThese inhibitors climbed into the very best following viewing over 50 present protease chemicals for possible Re-purposing:\r\n\r\nIts dose that is effective, safety profile, formula, and also the way your human body processes the medication (pharmacokinetics) already are known, which could greatly accelerate the actions required to find boceprevir to clinical trials for COVID-19, Dr. Chen said. This broker was the very powerful inhibitor of this Mpro receptor in Laboratory evaluations, Dr. Chen said, however before human trials may begin it could want to be analyzed in animal models of SARS-CoV-2. Dr. Chen and his doctoral student Michael Sacco ascertained the xray crystal arrangement of GC-376 jumped by Mpro, also characterized molecular connections between your chemical and viral receptor utilizing 3D computer modeling.\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.nature.com/articles/s41598-020-66875-0\">All compounds were more advanced than additional Mpro inhibitors previously defined as convenient to evaluate for curing SARS-CoV-2, Dr. Chen said.</a></span>\r\n\r\nA promising drug candidate one which interrupts or kills herpes without destroying healthy cells fits snugly, in the exceptional shape of their viral receptor\'s\"pocket\" GC-376 worked especially well at adapting to (complementing) the model of targeted Mpro receptor binding websites, Dr. Chen said.\r\n\r\nEmploying a lock (binding pocket, or receptor) and vital (medication ) analogy,\"GC-376 was far the secret with the most useful, or tightestmatch, healthy,\" he further added. \"Our modeling demonstrates the way the inhibitor may mimic the authentic peptide substrate once it binds to the active site onto the top layer of the SARS-CoV-2 main protease.\"\r\n\r\nRather than boosting the experience of the viral receptor, such as the bacterium generally does, that the inhibitor somewhat reduces the action of this enzyme which helps SARS-CoV-2 create copies of it self.\r\n\r\nVisualizing 3 d interactions involving the antibacterial substances and also the viral protein supplies a better knowledge of the way a Mpro complex works and also, at the longterm, may result in the style of fresh COVID-19 drugs, Dr. Chen said.\r\n\r\nMeanwhile, he added, researchers concentrate on getting targeted antifungal treatments into the front lines quicker by tweaking existing coronavirus medication candidates to enhance their stability and operation.\r\n\r\n<strong>Story Source:</strong>\r\n\r\nMaterials provided by Lehigh University and Content may be edited for style and length.\r\n\r\n<strong>Journal Reference:</strong>\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.nature.com/articles/s41598-020-66875-0\">Thitiporn Kaewpetch, James F. Gilchrist. Chemical vs. mechanical microstructure evolution in drying colloid and polymer coatings. Scientific Reports, 2020; 10 (1) DOI: 10.1038/s41598-020-66875-0</a></span>','Microscopy method uncovers nanoscale detail of coatings as they dry','','inherit','closed','closed','','6555-revision-v1','','','2020-07-12 13:24:37','2020-07-12 13:24:37','',6555,'https://microbiozindia.com/uncategorized/6555-revision-v1/',0,'revision','',0),(6560,2,'2020-07-12 13:30:15','2020-07-12 13:30:15','Whilst the death toll from the COVID-19 pandemic mounts, the boffins worldwide carry on their push to create effective treatments and a vaccine to its highly infectious respiratory tract.\r\n\r\nThe inhibitors demonstrate potent structural and chemical connections with an viral critical to this herpes virus\'s capacity to proliferate.\r\n\r\nThe very promising drug candidates - like the FDA-approved Hepatitis-C drugs boceprevir and also an investigational veterinary antifungal medication called GC-376 - target that the SARS-CoV-2 main protease (Mpro), a molecule which cuts proteins out form a very long strand which the herpes virus produces as it invades an individual cell.\r\n\r\n<em>A lot of good drug candidates are already out there as a starting point. But, with new information from studies like ours and current technology, we can help design even better (repurposed) drugs much faster.\"-Yu Chen, PhD, Study Co-Author and Associate Professor, Department of Molecular Medicine, University of South Florida Health</em>\r\n\r\nThis receptor had been confirmed as an antiviral drug target for its initial SARS and MERS, both genetically much like SARS-CoV-2.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.nature.com/articles/s41422-020-0356-z\">\"Having a fast emerging infectious illness such as COVID-19, we do not have enough time to create new antiviral medication from scratch,\" explained Yu Chen, Ph.D., USF Health associate professor of molecular medicine and also a co author of this Cell Research newspaper.</a></span>\r\n\r\nAhead of the outbreak, Dr. Chen implemented his expertise from structure-based medication design to help grow inhibitors (medication compounds) which aim bacterial enzymes inducing immunity to certain widely prescribed antibiotics like penicillin.\r\n\r\nHis lab focuses its complex methods, for example xray crystallography and molecular docking, on searching for strategies to halt SARS-CoV-2.\r\n\r\nSince people don\'t need the receptor, drugs targeting this protein tend to be not as prone to induce negative effects, \'\' he clarified.\r\n\r\nThese inhibitors climbed into the very best following viewing over 50 present protease chemicals for possible Re-purposing:\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.nature.com/articles/s41422-020-0356-z\">Its dose that is effective, safety profile, formula, and also the way your human body processes the medication (pharmacokinetics) already are known, which could greatly accelerate the actions required to find boceprevir to clinical trials for COVID-19, Dr. Chen said.</a> </span>This broker was the very powerful inhibitor of this Mpro receptor in Laboratory evaluations, Dr. Chen said, however before human trials may begin it could want to be analyzed in animal models of SARS-CoV-2. Dr. Chen and his doctoral student Michael Sacco ascertained the xray crystal arrangement of GC-376 jumped by Mpro, also characterized molecular connections between your chemical and viral receptor utilizing 3D computer modeling.\r\nAll compounds were more advanced than additional Mpro inhibitors previously defined as convenient to evaluate for curing SARS-CoV-2, Dr. Chen said.\r\n\r\nA promising drug candidate one which interrupts or kills herpes without destroying healthy cells fits snugly, in the exceptional shape of their viral receptor\'s\"pocket\" GC-376 worked especially well at adapting to (complementing) the model of targeted Mpro receptor binding websites, Dr. Chen said.\r\n\r\nEmploying a lock (binding pocket, or receptor) and vital (medication ) analogy,\"GC-376 was far the secret with the most useful, or tightestmatch, healthy,\" he further added. \"Our modeling demonstrates the way the inhibitor may mimic the authentic peptide substrate once it binds to the active site onto the top layer of the SARS-CoV-2 main protease.\"\r\n\r\nRather than boosting the experience of the viral receptor, such as the bacterium generally does, that the inhibitor somewhat reduces the action of this enzyme which helps SARS-CoV-2 create copies of it self.\r\n\r\nVisualizing 3 d interactions involving the antibacterial substances and also the viral protein supplies a better knowledge of the way a Mpro complex works and also, at the longterm, may result in the style of fresh COVID-19 drugs, Dr. Chen said.\r\n\r\nMeanwhile, he added, researchers concentrate on getting targeted antifungal treatments into the front lines quicker by tweaking existing coronavirus medication candidates to enhance their stability and operation.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://hscweb3.hsc.usf.edu/blog/2020/07/06/compounds-halt-sars-cov-2-replication-by-targeting-key-viral-enzyme\" target=\"_blank\" rel=\"noopener noreferrer\">University of South Florida (USF Health)</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nMa, C., <em>et al</em>. (2020) Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. <em>Cell Research</em>.<span style=\"color: #ff6600;\"> <a style=\"color: #ff6600;\" href=\"https://doi.org/10.1038/s41422-020-0356-z\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1038/s41422-020-0356-z.</a></span>\r\n\r\n</div>','Researchers distinguish aggravates that square replication of COVID-19 infection','','publish','open','open','','6560','','','2020-07-12 13:30:44','2020-07-12 13:30:44','',0,'https://microbiozindia.com/?p=6560',0,'post','',0),(6561,2,'2020-07-12 13:30:15','2020-07-12 13:30:15','Whilst the death toll from the COVID-19 pandemic mounts, the boffins worldwide carry on their push to create effective treatments and a vaccine to its highly infectious respiratory tract.\r\n\r\nThe inhibitors demonstrate potent structural and chemical connections with an viral critical to this herpes virus\'s capacity to proliferate.\r\n\r\nThe very promising drug candidates - like the FDA-approved Hepatitis-C drugs boceprevir and also an investigational veterinary antifungal medication called GC-376 - target that the SARS-CoV-2 main protease (Mpro), a molecule which cuts proteins out form a very long strand which the herpes virus produces as it invades an individual cell.\r\n\r\n<em>A lot of good drug candidates are already out there as a starting point. But, with new information from studies like ours and current technology, we can help design even better (repurposed) drugs much faster.\"-Yu Chen, PhD, Study Co-Author and Associate Professor, Department of Molecular Medicine, University of South Florida Health</em>\r\n\r\nThis receptor had been confirmed as an antiviral drug target for its initial SARS and MERS, both genetically much like SARS-CoV-2.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.nature.com/articles/s41422-020-0356-z\">\"Having a fast emerging infectious illness such as COVID-19, we do not have enough time to create new antiviral medication from scratch,\" explained Yu Chen, Ph.D., USF Health associate professor of molecular medicine and also a co author of this Cell Research newspaper.</a></span>\r\n\r\nAhead of the outbreak, Dr. Chen implemented his expertise from structure-based medication design to help grow inhibitors (medication compounds) which aim bacterial enzymes inducing immunity to certain widely prescribed antibiotics like penicillin.\r\n\r\nHis lab focuses its complex methods, for example xray crystallography and molecular docking, on searching for strategies to halt SARS-CoV-2.\r\n\r\nSince people don\'t need the receptor, drugs targeting this protein tend to be not as prone to induce negative effects, \'\' he clarified.\r\n\r\nThese inhibitors climbed into the very best following viewing over 50 present protease chemicals for possible Re-purposing:\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.nature.com/articles/s41422-020-0356-z\">Its dose that is effective, safety profile, formula, and also the way your human body processes the medication (pharmacokinetics) already are known, which could greatly accelerate the actions required to find boceprevir to clinical trials for COVID-19, Dr. Chen said.</a> </span>This broker was the very powerful inhibitor of this Mpro receptor in Laboratory evaluations, Dr. Chen said, however before human trials may begin it could want to be analyzed in animal models of SARS-CoV-2. Dr. Chen and his doctoral student Michael Sacco ascertained the xray crystal arrangement of GC-376 jumped by Mpro, also characterized molecular connections between your chemical and viral receptor utilizing 3D computer modeling.\r\nAll compounds were more advanced than additional Mpro inhibitors previously defined as convenient to evaluate for curing SARS-CoV-2, Dr. Chen said.\r\n\r\nA promising drug candidate one which interrupts or kills herpes without destroying healthy cells fits snugly, in the exceptional shape of their viral receptor\'s\"pocket\" GC-376 worked especially well at adapting to (complementing) the model of targeted Mpro receptor binding websites, Dr. Chen said.\r\n\r\nEmploying a lock (binding pocket, or receptor) and vital (medication ) analogy,\"GC-376 was far the secret with the most useful, or tightestmatch, healthy,\" he further added. \"Our modeling demonstrates the way the inhibitor may mimic the authentic peptide substrate once it binds to the active site onto the top layer of the SARS-CoV-2 main protease.\"\r\n\r\nRather than boosting the experience of the viral receptor, such as the bacterium generally does, that the inhibitor somewhat reduces the action of this enzyme which helps SARS-CoV-2 create copies of it self.\r\n\r\nVisualizing 3 d interactions involving the antibacterial substances and also the viral protein supplies a better knowledge of the way a Mpro complex works and also, at the longterm, may result in the style of fresh COVID-19 drugs, Dr. Chen said.\r\n\r\nMeanwhile, he added, researchers concentrate on getting targeted antifungal treatments into the front lines quicker by tweaking existing coronavirus medication candidates to enhance their stability and operation.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://hscweb3.hsc.usf.edu/blog/2020/07/06/compounds-halt-sars-cov-2-replication-by-targeting-key-viral-enzyme\" target=\"_blank\" rel=\"noopener noreferrer\">University of South Florida (USF Health)</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nMa, C., <em>et al</em>. (2020) Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. <em>Cell Research</em>.<span style=\"color: #ff6600;\"> <a style=\"color: #ff6600;\" href=\"https://doi.org/10.1038/s41422-020-0356-z\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1038/s41422-020-0356-z.</a></span>\r\n\r\n</div>','','','inherit','closed','closed','','6560-revision-v1','','','2020-07-12 13:30:15','2020-07-12 13:30:15','',6560,'https://microbiozindia.com/uncategorized/6560-revision-v1/',0,'revision','',0),(6562,2,'2020-07-12 13:30:44','2020-07-12 13:30:44','Whilst the death toll from the COVID-19 pandemic mounts, the boffins worldwide carry on their push to create effective treatments and a vaccine to its highly infectious respiratory tract.\r\n\r\nThe inhibitors demonstrate potent structural and chemical connections with an viral critical to this herpes virus\'s capacity to proliferate.\r\n\r\nThe very promising drug candidates - like the FDA-approved Hepatitis-C drugs boceprevir and also an investigational veterinary antifungal medication called GC-376 - target that the SARS-CoV-2 main protease (Mpro), a molecule which cuts proteins out form a very long strand which the herpes virus produces as it invades an individual cell.\r\n\r\n<em>A lot of good drug candidates are already out there as a starting point. But, with new information from studies like ours and current technology, we can help design even better (repurposed) drugs much faster.\"-Yu Chen, PhD, Study Co-Author and Associate Professor, Department of Molecular Medicine, University of South Florida Health</em>\r\n\r\nThis receptor had been confirmed as an antiviral drug target for its initial SARS and MERS, both genetically much like SARS-CoV-2.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.nature.com/articles/s41422-020-0356-z\">\"Having a fast emerging infectious illness such as COVID-19, we do not have enough time to create new antiviral medication from scratch,\" explained Yu Chen, Ph.D., USF Health associate professor of molecular medicine and also a co author of this Cell Research newspaper.</a></span>\r\n\r\nAhead of the outbreak, Dr. Chen implemented his expertise from structure-based medication design to help grow inhibitors (medication compounds) which aim bacterial enzymes inducing immunity to certain widely prescribed antibiotics like penicillin.\r\n\r\nHis lab focuses its complex methods, for example xray crystallography and molecular docking, on searching for strategies to halt SARS-CoV-2.\r\n\r\nSince people don\'t need the receptor, drugs targeting this protein tend to be not as prone to induce negative effects, \'\' he clarified.\r\n\r\nThese inhibitors climbed into the very best following viewing over 50 present protease chemicals for possible Re-purposing:\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.nature.com/articles/s41422-020-0356-z\">Its dose that is effective, safety profile, formula, and also the way your human body processes the medication (pharmacokinetics) already are known, which could greatly accelerate the actions required to find boceprevir to clinical trials for COVID-19, Dr. Chen said.</a> </span>This broker was the very powerful inhibitor of this Mpro receptor in Laboratory evaluations, Dr. Chen said, however before human trials may begin it could want to be analyzed in animal models of SARS-CoV-2. Dr. Chen and his doctoral student Michael Sacco ascertained the xray crystal arrangement of GC-376 jumped by Mpro, also characterized molecular connections between your chemical and viral receptor utilizing 3D computer modeling.\r\nAll compounds were more advanced than additional Mpro inhibitors previously defined as convenient to evaluate for curing SARS-CoV-2, Dr. Chen said.\r\n\r\nA promising drug candidate one which interrupts or kills herpes without destroying healthy cells fits snugly, in the exceptional shape of their viral receptor\'s\"pocket\" GC-376 worked especially well at adapting to (complementing) the model of targeted Mpro receptor binding websites, Dr. Chen said.\r\n\r\nEmploying a lock (binding pocket, or receptor) and vital (medication ) analogy,\"GC-376 was far the secret with the most useful, or tightestmatch, healthy,\" he further added. \"Our modeling demonstrates the way the inhibitor may mimic the authentic peptide substrate once it binds to the active site onto the top layer of the SARS-CoV-2 main protease.\"\r\n\r\nRather than boosting the experience of the viral receptor, such as the bacterium generally does, that the inhibitor somewhat reduces the action of this enzyme which helps SARS-CoV-2 create copies of it self.\r\n\r\nVisualizing 3 d interactions involving the antibacterial substances and also the viral protein supplies a better knowledge of the way a Mpro complex works and also, at the longterm, may result in the style of fresh COVID-19 drugs, Dr. Chen said.\r\n\r\nMeanwhile, he added, researchers concentrate on getting targeted antifungal treatments into the front lines quicker by tweaking existing coronavirus medication candidates to enhance their stability and operation.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://hscweb3.hsc.usf.edu/blog/2020/07/06/compounds-halt-sars-cov-2-replication-by-targeting-key-viral-enzyme\" target=\"_blank\" rel=\"noopener noreferrer\">University of South Florida (USF Health)</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nMa, C., <em>et al</em>. (2020) Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. <em>Cell Research</em>.<span style=\"color: #ff6600;\"> <a style=\"color: #ff6600;\" href=\"https://doi.org/10.1038/s41422-020-0356-z\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1038/s41422-020-0356-z.</a></span>\r\n\r\n</div>','Researchers distinguish aggravates that square replication of COVID-19 infection','','inherit','closed','closed','','6560-revision-v1','','','2020-07-12 13:30:44','2020-07-12 13:30:44','',6560,'https://microbiozindia.com/uncategorized/6560-revision-v1/',0,'revision','',0),(6563,2,'2020-07-12 13:35:05','2020-07-12 13:35:05','Researchers have revealed a fatty acid named dihomogamma-linolenic acid, or DGLA, may kill individual cells.\r\n\r\nThe analysis, published in Developmental Cell on July 10, unearthed that DGLA can cause ferroptosis within an animal model as well as at actual individual cancer cells. Ferroptosis is a iron-dependent kind of cell death which has been discovered lately and is now a focus for illness research since it\'s closely linked to many disease processes.\r\n\r\nDGLA can be just a polyunsaturated fatty acid present in tiny quantities from the body, though infrequently in the diet.\r\n\r\nWatts was researching fat molecules for example DGLA for almost 20 decades, with all the nematode Caenorhabditis elegans as an animal version. A worm, C. elegans is most usually utilized in molecular research since it\'s transparent and allows scientists to readily study cell-level task in a complete monster within its relatively short life span. Results found from the C. elegans cells are additionally often localized to individual cells.\r\n\r\n<em>If you could deliver DGLA precisely to a cancer cell, it could promote ferroptosis and lead to tumor cell death. Also, just knowing that this fat promotes ferroptosis might also affect how we think about conditions such as kidney disease and neurodegeneration where we want to prevent this type of cell death.\"-Jennifer Watts, Associate Professor, Washington State University</em>\r\n\r\nWatts\' research team discovered that ingesting nematodes a daily diet of DGLA-laden bacteria murdered all of the cells from the rats in addition to the stem cells which produce cells. The manner by which the cells expired transported lots of indications of ferroptosis.\r\n\"A lot of these mechanics we saw from the nematodes had been in keeping with all the hallmarks of both ferroptosis in mammalian procedures, for example, existence of redox-active iron and also the inability to mend oxidized lipids, which can be similar to molecular executioners,\" explained Marcos Perez, also a WSU doctoral student and first author on the paper.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://linkinghub.elsevier.com/retrieve/pii/S1534580720304986\">To see whether the outcome would interpret to individual cells,\'\' Watts and Perez collaborated with Scott Dixon of Stanford University, that has been analyzing ferroptosis and its own possibility of combating cancer for many decades.</a></span>\r\n\r\nConsidering that which they\'d heard from the nematode job, the researchers revealed that DGLA could cause ferroptosis in human cancer cells. In addition they uncovered an interaction with yet another fatty-acid category, also called an ether lipid, which had a protective effect against DGLA. Once they shot the ether lipidsthe cells expired faster while in the existence of DGLA.\r\n\r\nBesides the fresh expertise, the analysis also revealed that C. elegans might be practical animal research version within the analysis of ferroptosis, an area that\'s had to rely chiefly on cell cultures.\r\n\r\nTo do this research further, Watts\' team recently got a $1.4 million award by the National Institutes of Health to explore exactly what generates the nematode germ cells susceptible to DGLA and learn more about the use of mitochondria, the cell organelles involved with burning regulating and fat metabolism, even in ferroptosis.\r\n\r\n<strong>Source:</strong>\r\nWashington State University\r\n\r\n<strong>Journal reference:</strong>\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://linkinghub.elsevier.com/retrieve/pii/S1534580720304986\">Perez, M.A., et al. (2020) Dietary Lipids Induce Ferroptosis in Caenorhabditis elegans and Human Cancer Cells. Developmental Cell. doi.org/10.1016/j.devcel.2020.06.019.</a></span>','Unsaturated fat can execute human malignant growth cells, study appears','','publish','open','open','','unsaturated-fat-can-execute-human-malignant-growth-cells-study-appears','','','2020-07-12 13:35:05','2020-07-12 13:35:05','',0,'https://microbiozindia.com/?p=6563',0,'post','',0),(6564,2,'2020-07-12 13:35:05','2020-07-12 13:35:05','Researchers have revealed a fatty acid named dihomogamma-linolenic acid, or DGLA, may kill individual cells.\r\n\r\nThe analysis, published in Developmental Cell on July 10, unearthed that DGLA can cause ferroptosis within an animal model as well as at actual individual cancer cells. Ferroptosis is a iron-dependent kind of cell death which has been discovered lately and is now a focus for illness research since it\'s closely linked to many disease processes.\r\n\r\nDGLA can be just a polyunsaturated fatty acid present in tiny quantities from the body, though infrequently in the diet.\r\n\r\nWatts was researching fat molecules for example DGLA for almost 20 decades, with all the nematode Caenorhabditis elegans as an animal version. A worm, C. elegans is most usually utilized in molecular research since it\'s transparent and allows scientists to readily study cell-level task in a complete monster within its relatively short life span. Results found from the C. elegans cells are additionally often localized to individual cells.\r\n\r\n<em>If you could deliver DGLA precisely to a cancer cell, it could promote ferroptosis and lead to tumor cell death. Also, just knowing that this fat promotes ferroptosis might also affect how we think about conditions such as kidney disease and neurodegeneration where we want to prevent this type of cell death.\"-Jennifer Watts, Associate Professor, Washington State University</em>\r\n\r\nWatts\' research team discovered that ingesting nematodes a daily diet of DGLA-laden bacteria murdered all of the cells from the rats in addition to the stem cells which produce cells. The manner by which the cells expired transported lots of indications of ferroptosis.\r\n\"A lot of these mechanics we saw from the nematodes had been in keeping with all the hallmarks of both ferroptosis in mammalian procedures, for example, existence of redox-active iron and also the inability to mend oxidized lipids, which can be similar to molecular executioners,\" explained Marcos Perez, also a WSU doctoral student and first author on the paper.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://linkinghub.elsevier.com/retrieve/pii/S1534580720304986\">To see whether the outcome would interpret to individual cells,\'\' Watts and Perez collaborated with Scott Dixon of Stanford University, that has been analyzing ferroptosis and its own possibility of combating cancer for many decades.</a></span>\r\n\r\nConsidering that which they\'d heard from the nematode job, the researchers revealed that DGLA could cause ferroptosis in human cancer cells. In addition they uncovered an interaction with yet another fatty-acid category, also called an ether lipid, which had a protective effect against DGLA. Once they shot the ether lipidsthe cells expired faster while in the existence of DGLA.\r\n\r\nBesides the fresh expertise, the analysis also revealed that C. elegans might be practical animal research version within the analysis of ferroptosis, an area that\'s had to rely chiefly on cell cultures.\r\n\r\nTo do this research further, Watts\' team recently got a $1.4 million award by the National Institutes of Health to explore exactly what generates the nematode germ cells susceptible to DGLA and learn more about the use of mitochondria, the cell organelles involved with burning regulating and fat metabolism, even in ferroptosis.\r\n\r\n<strong>Source:</strong>\r\nWashington State University\r\n\r\n<strong>Journal reference:</strong>\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://linkinghub.elsevier.com/retrieve/pii/S1534580720304986\">Perez, M.A., et al. (2020) Dietary Lipids Induce Ferroptosis in Caenorhabditis elegans and Human Cancer Cells. Developmental Cell. doi.org/10.1016/j.devcel.2020.06.019.</a></span>','Unsaturated fat can execute human malignant growth cells, study appears','','inherit','closed','closed','','6563-revision-v1','','','2020-07-12 13:35:05','2020-07-12 13:35:05','',6563,'https://microbiozindia.com/uncategorized/6563-revision-v1/',0,'revision','',0),(6565,2,'2020-07-12 13:37:46','2020-07-12 13:37:46','Mesenchymal stem cells (MSCs) have the potential to differentiate into a range of different cell types, including bone, fat, and muscle cells. But it\'s their ability to stimulate the repair of damaged tissue that has captured the interest of researchers worldwide, with MSCs demonstrating therapeutic effects in the treatment of conditions such as heart disease, liver cirrhosis, and diabetes.\r\n\r\nHowever, despite the success of several clinical trials, researchers have struggled to explain the sometimes variable results of MSC therapy.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://linkinghub.elsevier.com/retrieve/pii/S1525001620303166\">In a recent study published in Molecular Therapy, a research team led by Osaka University investigated possible reasons for the inconsistent outcomes of MSC therapy, showing that host factors and not just the MSCs themselves may be to blame.</a></span>\r\n\r\nAdiponectin is found in high concentrations in blood and has been shown to stimulate the production of exosomes, small membrane-bound vesicles that carry proteins, lipids, and DNA between cells. Interestingly, exosomes secreted by stem cells carry signals that stimulate the repair of recipient cells.\r\n\r\n<em>We recently reported that adiponectin, a beneficial hormone secreted by fat cells that plays a role in muscle regeneration, binds to receptor protein T-cadherin on cell surfaces. Given that T-cadherin is abundant on the surfaces of MSCs, we investigated whether adiponectin is involved in the regenerative activity of MSCs in a model of heart failure.\"-Yuto Nakamura, Lead Author</em>\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://linkinghub.elsevier.com/retrieve/pii/S1525001620303166\">By first measuring exosome production in a cell culture-based system, the researchers confirmed that increasing amounts of adiponectin led to a corresponding increase in the abundance of MSC-derived exosomes, which was reliant on the expression of T-cadherin.</a></span>\r\n\r\nInjection of the MSCs into mice suffering from heart failure resulted in a significant improvement in left ventricular cardiac function, which was associated with the increased number of exosomes in circulation. Most importantly though, cardiac function following MSC therapy could be further strengthened by the increases of adiponectin level in blood.\r\n\r\n\"Together, our assays showed that MSCs exert their therapeutic effects on cardiac function through the production of exosomes, which is influenced by host plasma adiponectin levels and is reliant on MSC T-cadherin expression,\" says study corresponding author Shunbun Kita.\r\n\r\n\"Given these results, drugs such as a PPARγ agonists, which increase adiponectin production, could be administered in combination with MSC therapy to significantly enhance the therapeutic potential--not only for severe heart failure, but also for a variety of diseases involving tissue damage, including COVID-19-associated acute respiratory distress syndrome.\"\r\n\r\nAnd in case you were wondering, it turns out that too much fat is actually detrimental to adiponectin production, so doctors won\'t be prescribing a high fat diet any time soon!\r\n\r\n<strong>Source:</strong>\r\nOsaka University\r\n\r\n<strong>Journal reference:</strong>\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://linkinghub.elsevier.com/retrieve/pii/S1525001620303166\">Nakamura, Y., et al. (2020) Adiponectin Stimulates Exosome Release to Enhance Mesenchymal Stem-Cell-Driven Therapy of Heart Failure in Mice. Molecular Therapy. doi.org/10.1016/j.ymthe.2020.06.026.</a></span>','Fat cell hormone upgrades helpful capability of MSC treatment','','publish','open','open','','fat-cell-hormone-upgrades-helpful-capability-of-msc-treatment','','','2020-07-12 13:37:46','2020-07-12 13:37:46','',0,'https://microbiozindia.com/?p=6565',0,'post','',0),(6566,2,'2020-07-12 13:37:46','2020-07-12 13:37:46','Mesenchymal stem cells (MSCs) have the potential to differentiate into a range of different cell types, including bone, fat, and muscle cells. But it\'s their ability to stimulate the repair of damaged tissue that has captured the interest of researchers worldwide, with MSCs demonstrating therapeutic effects in the treatment of conditions such as heart disease, liver cirrhosis, and diabetes.\r\n\r\nHowever, despite the success of several clinical trials, researchers have struggled to explain the sometimes variable results of MSC therapy.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://linkinghub.elsevier.com/retrieve/pii/S1525001620303166\">In a recent study published in Molecular Therapy, a research team led by Osaka University investigated possible reasons for the inconsistent outcomes of MSC therapy, showing that host factors and not just the MSCs themselves may be to blame.</a></span>\r\n\r\nAdiponectin is found in high concentrations in blood and has been shown to stimulate the production of exosomes, small membrane-bound vesicles that carry proteins, lipids, and DNA between cells. Interestingly, exosomes secreted by stem cells carry signals that stimulate the repair of recipient cells.\r\n\r\n<em>We recently reported that adiponectin, a beneficial hormone secreted by fat cells that plays a role in muscle regeneration, binds to receptor protein T-cadherin on cell surfaces. Given that T-cadherin is abundant on the surfaces of MSCs, we investigated whether adiponectin is involved in the regenerative activity of MSCs in a model of heart failure.\"-Yuto Nakamura, Lead Author</em>\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://linkinghub.elsevier.com/retrieve/pii/S1525001620303166\">By first measuring exosome production in a cell culture-based system, the researchers confirmed that increasing amounts of adiponectin led to a corresponding increase in the abundance of MSC-derived exosomes, which was reliant on the expression of T-cadherin.</a></span>\r\n\r\nInjection of the MSCs into mice suffering from heart failure resulted in a significant improvement in left ventricular cardiac function, which was associated with the increased number of exosomes in circulation. Most importantly though, cardiac function following MSC therapy could be further strengthened by the increases of adiponectin level in blood.\r\n\r\n\"Together, our assays showed that MSCs exert their therapeutic effects on cardiac function through the production of exosomes, which is influenced by host plasma adiponectin levels and is reliant on MSC T-cadherin expression,\" says study corresponding author Shunbun Kita.\r\n\r\n\"Given these results, drugs such as a PPARγ agonists, which increase adiponectin production, could be administered in combination with MSC therapy to significantly enhance the therapeutic potential--not only for severe heart failure, but also for a variety of diseases involving tissue damage, including COVID-19-associated acute respiratory distress syndrome.\"\r\n\r\nAnd in case you were wondering, it turns out that too much fat is actually detrimental to adiponectin production, so doctors won\'t be prescribing a high fat diet any time soon!\r\n\r\n<strong>Source:</strong>\r\nOsaka University\r\n\r\n<strong>Journal reference:</strong>\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://linkinghub.elsevier.com/retrieve/pii/S1525001620303166\">Nakamura, Y., et al. (2020) Adiponectin Stimulates Exosome Release to Enhance Mesenchymal Stem-Cell-Driven Therapy of Heart Failure in Mice. Molecular Therapy. doi.org/10.1016/j.ymthe.2020.06.026.</a></span>','Fat cell hormone upgrades helpful capability of MSC treatment','','inherit','closed','closed','','6565-revision-v1','','','2020-07-12 13:37:46','2020-07-12 13:37:46','',6565,'https://microbiozindia.com/uncategorized/6565-revision-v1/',0,'revision','',0),(6568,2,'2020-07-12 17:19:12','2020-07-12 17:19:12','Sechenov University researchers have successfully completed clinical trials from the world\'s very first COVID-19 vaccine on volunteers, chief researcher Elena Smolyarchuk told a Russian news socket Sunday, July 12.\r\n\r\nThe Russian mission to India, at a tweet, quoted Smolyarchuk saying\'the vaccine is\' safe\'. Alexander Lukashev, Director of the Institute of Medical Parasitology Tropical and Vector-Borne disorders at Sechenov University, also vouched for the safety of the drug when speaking to local media.\r\n<iframe src=\"https://www.youtube.com/embed/bgSsUAorgA4\" width=\"560\" height=\"315\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"></iframe>\r\nAs per accounts, the first group of volunteers would be discharged July 15 and the 2nd batch would be discharged July 20. Moreover, the volunteers will stay under medical oversight in an outpatient basis after getting discharged.\r\n\r\nSechenov University has been reported to have started with the very first period of research on June 18 having a group of 18 volunteers. The 2nd group of 20 volunteers had been tested for the COVID-19 vaccine on June 2-3.','Russian experts Successfully Complete World\'s First COVID-19 Vaccine trial','','publish','open','open','','russian-experts-successfully-complete-worlds-first-covid-19-vaccine-trial','','','2020-07-12 17:55:25','2020-07-12 17:55:25','',0,'https://microbiozindia.com/?p=6568',0,'post','',0),(6569,2,'2020-07-12 17:19:12','2020-07-12 17:19:12','Sechenov University researchers have successfully completed clinical trials from the world\'s very first COVID-19 vaccine on volunteers, chief researcher Elena Smolyarchuk told a Russian news socket Sunday, July 12.\r\n\r\nThe Russian mission to India, at a tweet, quoted Smolyarchuk saying\'the vaccine is\' safe\'. Alexander Lukashev, Director of the Institute of Medical Parasitology Tropical and Vector-Borne disorders at Sechenov University, also vouched for the safety of the drug when speaking to local media.\r\n\r\nAs per accounts, the first group of volunteers would be discharged July 15 and the 2nd batch would be discharged July 20. Moreover, the volunteers will stay under medical oversight in an outpatient basis after getting discharged.\r\n\r\nSechenov University has been reported to have started with the very first period of research on June 18 having a group of 18 volunteers. The 2nd group of 20 volunteers had been tested for the COVID-19 vaccine on June 2-3.','Russian experts Successfully Complete World\'s First COVID-19 Vaccine trial','','inherit','closed','closed','','6568-revision-v1','','','2020-07-12 17:19:12','2020-07-12 17:19:12','',6568,'https://microbiozindia.com/uncategorized/6568-revision-v1/',0,'revision','',0),(6570,2,'2020-07-12 17:55:22','2020-07-12 17:55:22','Sechenov University researchers have successfully completed clinical trials from the world\'s very first COVID-19 vaccine on volunteers, chief researcher Elena Smolyarchuk told a Russian news socket Sunday, July 12.\n\nThe Russian mission to India, at a tweet, quoted Smolyarchuk saying\'the vaccine is\' safe\'. Alexander Lukashev, Director of the Institute of Medical Parasitology Tropical and Vector-Borne disorders at Sechenov University, also vouched for the safety of the drug when speaking to local media.\n<iframe src=\"https://www.youtube.com/embed/bgSsUAorgA4\" width=\"560\" height=\"315\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"></iframe>\nAs per accounts, the first group of volunteers would be discharged July 15 and the 2nd batch would be discharged July 20. Moreover, the volunteers will stay under medical oversight in an outpatient basis after getting discharged.\n\nSechenov University has been reported to have started with the very first period of research on June 18 having a group of 18 volunteers. The 2nd group of 20 volunteers had been tested for the COVID-19 vaccine on June 2-3.','Russian experts Successfully Complete World\'s First COVID-19 Vaccine trial','','inherit','closed','closed','','6568-autosave-v1','','','2020-07-12 17:55:22','2020-07-12 17:55:22','',6568,'https://microbiozindia.com/uncategorized/6568-autosave-v1/',0,'revision','',0),(6571,2,'2020-07-12 17:55:25','2020-07-12 17:55:25','Sechenov University researchers have successfully completed clinical trials from the world\'s very first COVID-19 vaccine on volunteers, chief researcher Elena Smolyarchuk told a Russian news socket Sunday, July 12.\r\n\r\nThe Russian mission to India, at a tweet, quoted Smolyarchuk saying\'the vaccine is\' safe\'. Alexander Lukashev, Director of the Institute of Medical Parasitology Tropical and Vector-Borne disorders at Sechenov University, also vouched for the safety of the drug when speaking to local media.\r\n<iframe src=\"https://www.youtube.com/embed/bgSsUAorgA4\" width=\"560\" height=\"315\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"></iframe>\r\nAs per accounts, the first group of volunteers would be discharged July 15 and the 2nd batch would be discharged July 20. Moreover, the volunteers will stay under medical oversight in an outpatient basis after getting discharged.\r\n\r\nSechenov University has been reported to have started with the very first period of research on June 18 having a group of 18 volunteers. The 2nd group of 20 volunteers had been tested for the COVID-19 vaccine on June 2-3.','Russian experts Successfully Complete World\'s First COVID-19 Vaccine trial','','inherit','closed','closed','','6568-revision-v1','','','2020-07-12 17:55:25','2020-07-12 17:55:25','',6568,'https://microbiozindia.com/uncategorized/6568-revision-v1/',0,'revision','',0),(6572,2,'2020-07-13 09:34:49','2020-07-13 09:34:49','Researchers at IIT-Istituto Italiano di Tecnologia (Italian Institute of Technology) discovered a novel compound compound, that has got the capacity to became a new medication for the treatment of heart symptoms of brain ailments such as Down syndrome and pneumonia.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://dx.doi.org/10.1016/j.chempr.2020.06.017\">These results are available in preclinical models where the new chemical ameliorated difficulties in cognitive activities, as well as societal interactions and repetitive behaviours, which are present in neurodevelopmental and neurological disorders.</a></span> Researchers currently aim to develop a dedicated startup company with assistance from interested investors in order to further develop this compound and make it remedy for patients. The research was published in the scientific journal Chem: <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.cell.com/chem/fulltext/S2451-9294(20)30298-9\">https://www.cell.com/chem/fulltext/S2451-9294(20)30298-9</a></span>\r\n\r\nThese breakthrough findings are caused by a joint effort of 2 Italian research teams directed by Laura Cancedda and Marco De Vivo, at the Istituto Italiano di Tecnologia at Genova (Italy). Laura Cancedda is head of the IIT\'s Brain Development and Disease Laboratory as Well as an assistant scientist at the Dulbecco Telethon Institute.\r\n\r\n<em>This study and exciting results come at a time where neuroscience drug discovery in industry struggles to deliver novel breakthrough classes of effective molecules. As a matter of fact, therapeutic options for most of neurodevelopmental disorders have remained scant, or not highly effective over the last decades. This is mainly due to a poor understanding of the mechanisms underlying these challenging pathological conditions. This discovery follows several years of work on NKCC1 function and inhibition at IIT and will possibly bring us closer to the development of sustainable therapeutics for the treatment of a number of brain disorders\"-</em>Laura Cancedda, Head of IIT\'s Brain Development and Disease Laboratory\r\n\r\nThe two classes done complementary aspects of the research study: the De Vivo\'s group designed the new molecules with the aid of computational procedures, and synthetize them where as the Cancedda\'s laboratory centered on extensive biological evaluations of such compounds. The final outcome reflects the development of a promising chemical compound, that is typically referred in pharmaceutical industry called\'drug candidate\' due to its potential to be clinical drug from the coming years.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://dx.doi.org/10.1016/j.chempr.2020.06.017\">Co-first authors of the research article are Annalisa Savardi (Cancedda\'s Laboratory ) and Marco Borgogno (De Vivo\'s laboratory ) who worked synergistically to spot the novel compounds and investigate their biological consequences in mental performance of preclinical models of neurodevelopmental disorders.</a></span> These models will be the very first experimental steps to validate the advantages and safety of their newest medication.\r\n\r\nParticularly, researchers dedicated to the effect of the molecules onto the protein NKCC1, a very promising target for drugs to treat brain disorders. NKCC1 is actually a transporter of chorine (and other) ions from the mind, and also the correct concentration of such ions is also crucial for brain functioning. In a number of brain ailments such as Down syndrome, autism and epilepsy, the concentration of such growths in the mind is dysregulated as a result of NKCC1 abnormal function. These newly discovered compounds can potently and selectively block NKCC1, without undesired side effects (excess diuresis) due to fact by other existing drugs that are non-selective NKCC1 inhibitors.\r\n\"Now, our most promising compound could come right into clinical evaluations at hospitals in less than two years from now. This extra step toward making of this chemical an approved medication, nevertheless, requires further work and more funds. Because of this , we plan to establish a fresh start up company focused on this project. It would be wonderful to see our discovery affecting those in demands\" - adds Marco De Vivo.\r\nThe newly discovered and promising drug candidate is presently undergoing advanced preclinical studies to move forward and reach soon clinical studies. More studies will enable specifying the general security profile of the molecule and other important parameters, like pharmacokinetics, formulation and dosing, essential to fulfill the regulatory requirements to access clinical studies.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.iit.it/\" target=\"_blank\" rel=\"noopener noreferrer\">IIT-Istituto Italiano di Tecnologia (Italian Institute of Technology)</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nSavardi, A., <em>et al.</em> (2020) Discovery of a Small Molecule Drug Candidate for Selective NKCC1 Inhibition in Brain Disorders. <em>Chem<span style=\"color: #ff6600;\">.</span></em><span style=\"color: #ff6600;\"> <a style=\"color: #ff6600;\" href=\"http://dx.doi.org/10.1016/j.chempr.2020.06.017\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1016/j.chempr.2020.06.017</a>.</span>\r\n\r\n</div>','Newfound substance compound demonstrates potential to become treatment for mind issues','','publish','open','open','','newfound-substance-compound-demonstrates-potential-to-become-treatment-for-mind-issues','','','2020-07-13 09:34:49','2020-07-13 09:34:49','',0,'https://microbiozindia.com/?p=6572',0,'post','',0),(6573,2,'2020-07-13 09:33:18','2020-07-13 09:33:18','','brain-2062057_640','','inherit','open','closed','','brain-2062057_640','','','2020-07-13 09:33:18','2020-07-13 09:33:18','',6572,'https://microbiozindia.com/wp-content/uploads/2020/07/brain-2062057_640.jpg',0,'attachment','image/jpeg',0),(6574,2,'2020-07-13 09:34:49','2020-07-13 09:34:49','Researchers at IIT-Istituto Italiano di Tecnologia (Italian Institute of Technology) discovered a novel compound compound, that has got the capacity to became a new medication for the treatment of heart symptoms of brain ailments such as Down syndrome and pneumonia.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://dx.doi.org/10.1016/j.chempr.2020.06.017\">These results are available in preclinical models where the new chemical ameliorated difficulties in cognitive activities, as well as societal interactions and repetitive behaviours, which are present in neurodevelopmental and neurological disorders.</a></span> Researchers currently aim to develop a dedicated startup company with assistance from interested investors in order to further develop this compound and make it remedy for patients. The research was published in the scientific journal Chem: <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.cell.com/chem/fulltext/S2451-9294(20)30298-9\">https://www.cell.com/chem/fulltext/S2451-9294(20)30298-9</a></span>\r\n\r\nThese breakthrough findings are caused by a joint effort of 2 Italian research teams directed by Laura Cancedda and Marco De Vivo, at the Istituto Italiano di Tecnologia at Genova (Italy). Laura Cancedda is head of the IIT\'s Brain Development and Disease Laboratory as Well as an assistant scientist at the Dulbecco Telethon Institute.\r\n\r\n<em>This study and exciting results come at a time where neuroscience drug discovery in industry struggles to deliver novel breakthrough classes of effective molecules. As a matter of fact, therapeutic options for most of neurodevelopmental disorders have remained scant, or not highly effective over the last decades. This is mainly due to a poor understanding of the mechanisms underlying these challenging pathological conditions. This discovery follows several years of work on NKCC1 function and inhibition at IIT and will possibly bring us closer to the development of sustainable therapeutics for the treatment of a number of brain disorders\"-</em>Laura Cancedda, Head of IIT\'s Brain Development and Disease Laboratory\r\n\r\nThe two classes done complementary aspects of the research study: the De Vivo\'s group designed the new molecules with the aid of computational procedures, and synthetize them where as the Cancedda\'s laboratory centered on extensive biological evaluations of such compounds. The final outcome reflects the development of a promising chemical compound, that is typically referred in pharmaceutical industry called\'drug candidate\' due to its potential to be clinical drug from the coming years.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://dx.doi.org/10.1016/j.chempr.2020.06.017\">Co-first authors of the research article are Annalisa Savardi (Cancedda\'s Laboratory ) and Marco Borgogno (De Vivo\'s laboratory ) who worked synergistically to spot the novel compounds and investigate their biological consequences in mental performance of preclinical models of neurodevelopmental disorders.</a></span> These models will be the very first experimental steps to validate the advantages and safety of their newest medication.\r\n\r\nParticularly, researchers dedicated to the effect of the molecules onto the protein NKCC1, a very promising target for drugs to treat brain disorders. NKCC1 is actually a transporter of chorine (and other) ions from the mind, and also the correct concentration of such ions is also crucial for brain functioning. In a number of brain ailments such as Down syndrome, autism and epilepsy, the concentration of such growths in the mind is dysregulated as a result of NKCC1 abnormal function. These newly discovered compounds can potently and selectively block NKCC1, without undesired side effects (excess diuresis) due to fact by other existing drugs that are non-selective NKCC1 inhibitors.\r\n\"Now, our most promising compound could come right into clinical evaluations at hospitals in less than two years from now. This extra step toward making of this chemical an approved medication, nevertheless, requires further work and more funds. Because of this , we plan to establish a fresh start up company focused on this project. It would be wonderful to see our discovery affecting those in demands\" - adds Marco De Vivo.\r\nThe newly discovered and promising drug candidate is presently undergoing advanced preclinical studies to move forward and reach soon clinical studies. More studies will enable specifying the general security profile of the molecule and other important parameters, like pharmacokinetics, formulation and dosing, essential to fulfill the regulatory requirements to access clinical studies.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.iit.it/\" target=\"_blank\" rel=\"noopener noreferrer\">IIT-Istituto Italiano di Tecnologia (Italian Institute of Technology)</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nSavardi, A., <em>et al.</em> (2020) Discovery of a Small Molecule Drug Candidate for Selective NKCC1 Inhibition in Brain Disorders. <em>Chem<span style=\"color: #ff6600;\">.</span></em><span style=\"color: #ff6600;\"> <a style=\"color: #ff6600;\" href=\"http://dx.doi.org/10.1016/j.chempr.2020.06.017\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1016/j.chempr.2020.06.017</a>.</span>\r\n\r\n</div>','Newfound substance compound demonstrates potential to become treatment for mind issues','','inherit','closed','closed','','6572-revision-v1','','','2020-07-13 09:34:49','2020-07-13 09:34:49','',6572,'https://microbiozindia.com/uncategorized/6572-revision-v1/',0,'revision','',0),(6575,2,'2020-07-13 16:27:36','2020-07-13 16:27:36','The existing SARS-CoV-2 outbreak has a probable link with rodents, and also the upcoming viral outbreak will probably too, unless scientists could certainly find out more about the countless viruses transported by a few of their very diverse mammals on Earth.\r\n\r\nBeyond those links, there\'s very little understood, and also a recent article from Nature Reviews Microbiology involves more research to nerves\' molecular research along with their ecologyto help predict, and ultimately prevent, the following outbreak.\r\n\r\n\"Through the years, we\'ve accumulated a great deal of advice regarding a number of the species of rodents and a few of the viruses that they take, however there continue to be those massive glaring holes in our comprehension \"\r\n\r\nWith over 1,400 species, athletes represent a very varied hierarchical arrangement, next only to rodents, which can be known hosts that are viral. But, unlike mice and rats, bats aren\'t fantastic lab creatures. Simply keeping flying critters in labs is not difficult. Additionally, the majority of the mammalian cell lines developed for research originated out of different creatures and can\'t be employed to study viruses located in rodents.\r\n\r\nThis knowledge gap is equally dangerous whilst the existing outbreak shows. Bats are located nearly everywhere scientists have emerged, as well as enlarging human encroachment on their lands, viral illness is all but inevitable,\'\' Letko explained.\r\n\r\n\"We\'re getting to contact animal species in general, after which we find these species are filled with germs,\" he explained. \"The COVID-19 pandemic is regrettable, however it is maybe not surprising. We roll up the dice for twenty decades maybe not doing such a thing to decrease touch with those creatures. It had been less an issue of time before something like that will occur\"\r\n\r\nFrom the newspaper, Letko, along with also his co authors including WSU assistant professor Stephanie Seifert and also Vincent Munster in Rocky Mountain Laboratories, summarize approaches to lower the likelihood of this upcoming outbreak by increasing research to bats around the lowest, molecular degree and also on the wider macro-level of their environment.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://news.wsu.edu/2020/07/13/bat-research-critical-preventing-next-pandemic/\">When many pathogens are identified, the writers mention the requirement to proceed beyond detection and apply the most recent genetic technologies to understand the viruses might be transmitted. This knowledge may raise the capability to come up with drugs quickly following a pathogen was found -- and sometimes better still, make vaccines to protect against whole virus collections until they emerge.</a></span>\r\n\r\nBefore the present crisis, he assembled a stage utilizing synthetic coronavirus contaminants to examine that were likely to infect cells. After the existing outbreak began, Letko analyzed the SARS-Cov-2 genome the moment the arrangement was available and immediately identified the probable receptor on individual cells. That analysis, published in Nature Micro Biology on Feb. 2-4, was among those very first ever to supply operational lab data on the virus, supplying scientists with vital details and tools to help determine which existing medication may possibly work contrary to SARS-Cov-2 and start developing on fresh ones in addition to test various facets of SARS-CoV-2 vaccine efficiency.\r\n\r\nLetko is putting his laboratory at WSU to keep on that job, providing initial screening of bat-borne viruses that will help identify the ones which are likely to be sent to humans.\r\n\r\nBeyond the laboratory, Letko along with his colleagues indicate the demand for much better comprehension of bat ecology that could cause solutions which are comparatively straightforward to execute. The investigators state cases like the attempt to segregate horses from Australia to block the Hendra virus that has been dispersing from fresh fruit bats to horses after which potentially onto humans. Still another intervention in Bangladesh involved only placing arrows on hand sap containers to help keep out bats and avoid human outbreaks of Nipah virus.\r\n\r\n\"Occasionally, that you never desire drugs or vaccines. It\'s only a behavioral modification which helps mitigate and lessen the connection between the critters,\" Letko explained. \"All these are a few of the forms of interventions which we are able to take as we begin to determine these viruses really do.\"\r\n\r\n<strong>Story Source:</strong>\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://news.wsu.edu/2020/07/13/bat-research-critical-preventing-next-pandemic/\">Materials</a> </span>provided by Washington State University. Original written by Sara Zaske and Content may be edited for style and length.\r\n\r\n<strong>Journal Reference:</strong>\r\n\r\nMichael Letko, Stephanie N. Seifert, Kevin J. Olival, Raina K. Plowright, Vincent J. Munster. Bat-borne virus diversity, spillover and emergence. Nature Reviews Microbiology, 2020; 18 (8):<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://news.wsu.edu/2020/07/13/bat-research-critical-preventing-next-pandemic/\"> 461 DOI: 10.1038/s41579-020-0394-z</a></span>','Bat research basic to forestalling next pandemic','','publish','open','open','','bat-research-basic-to-forestalling-next-pandemic','','','2020-07-13 16:27:36','2020-07-13 16:27:36','',0,'https://microbiozindia.com/?p=6575',0,'post','',0),(6576,2,'2020-07-13 16:27:36','2020-07-13 16:27:36','The existing SARS-CoV-2 outbreak has a probable link with rodents, and also the upcoming viral outbreak will probably too, unless scientists could certainly find out more about the countless viruses transported by a few of their very diverse mammals on Earth.\r\n\r\nBeyond those links, there\'s very little understood, and also a recent article from Nature Reviews Microbiology involves more research to nerves\' molecular research along with their ecologyto help predict, and ultimately prevent, the following outbreak.\r\n\r\n\"Through the years, we\'ve accumulated a great deal of advice regarding a number of the species of rodents and a few of the viruses that they take, however there continue to be those massive glaring holes in our comprehension \"\r\n\r\nWith over 1,400 species, athletes represent a very varied hierarchical arrangement, next only to rodents, which can be known hosts that are viral. But, unlike mice and rats, bats aren\'t fantastic lab creatures. Simply keeping flying critters in labs is not difficult. Additionally, the majority of the mammalian cell lines developed for research originated out of different creatures and can\'t be employed to study viruses located in rodents.\r\n\r\nThis knowledge gap is equally dangerous whilst the existing outbreak shows. Bats are located nearly everywhere scientists have emerged, as well as enlarging human encroachment on their lands, viral illness is all but inevitable,\'\' Letko explained.\r\n\r\n\"We\'re getting to contact animal species in general, after which we find these species are filled with germs,\" he explained. \"The COVID-19 pandemic is regrettable, however it is maybe not surprising. We roll up the dice for twenty decades maybe not doing such a thing to decrease touch with those creatures. It had been less an issue of time before something like that will occur\"\r\n\r\nFrom the newspaper, Letko, along with also his co authors including WSU assistant professor Stephanie Seifert and also Vincent Munster in Rocky Mountain Laboratories, summarize approaches to lower the likelihood of this upcoming outbreak by increasing research to bats around the lowest, molecular degree and also on the wider macro-level of their environment.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://news.wsu.edu/2020/07/13/bat-research-critical-preventing-next-pandemic/\">When many pathogens are identified, the writers mention the requirement to proceed beyond detection and apply the most recent genetic technologies to understand the viruses might be transmitted. This knowledge may raise the capability to come up with drugs quickly following a pathogen was found -- and sometimes better still, make vaccines to protect against whole virus collections until they emerge.</a></span>\r\n\r\nBefore the present crisis, he assembled a stage utilizing synthetic coronavirus contaminants to examine that were likely to infect cells. After the existing outbreak began, Letko analyzed the SARS-Cov-2 genome the moment the arrangement was available and immediately identified the probable receptor on individual cells. That analysis, published in Nature Micro Biology on Feb. 2-4, was among those very first ever to supply operational lab data on the virus, supplying scientists with vital details and tools to help determine which existing medication may possibly work contrary to SARS-Cov-2 and start developing on fresh ones in addition to test various facets of SARS-CoV-2 vaccine efficiency.\r\n\r\nLetko is putting his laboratory at WSU to keep on that job, providing initial screening of bat-borne viruses that will help identify the ones which are likely to be sent to humans.\r\n\r\nBeyond the laboratory, Letko along with his colleagues indicate the demand for much better comprehension of bat ecology that could cause solutions which are comparatively straightforward to execute. The investigators state cases like the attempt to segregate horses from Australia to block the Hendra virus that has been dispersing from fresh fruit bats to horses after which potentially onto humans. Still another intervention in Bangladesh involved only placing arrows on hand sap containers to help keep out bats and avoid human outbreaks of Nipah virus.\r\n\r\n\"Occasionally, that you never desire drugs or vaccines. It\'s only a behavioral modification which helps mitigate and lessen the connection between the critters,\" Letko explained. \"All these are a few of the forms of interventions which we are able to take as we begin to determine these viruses really do.\"\r\n\r\n<strong>Story Source:</strong>\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://news.wsu.edu/2020/07/13/bat-research-critical-preventing-next-pandemic/\">Materials</a> </span>provided by Washington State University. Original written by Sara Zaske and Content may be edited for style and length.\r\n\r\n<strong>Journal Reference:</strong>\r\n\r\nMichael Letko, Stephanie N. Seifert, Kevin J. Olival, Raina K. Plowright, Vincent J. Munster. Bat-borne virus diversity, spillover and emergence. Nature Reviews Microbiology, 2020; 18 (8):<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://news.wsu.edu/2020/07/13/bat-research-critical-preventing-next-pandemic/\"> 461 DOI: 10.1038/s41579-020-0394-z</a></span>','Bat research basic to forestalling next pandemic','','inherit','closed','closed','','6575-revision-v1','','','2020-07-13 16:27:36','2020-07-13 16:27:36','',6575,'https://microbiozindia.com/uncategorized/6575-revision-v1/',0,'revision','',0),(6578,2,'2020-07-13 16:30:39','2020-07-13 16:30:39','One of those emerging questions about this coronavirus that scientists have been attempting to understand is the reason developing countries are showing markedly lower rates of mortality in COVID-19 cases than anticipated.\r\n\r\nResearch by assistant-professor Luis Escobar at this College of Natural Resources and Environment and 2 coworkers at the National Institutes of Health shows that Bacille Calmette-Guérin (BCG), a tuberculosis vaccine routinely given to children in countries with high rates of tuberculosis infection, might play a substantial part in simplifying mortality rates in COVID-19. Their findings have been published in the Proceedings of the National Academy of Sciences.\r\n\r\n\"In our original research, we found that countries with high levels of BCG vaccinations had lower levels of mortality,\" clarified Escobar, a faculty member in the Department of Fish and Wildlife Conservation and a affiliate of the International Change Center placed from the Fralin Life Sciences Institute. \"However, all states are different: Guatemala has a younger population compared to, say, Italy, so that we had to make alterations to this data to adapt those gaps \"\r\n\r\nEscobar, working with NIH researchers Alvaro Molina-Cruz and Carolina Barillas-Mury, collected coronavirus mortality data from all over the world. From that data, the team assessed for factors, such as income, access to education and health services, population size and densities, and age distribution. During each one the factors, a correlation held revealing that countries with high degrees of BCG vaccinations had lower peak mortality rates from COVID-19.\r\n\r\n1 sample which stood out was Germany, which had different embryo plans prior to this nation\'s unification in 1990. While West Germany provided BCG vaccines to infants from 1961 to 1998, East Germany started their BCG vaccinations per decade earlier in the day, but ceased in 1975. Which means that older Germans -- the population most at risk from COVID-19 -- from the country\'s eastern nations would have more security from the existing pandemic than their peers in western Western countries. Recent statistics shows this to be true: western German countries have undergone mortality rates that are 2.9 times greater compared to people in eastern Germany.\r\n\r\n\"The intent of using the BCG method to protect from severe COVID-19 would be to excite a broad, inherent, rapid-response immunity,\" said Escobar, who noted that the BCG vaccines have been already shown to present comprehensive cross-protections for a number of viral respiratory illnesses in addition to tuberculosis.\r\n\r\nEscobar worries that the team\'s findings are preliminary, and further research is required to support their results and determine what the upcoming steps should be for research workers. The World Health Organization noted that there\'s no current evidence that the BCG vaccine can protect people from COVID-19 infections, also said that it does not currently recommend BCG vaccinations to preventing COVID-19.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.pnas.org/content/early/2020/07/07/2008410117\">\"We are not trying to notify coverage for this particular paper,\" Escobar said. \"That is, as an alternative, a call for more research. We will need to see when we can reproduce this in experiments also, potentially, in clinical trials. In addition, we will need to get back to the data once we get more details, therefore we can reevaluate our understanding of the coronavirus pandemic\"</a></span>\r\n\r\nBarillas-Mury, a primary researcher that specializes at mosquito-borne disease vectors, reported that demonstrating a connection between BCG vaccines and COVID-19 case severity could lead to attempts to stockpile doses of the BCG vaccine, placing countries with high tuberculosis rates at risk.\r\n\r\n\"If the BCG vaccine is protective, production would need to increase to match the sudden spike in vaccine requirement to be able to prevent a delay in supply to countries that very much desire it to fight tuberculosis,\" she said.\r\n\r\nWhile a direct correlation between BCG vaccinations and a decrease in coronavirus mortalities still needs to be known more fully, researchers hold expect that the BCG vaccine might find a way to supply at least short-term protections against severe COVID-19, especially for frontline health workers or high-risk patients. And, in case BCG does provide short term security, you will find longer term considerations about how countries could best utilize BCG vaccines to reduce mortality levels for future viral outbreaks that target the human reproductive system.\r\n\r\n<strong>Story Source:</strong>\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.pnas.org/content/early/2020/07/07/2008410117\">Materials</a> </span>provided by Virginia Tech. Original written by David Fleming. Note: Content may be edited for style and length.\r\n\r\n<strong>Journal Reference:</strong>\r\n\r\nLuis E. Escobar, Alvaro Molina-Cruz, Carolina Barillas-Mury. BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.pnas.org/content/early/2020/07/07/2008410117\">Proceedings of the National Academy of Sciences, July 9, 2020; DOI: 10.1073/pnas.2008410117</a></span>','Preliminary examination recommends tuberculosis antibody might be restricting COVID-19 passings','','publish','open','open','','preliminary-examination-recommends-tuberculosis-antibody-might-be-restricting-covid-19-passings','','','2020-07-13 16:30:39','2020-07-13 16:30:39','',0,'https://microbiozindia.com/?p=6578',0,'post','',0),(6579,2,'2020-07-13 16:30:39','2020-07-13 16:30:39','One of those emerging questions about this coronavirus that scientists have been attempting to understand is the reason developing countries are showing markedly lower rates of mortality in COVID-19 cases than anticipated.\r\n\r\nResearch by assistant-professor Luis Escobar at this College of Natural Resources and Environment and 2 coworkers at the National Institutes of Health shows that Bacille Calmette-Guérin (BCG), a tuberculosis vaccine routinely given to children in countries with high rates of tuberculosis infection, might play a substantial part in simplifying mortality rates in COVID-19. Their findings have been published in the Proceedings of the National Academy of Sciences.\r\n\r\n\"In our original research, we found that countries with high levels of BCG vaccinations had lower levels of mortality,\" clarified Escobar, a faculty member in the Department of Fish and Wildlife Conservation and a affiliate of the International Change Center placed from the Fralin Life Sciences Institute. \"However, all states are different: Guatemala has a younger population compared to, say, Italy, so that we had to make alterations to this data to adapt those gaps \"\r\n\r\nEscobar, working with NIH researchers Alvaro Molina-Cruz and Carolina Barillas-Mury, collected coronavirus mortality data from all over the world. From that data, the team assessed for factors, such as income, access to education and health services, population size and densities, and age distribution. During each one the factors, a correlation held revealing that countries with high degrees of BCG vaccinations had lower peak mortality rates from COVID-19.\r\n\r\n1 sample which stood out was Germany, which had different embryo plans prior to this nation\'s unification in 1990. While West Germany provided BCG vaccines to infants from 1961 to 1998, East Germany started their BCG vaccinations per decade earlier in the day, but ceased in 1975. Which means that older Germans -- the population most at risk from COVID-19 -- from the country\'s eastern nations would have more security from the existing pandemic than their peers in western Western countries. Recent statistics shows this to be true: western German countries have undergone mortality rates that are 2.9 times greater compared to people in eastern Germany.\r\n\r\n\"The intent of using the BCG method to protect from severe COVID-19 would be to excite a broad, inherent, rapid-response immunity,\" said Escobar, who noted that the BCG vaccines have been already shown to present comprehensive cross-protections for a number of viral respiratory illnesses in addition to tuberculosis.\r\n\r\nEscobar worries that the team\'s findings are preliminary, and further research is required to support their results and determine what the upcoming steps should be for research workers. The World Health Organization noted that there\'s no current evidence that the BCG vaccine can protect people from COVID-19 infections, also said that it does not currently recommend BCG vaccinations to preventing COVID-19.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.pnas.org/content/early/2020/07/07/2008410117\">\"We are not trying to notify coverage for this particular paper,\" Escobar said. \"That is, as an alternative, a call for more research. We will need to see when we can reproduce this in experiments also, potentially, in clinical trials. In addition, we will need to get back to the data once we get more details, therefore we can reevaluate our understanding of the coronavirus pandemic\"</a></span>\r\n\r\nBarillas-Mury, a primary researcher that specializes at mosquito-borne disease vectors, reported that demonstrating a connection between BCG vaccines and COVID-19 case severity could lead to attempts to stockpile doses of the BCG vaccine, placing countries with high tuberculosis rates at risk.\r\n\r\n\"If the BCG vaccine is protective, production would need to increase to match the sudden spike in vaccine requirement to be able to prevent a delay in supply to countries that very much desire it to fight tuberculosis,\" she said.\r\n\r\nWhile a direct correlation between BCG vaccinations and a decrease in coronavirus mortalities still needs to be known more fully, researchers hold expect that the BCG vaccine might find a way to supply at least short-term protections against severe COVID-19, especially for frontline health workers or high-risk patients. And, in case BCG does provide short term security, you will find longer term considerations about how countries could best utilize BCG vaccines to reduce mortality levels for future viral outbreaks that target the human reproductive system.\r\n\r\n<strong>Story Source:</strong>\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.pnas.org/content/early/2020/07/07/2008410117\">Materials</a> </span>provided by Virginia Tech. Original written by David Fleming. Note: Content may be edited for style and length.\r\n\r\n<strong>Journal Reference:</strong>\r\n\r\nLuis E. Escobar, Alvaro Molina-Cruz, Carolina Barillas-Mury. BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.pnas.org/content/early/2020/07/07/2008410117\">Proceedings of the National Academy of Sciences, July 9, 2020; DOI: 10.1073/pnas.2008410117</a></span>','Preliminary examination recommends tuberculosis antibody might be restricting COVID-19 passings','','inherit','closed','closed','','6578-revision-v1','','','2020-07-13 16:30:39','2020-07-13 16:30:39','',6578,'https://microbiozindia.com/uncategorized/6578-revision-v1/',0,'revision','',0),(6580,2,'2020-07-13 16:33:13','2020-07-13 16:33:13','The candidates, both BNT162b1 and BNT162b2, would be the most complex of at least four vaccines getting analyzed by most firms in ongoing trials in the United States and Germany.\r\n\r\nPfizer\'s shares were up roughly 2% and U.S.-listed stocks of BioNTech were up roughly 6 percent before the bell.\r\n\r\nEarlier this month, the firms said BNT162b1 showed potential against the virus also was proven to be well expressed in early-stage human trials.\r\n\r\nHistorical data from the trial of BNT162b1 have to be released in July, the firms said.\r\n\r\nIf the ongoing studies are successful, and also the vaccine candidate receives regulatory approval, the organizations said that they expect to make up to 100 million doses by the end of the year and potentially more than 1.2 billion doses by 2021-end.\r\n\r\nThe companies said they expect to begin a massive trial with up to 30,000 participants just as later this month, should they receive regulatory approval.\r\n\r\nThe fast track status by the Food and Drug Administration is granted to accelerate the overview of new drugs and vaccines which show the capacity to address unmet medical needs.','Pfizer, BioNTech\'s coronavirus immunizations get FDA\'s \'most optimized plan of attack\' status','','publish','open','open','','pfizer-biontechs-coronavirus-immunizations-get-fdas-most-optimized-plan-of-attack-status','','','2020-07-13 16:33:13','2020-07-13 16:33:13','',0,'https://microbiozindia.com/?p=6580',0,'post','',0),(6581,2,'2020-07-13 16:33:13','2020-07-13 16:33:13','The candidates, both BNT162b1 and BNT162b2, would be the most complex of at least four vaccines getting analyzed by most firms in ongoing trials in the United States and Germany.\r\n\r\nPfizer\'s shares were up roughly 2% and U.S.-listed stocks of BioNTech were up roughly 6 percent before the bell.\r\n\r\nEarlier this month, the firms said BNT162b1 showed potential against the virus also was proven to be well expressed in early-stage human trials.\r\n\r\nHistorical data from the trial of BNT162b1 have to be released in July, the firms said.\r\n\r\nIf the ongoing studies are successful, and also the vaccine candidate receives regulatory approval, the organizations said that they expect to make up to 100 million doses by the end of the year and potentially more than 1.2 billion doses by 2021-end.\r\n\r\nThe companies said they expect to begin a massive trial with up to 30,000 participants just as later this month, should they receive regulatory approval.\r\n\r\nThe fast track status by the Food and Drug Administration is granted to accelerate the overview of new drugs and vaccines which show the capacity to address unmet medical needs.','Pfizer, BioNTech\'s coronavirus immunizations get FDA\'s \'most optimized plan of attack\' status','','inherit','closed','closed','','6580-revision-v1','','','2020-07-13 16:33:13','2020-07-13 16:33:13','',6580,'https://microbiozindia.com/uncategorized/6580-revision-v1/',0,'revision','',0),(6582,2,'2020-07-13 16:35:11','2020-07-13 16:35:11','Biocon\'s partner Equillium has said it is planning to conduct a global randomised controlled clinical trial of Itolizumab in COVID-19 patients, for the American biotech firm will record a US investigational new drug application (IND).\r\n\r\nItolizumab, which is used for the treatment of psoriasis, is repurposed for COVID-19, as it regulates the production of inflammatory cytokines or cytokine storm, seen in acute COVID-19 patients at which the immune system attacks the organs, leading to death.\r\n\r\nBiocon has out-licensed Itolizumab to US-based Equillium at 2017 for growth in the Usa and Canada. Equillium has been awarded\'fast track\' and\'orphan drug\' designations for its molecule in both prevention and treatment for Graft versus host disease (GHVD) by the USFDA.\r\n\r\n\"The outcome of this clinical trial reported by Biocon are encouraging and support the hypothesis that Itolizumab\'s novel immune-modulating mechanism could have promise in treating the severe immuno-inflammatory complications experienced from COVID-19 patients,\" explained Bruce Steel,\'\' co founder and CEO of Equillium.\r\n\r\n\"We\'re working with Biocon to critique its own entire data set with the objective to maneuver rapidly in discovering appropriate next actions to accelerate further development of Itolizumab to treat moderate to severely ill COVID-19 patients in the united states and overseas at the face of the global crisis,\" Steel added.\r\n\r\nKiran Mazumdar-Shaw, Chair Person of Biocon, said that the company is now focussing on India, but if she receives any enquiries from different regions of earth, she\'d be looking at that. In case US approval comes through, there\'ll be a massive demand for that medication, \'\' she noted.\r\n\r\nOn July 11, the DCGI approved restricted unexpected emergency use of Itolizumab injection for treating mild to severe coronavirus disorder (COVID-19) cases. The approval was given based on a randomised, controlled, and open-label study at four hospitals in India, enrolling a total of 30 hospitalised COVID-19 patients having moderate to severe ARDS.\r\n\r\nThe principal end point was mortality at a month. The business stated that from the Itolizumab arm were no deaths and all patients have recovered; at the control arm three patients died and the rest have regained. The organization claimed that the patients that received Itolizumab also experienced significant reductions in inflammatory cytokines such as IL-6 and TNFα.\r\n\r\n\"The mortality benefit observed in the Itolizumab arm proved to be statistically significant,\" the organization stated.\r\n\r\n<strong>The medication costs Rs 8,000 each vial</strong>\r\n\r\nBiocon announced that Itolizumab is going to cost around Rs 8,000 per 25mg/5mL vial. A patient would take four doses of this drug, taking the complete price of the treatment to Rs 32,000.\r\n\r\nThe two doses of Tocilizumab said to cost about Rs 90,000, and now, there\'s a severe deficit of this medication.\r\n\r\n\"With Itolizumab you can release the individual much earlier, saving the costs of putting people on ventilator, which is quite significant. The cost of Rs 25,000 and Rs 30,000 is hugely beneficial and perhaps not pricey,\" Mazumdar-Shaw said.\r\n\r\nShe added that the distribution is going to be done through a close channel to ensure that there is no recreation of the drug into the blackmarket.\r\n\r\n\"We would ensure that there isn\'t any question of folks hoping to blackmarket it. If we find any such activities we\'ll require strong actions. We are ramping up capacity as far as possible as soon as you can make it available to India first,\" Mazumdar Shaw added.\r\n\r\nItolizumab was initially developed by Cuba\'s state-owned research lab, Centre for Molecular Immunology. The molecule was created for treating cancers such as lymphomas and leukaemia, however it\'d found usage in autoimmune disorders, where the immune system attacks your system. Biocon licensed the medication a few 20 decades back and invested significant time and tools to developing and making the medication.\r\n\r\nCuba is using the drug to treat patients.','Biocon\'s accomplice Equillium plans Itolizumab\'s worldwide clinical preliminary for COVID-19','','publish','open','open','','biocons-accomplice-equillium-plans-itolizumabs-worldwide-clinical-preliminary-for-covid-19','','','2020-07-13 16:35:26','2020-07-13 16:35:26','',0,'https://microbiozindia.com/?p=6582',0,'post','',0),(6583,2,'2020-07-13 16:35:11','2020-07-13 16:35:11','Biocon\'s partner Equillium has said it is planning to conduct a global randomised controlled clinical trial of Itolizumab in COVID-19 patients, for the American biotech firm will record a US investigational new drug application (IND).\r\n\r\nItolizumab, which is used for the treatment of psoriasis, is repurposed for COVID-19, as it regulates the production of inflammatory cytokines or cytokine storm, seen in acute COVID-19 patients at which the immune system attacks the organs, leading to death.\r\n\r\nBiocon has out-licensed Itolizumab to US-based Equillium at 2017 for growth in the Usa and Canada. Equillium has been awarded\'fast track\' and\'orphan drug\' designations for its molecule in both prevention and treatment for Graft versus host disease (GHVD) by the USFDA.\r\n\r\n\"The outcome of this clinical trial reported by Biocon are encouraging and support the hypothesis that Itolizumab\'s novel immune-modulating mechanism could have promise in treating the severe immuno-inflammatory complications experienced from COVID-19 patients,\" explained Bruce Steel,\'\' co founder and CEO of Equillium.\r\n\r\n\"We\'re working with Biocon to critique its own entire data set with the objective to maneuver rapidly in discovering appropriate next actions to accelerate further development of Itolizumab to treat moderate to severely ill COVID-19 patients in the united states and overseas at the face of the global crisis,\" Steel added.\r\n\r\nKiran Mazumdar-Shaw, Chair Person of Biocon, said that the company is now focussing on India, but if she receives any enquiries from different regions of earth, she\'d be looking at that. In case US approval comes through, there\'ll be a massive demand for that medication, \'\' she noted.\r\n\r\nOn July 11, the DCGI approved restricted unexpected emergency use of Itolizumab injection for treating mild to severe coronavirus disorder (COVID-19) cases. The approval was given based on a randomised, controlled, and open-label study at four hospitals in India, enrolling a total of 30 hospitalised COVID-19 patients having moderate to severe ARDS.\r\n\r\nThe principal end point was mortality at a month. The business stated that from the Itolizumab arm were no deaths and all patients have recovered; at the control arm three patients died and the rest have regained. The organization claimed that the patients that received Itolizumab also experienced significant reductions in inflammatory cytokines such as IL-6 and TNFα.\r\n\r\n\"The mortality benefit observed in the Itolizumab arm proved to be statistically significant,\" the organization stated.\r\n\r\nThe medication costs Rs 8,000 each vial\r\n\r\nBiocon announced that Itolizumab is going to cost around Rs 8,000 per 25mg/5mL vial. A patient would take four doses of this drug, taking the complete price of the treatment to Rs 32,000.\r\n\r\nThe two doses of Tocilizumab said to cost about Rs 90,000, and now, there\'s a severe deficit of this medication.\r\n\r\n\"With Itolizumab you can release the individual much earlier, saving the costs of putting people on ventilator, which is quite significant. The cost of Rs 25,000 and Rs 30,000 is hugely beneficial and perhaps not pricey,\" Mazumdar-Shaw said.\r\n\r\nShe added that the distribution is going to be done through a close channel to ensure that there is no recreation of the drug into the blackmarket.\r\n\r\n\"We would ensure that there isn\'t any question of folks hoping to blackmarket it. If we find any such activities we\'ll require strong actions. We are ramping up capacity as far as possible as soon as you can make it available to India first,\" Mazumdar Shaw added.\r\n\r\nItolizumab was initially developed by Cuba\'s state-owned research lab, Centre for Molecular Immunology. The molecule was created for treating cancers such as lymphomas and leukaemia, however it\'d found usage in autoimmune disorders, where the immune system attacks your system. Biocon licensed the medication a few 20 decades back and invested significant time and tools to developing and making the medication.\r\n\r\nCuba is using the drug to treat patients.','Biocon\'s accomplice Equillium plans Itolizumab\'s worldwide clinical preliminary for COVID-19','','inherit','closed','closed','','6582-revision-v1','','','2020-07-13 16:35:11','2020-07-13 16:35:11','',6582,'https://microbiozindia.com/uncategorized/6582-revision-v1/',0,'revision','',0),(6584,2,'2020-07-13 16:35:26','2020-07-13 16:35:26','Biocon\'s partner Equillium has said it is planning to conduct a global randomised controlled clinical trial of Itolizumab in COVID-19 patients, for the American biotech firm will record a US investigational new drug application (IND).\r\n\r\nItolizumab, which is used for the treatment of psoriasis, is repurposed for COVID-19, as it regulates the production of inflammatory cytokines or cytokine storm, seen in acute COVID-19 patients at which the immune system attacks the organs, leading to death.\r\n\r\nBiocon has out-licensed Itolizumab to US-based Equillium at 2017 for growth in the Usa and Canada. Equillium has been awarded\'fast track\' and\'orphan drug\' designations for its molecule in both prevention and treatment for Graft versus host disease (GHVD) by the USFDA.\r\n\r\n\"The outcome of this clinical trial reported by Biocon are encouraging and support the hypothesis that Itolizumab\'s novel immune-modulating mechanism could have promise in treating the severe immuno-inflammatory complications experienced from COVID-19 patients,\" explained Bruce Steel,\'\' co founder and CEO of Equillium.\r\n\r\n\"We\'re working with Biocon to critique its own entire data set with the objective to maneuver rapidly in discovering appropriate next actions to accelerate further development of Itolizumab to treat moderate to severely ill COVID-19 patients in the united states and overseas at the face of the global crisis,\" Steel added.\r\n\r\nKiran Mazumdar-Shaw, Chair Person of Biocon, said that the company is now focussing on India, but if she receives any enquiries from different regions of earth, she\'d be looking at that. In case US approval comes through, there\'ll be a massive demand for that medication, \'\' she noted.\r\n\r\nOn July 11, the DCGI approved restricted unexpected emergency use of Itolizumab injection for treating mild to severe coronavirus disorder (COVID-19) cases. The approval was given based on a randomised, controlled, and open-label study at four hospitals in India, enrolling a total of 30 hospitalised COVID-19 patients having moderate to severe ARDS.\r\n\r\nThe principal end point was mortality at a month. The business stated that from the Itolizumab arm were no deaths and all patients have recovered; at the control arm three patients died and the rest have regained. The organization claimed that the patients that received Itolizumab also experienced significant reductions in inflammatory cytokines such as IL-6 and TNFα.\r\n\r\n\"The mortality benefit observed in the Itolizumab arm proved to be statistically significant,\" the organization stated.\r\n\r\n<strong>The medication costs Rs 8,000 each vial</strong>\r\n\r\nBiocon announced that Itolizumab is going to cost around Rs 8,000 per 25mg/5mL vial. A patient would take four doses of this drug, taking the complete price of the treatment to Rs 32,000.\r\n\r\nThe two doses of Tocilizumab said to cost about Rs 90,000, and now, there\'s a severe deficit of this medication.\r\n\r\n\"With Itolizumab you can release the individual much earlier, saving the costs of putting people on ventilator, which is quite significant. The cost of Rs 25,000 and Rs 30,000 is hugely beneficial and perhaps not pricey,\" Mazumdar-Shaw said.\r\n\r\nShe added that the distribution is going to be done through a close channel to ensure that there is no recreation of the drug into the blackmarket.\r\n\r\n\"We would ensure that there isn\'t any question of folks hoping to blackmarket it. If we find any such activities we\'ll require strong actions. We are ramping up capacity as far as possible as soon as you can make it available to India first,\" Mazumdar Shaw added.\r\n\r\nItolizumab was initially developed by Cuba\'s state-owned research lab, Centre for Molecular Immunology. The molecule was created for treating cancers such as lymphomas and leukaemia, however it\'d found usage in autoimmune disorders, where the immune system attacks your system. Biocon licensed the medication a few 20 decades back and invested significant time and tools to developing and making the medication.\r\n\r\nCuba is using the drug to treat patients.','Biocon\'s accomplice Equillium plans Itolizumab\'s worldwide clinical preliminary for COVID-19','','inherit','closed','closed','','6582-revision-v1','','','2020-07-13 16:35:26','2020-07-13 16:35:26','',6582,'https://microbiozindia.com/uncategorized/6582-revision-v1/',0,'revision','',0),(6585,2,'2020-07-14 04:33:24','2020-07-14 04:33:24','Mumbai, India; July 14, 2020: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as \"Cipla\") today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Icatibant Injectable 30mg/3mL from the United States Food and Drug Administration (US FDA).\r\n\r\nCipla’s Icatibant Injectable Pre-Filled Syringe 30mg/3mL is AP-rated generic version of Shire’s Firazyr®. Icatibant injection is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.\r\n\r\nAccording to IQVIA (IMS Health), Firazyr® and its generic equivalents had US sales of approximately $270M for the 12-month period ending May 2020.','Cipla receives final approval for generic version of Shire’s Firazyr®','','publish','open','open','','cipla-receives-final-approval-for-generic-version-of-shires-firazyr','','','2020-07-14 04:33:24','2020-07-14 04:33:24','',0,'https://microbiozindia.com/?p=6585',0,'post','',0),(6586,2,'2020-07-14 04:33:24','2020-07-14 04:33:24','Mumbai, India; July 14, 2020: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as \"Cipla\") today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Icatibant Injectable 30mg/3mL from the United States Food and Drug Administration (US FDA).\r\n\r\nCipla’s Icatibant Injectable Pre-Filled Syringe 30mg/3mL is AP-rated generic version of Shire’s Firazyr®. Icatibant injection is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.\r\n\r\nAccording to IQVIA (IMS Health), Firazyr® and its generic equivalents had US sales of approximately $270M for the 12-month period ending May 2020.','Cipla receives final approval for generic version of Shire’s Firazyr®','','inherit','closed','closed','','6585-revision-v1','','','2020-07-14 04:33:24','2020-07-14 04:33:24','',6585,'https://microbiozindia.com/uncategorized/6585-revision-v1/',0,'revision','',0),(6588,2,'2020-07-14 07:05:09','2020-07-14 07:05:09','LosAngeles, Jul 14 Researchers have discovered a frequent feature present in many of the human embryo which neutralise the publication coronavirus, a finding which they state can certainly help successful vaccine development against COVID-19.\r\n\r\nWhile multiple drug candidates have entered clinical trials, the investigators, including those from the Scripps Research Institute in the united states, said the utilization of individual embryo which give rise to the best immune response against the novel coronavirus -- SARS-CoV-2 -- remain unclear.\r\n\r\nIn the study, published in the journal Sciencethey assessed almost 300 recently identified individual SARS-CoV-2 antibodies, also discovered a gene usually associated with those most effective against the herpes virus.\r\n\r\nThe researchers clarified that SARS-CoV-2 utilizes the receptor binding domain (RBD) because of its spike protein to bind to the host cell-surface receptor, ACE2, and infect human cells.\r\n\r\nThey said antibodies that could target the RBD and obstruct binding to ACE2 are highly soughtafter, and a number have been discovered.\r\n\r\nFrom the recent research, the scientists, including Yuan Meng from The Scripps Research Institute, evaluated an inventory of 294 such RBD-targeting anti bodies.\r\n\r\nThey found that a receptor at the IGHV gene family, known as IGHV3-53, could be the most frequently employed IGHV receptor for controlling the RBD of this virus spike protein.\r\n\r\nIGHV3-53 antibodies, the investigators said, not just have lower mutation levels but may also be stronger in neutralising the virus.\r\n\r\nBy studying the 3D structures of 2 IGHV3-53 antibodies bound into the RBD, the researchers identified the features which made them promising and effective to get vaccine design.\r\n\r\n\"Overall, our atomic analysis demonstrates that IGHV3-53 provides a versatile framework to target the most ACE2 binding site in SARS-CoV-2 RBD,\" the study noted.\r\n\r\nThe researchers said the study results can ease the layout of vaccine agents which could elicit strong neutralising antibody response.\r\n\r\n\"Since IGHV3-53 is available at an affordable frequency of healthy individuals, this specific antibody response may possibly be commonly elicited through hepatitis,\" they wrote in the analysis.','\'\'Key component of solid counter acting agent reaction to COVID-19 decoded\'\'','','publish','open','open','','key-component-of-solid-counter-acting-agent-reaction-to-covid-19-decoded','','','2020-07-14 07:05:09','2020-07-14 07:05:09','',0,'https://microbiozindia.com/?p=6588',0,'post','',0),(6589,2,'2020-07-14 07:05:09','2020-07-14 07:05:09','LosAngeles, Jul 14 Researchers have discovered a frequent feature present in many of the human embryo which neutralise the publication coronavirus, a finding which they state can certainly help successful vaccine development against COVID-19.\r\n\r\nWhile multiple drug candidates have entered clinical trials, the investigators, including those from the Scripps Research Institute in the united states, said the utilization of individual embryo which give rise to the best immune response against the novel coronavirus -- SARS-CoV-2 -- remain unclear.\r\n\r\nIn the study, published in the journal Sciencethey assessed almost 300 recently identified individual SARS-CoV-2 antibodies, also discovered a gene usually associated with those most effective against the herpes virus.\r\n\r\nThe researchers clarified that SARS-CoV-2 utilizes the receptor binding domain (RBD) because of its spike protein to bind to the host cell-surface receptor, ACE2, and infect human cells.\r\n\r\nThey said antibodies that could target the RBD and obstruct binding to ACE2 are highly soughtafter, and a number have been discovered.\r\n\r\nFrom the recent research, the scientists, including Yuan Meng from The Scripps Research Institute, evaluated an inventory of 294 such RBD-targeting anti bodies.\r\n\r\nThey found that a receptor at the IGHV gene family, known as IGHV3-53, could be the most frequently employed IGHV receptor for controlling the RBD of this virus spike protein.\r\n\r\nIGHV3-53 antibodies, the investigators said, not just have lower mutation levels but may also be stronger in neutralising the virus.\r\n\r\nBy studying the 3D structures of 2 IGHV3-53 antibodies bound into the RBD, the researchers identified the features which made them promising and effective to get vaccine design.\r\n\r\n\"Overall, our atomic analysis demonstrates that IGHV3-53 provides a versatile framework to target the most ACE2 binding site in SARS-CoV-2 RBD,\" the study noted.\r\n\r\nThe researchers said the study results can ease the layout of vaccine agents which could elicit strong neutralising antibody response.\r\n\r\n\"Since IGHV3-53 is available at an affordable frequency of healthy individuals, this specific antibody response may possibly be commonly elicited through hepatitis,\" they wrote in the analysis.','\'\'Key component of solid counter acting agent reaction to COVID-19 decoded\'\'','','inherit','closed','closed','','6588-revision-v1','','','2020-07-14 07:05:09','2020-07-14 07:05:09','',6588,'https://microbiozindia.com/uncategorized/6588-revision-v1/',0,'revision','',0),(6590,2,'2020-07-14 07:44:47','2020-07-14 07:44:47','New England Biolabs, Ipswich, Mass, recently established the SARS-CoV-2 Quick Colorimetric LAMP Assay Kit, an investigation use only (RUO) product which can be used for the discovery of novel coronavirus RNA. The kit acts as a simple alternative to RT-qPCR and enables visual discovery of amplification of SARS-CoV-2 nucleic acid in only 30 minutes.\r\n\r\n[caption id=\"attachment_6592\" align=\"alignright\" width=\"315\"]<span style=\"font-size: 8pt;\"><img class=\"wp-image-6592 \" src=\"https://microbiozindia.com/wp-content/uploads/2020/07/New-England-Biolabs_SARS_CoV_2_Kit_PosNegExamples_0620_2-181x300.jpg\" alt=\"\" width=\"315\" height=\"522\" /></span> <span style=\"font-size: 8pt;\">The SARS-CoV-2 Rapid Colorimetric LAMP Assay was carried out using the indicated controls and either positive sample (human total RNA + synthetic SARS-CoV-2 RNA) or negative sample (human total RNA alone). Valid results for Non-Template Control (NTC, pink), Positive Control (PC, yellow) and Internal Control (IC, yellow) are shown. In the positive test sample, isothermal amplification of SARS-CoV-2 RNA leads to a color change from pink to yellow.</span>[/caption]\r\n\r\nThe kit uses loop-mediated isothermal amplification (LAMP) to find certain parts of the viral genome. This method gives a definite visual discovery of amplification, dependent on the creation of protons as well as also the subsequent drop in pH that occurs from the extensive DNA polymerase activity within an LAMP reaction. The reduction in pH produces a color shift, together with pink suggesting a negative effect and yellow suggesting a positive outcome.\r\n\r\n“RT-qPCR, the predominant nucleic acid amplification technology, requires a laboratory with sophisticated equipment, and can take hours to produce a readout,” says Steven Chiu, product marketing manager, DNA amplification at New England Biolabs. “With the SARS-CoV-2 Rapid Colorimetric LAMP Assay Kit, all you need is a simple heat source and 30 minutes to visually detect amplification of SARS CoV-2 RNA. This assay thus has the potential to be very beneficial in a low-resource or point-of-care setting.”\r\n\r\nFor more information: <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.neb.com/applications/dna-amplification-pcr-and-qpcr/isothermal-amplification/loop-mediated-isothermal-amplification-lamp\">New England Biolabs</a></span>','LAMP Assay Detects Covid-19 in Half an Hour','','publish','open','open','','lamp-assay-detects-covid-19-in-half-an-hour','','','2020-07-14 07:44:47','2020-07-14 07:44:47','',0,'https://microbiozindia.com/?p=6590',0,'post','',0),(6591,2,'2020-07-14 07:41:16','2020-07-14 07:41:16','','Screen-Shot-2020-07-14-at-12.18.41-AM-466x295','','inherit','open','closed','','screen-shot-2020-07-14-at-12-18-41-am-466x295','','','2020-07-14 07:41:16','2020-07-14 07:41:16','',6590,'https://microbiozindia.com/wp-content/uploads/2020/07/Screen-Shot-2020-07-14-at-12.18.41-AM-466x295-1.png',0,'attachment','image/png',0),(6592,2,'2020-07-14 07:41:54','2020-07-14 07:41:54','','SARS-CoV-2-Kit-PosNegExamples-0620-2','Rapid, simple, color-based detection of SARS-CoV-2 RNA. The SARS-CoV-2 Rapid Colorimetric LAMP Assay was carried out using the indicated controls and either positive sample (human total RNA + synthetic SARS-CoV-2 RNA) or negative sample (human total RNA alone). Valid results for Non-Template Control (NTC, pink), Positive Control (PC, yellow) and Internal Control (IC, yellow) are shown. In the positive test sample, isothermal amplification of SARS-CoV-2 RNA leads to a color change from pink to yellow','inherit','open','closed','','sars-cov-2-kit-posnegexamples-0620-2','','','2020-07-14 07:41:54','2020-07-14 07:41:54','',6590,'https://microbiozindia.com/wp-content/uploads/2020/07/New-England-Biolabs_SARS_CoV_2_Kit_PosNegExamples_0620_2.jpg',0,'attachment','image/jpeg',0),(6593,2,'2020-07-14 07:44:47','2020-07-14 07:44:47','New England Biolabs, Ipswich, Mass, recently established the SARS-CoV-2 Quick Colorimetric LAMP Assay Kit, an investigation use only (RUO) product which can be used for the discovery of novel coronavirus RNA. The kit acts as a simple alternative to RT-qPCR and enables visual discovery of amplification of SARS-CoV-2 nucleic acid in only 30 minutes.\r\n\r\n[caption id=\"attachment_6592\" align=\"alignright\" width=\"315\"]<span style=\"font-size: 8pt;\"><img class=\"wp-image-6592 \" src=\"https://microbiozindia.com/wp-content/uploads/2020/07/New-England-Biolabs_SARS_CoV_2_Kit_PosNegExamples_0620_2-181x300.jpg\" alt=\"\" width=\"315\" height=\"522\" /></span> <span style=\"font-size: 8pt;\">The SARS-CoV-2 Rapid Colorimetric LAMP Assay was carried out using the indicated controls and either positive sample (human total RNA + synthetic SARS-CoV-2 RNA) or negative sample (human total RNA alone). Valid results for Non-Template Control (NTC, pink), Positive Control (PC, yellow) and Internal Control (IC, yellow) are shown. In the positive test sample, isothermal amplification of SARS-CoV-2 RNA leads to a color change from pink to yellow.</span>[/caption]\r\n\r\nThe kit uses loop-mediated isothermal amplification (LAMP) to find certain parts of the viral genome. This method gives a definite visual discovery of amplification, dependent on the creation of protons as well as also the subsequent drop in pH that occurs from the extensive DNA polymerase activity within an LAMP reaction. The reduction in pH produces a color shift, together with pink suggesting a negative effect and yellow suggesting a positive outcome.\r\n\r\n“RT-qPCR, the predominant nucleic acid amplification technology, requires a laboratory with sophisticated equipment, and can take hours to produce a readout,” says Steven Chiu, product marketing manager, DNA amplification at New England Biolabs. “With the SARS-CoV-2 Rapid Colorimetric LAMP Assay Kit, all you need is a simple heat source and 30 minutes to visually detect amplification of SARS CoV-2 RNA. This assay thus has the potential to be very beneficial in a low-resource or point-of-care setting.”\r\n\r\nFor more information: <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.neb.com/applications/dna-amplification-pcr-and-qpcr/isothermal-amplification/loop-mediated-isothermal-amplification-lamp\">New England Biolabs</a></span>','LAMP Assay Detects Covid-19 in Half an Hour','','inherit','closed','closed','','6590-revision-v1','','','2020-07-14 07:44:47','2020-07-14 07:44:47','',6590,'https://microbiozindia.com/uncategorized/6590-revision-v1/',0,'revision','',0),(6594,2,'2020-07-14 09:02:30','2020-07-14 09:02:30','Bangalore, July 14, 2020: Punyashree a five- year-old child, was undergoing a liver transplant surgery at Aster CMI Hospital recently, was revived on the operating table, 40 minutes after her heart stopped beating. Punyashree was suffering from jaundice from the age of seven months due to a rare disorder called PFIC – progressive familial intra-hepatic cholestasis. This disease had resulted in irreversible liver damage and growth failure necessitating a liver transplant.\r\n\r\nThe patient’s heart stopped beating and her blood pressure dropped to zero. The doctors wasted no time, and for the next 40 minutes, kept giving her cardiac massage and instituted other resuscitation and life support measures, to keep pumping blood and maintaining circulation to Punyashree’s vital organs. The patient’s heartbeat was fluctuating in between, and it took nearly 40 minutes for her to become stable.\r\n\r\nIn a surgery that lasted for 14 hours, a team of doctors consisting of D<strong>r. Rajiv Lochan J, Sr. Consultant, HPB &amp; Liver Transplant Surgery, Dr. Sonal Asthana, Sr. Consultant, HPB &amp; Liver Transplant Surgery, Dr. Mallikarjun Sakpal, Consultant, Hepatology &amp; Liver Transplantation, Dr. Arun V, Lead Consultant - Critical Care &amp; Anaesthesiology and Dr. Chetan Ginigeri, Consultant - Paediatrics &amp; Paediatric Intensive Care,</strong> transplanted the mother’s liver into her child.\r\n\r\nThe young child was presented to the doctors with a history of cyclical jaundice, severe itching, and growth failure. She had been diagnosed with PFIC (Progressive familial intra-hepatic cholestasis and had developed jaundice when she was seven months old. Extensive investigation at various places including a specialist children’s hospital revealed that the main symptom at that time was jaundice and itching. Even after undergoing an operation to relieve the itching, the child continued to have cyclical episodes of jaundice and growth failure set in. The case was then referred to Aster CMI Hospital where further investigations suggested that the child had developed decompensated liver disease and required an urgent liver transplant.\r\n\r\n<strong>Explaining the cause of the cardiac arrest, Dr. Rajiv Lochan J, Sr. Consultant, HPB &amp; Liver Transplant Surgery, Aster CMI Hospital said,</strong> “The arrest occurred when the donated liver from the mother was being reconnected to Punyashree\'s blood vessels. After 40 minutes of external cardiac massage, we were able to recommence the baby\'s heart and continue her surgery to successfully complete the transplant operation. The cause of Punyashree’s heart stoppage was probably a metabolic event caused due to the derangement of electrolytes and acid levels in her body.\r\n\r\n<strong>Dr. Rajiv Lochan J</strong> added, “Mortality in India due to liver failure is twice that of the developed world and a majority of this is due to liver disease in children. Punyashree’s surgery was performed under the affordable liver transplant initiative of the hospital, which helped the family in raising funds through a CSR grant, crowd funding and donation from a foreign national. The result of all this collective effort has been the successful recovery of the child who is happily back with her family in Tumkur. It is indeed a moment of joy for us to see this <strong>“miracle child”</strong> recover fully during such difficult times.”\r\n\r\n\"We did not have a second to waste at that time, because if we stopped her heart monitor was a straight line. This phenomenon is very uncommon in case of a transplant. There is only a risk of 1 % or 2% that one will have a cardiac arrest during the transplant. The rarity of the case fell in this percentage hence this led us to do a CPR, we had given her immediate medications through adrenaline and medicines to bring her heart back to normal. It took almost about 30 to 40 minutes to get her back” said Dr. Arun V, Lead Consultant - Critical Care &amp; Anaesthesiology, Aster CMI.\r\n\r\nSpeaking on the recovery of the patient, Dr. Chetan Ginigeri, Consultant - Paediatrics &amp; Paediatric Intensive Care, Aster CMI Hospital, said: “Post-operative period with a weak heart, flooded lungs and a new liver is always difficult to manage as we have to salvage every organ interacting with one another. However, with judicious mechanical ventilation, medicines to protect and pump the heart, very tight fluid balance, and intensive monitoring, Punyashree woke up to a new life and walked home after 3 and a half weeks in hospital.”\r\n\r\n<strong>Expressing his views on the success of the Affordable Liver Transplant, Dr. Sonal Asthana, Sr. Consultant, HPB &amp; Liver Transplant Surgery, Aster CMI said:</strong> “It is indeed heartening to see Punyashree recover fully after her very eventful transplant The Affordable transplant initiative allowed us to offer lifesaving liver transplantation to children whose families have limited economic means, we hope to tie-up with the state governments in the near future to provide this facility to a larger number of children.”\r\nPunyashree’s mother, Ramya P, who donated the left side of her liver to her daughter expressed her gratitude to the doctors and their expertise, said: “We are extremely thankful to the hospital and the expert doctors who provided the lifesaving transplant to our child. It is an unexplainable moment for us to see our child living a normal life.”\r\n\r\n<strong>Aster’s ILC team includes specialist doctors - Dr Rajiv Lochan J, Dr Sonal Asthana, and Dr Mallikarjun</strong> Sakpal who have been adopting several methods to make liver care affordable and manageable for all. The team of expert doctors have devised ways to significantly reduce the cost of liver transplants by making use of crowd funding, corporate sponsorships from CSR budgets, cross-subsidies, matched funding and tie-ups with state governments which helps in creating a budget pool leading to overall reduction in the cost of the surgery and out of pocket expenses of the patient. While a normal liver transplant ranges from Rs 12 to Rs 30 lakh, the affordable liver transplant at Aster has gradually brought down the cost of a transplant and post-care management to just Rs 2.5 lakh to the family. With the use of this unique method, Aster hospitals have been able to subsidize the overall cost for liver transplantation for children, Aster’s ILC team has so far performed 95 transplants for the needy children and raised close to Rs 10 crore to support this initiative.','Aster CMI doctors revive 5-yr-old child from a 40-minute-long cardiac arrest during a liver transplant','','publish','open','open','','aster-cmi-doctors-revive-5-yr-old-child-from-a-40-minute-long-cardiac-arrest-during-a-liver-transplant','','','2020-07-14 09:03:52','2020-07-14 09:03:52','',0,'https://microbiozindia.com/?p=6594',0,'post','',0),(6595,2,'2020-07-14 09:01:59','2020-07-14 09:01:59','','Punyashree with her Parents and Doctors who saved her life','','inherit','open','closed','','punyashree-with-her-parents-and-doctors-who-saved-her-life','','','2020-07-14 09:01:59','2020-07-14 09:01:59','',6594,'https://microbiozindia.com/wp-content/uploads/2020/07/Punyashree-with-her-Parents-and-Doctors-who-saved-her-life.jpg',0,'attachment','image/jpeg',0),(6596,2,'2020-07-14 09:02:30','2020-07-14 09:02:30','Bangalore, July 14, 2020: Punyashree a five- year-old child, was undergoing a liver transplant surgery at Aster CMI Hospital recently, was revived on the operating table, 40 minutes after her heart stopped beating. Punyashree was suffering from jaundice from the age of seven months due to a rare disorder called PFIC – progressive familial intra-hepatic cholestasis. This disease had resulted in irreversible liver damage and growth failure necessitating a liver transplant.\r\n\r\nThe patient’s heart stopped beating and her blood pressure dropped to zero. The doctors wasted no time, and for the next 40 minutes, kept giving her cardiac massage and instituted other resuscitation and life support measures, to keep pumping blood and maintaining circulation to Punyashree’s vital organs. The patient’s heartbeat was fluctuating in between, and it took nearly 40 minutes for her to become stable.\r\n\r\nIn a surgery that lasted for 14 hours, a team of doctors consisting of D<strong>r. Rajiv Lochan J, Sr. Consultant, HPB &amp; Liver Transplant Surgery, Dr. Sonal Asthana, Sr. Consultant, HPB &amp; Liver Transplant Surgery, Dr. Mallikarjun Sakpal, Consultant, Hepatology &amp; Liver Transplantation, Dr. Arun V, Lead Consultant - Critical Care &amp; Anaesthesiology and Dr. Chetan Ginigeri, Consultant - Paediatrics &amp; Paediatric Intensive Care,</strong> transplanted the mother’s liver into her child.\r\n\r\nThe young child was presented to the doctors with a history of cyclical jaundice, severe itching, and growth failure. She had been diagnosed with PFIC (Progressive familial intra-hepatic cholestasis and had developed jaundice when she was seven months old. Extensive investigation at various places including a specialist children’s hospital revealed that the main symptom at that time was jaundice and itching. Even after undergoing an operation to relieve the itching, the child continued to have cyclical episodes of jaundice and growth failure set in. The case was then referred to Aster CMI Hospital where further investigations suggested that the child had developed decompensated liver disease and required an urgent liver transplant.\r\n\r\n<strong>Explaining the cause of the cardiac arrest, Dr. Rajiv Lochan J, Sr. Consultant, HPB &amp; Liver Transplant Surgery, Aster CMI Hospital said,</strong> “The arrest occurred when the donated liver from the mother was being reconnected to Punyashree\'s blood vessels. After 40 minutes of external cardiac massage, we were able to recommence the baby\'s heart and continue her surgery to successfully complete the transplant operation. The cause of Punyashree’s heart stoppage was probably a metabolic event caused due to the derangement of electrolytes and acid levels in her body.\r\n\r\n<strong>Dr. Rajiv Lochan J</strong> added, “Mortality in India due to liver failure is twice that of the developed world and a majority of this is due to liver disease in children. Punyashree’s surgery was performed under the affordable liver transplant initiative of the hospital, which helped the family in raising funds through a CSR grant, crowd funding and donation from a foreign national. The result of all this collective effort has been the successful recovery of the child who is happily back with her family in Tumkur. It is indeed a moment of joy for us to see this <strong>“miracle child”</strong> recover fully during such difficult times.”\r\n\r\n\"We did not have a second to waste at that time, because if we stopped her heart monitor was a straight line. This phenomenon is very uncommon in case of a transplant. There is only a risk of 1 % or 2% that one will have a cardiac arrest during the transplant. The rarity of the case fell in this percentage hence this led us to do a CPR, we had given her immediate medications through adrenaline and medicines to bring her heart back to normal. It took almost about 30 to 40 minutes to get her back” said Dr. Arun V, Lead Consultant - Critical Care &amp; Anaesthesiology, Aster CMI.\r\n\r\nSpeaking on the recovery of the patient, Dr. Chetan Ginigeri, Consultant - Paediatrics &amp; Paediatric Intensive Care, Aster CMI Hospital, said: “Post-operative period with a weak heart, flooded lungs and a new liver is always difficult to manage as we have to salvage every organ interacting with one another. However, with judicious mechanical ventilation, medicines to protect and pump the heart, very tight fluid balance, and intensive monitoring, Punyashree woke up to a new life and walked home after 3 and a half weeks in hospital.”\r\n\r\n<strong>Expressing his views on the success of the Affordable Liver Transplant, Dr. Sonal Asthana, Sr. Consultant, HPB &amp; Liver Transplant Surgery, Aster CMI said:</strong> “It is indeed heartening to see Punyashree recover fully after her very eventful transplant The Affordable transplant initiative allowed us to offer lifesaving liver transplantation to children whose families have limited economic means, we hope to tie-up with the state governments in the near future to provide this facility to a larger number of children.”\r\nPunyashree’s mother, Ramya P, who donated the left side of her liver to her daughter expressed her gratitude to the doctors and their expertise, said: “We are extremely thankful to the hospital and the expert doctors who provided the lifesaving transplant to our child. It is an unexplainable moment for us to see our child living a normal life.”\r\n\r\n<strong>Aster’s ILC team includes specialist doctors - Dr Rajiv Lochan J, Dr Sonal Asthana, and Dr Mallikarjun</strong> Sakpal who have been adopting several methods to make liver care affordable and manageable for all. The team of expert doctors have devised ways to significantly reduce the cost of liver transplants by making use of crowd funding, corporate sponsorships from CSR budgets, cross-subsidies, matched funding and tie-ups with state governments which helps in creating a budget pool leading to overall reduction in the cost of the surgery and out of pocket expenses of the patient. While a normal liver transplant ranges from Rs 12 to Rs 30 lakh, the affordable liver transplant at Aster has gradually brought down the cost of a transplant and post-care management to just Rs 2.5 lakh to the family. With the use of this unique method, Aster hospitals have been able to subsidize the overall cost for liver transplantation for children, Aster’s ILC team has so far performed 95 transplants for the needy children and raised close to Rs 10 crore to support this initiative.','Aster CMI doctors revive 5-yr-old child from a 40-minute-long cardiac arrest during a liver transplant','','inherit','closed','closed','','6594-revision-v1','','','2020-07-14 09:02:30','2020-07-14 09:02:30','',6594,'https://microbiozindia.com/uncategorized/6594-revision-v1/',0,'revision','',0),(6597,2,'2020-07-14 09:27:15','2020-07-14 09:27:15','Bharat Biotech has started human trials on its vaccine offender,\'Covaxin\'. Covaxin, being developed by the Hyderabad-based bio tech business and Indian Council of Medical Research (ICMR) is now India\'s first native COVID-19 vaccine.\r\nBharat Biotech had said that it really is trying to build up a preliminary capacity of 200 million vials of the vaccine.\r\n<iframe src=\"https://www.youtube.com/embed/b0a2nsYWrRc\" width=\"560\" height=\"315\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"></iframe>\r\nThe organization had earlier received approval by the Drug Controller General of India (DCGI) to conduct phase I and II human clinical trials.\r\nVolunteers from across the state will first undergo health tests to guarantee good liver function and lack of disorder prior to being cleared for small doses of their COVID-19 vaccine.\r\nCOVAXIN comes from a strain of SARS-CoV-2 virus that had been isolated at National Institute of Virology, Puneand also a translational science figures part of ICMR. The strain was then later moved to Bharat Biotech to produce into a vaccine candidate.','Bharat Biotech begins human preliminaries for Covaxin, India\'s first COVID-19 antibody','','publish','open','open','','bharat-biotech-begins-human-preliminaries-for-covaxin-indias-first-covid-19-antibody','','','2020-07-14 11:42:58','2020-07-14 11:42:58','',0,'https://microbiozindia.com/?p=6597',0,'post','',0),(6598,2,'2020-07-14 09:27:15','2020-07-14 09:27:15','Bharat Biotech has started human trials on its vaccine offender,\'Covaxin\'. Covaxin, being developed by the Hyderabad-based bio tech business and Indian Council of Medical Research (ICMR) is now India\'s first native COVID-19 vaccine.\r\nBharat Biotech had said that it really is trying to build up a preliminary capacity of 200 million vials of the vaccine.\r\nThe organization had earlier received approval by the Drug Controller General of India (DCGI) to conduct phase I and II human clinical trials.\r\nVolunteers from across the state will first undergo health tests to guarantee good liver function and lack of disorder prior to being cleared for small doses of their COVID-19 vaccine.\r\nCOVAXIN comes from a strain of SARS-CoV-2 virus that had been isolated at National Institute of Virology, Puneand also a translational science figures part of ICMR. The strain was then later moved to Bharat Biotech to produce into a vaccine candidate.','Bharat Biotech begins human preliminaries for Covaxin, India\'s first COVID-19 antibody','','inherit','closed','closed','','6597-revision-v1','','','2020-07-14 09:27:15','2020-07-14 09:27:15','',6597,'https://microbiozindia.com/uncategorized/6597-revision-v1/',0,'revision','',0),(6599,2,'2020-07-14 09:28:28','2020-07-14 09:28:28','Bharat Biotech has started human trials on its vaccine offender,\'Covaxin\'. Covaxin, being developed by the Hyderabad-based bio tech business and Indian Council of Medical Research (ICMR) is now India\'s first native COVID-19 vaccine.\r\nBharat Biotech had said that it really is trying to build up a preliminary capacity of 200 million vials of the vaccine.\r\nThe organization had earlier received approval by the Drug Controller General of India (DCGI) to conduct phase I and II human clinical trials.\r\nVolunteers from across the state will first undergo health tests to guarantee good liver function and lack of disorder prior to being cleared for small doses of their COVID-19 vaccine.\r\nCOVAXIN comes from a strain of SARS-CoV-2 virus that had been isolated at National Institute of Virology, Puneand also a translational science figures part of ICMR. The strain was then later moved to Bharat Biotech to produce into a vaccine candidate.','Bharat Biotech begins human preliminaries for Covaxin, India\'s first COVID-19 antibody','','inherit','closed','closed','','6597-revision-v1','','','2020-07-14 09:28:28','2020-07-14 09:28:28','',6597,'https://microbiozindia.com/uncategorized/6597-revision-v1/',0,'revision','',0),(6600,2,'2020-07-14 11:42:58','2020-07-14 11:42:58','Bharat Biotech has started human trials on its vaccine offender,\'Covaxin\'. Covaxin, being developed by the Hyderabad-based bio tech business and Indian Council of Medical Research (ICMR) is now India\'s first native COVID-19 vaccine.\r\nBharat Biotech had said that it really is trying to build up a preliminary capacity of 200 million vials of the vaccine.\r\n<iframe src=\"https://www.youtube.com/embed/b0a2nsYWrRc\" width=\"560\" height=\"315\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"></iframe>\r\nThe organization had earlier received approval by the Drug Controller General of India (DCGI) to conduct phase I and II human clinical trials.\r\nVolunteers from across the state will first undergo health tests to guarantee good liver function and lack of disorder prior to being cleared for small doses of their COVID-19 vaccine.\r\nCOVAXIN comes from a strain of SARS-CoV-2 virus that had been isolated at National Institute of Virology, Puneand also a translational science figures part of ICMR. The strain was then later moved to Bharat Biotech to produce into a vaccine candidate.','Bharat Biotech begins human preliminaries for Covaxin, India\'s first COVID-19 antibody','','inherit','closed','closed','','6597-revision-v1','','','2020-07-14 11:42:58','2020-07-14 11:42:58','',6597,'https://microbiozindia.com/uncategorized/6597-revision-v1/',0,'revision','',0),(6601,2,'2020-07-15 07:49:06','2020-07-15 07:49:06','Scientists can see potential target issues on the genome of their book coronavirus, an improvement which they claim could lead to the growth of new treatments for the deadly disorder.\r\n\r\nThe investigators, for example Ali Hosseini and Alex McLellan from the University of Otago in New Zealand examined previously unrecognised\"flaws\" on the publication coronavirus SARS-CoV-2\'s genome -- its own RNA -- that may be used to destroy the virus, or help make new vaccines.\r\n\r\nAccording to the research , published in the International Journal of Molecular Sciencesthese regions within the viral genome are target web sites recognised by sponsor miRNA -- which can be nucleic acid-based\'defense mechanisms\' operating inside your human body\'s cells.\r\n\r\nThe scientists also said these miRNAs are crucial for controlling the activity of enzymes within cells, and will also be essential players in the recognition and degradation of viruses.\r\n\r\nThey said just one aim site on SARS-CoV-2 matches a plentiful miRNA -- miR197 -- pose in very significant levels in patients with cardiovascular disease complications or having respiratory viral diseases.\r\n\r\nThe analysis mentioned that the miR197 binding site around SARS-CoV-2 had been independently mutated almost 40 times since March this season using this specific mutation present currently in a lot more than 75 percent of SARS-CoV-2 global isolates.\r\n\r\n\"Patients with cardiovascular disease complications are demonstrated to be in an increased risk from COVID-19,\" McLellan said.\r\n\r\n\"Our study shows that an ordinary defence pathway in these patients may have been blocked through this mutation from the virus,\" he further added.\r\n\r\nHowever, the scientists also cautioned it is too early to state if such mutations will help the herpes virus, or are just impartial hitchhikers that confer no advantage to the virus.\r\n\r\n\"We need direct experimental approaches utilizing live virus, as well over study of the transmission of such mutants around the world,\" they said.\r\n\r\n\"Our study only says: Let us keep close track of those websites and see what happens to these in future,\" McLellan said.\r\n\r\nHosseini said many miRNA are very different between species, so adding that the newly emerged SARS-CoV-2 may face trademark human miRNA assault, and perhaps not those the virus previously undergone in its supposed species of source, bats.\r\n\r\nThe scientists believe that their findings also open the chance to engineer in artificial miRNA websites.\r\n\r\nThey said this may be useful for weakening the virus for vaccine research and also had been successfully performed unfairly for other respiratory ailments.\r\n\r\nSuch plans, in accordance with the scientists, may donate to worldwide vaccine efforts.','Researchers recognize potential medication focuses in COVID-19 genome','','publish','open','open','','researchers-recognize-potential-medication-focuses-in-covid-19-genome','','','2020-07-15 07:49:06','2020-07-15 07:49:06','',0,'https://microbiozindia.com/?p=6601',0,'post','',0),(6602,2,'2020-07-15 07:49:06','2020-07-15 07:49:06','Scientists can see potential target issues on the genome of their book coronavirus, an improvement which they claim could lead to the growth of new treatments for the deadly disorder.\r\n\r\nThe investigators, for example Ali Hosseini and Alex McLellan from the University of Otago in New Zealand examined previously unrecognised\"flaws\" on the publication coronavirus SARS-CoV-2\'s genome -- its own RNA -- that may be used to destroy the virus, or help make new vaccines.\r\n\r\nAccording to the research , published in the International Journal of Molecular Sciencesthese regions within the viral genome are target web sites recognised by sponsor miRNA -- which can be nucleic acid-based\'defense mechanisms\' operating inside your human body\'s cells.\r\n\r\nThe scientists also said these miRNAs are crucial for controlling the activity of enzymes within cells, and will also be essential players in the recognition and degradation of viruses.\r\n\r\nThey said just one aim site on SARS-CoV-2 matches a plentiful miRNA -- miR197 -- pose in very significant levels in patients with cardiovascular disease complications or having respiratory viral diseases.\r\n\r\nThe analysis mentioned that the miR197 binding site around SARS-CoV-2 had been independently mutated almost 40 times since March this season using this specific mutation present currently in a lot more than 75 percent of SARS-CoV-2 global isolates.\r\n\r\n\"Patients with cardiovascular disease complications are demonstrated to be in an increased risk from COVID-19,\" McLellan said.\r\n\r\n\"Our study shows that an ordinary defence pathway in these patients may have been blocked through this mutation from the virus,\" he further added.\r\n\r\nHowever, the scientists also cautioned it is too early to state if such mutations will help the herpes virus, or are just impartial hitchhikers that confer no advantage to the virus.\r\n\r\n\"We need direct experimental approaches utilizing live virus, as well over study of the transmission of such mutants around the world,\" they said.\r\n\r\n\"Our study only says: Let us keep close track of those websites and see what happens to these in future,\" McLellan said.\r\n\r\nHosseini said many miRNA are very different between species, so adding that the newly emerged SARS-CoV-2 may face trademark human miRNA assault, and perhaps not those the virus previously undergone in its supposed species of source, bats.\r\n\r\nThe scientists believe that their findings also open the chance to engineer in artificial miRNA websites.\r\n\r\nThey said this may be useful for weakening the virus for vaccine research and also had been successfully performed unfairly for other respiratory ailments.\r\n\r\nSuch plans, in accordance with the scientists, may donate to worldwide vaccine efforts.','Researchers recognize potential medication focuses in COVID-19 genome','','inherit','closed','closed','','6601-revision-v1','','','2020-07-15 07:49:06','2020-07-15 07:49:06','',6601,'https://microbiozindia.com/uncategorized/6601-revision-v1/',0,'revision','',0),(6603,2,'2020-07-15 07:50:41','2020-07-15 07:50:41','Hetero Healthcare Ltd is supplying 60,000 vials of Covifor, generic variant of Remdesivir shot in the country in July 13 to 20, \'\' the company website said.\r\n\r\nCovifor is your first generic variant of Remdesivir, which is supposed for treatment of COVID-19 patients who are adults and kids, hospitalised with severe signs of the disorder.\r\n\r\nThe medication is available at 100 mg vial (Injectable). It needs to be administered in a hospital, critical care setting, under the oversight of a registered medical practitioner.\r\n\r\nOut of 60,000 vials, Maharashtra, which gets the maximum quantity of COVID-19 cases while in the country will probably get 12,500 followed by Delhi along with Telangana with 10,000 and 9,000 respectively.\r\n\r\nThe company has supplied the medication as much as 166 hospitals in Maharashtra and 5-3 from the national capital.\r\n\r\nWhen it concerns Telangana, Hetero supplied 14,502 vials, the information available at 11 am on the webpage on Wednesday said.\r\n\r\nRemdesivir is the only drug approved by the United States Food and Drug Administration (USFDA) for Emergency Usage Authorisation (EUA) treatment of adult and paediatric patients hospitalised with suspected or lab confirmed COVID-19 disease.\r\n\r\nMeanwhile, Dr Reddy\'s Laboratories Ltd, which likewise has a non-exclusive licensing agreement with Gilead Sciences Inc to enroll, manufacture and sell the investigational medication, Remdesivir from 127 countries including India is yet to have a nod from the DCGI to start making the drug in the country, sources said.','Hetero Healthcare to flexibly 60,000 vials of nonexclusive Remdesvir from July 13','','publish','open','open','','hetero-healthcare-to-flexibly-60000-vials-of-nonexclusive-remdesvir-from-july-13','','','2020-07-15 07:50:41','2020-07-15 07:50:41','',0,'https://microbiozindia.com/?p=6603',0,'post','',0),(6604,2,'2020-07-15 07:50:13','2020-07-15 07:50:13','','Hetero Logo','Hetero Logo','inherit','open','closed','','hetero-logo','','','2020-07-15 07:50:13','2020-07-15 07:50:13','',6603,'https://microbiozindia.com/wp-content/uploads/2020/07/1.jpg',0,'attachment','image/jpeg',0),(6605,2,'2020-07-15 07:50:41','2020-07-15 07:50:41','Hetero Healthcare Ltd is supplying 60,000 vials of Covifor, generic variant of Remdesivir shot in the country in July 13 to 20, \'\' the company website said.\r\n\r\nCovifor is your first generic variant of Remdesivir, which is supposed for treatment of COVID-19 patients who are adults and kids, hospitalised with severe signs of the disorder.\r\n\r\nThe medication is available at 100 mg vial (Injectable). It needs to be administered in a hospital, critical care setting, under the oversight of a registered medical practitioner.\r\n\r\nOut of 60,000 vials, Maharashtra, which gets the maximum quantity of COVID-19 cases while in the country will probably get 12,500 followed by Delhi along with Telangana with 10,000 and 9,000 respectively.\r\n\r\nThe company has supplied the medication as much as 166 hospitals in Maharashtra and 5-3 from the national capital.\r\n\r\nWhen it concerns Telangana, Hetero supplied 14,502 vials, the information available at 11 am on the webpage on Wednesday said.\r\n\r\nRemdesivir is the only drug approved by the United States Food and Drug Administration (USFDA) for Emergency Usage Authorisation (EUA) treatment of adult and paediatric patients hospitalised with suspected or lab confirmed COVID-19 disease.\r\n\r\nMeanwhile, Dr Reddy\'s Laboratories Ltd, which likewise has a non-exclusive licensing agreement with Gilead Sciences Inc to enroll, manufacture and sell the investigational medication, Remdesivir from 127 countries including India is yet to have a nod from the DCGI to start making the drug in the country, sources said.','Hetero Healthcare to flexibly 60,000 vials of nonexclusive Remdesvir from July 13','','inherit','closed','closed','','6603-revision-v1','','','2020-07-15 07:50:41','2020-07-15 07:50:41','',6603,'https://microbiozindia.com/uncategorized/6603-revision-v1/',0,'revision','',0),(6606,2,'2020-07-15 07:53:30','2020-07-15 07:53:30','Zydus Cadila, on July 1-5 said that it has begun giving its possible coronavirus (COVID-19) vaccine to healthy volunteers in the first and second phases of human clinical trials across multiple sites.\r\n\r\n\"Zydus has already manufactured clinical GMP batches of this vaccine candidate and intends to commence the clinical trials in July 2020 across multiple web sites in India in over 1000 subjects,\" the company said.\r\n\r\nIn accordance with the Clinical Trial Registry of India (CTRI) data that was upgraded on July 4, the Phase 1 at which the vaccine is going to be tested for safety is forecast to be completed in 84 days, and Phase 2 at which the vaccine will be analyzed for safety, efficacy, will compared with placebo and it is predicted to take 8-4 days.\r\n\r\nThe CTRI data mentions one clinical trial site of Zydus Research Centre at Ahmedabad. The ethics committee related to site has declared the trial.\r\n\r\nZydus had earlier this month announced that its plasmid DNA vaccine candidate (ZyCoV-D) grown in its Vaccine Technology Centre in Ahmedabad, India had successfully completed the preclinical period and had received permission from the Drug Controller General of India (DCGI) consent to commence Adaptive Phase I/II human clinical trials in India.\r\n\r\n\"From the pre-clinical phase, the vaccine has been found to evoke a robust immune response in multiple animal species like rats, rodents, guinea pigs and rabbits. The antibodies made by the vaccine could neutralize the wild type virus in virus neutralization assay indicating the protective potential for the disease candidate. No safety concerns were observed for its vaccine candidate at repeat dose toxicology studies by both intramuscular and intradermal routes of administration,\" the company said.\r\n\r\nWith ZyCoV-D,\'\' the company said that it has successfully established the DNA vaccine platform in the country utilizing non-replicating and non-integrating plasmid carrying the gene of interest which makes it very safe and sound.\r\n\r\n\"Further, no vector answer with lack of any contagious agent, the platform provides simple fabricating the vaccine using minimal biosafety conditions (BSL-1),\" the company added.','Zydus Cadila starts human preliminaries of its expected immunization for coronavirus','','publish','open','open','','zydus-cadila-starts-human-preliminaries-of-its-expected-immunization-for-coronavirus','','','2020-07-15 07:53:30','2020-07-15 07:53:30','',0,'https://microbiozindia.com/?p=6606',0,'post','',0),(6607,2,'2020-07-15 07:53:30','2020-07-15 07:53:30','Zydus Cadila, on July 1-5 said that it has begun giving its possible coronavirus (COVID-19) vaccine to healthy volunteers in the first and second phases of human clinical trials across multiple sites.\r\n\r\n\"Zydus has already manufactured clinical GMP batches of this vaccine candidate and intends to commence the clinical trials in July 2020 across multiple web sites in India in over 1000 subjects,\" the company said.\r\n\r\nIn accordance with the Clinical Trial Registry of India (CTRI) data that was upgraded on July 4, the Phase 1 at which the vaccine is going to be tested for safety is forecast to be completed in 84 days, and Phase 2 at which the vaccine will be analyzed for safety, efficacy, will compared with placebo and it is predicted to take 8-4 days.\r\n\r\nThe CTRI data mentions one clinical trial site of Zydus Research Centre at Ahmedabad. The ethics committee related to site has declared the trial.\r\n\r\nZydus had earlier this month announced that its plasmid DNA vaccine candidate (ZyCoV-D) grown in its Vaccine Technology Centre in Ahmedabad, India had successfully completed the preclinical period and had received permission from the Drug Controller General of India (DCGI) consent to commence Adaptive Phase I/II human clinical trials in India.\r\n\r\n\"From the pre-clinical phase, the vaccine has been found to evoke a robust immune response in multiple animal species like rats, rodents, guinea pigs and rabbits. The antibodies made by the vaccine could neutralize the wild type virus in virus neutralization assay indicating the protective potential for the disease candidate. No safety concerns were observed for its vaccine candidate at repeat dose toxicology studies by both intramuscular and intradermal routes of administration,\" the company said.\r\n\r\nWith ZyCoV-D,\'\' the company said that it has successfully established the DNA vaccine platform in the country utilizing non-replicating and non-integrating plasmid carrying the gene of interest which makes it very safe and sound.\r\n\r\n\"Further, no vector answer with lack of any contagious agent, the platform provides simple fabricating the vaccine using minimal biosafety conditions (BSL-1),\" the company added.','Zydus Cadila starts human preliminaries of its expected immunization for coronavirus','','inherit','closed','closed','','6606-revision-v1','','','2020-07-15 07:53:30','2020-07-15 07:53:30','',6606,'https://microbiozindia.com/uncategorized/6606-revision-v1/',0,'revision','',0),(6608,2,'2020-07-15 07:56:07','2020-07-15 07:56:07','Indian drugmaker Lupin Ltd has closed among its manufacturing plants at Gujarat after at 17 employees at your website tested positive for COVID-19, two government officials said on Tuesday.\r\n\r\nLupin, one of India\'s top five drugmakers, failed to immediately answer requests for comment. The business has some 1-1 manufacturing plants at the Ankleshwar site in Gujarat state, which is spread out over 40 acres and it has 984 employees, according to the company site.\r\n\r\nEmployees in one of those plants, which produces tuberculosis medication, have tested positive recently, said MD Modia, \'\' a senior district official. \"The plant was shut on July 12 after the cases were confirmed,\" explained Modia, adding that the site has been sanitized. \"No cases have been reported by the other plants at the center and their operations are untouched,\" he said.\r\n\r\nOther employees who come in contact with those who have tested positive may also be in the process of being analyzed, said the other senior government officer by the Bharuch district.\r\n\r\nLupin makes all from heart drugs to diabetes and asthma medicines that are sold in over 100 countries, with its biggest market being the united states.\r\n\r\nAs the number of infections from the book coronavirus is falling from several countries, in India, cases have been rising by the thousands in recent weeks.\r\n\r\nIndia had 906,752 cases of the coronavirus using 28,498 new ailments reported on Tuesday, according to statistics from the national health ministry, that the next highest total in the world behind Brazil and the USA.','Lupin closes sedate plant in Gujarat after 17 staff test positive for COVID-19','','publish','open','open','','lupin-closes-sedate-plant-in-gujarat-after-17-staff-test-positive-for-covid-19','','','2020-07-15 07:56:07','2020-07-15 07:56:07','',0,'https://microbiozindia.com/?p=6608',0,'post','',0),(6609,2,'2020-07-15 07:56:07','2020-07-15 07:56:07','Indian drugmaker Lupin Ltd has closed among its manufacturing plants at Gujarat after at 17 employees at your website tested positive for COVID-19, two government officials said on Tuesday.\r\n\r\nLupin, one of India\'s top five drugmakers, failed to immediately answer requests for comment. The business has some 1-1 manufacturing plants at the Ankleshwar site in Gujarat state, which is spread out over 40 acres and it has 984 employees, according to the company site.\r\n\r\nEmployees in one of those plants, which produces tuberculosis medication, have tested positive recently, said MD Modia, \'\' a senior district official. \"The plant was shut on July 12 after the cases were confirmed,\" explained Modia, adding that the site has been sanitized. \"No cases have been reported by the other plants at the center and their operations are untouched,\" he said.\r\n\r\nOther employees who come in contact with those who have tested positive may also be in the process of being analyzed, said the other senior government officer by the Bharuch district.\r\n\r\nLupin makes all from heart drugs to diabetes and asthma medicines that are sold in over 100 countries, with its biggest market being the united states.\r\n\r\nAs the number of infections from the book coronavirus is falling from several countries, in India, cases have been rising by the thousands in recent weeks.\r\n\r\nIndia had 906,752 cases of the coronavirus using 28,498 new ailments reported on Tuesday, according to statistics from the national health ministry, that the next highest total in the world behind Brazil and the USA.','Lupin closes sedate plant in Gujarat after 17 staff test positive for COVID-19','','inherit','closed','closed','','6608-revision-v1','','','2020-07-15 07:56:07','2020-07-15 07:56:07','',6608,'https://microbiozindia.com/uncategorized/6608-revision-v1/',0,'revision','',0),(6610,2,'2020-07-15 11:02:25','2020-07-15 11:02:25','At the University of Texas MD Anderson Cancer Center and Sanofi currently declared a last-minute tactical alliance to hasten the evolution of investigational treatments, for example immune and targeted treatments, for patients with cancer.\r\n\r\n\"Our goal is to enhance the results for patients using a selection of difficult-to-treat cancers, that will be best achieved via a profound comprehension of how investigational new drugs work,\" said Peter Adamson, M.D., world wide development thoughts, Oncology and Pediatric Innovation in Sanofi. \"This alliance leverages MD Anderson\'s pragmatic approach to early phase clinical trials, their own laboratory capabilities and broad scientific expertise. This will make us to go/no-go decisions substantially faster and allow us to identify potential new combinations and signs more accurately. That helps you to save you precious time and help us expand the range of patients who might potentially benefit from our therapies.\"\r\n\r\n<em>Not only do clinical trials help us to advance life-saving new treatments for our patients in need, they provide us with valuable information to understand which therapies may be more effective for which patients. We are pleased to collaborate with Sanofi in this effort to accelerate the development of a pipeline of innovative cancer therapies.\"-</em>Funda Meric-Bernstam, M.D., Chair of Investigational Cancer Therapeutics\r\n\r\nMD Anderson oversees one among the country\'s largest <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.cancer.gov/about-cancer/treatment/clinical-trials/what-are-trials\">oncology clinical trial</a></span> programs, together with well-established platforms such as tissue accumulation, immune and molecular profiling, and data investigation. This infrastructure enables the thorough analysis of chemical samples taken prior to, during and after treatment to uncover valuable insights which help streamline patient decision and also quicken the identification of fresh therapy combinations and indications.\r\n\r\nThe brand new alliance also will encourage analyses in to additional indications and combinations for studies in the clinic. <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.mdanderson.org/newsroom/md-anderson-and-sanofi-announce-strategic-collaboration-to-accelerate-oncology-research-and-development.h00-159383523.html#:~:text=Sanofi%20and%20MD%20Anderson%20scientists,effects%20at%20different%20disease%20stages.\">Sanofi and MD Anderson scientists</a> </span>can collaborate on civic design, employing a core group of biomarkers and assays. Joint projects additionally will apply book investigational agents developed in Sanofi to present receptor samples to acquire additional data in their effects at different disease stages.\r\n\r\n<em>MD Anderson\'s expertise in deep immune phenotyping and molecular profiling will provide invaluable insights into our emerging immunotherapy assets, helping us refine our selection of indications and explore new avenues. The knowledge we gain in this collaboration will also deepen our shared understanding of cancers\' potential vulnerabilities.\"-Dmitri Wiederschain, Ph.D., Global Head of Immuno-Oncology Research at Sanofi</em>\r\n\r\nNew findings, in addition to large scale molecular and phenotype datasets, will likely be applied to the style of new translational studies on selected Sanofi molecules, and also guide the choice of signals. The collaboration is expected to launch its first endeavors in the summer 2020.','MD Anderson and Sanofi work together to quicken improvement of imaginative malignant growth treatments','','publish','open','open','','md-anderson-and-sanofi-work-together-to-quicken-improvement-of-imaginative-malignant-growth-treatments','','','2020-07-15 11:02:25','2020-07-15 11:02:25','',0,'https://microbiozindia.com/?p=6610',0,'post','',0),(6611,2,'2020-07-15 11:02:25','2020-07-15 11:02:25','At the University of Texas MD Anderson Cancer Center and Sanofi currently declared a last-minute tactical alliance to hasten the evolution of investigational treatments, for example immune and targeted treatments, for patients with cancer.\r\n\r\n\"Our goal is to enhance the results for patients using a selection of difficult-to-treat cancers, that will be best achieved via a profound comprehension of how investigational new drugs work,\" said Peter Adamson, M.D., world wide development thoughts, Oncology and Pediatric Innovation in Sanofi. \"This alliance leverages MD Anderson\'s pragmatic approach to early phase clinical trials, their own laboratory capabilities and broad scientific expertise. This will make us to go/no-go decisions substantially faster and allow us to identify potential new combinations and signs more accurately. That helps you to save you precious time and help us expand the range of patients who might potentially benefit from our therapies.\"\r\n\r\n<em>Not only do clinical trials help us to advance life-saving new treatments for our patients in need, they provide us with valuable information to understand which therapies may be more effective for which patients. We are pleased to collaborate with Sanofi in this effort to accelerate the development of a pipeline of innovative cancer therapies.\"-</em>Funda Meric-Bernstam, M.D., Chair of Investigational Cancer Therapeutics\r\n\r\nMD Anderson oversees one among the country\'s largest <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.cancer.gov/about-cancer/treatment/clinical-trials/what-are-trials\">oncology clinical trial</a></span> programs, together with well-established platforms such as tissue accumulation, immune and molecular profiling, and data investigation. This infrastructure enables the thorough analysis of chemical samples taken prior to, during and after treatment to uncover valuable insights which help streamline patient decision and also quicken the identification of fresh therapy combinations and indications.\r\n\r\nThe brand new alliance also will encourage analyses in to additional indications and combinations for studies in the clinic. <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.mdanderson.org/newsroom/md-anderson-and-sanofi-announce-strategic-collaboration-to-accelerate-oncology-research-and-development.h00-159383523.html#:~:text=Sanofi%20and%20MD%20Anderson%20scientists,effects%20at%20different%20disease%20stages.\">Sanofi and MD Anderson scientists</a> </span>can collaborate on civic design, employing a core group of biomarkers and assays. Joint projects additionally will apply book investigational agents developed in Sanofi to present receptor samples to acquire additional data in their effects at different disease stages.\r\n\r\n<em>MD Anderson\'s expertise in deep immune phenotyping and molecular profiling will provide invaluable insights into our emerging immunotherapy assets, helping us refine our selection of indications and explore new avenues. The knowledge we gain in this collaboration will also deepen our shared understanding of cancers\' potential vulnerabilities.\"-Dmitri Wiederschain, Ph.D., Global Head of Immuno-Oncology Research at Sanofi</em>\r\n\r\nNew findings, in addition to large scale molecular and phenotype datasets, will likely be applied to the style of new translational studies on selected Sanofi molecules, and also guide the choice of signals. The collaboration is expected to launch its first endeavors in the summer 2020.','MD Anderson and Sanofi work together to quicken improvement of imaginative malignant growth treatments','','inherit','closed','closed','','6610-revision-v1','','','2020-07-15 11:02:25','2020-07-15 11:02:25','',6610,'https://microbiozindia.com/uncategorized/6610-revision-v1/',0,'revision','',0),(6614,2,'2020-07-16 09:02:23','2020-07-16 09:02:23','The top US expert on infectious diseases, Dr. Anthony Fauci, predicted on Wednesday that the country will fulfill its own objective of a coronavirus vaccine by the year end and has been unmoved by the possibility that China would arrive there .\r\n\r\nWhen there aren\'t any warranties,\"I\'m well about the projected schedule,\" Fauci told Reuters in an interview.\r\n\r\nMany experts find a secure and efficient vaccine while the sole way from this pandemic which has infected countless murdered more than 575,000 people worldwide.\r\n\r\nFauci said Moderna\'s consequences were particularly promising as the vaccine appeared to offer you the sort of protection found at a natural disorder.\r\n\r\nIn vaccine development,\"certainly one of things which you expect is your disease triggers a reply that is like a natural disorder, as technically, the ideal vaccine that you might ever get is really a pure disease\"\r\n\r\nModerna\'s offender, that will be placed to input the last period of analyzing about July 27, is only one of over just a trillion vaccines in evolution worldwide, but one of several contenders which have earned tens of thousands of dollars in financing from Operation Warp Hurry, the WhiteHouse program that intends to deliver over 300 million doses of a safe and beneficial COVID-19 vaccine by January.\r\n\r\nFauci, who\'s come to be a trusted and popular strategy throughout the coronavirus epidemic, came under criticism against President Donald Trump plus a number of his Democratic allies since Fauci cautioned against reopening the united states market too so on.\r\n\r\nAsked how he deals with the strikes on his own personality and allegiance to the president,\'\' Fauci told Reuters,\"I actually don\'t allow it to disturb me.\r\n\r\nEven though he said he expects China succeeds, so he doesn\'t believe that they are going to win against the vaccine raceat least not by far.\r\n\r\n\"I think everyone\'s type of on exactly the exact same track.\" If they really do make it happen, \'\' he stated,\"They are not planning to receive it especially prior to we do it. That is for certain.\"\r\n\r\nFundamentally, he expects multiple candidates that are successful prevail. \"I really don\'t be concerned about anyone getting there .\"\r\n\r\nEven in case your vaccine succeeds in sparking an immune reaction,\'\' Fauci said it remains unclear the length of time protection can survive.\r\n\r\n\"All these are questions which do not have answers at the moment, because we\'re just half an hour into the out break \" He said it usually takes a year until that resistance question is replied.\r\n\r\nA recent Reuters survey discovered that the quarter of Americans are reluctant about carrying a vaccine, expressing concern the recording pace of development may undermine security. Fauci said he knows of such concerns.\r\n\r\n\"It is clear, however unjustified,\" he explained. \"We are not undermining security; we aren\'t compromising scientific ethics.\"\r\n\r\nFauci stated the conventional evolution means of waiting patiently to get a vaccine has to be shown effective before manufacturing begins wastes time.\r\n\r\n\"When the vaccine does not get the job done, the one factor you\'ve lost is money\"','Anthony Fauci bullish on possibilities for US antibody, not stressed over China winning race','','publish','open','open','','anthony-fauci-bullish-on-possibilities-for-us-antibody-not-stressed-over-china-winning-race','','','2020-07-16 09:02:23','2020-07-16 09:02:23','',0,'https://microbiozindia.com/?p=6614',0,'post','',0),(6615,2,'2020-07-16 09:01:48','2020-07-16 09:01:48','','Anthony-Fauci-1-770x433','','inherit','open','closed','','anthony-fauci-1-770x433','','','2020-07-16 09:01:48','2020-07-16 09:01:48','',6614,'https://microbiozindia.com/wp-content/uploads/2020/07/Anthony-Fauci-1-770x433-1.jpg',0,'attachment','image/jpeg',0),(6616,2,'2020-07-16 09:02:23','2020-07-16 09:02:23','The top US expert on infectious diseases, Dr. Anthony Fauci, predicted on Wednesday that the country will fulfill its own objective of a coronavirus vaccine by the year end and has been unmoved by the possibility that China would arrive there .\r\n\r\nWhen there aren\'t any warranties,\"I\'m well about the projected schedule,\" Fauci told Reuters in an interview.\r\n\r\nMany experts find a secure and efficient vaccine while the sole way from this pandemic which has infected countless murdered more than 575,000 people worldwide.\r\n\r\nFauci said Moderna\'s consequences were particularly promising as the vaccine appeared to offer you the sort of protection found at a natural disorder.\r\n\r\nIn vaccine development,\"certainly one of things which you expect is your disease triggers a reply that is like a natural disorder, as technically, the ideal vaccine that you might ever get is really a pure disease\"\r\n\r\nModerna\'s offender, that will be placed to input the last period of analyzing about July 27, is only one of over just a trillion vaccines in evolution worldwide, but one of several contenders which have earned tens of thousands of dollars in financing from Operation Warp Hurry, the WhiteHouse program that intends to deliver over 300 million doses of a safe and beneficial COVID-19 vaccine by January.\r\n\r\nFauci, who\'s come to be a trusted and popular strategy throughout the coronavirus epidemic, came under criticism against President Donald Trump plus a number of his Democratic allies since Fauci cautioned against reopening the united states market too so on.\r\n\r\nAsked how he deals with the strikes on his own personality and allegiance to the president,\'\' Fauci told Reuters,\"I actually don\'t allow it to disturb me.\r\n\r\nEven though he said he expects China succeeds, so he doesn\'t believe that they are going to win against the vaccine raceat least not by far.\r\n\r\n\"I think everyone\'s type of on exactly the exact same track.\" If they really do make it happen, \'\' he stated,\"They are not planning to receive it especially prior to we do it. That is for certain.\"\r\n\r\nFundamentally, he expects multiple candidates that are successful prevail. \"I really don\'t be concerned about anyone getting there .\"\r\n\r\nEven in case your vaccine succeeds in sparking an immune reaction,\'\' Fauci said it remains unclear the length of time protection can survive.\r\n\r\n\"All these are questions which do not have answers at the moment, because we\'re just half an hour into the out break \" He said it usually takes a year until that resistance question is replied.\r\n\r\nA recent Reuters survey discovered that the quarter of Americans are reluctant about carrying a vaccine, expressing concern the recording pace of development may undermine security. Fauci said he knows of such concerns.\r\n\r\n\"It is clear, however unjustified,\" he explained. \"We are not undermining security; we aren\'t compromising scientific ethics.\"\r\n\r\nFauci stated the conventional evolution means of waiting patiently to get a vaccine has to be shown effective before manufacturing begins wastes time.\r\n\r\n\"When the vaccine does not get the job done, the one factor you\'ve lost is money\"','Anthony Fauci bullish on possibilities for US antibody, not stressed over China winning race','','inherit','closed','closed','','6614-revision-v1','','','2020-07-16 09:02:23','2020-07-16 09:02:23','',6614,'https://microbiozindia.com/uncategorized/6614-revision-v1/',0,'revision','',0),(6617,2,'2020-07-16 09:04:29','2020-07-16 09:04:29','While paths have previously reached Stage III -- i.e. large scale human trials to gain access security against the publication coronavirus, programmers haven\'t revealed Period 1 data, that might demonstrate the immune response triggered by the prospective disease.\r\n\r\nEarlier in the day in July, programmers said resistant response gleaned out of the trials has been\"encouraging\" and so they hope to print data for Stage 1 from month-end. The Lancet medical journal is predicted to print it.\r\n\r\nIn a post, Peston said:\"I\'m hearing that there will probably undoubtedly be positive news so on (perhaps tomorrow) on first samples of this Oxford Covid-19 vaccine that\'s endorsed by Astra Zeneca.\"\r\n\r\n\"We\'re awaiting confirmation by a research on the novel time and date for the info and aren\'t equipped to confirm when it\'ll soon be published,\" an Oxford University spokeswoman told Reuters.\r\n\r\nAt least a hundred vaccines have been developed and analyzed across the globe to attempt and block the COVID-19 pandemic. Till July 16, 13,516,656 cases are recorded worldwide and also herpes has killed as much as 583,450, in accordance with the Johns Hopkins Coronavirus Research.','Uplifting news likely today on Oxford University\'s AstraZeneca beginning preliminaries','','publish','open','open','','uplifting-news-likely-today-on-oxford-universitys-astrazeneca-beginning-preliminaries','','','2020-07-16 09:04:29','2020-07-16 09:04:29','',0,'https://microbiozindia.com/?p=6617',0,'post','',0),(6618,2,'2020-07-16 09:04:29','2020-07-16 09:04:29','While paths have previously reached Stage III -- i.e. large scale human trials to gain access security against the publication coronavirus, programmers haven\'t revealed Period 1 data, that might demonstrate the immune response triggered by the prospective disease.\r\n\r\nEarlier in the day in July, programmers said resistant response gleaned out of the trials has been\"encouraging\" and so they hope to print data for Stage 1 from month-end. The Lancet medical journal is predicted to print it.\r\n\r\nIn a post, Peston said:\"I\'m hearing that there will probably undoubtedly be positive news so on (perhaps tomorrow) on first samples of this Oxford Covid-19 vaccine that\'s endorsed by Astra Zeneca.\"\r\n\r\n\"We\'re awaiting confirmation by a research on the novel time and date for the info and aren\'t equipped to confirm when it\'ll soon be published,\" an Oxford University spokeswoman told Reuters.\r\n\r\nAt least a hundred vaccines have been developed and analyzed across the globe to attempt and block the COVID-19 pandemic. Till July 16, 13,516,656 cases are recorded worldwide and also herpes has killed as much as 583,450, in accordance with the Johns Hopkins Coronavirus Research.','Uplifting news likely today on Oxford University\'s AstraZeneca beginning preliminaries','','inherit','closed','closed','','6617-revision-v1','','','2020-07-16 09:04:29','2020-07-16 09:04:29','',6617,'https://microbiozindia.com/uncategorized/6617-revision-v1/',0,'revision','',0),(6619,2,'2020-07-16 09:07:28','2020-07-16 09:07:28','Screening individuals aged 60 and administering them along with all the BCG vaccine has begun, a senior officer said.\r\n\r\nThe aim of this multi-centric study, by which older individuals not influenced by the publication coronavirus are all vaccinated, would be to check if this immunisation drive reduces mortality rate and also helps decrease COVID-19 incidence.\r\n\r\nAfter Legislation, those immunised are followed . In case a few of them become infected by COVID-19, it could be evaluated in the event the BCG vaccination endured them in good stead compared to all others of the similar age bracket who weren\'t vaccinated.\r\n\r\nAn senior NIRT official told news bureau PTI that the sample size would be\"adequate and sufficient\" to meet with the trial\'s goal and how long is\"approximately half a year and it might well become extended farther as most of the vaccinated people necessary to be followed for results\"\r\n\r\nBesides Chennai, the BCG-COVID trial, even under the auspices of ICMR could be hauled in five different centers and\"they truly are in the procedure of launching which really is likely to begin soon,\" the state said.\r\n\r\nMedical Minister is expecting that vaccinating highrisk groups with high risk BCG will help cut the high degree of COVID-19, admissions at mortality and hospital prices.\r\n\r\nVijayabaskar said anti-microbial steps will probably soon be further stepped down. The NIRT, underneath the ICMR, can be a worldwide recognized association for TB research.','BCG-COVID preliminary starts at ICMR\'s Chennai establishment','','publish','open','open','','bcg-covid-preliminary-starts-at-icmrs-chennai-establishment','','','2020-07-16 09:07:28','2020-07-16 09:07:28','',0,'https://microbiozindia.com/?p=6619',0,'post','',0),(6620,2,'2020-07-16 09:07:28','2020-07-16 09:07:28','Screening individuals aged 60 and administering them along with all the BCG vaccine has begun, a senior officer said.\r\n\r\nThe aim of this multi-centric study, by which older individuals not influenced by the publication coronavirus are all vaccinated, would be to check if this immunisation drive reduces mortality rate and also helps decrease COVID-19 incidence.\r\n\r\nAfter Legislation, those immunised are followed . In case a few of them become infected by COVID-19, it could be evaluated in the event the BCG vaccination endured them in good stead compared to all others of the similar age bracket who weren\'t vaccinated.\r\n\r\nAn senior NIRT official told news bureau PTI that the sample size would be\"adequate and sufficient\" to meet with the trial\'s goal and how long is\"approximately half a year and it might well become extended farther as most of the vaccinated people necessary to be followed for results\"\r\n\r\nBesides Chennai, the BCG-COVID trial, even under the auspices of ICMR could be hauled in five different centers and\"they truly are in the procedure of launching which really is likely to begin soon,\" the state said.\r\n\r\nMedical Minister is expecting that vaccinating highrisk groups with high risk BCG will help cut the high degree of COVID-19, admissions at mortality and hospital prices.\r\n\r\nVijayabaskar said anti-microbial steps will probably soon be further stepped down. The NIRT, underneath the ICMR, can be a worldwide recognized association for TB research.','BCG-COVID preliminary starts at ICMR\'s Chennai establishment','','inherit','closed','closed','','6619-revision-v1','','','2020-07-16 09:07:28','2020-07-16 09:07:28','',6619,'https://microbiozindia.com/uncategorized/6619-revision-v1/',0,'revision','',0),(6621,2,'2020-07-16 15:42:22','2020-07-16 15:42:22','Russia plans to make 30 million doses of an experimental COVID-19 vaccine domestically this year, with the possibility to produce a further 170 million doses abroad, the head of the nation\'s autonomous wealth fund said. The first human trial of the vaccine, a month-long evaluation on 38 people, stopped this past week. Researchers concluded that it is safe for usage and causes an immune reaction, even though the strength of the response is yet uncertain.\r\n\r\nA bigger Phase III trial involving several thousand people is forecast to begin in August, Russian Direct Investment Fund (RDIF) mind Kirill Dmitriev.\r\n\r\n\"We feel based on the recent results it will soon be approved at Russia in August and in various other nations in September...,\'\' making it possibly the first vaccine to be approved in the planet,\" he told Reuters in an interview.\r\n\r\nThe Russian Stage III trial will be run from Russia and also two Middle Eastern states, Dmitriev said, and will begin after having a smaller, 100-person Phase II trial wraps up on August 3.\r\n\r\nRussia\'s official coronavirus instance tally moved past 7.5 lakh, the fourth largest in the world, after police reported 6,428 new cases from the previous 2-4 hours.\r\n\r\nThe Russian defence ministry on Wednesday said it was developed a more\"safe\" coronavirus vaccine following clinical trials on a group of volunteers.\r\n\r\nThe results of the trials\"let us consult with optimism about the safety and good tolerability of the vaccine\", it said in an announcement.\r\n\r\nMeanwhile, the early-stage human trial data on a vaccine currently being produced by AstraZeneca and also Oxford University will be released on July 20, \'\' The Lancet medical journal said. The Oxford vaccine offender is already in large scale Stage III human trials in Brazil to check whether it can force away COVID-19, however, its developers have yet to report Stage I results.','Russia confident of propelling coronavirus immunization one month from now','','publish','open','open','','russia-confident-of-propelling-coronavirus-immunization-one-month-from-now','','','2020-07-16 15:42:22','2020-07-16 15:42:22','',0,'https://microbiozindia.com/?p=6621',0,'post','',0),(6622,2,'2020-07-16 15:42:22','2020-07-16 15:42:22','Russia plans to make 30 million doses of an experimental COVID-19 vaccine domestically this year, with the possibility to produce a further 170 million doses abroad, the head of the nation\'s autonomous wealth fund said. The first human trial of the vaccine, a month-long evaluation on 38 people, stopped this past week. Researchers concluded that it is safe for usage and causes an immune reaction, even though the strength of the response is yet uncertain.\r\n\r\nA bigger Phase III trial involving several thousand people is forecast to begin in August, Russian Direct Investment Fund (RDIF) mind Kirill Dmitriev.\r\n\r\n\"We feel based on the recent results it will soon be approved at Russia in August and in various other nations in September...,\'\' making it possibly the first vaccine to be approved in the planet,\" he told Reuters in an interview.\r\n\r\nThe Russian Stage III trial will be run from Russia and also two Middle Eastern states, Dmitriev said, and will begin after having a smaller, 100-person Phase II trial wraps up on August 3.\r\n\r\nRussia\'s official coronavirus instance tally moved past 7.5 lakh, the fourth largest in the world, after police reported 6,428 new cases from the previous 2-4 hours.\r\n\r\nThe Russian defence ministry on Wednesday said it was developed a more\"safe\" coronavirus vaccine following clinical trials on a group of volunteers.\r\n\r\nThe results of the trials\"let us consult with optimism about the safety and good tolerability of the vaccine\", it said in an announcement.\r\n\r\nMeanwhile, the early-stage human trial data on a vaccine currently being produced by AstraZeneca and also Oxford University will be released on July 20, \'\' The Lancet medical journal said. The Oxford vaccine offender is already in large scale Stage III human trials in Brazil to check whether it can force away COVID-19, however, its developers have yet to report Stage I results.','Russia confident of propelling coronavirus immunization one month from now','','inherit','closed','closed','','6621-revision-v1','','','2020-07-16 15:42:22','2020-07-16 15:42:22','',6621,'https://microbiozindia.com/uncategorized/6621-revision-v1/',0,'revision','',0),(6623,2,'2020-07-16 16:00:35','2020-07-16 16:00:35','Pharmacists in Martin Luther University Halle-Wittenberg (MLU) have succeeded in detecting small amounts of coronavirus SARS-CoV-2 utilizing mass spectrometry. Because of their own investigation , they used naturopathic remedies of COVID-19 patients. The publication method might supplement conventional tests. It\'s undergoing developments and could be available as standard diagnostic tool for COVID-19 in the future. Initial results are released in the Journal of Proteome Research.\r\n\r\nThe most obvious test method getting used to find whether someone is affected with an acute COVID-19 disease is the polymerase chain reaction, or even briefly, PCR. The PCR technique is highly special as it detects the viral genome. <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://pubs.acs.org/doi/10.1021/acs.jproteome.0c00280\">Alternative tests detect antibodies against this disorder. As antibodies are generated in your system during the length of the infection, they can only be used to detect a past illness or an advanced stage of the disease.</a></span> Antibody tests are often nonspecific and sometimes struggling to distinguish between different corona viruses which can affect humans. Testing labs worldwide are therefore achieving the limits of these capacities.\r\n\r\n<em>We directly measure the proteins of the virus, not the genetic material.\"</em>\r\n\r\n<em>Professor Andrea Sinz, Mass Spectrometry Expert, Institute of Pharmacy at MLU</em>\r\n\r\nProfessor Andrea Sinza mass-spectrometry expert at the Institute of Pharmacy in MLU, had the idea of developing a fresh mass spectrometry-based evaluation to complement PCR. Mass spectrometry enables molecules to be just identified based on their mass and control. Sinz and her colleagues developed a process to look for the different parts of SARS-CoV-2 viruses.\r\n\r\nFor the experiments, University Medicine Halle provided gargle solutions of three COVID-19 patients. Sinz\'s research group developed a process to detect virus components in those highly diluted samples. \"Though we received only a little bit of gargle solution, we could detect components of viral proteins,\" says Dr Christian Ihling, that completed the tests. \"This was quite surprising, and I hadn\'t expected this to work myself,\" Sinz adds. The test is highly specific to the virus as the corresponding proteins are only contained in SARS-CoV-2. In addition, the evaluation may be utilised in early stages of this disease when many viruses are found in the throat and mouth.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://pubs.acs.org/doi/10.1021/acs.jproteome.0c00280\">Based on Sinz, the evaluation currently takes about fifteen minutes. The investigation group is currently hoping to significantly reduce the analysis time using artificially generated virus parts. Sinz is also looking for further collaborations, for example companies. </a></span>\r\n\r\n\"Using an organization from Hesse, we\'re likely to use yet another mass spectrometric system that would empower us to execute measurements within minutes\". This method would then be much like alleged\"biotyping\", and it is an established method used by physicians to diagnose bacterial or fungal diseases. Yet it must be seen if this process is also appropriate for discovering SARS-CoV-2. Sample preparation wouldn\'t longer be time-consuming and the dimensions might also be carried out by non-specialized employees.\r\n\r\nThe novel diagnostic method relying on mass-spectrometry will however not be available immediately. Sinz expects that it will be up and ready in a few months. \"I am in touch with colleagues worldwide, a few of whom have had a far worse connection with this pandemic than we\'ve got\" She\'s also a founding member of the\"COVID-19 mass-spectrometry Coalition\", a research association that relies on mass spectrometry at a better understanding of the disease.\r\n<div class=\"content-src-label\"><span style=\"color: #000000;\"><strong>Source:</strong></span></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://pressemitteilungen.pr.uni-halle.de/index.php?modus=pmanzeige&amp;pm_id=5034\" target=\"_blank\" rel=\"noopener noreferrer\">Martin-Luther-Universität Halle-Wittenberg</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nIhling, C., <em>et al.</em> (2020) Mass Spectrometric Identification of SARS-CoV-2 Proteins from Gargle Solution Samples of COVID-19 Patients. <em>Journal of Proteome Research.</em><span style=\"color: #ff6600;\"> <a style=\"color: #ff6600;\" href=\"https://doi.org/10.1021/acs.jproteome.0c00280\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1021/acs.jproteome.0c00280</a>.</span>\r\n\r\n</div>','New mass spectrometry-based test recognizes coronavirus in wash arrangements of patients','','publish','open','open','','new-mass-spectrometry-based-test-recognizes-coronavirus-in-wash-arrangements-of-patients','','','2020-07-16 16:00:35','2020-07-16 16:00:35','',0,'https://microbiozindia.com/?p=6623',0,'post','',0),(6624,2,'2020-07-16 15:58:34','2020-07-16 15:58:34','','8f121f731f96bfe075bd1cd7306c8d8b95c4bb22','','inherit','open','closed','','8f121f731f96bfe075bd1cd7306c8d8b95c4bb22','','','2020-07-16 15:58:34','2020-07-16 15:58:34','',6623,'https://microbiozindia.com/wp-content/uploads/2020/07/8f121f731f96bfe075bd1cd7306c8d8b95c4bb22.png',0,'attachment','image/png',0),(6625,2,'2020-07-16 16:00:35','2020-07-16 16:00:35','Pharmacists in Martin Luther University Halle-Wittenberg (MLU) have succeeded in detecting small amounts of coronavirus SARS-CoV-2 utilizing mass spectrometry. Because of their own investigation , they used naturopathic remedies of COVID-19 patients. The publication method might supplement conventional tests. It\'s undergoing developments and could be available as standard diagnostic tool for COVID-19 in the future. Initial results are released in the Journal of Proteome Research.\r\n\r\nThe most obvious test method getting used to find whether someone is affected with an acute COVID-19 disease is the polymerase chain reaction, or even briefly, PCR. The PCR technique is highly special as it detects the viral genome. <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://pubs.acs.org/doi/10.1021/acs.jproteome.0c00280\">Alternative tests detect antibodies against this disorder. As antibodies are generated in your system during the length of the infection, they can only be used to detect a past illness or an advanced stage of the disease.</a></span> Antibody tests are often nonspecific and sometimes struggling to distinguish between different corona viruses which can affect humans. Testing labs worldwide are therefore achieving the limits of these capacities.\r\n\r\n<em>We directly measure the proteins of the virus, not the genetic material.\"</em>\r\n\r\n<em>Professor Andrea Sinz, Mass Spectrometry Expert, Institute of Pharmacy at MLU</em>\r\n\r\nProfessor Andrea Sinza mass-spectrometry expert at the Institute of Pharmacy in MLU, had the idea of developing a fresh mass spectrometry-based evaluation to complement PCR. Mass spectrometry enables molecules to be just identified based on their mass and control. Sinz and her colleagues developed a process to look for the different parts of SARS-CoV-2 viruses.\r\n\r\nFor the experiments, University Medicine Halle provided gargle solutions of three COVID-19 patients. Sinz\'s research group developed a process to detect virus components in those highly diluted samples. \"Though we received only a little bit of gargle solution, we could detect components of viral proteins,\" says Dr Christian Ihling, that completed the tests. \"This was quite surprising, and I hadn\'t expected this to work myself,\" Sinz adds. The test is highly specific to the virus as the corresponding proteins are only contained in SARS-CoV-2. In addition, the evaluation may be utilised in early stages of this disease when many viruses are found in the throat and mouth.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://pubs.acs.org/doi/10.1021/acs.jproteome.0c00280\">Based on Sinz, the evaluation currently takes about fifteen minutes. The investigation group is currently hoping to significantly reduce the analysis time using artificially generated virus parts. Sinz is also looking for further collaborations, for example companies. </a></span>\r\n\r\n\"Using an organization from Hesse, we\'re likely to use yet another mass spectrometric system that would empower us to execute measurements within minutes\". This method would then be much like alleged\"biotyping\", and it is an established method used by physicians to diagnose bacterial or fungal diseases. Yet it must be seen if this process is also appropriate for discovering SARS-CoV-2. Sample preparation wouldn\'t longer be time-consuming and the dimensions might also be carried out by non-specialized employees.\r\n\r\nThe novel diagnostic method relying on mass-spectrometry will however not be available immediately. Sinz expects that it will be up and ready in a few months. \"I am in touch with colleagues worldwide, a few of whom have had a far worse connection with this pandemic than we\'ve got\" She\'s also a founding member of the\"COVID-19 mass-spectrometry Coalition\", a research association that relies on mass spectrometry at a better understanding of the disease.\r\n<div class=\"content-src-label\"><span style=\"color: #000000;\"><strong>Source:</strong></span></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://pressemitteilungen.pr.uni-halle.de/index.php?modus=pmanzeige&amp;pm_id=5034\" target=\"_blank\" rel=\"noopener noreferrer\">Martin-Luther-Universität Halle-Wittenberg</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nIhling, C., <em>et al.</em> (2020) Mass Spectrometric Identification of SARS-CoV-2 Proteins from Gargle Solution Samples of COVID-19 Patients. <em>Journal of Proteome Research.</em><span style=\"color: #ff6600;\"> <a style=\"color: #ff6600;\" href=\"https://doi.org/10.1021/acs.jproteome.0c00280\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1021/acs.jproteome.0c00280</a>.</span>\r\n\r\n</div>','New mass spectrometry-based test recognizes coronavirus in wash arrangements of patients','','inherit','closed','closed','','6623-revision-v1','','','2020-07-16 16:00:35','2020-07-16 16:00:35','',6623,'https://microbiozindia.com/uncategorized/6623-revision-v1/',0,'revision','',0),(6626,2,'2020-07-17 05:36:17','2020-07-17 05:36:17','London, A Covid-19 vaccine manufactured by researchers at Oxford University generated an immune response from the disease in Phase-1 trial,\'\' The Telegraph reported even as official book of those answers are awaited.\r\n\r\nEven the Oxford vaccine candidate is believed to be contributing the race among over 100 to obtain a successful protection against the disorder.\r\n\r\nOxford scientists have found that the jab activates a reply that could provide a\"double citizenship\" contrary to SARS-CoV-2, the virus that leads to Covid-19, The Telegraph report said on Wednesday.\r\n\r\nOxford in April announced an agreement with the UK-based global biopharmaceutical company AstraZeneca for the additional development, large-scale manufacture and potential supply of this Covid-19 vaccine candidate.\r\n\r\nAs the Phase 1 trial of the vaccine candidate began in April itself, a start of this Phase2/Phase-3 UK trial of this Oxford vaccine, named AZD1222, in roughly 10,000 adult volunteers, was first announced in May.\r\n\r\nHowever, the outcome of the Phase 1 trial were still awaited.\r\n\r\nIn June, Astrazeneca CEO Pascal Soriot told Belgian radio station Bel RTL that the Oxford vaccine will likely offer protection from the illness for one year.\r\n\r\n\"We think it\'s going to protect for approximately a year,\" Soriot was quoted as saying.\r\n\r\nAs per a study in City A.M., AstraZeneca is aiming to deliver two billion doses of this drug by the end of the year.\r\n\r\nThe drugmaker had stated it had reached a deal with Europe\'s Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses at the University of Oxford\'s Covid-19 vaccine, with deliveries starting by the end of 2020.\r\n\r\nThe business completed similar agreements with the UK, the US, the Coalition for Epidemic Preparedness Innovations and Gavi the Vaccine Alliance for 700 million dosages, and it agreed a licence with the Serum Institute of India for its distribution of an extra one billion doses, mostly for low- and - middle-income nations.','Oxford Covid antibody beginning phase preliminary shows promise','','publish','open','open','','oxford-covid-antibody-beginning-phase-preliminary-shows-promise-report','','','2020-07-17 05:36:58','2020-07-17 05:36:58','',0,'https://microbiozindia.com/?p=6626',0,'post','',0),(6627,2,'2020-07-17 05:36:17','2020-07-17 05:36:17','London, A Covid-19 vaccine manufactured by researchers at Oxford University generated an immune response from the disease in Phase-1 trial,\'\' The Telegraph reported even as official book of those answers are awaited.\r\n\r\nEven the Oxford vaccine candidate is believed to be contributing the race among over 100 to obtain a successful protection against the disorder.\r\n\r\nOxford scientists have found that the jab activates a reply that could provide a\"double citizenship\" contrary to SARS-CoV-2, the virus that leads to Covid-19, The Telegraph report said on Wednesday.\r\n\r\nOxford in April announced an agreement with the UK-based global biopharmaceutical company AstraZeneca for the additional development, large-scale manufacture and potential supply of this Covid-19 vaccine candidate.\r\n\r\nAs the Phase 1 trial of the vaccine candidate began in April itself, a start of this Phase2/Phase-3 UK trial of this Oxford vaccine, named AZD1222, in roughly 10,000 adult volunteers, was first announced in May.\r\n\r\nHowever, the outcome of the Phase 1 trial were still awaited.\r\n\r\nIn June, Astrazeneca CEO Pascal Soriot told Belgian radio station Bel RTL that the Oxford vaccine will likely offer protection from the illness for one year.\r\n\r\n\"We think it\'s going to protect for approximately a year,\" Soriot was quoted as saying.\r\n\r\nAs per a study in City A.M., AstraZeneca is aiming to deliver two billion doses of this drug by the end of the year.\r\n\r\nThe drugmaker had stated it had reached a deal with Europe\'s Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses at the University of Oxford\'s Covid-19 vaccine, with deliveries starting by the end of 2020.\r\n\r\nThe business completed similar agreements with the UK, the US, the Coalition for Epidemic Preparedness Innovations and Gavi the Vaccine Alliance for 700 million dosages, and it agreed a licence with the Serum Institute of India for its distribution of an extra one billion doses, mostly for low- and - middle-income nations.','Oxford Covid antibody beginning phase preliminary shows guarantee: Report','','inherit','closed','closed','','6626-revision-v1','','','2020-07-17 05:36:17','2020-07-17 05:36:17','',6626,'https://microbiozindia.com/uncategorized/6626-revision-v1/',0,'revision','',0),(6628,2,'2020-07-17 05:36:58','2020-07-17 05:36:58','London, A Covid-19 vaccine manufactured by researchers at Oxford University generated an immune response from the disease in Phase-1 trial,\'\' The Telegraph reported even as official book of those answers are awaited.\r\n\r\nEven the Oxford vaccine candidate is believed to be contributing the race among over 100 to obtain a successful protection against the disorder.\r\n\r\nOxford scientists have found that the jab activates a reply that could provide a\"double citizenship\" contrary to SARS-CoV-2, the virus that leads to Covid-19, The Telegraph report said on Wednesday.\r\n\r\nOxford in April announced an agreement with the UK-based global biopharmaceutical company AstraZeneca for the additional development, large-scale manufacture and potential supply of this Covid-19 vaccine candidate.\r\n\r\nAs the Phase 1 trial of the vaccine candidate began in April itself, a start of this Phase2/Phase-3 UK trial of this Oxford vaccine, named AZD1222, in roughly 10,000 adult volunteers, was first announced in May.\r\n\r\nHowever, the outcome of the Phase 1 trial were still awaited.\r\n\r\nIn June, Astrazeneca CEO Pascal Soriot told Belgian radio station Bel RTL that the Oxford vaccine will likely offer protection from the illness for one year.\r\n\r\n\"We think it\'s going to protect for approximately a year,\" Soriot was quoted as saying.\r\n\r\nAs per a study in City A.M., AstraZeneca is aiming to deliver two billion doses of this drug by the end of the year.\r\n\r\nThe drugmaker had stated it had reached a deal with Europe\'s Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses at the University of Oxford\'s Covid-19 vaccine, with deliveries starting by the end of 2020.\r\n\r\nThe business completed similar agreements with the UK, the US, the Coalition for Epidemic Preparedness Innovations and Gavi the Vaccine Alliance for 700 million dosages, and it agreed a licence with the Serum Institute of India for its distribution of an extra one billion doses, mostly for low- and - middle-income nations.','Oxford Covid antibody beginning phase preliminary shows promise','','inherit','closed','closed','','6626-revision-v1','','','2020-07-17 05:36:58','2020-07-17 05:36:58','',6626,'https://microbiozindia.com/uncategorized/6626-revision-v1/',0,'revision','',0),(6629,2,'2020-07-17 07:25:35','2020-07-17 07:25:35','A emerging hydrogel material with the capability to degrade and reform from the gastro intestinal tract can help scientists develop effective procedures for oral drug delivery.\r\n\r\nThe team\'s microrheology research is included within a guide and interior cover example from the present dilemma of Soft Issue .\r\n\r\nTo describe the material and supply insight to its pharmaceutical possibility, Wu has re purposed a microfluidic device originally manufactured in Schultz\'s laboratory for research to home and fabric care services and products to generate a\"GI tract-on-a-chip.\" <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://pubs.rsc.org/en/content/articlelanding/2020/SM/D0SM00630K#!divAbstract\">The experimental arrangement allows her to swap the fluid environment round the gel to mimic the pH environment of the organs at the GI tract, so mimicking the way the material might react as time passes when ingested.</a></span>\r\n\r\nEmploying microrheology, Wu collects microscopy statistics and measures just how particles within the gel with some experiments requiring others and hours crossing days, based on the digestive manhood she\'s replicating. Wu monitors the particles employing a algorithm which yields clinically authoritative details regarding the properties of this material, that has been originally manufactured by University of Colorado in Boulder professor Kristi S. Anseth.\r\n\r\n\"Usually, dyes wont irritate after which reevaluate with no additional stimulation since these do. We\'ve revealed viability of CAHs as a way of oral medication and nutrient delivery, now we\'re beginning to focus with molecular discharge studies and also adding in different components to help make the experiments more complicated\"\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://pubs.rsc.org/en/content/articlelanding/2020/SM/D0SM00630K#!divAbstract\">Wu was exploring these substances over the duration of her whole PhD studies, \'\' says Schultz. \"She is doing excellent work and is devoted to understanding each facet of the research</a></span>\"\r\n\r\nSchultz\'s research laboratory focuses on the characterization of colloidal and aloe vera scaffolds and also the growth of new strategies to describe these intricate systems, which play essential roles in areas like medical care and consumer solutions.\r\n\r\n\"That which we do at bio-materials is quite unique: There is a great deal of focus with the cross linking chemistry and actually developing those substances, also there exists plenty of animal research which tests and implants them, however there isn\'t so much job at the midst. A lot of puzzle is determined by designing a fabric and understanding what\'s going on if it is workingout. We\'re searching for new ways which individuals may replicate what\'s going on interior an animal or even a individual and collect essential dimensions to join the dots and also in form additional studies.\"\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://engineering.lehigh.edu/news/article/gel-breaks-down-puts-itself-back-together-could-improve-delivery-oral-drugs\" target=\"_blank\" rel=\"noopener noreferrer\">Lehigh University</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nWu, N., <em>et al.</em> (2020) Microrheological characterization of covalent adaptable hydrogel degradation in response to temporal pH changes that mimic the gastrointestinal tract. <em>Soft Matter.</em> <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://dx.doi.org/10.1039/D0SM00630K\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1039/D0SM00630K</a>.</span>\r\n\r\n</div>','Rising hydrogel material could improve oral drug delivery','','publish','open','open','','rising-hydrogel-material-could-improve-oral-drug-delivery','','','2020-07-17 07:25:35','2020-07-17 07:25:35','',0,'https://microbiozindia.com/?p=6629',0,'post','',0),(6630,2,'2020-07-17 07:25:26','2020-07-17 07:25:26','','improving-drug-delivery-through-mesoporous-materials-323549','','inherit','open','closed','','improving-drug-delivery-through-mesoporous-materials-323549','','','2020-07-17 07:25:26','2020-07-17 07:25:26','',6629,'https://microbiozindia.com/wp-content/uploads/2020/07/improving-drug-delivery-through-mesoporous-materials-323549.jpg',0,'attachment','image/jpeg',0),(6631,2,'2020-07-17 07:25:35','2020-07-17 07:25:35','A emerging hydrogel material with the capability to degrade and reform from the gastro intestinal tract can help scientists develop effective procedures for oral drug delivery.\r\n\r\nThe team\'s microrheology research is included within a guide and interior cover example from the present dilemma of Soft Issue .\r\n\r\nTo describe the material and supply insight to its pharmaceutical possibility, Wu has re purposed a microfluidic device originally manufactured in Schultz\'s laboratory for research to home and fabric care services and products to generate a\"GI tract-on-a-chip.\" <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://pubs.rsc.org/en/content/articlelanding/2020/SM/D0SM00630K#!divAbstract\">The experimental arrangement allows her to swap the fluid environment round the gel to mimic the pH environment of the organs at the GI tract, so mimicking the way the material might react as time passes when ingested.</a></span>\r\n\r\nEmploying microrheology, Wu collects microscopy statistics and measures just how particles within the gel with some experiments requiring others and hours crossing days, based on the digestive manhood she\'s replicating. Wu monitors the particles employing a algorithm which yields clinically authoritative details regarding the properties of this material, that has been originally manufactured by University of Colorado in Boulder professor Kristi S. Anseth.\r\n\r\n\"Usually, dyes wont irritate after which reevaluate with no additional stimulation since these do. We\'ve revealed viability of CAHs as a way of oral medication and nutrient delivery, now we\'re beginning to focus with molecular discharge studies and also adding in different components to help make the experiments more complicated\"\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://pubs.rsc.org/en/content/articlelanding/2020/SM/D0SM00630K#!divAbstract\">Wu was exploring these substances over the duration of her whole PhD studies, \'\' says Schultz. \"She is doing excellent work and is devoted to understanding each facet of the research</a></span>\"\r\n\r\nSchultz\'s research laboratory focuses on the characterization of colloidal and aloe vera scaffolds and also the growth of new strategies to describe these intricate systems, which play essential roles in areas like medical care and consumer solutions.\r\n\r\n\"That which we do at bio-materials is quite unique: There is a great deal of focus with the cross linking chemistry and actually developing those substances, also there exists plenty of animal research which tests and implants them, however there isn\'t so much job at the midst. A lot of puzzle is determined by designing a fabric and understanding what\'s going on if it is workingout. We\'re searching for new ways which individuals may replicate what\'s going on interior an animal or even a individual and collect essential dimensions to join the dots and also in form additional studies.\"\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://engineering.lehigh.edu/news/article/gel-breaks-down-puts-itself-back-together-could-improve-delivery-oral-drugs\" target=\"_blank\" rel=\"noopener noreferrer\">Lehigh University</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nWu, N., <em>et al.</em> (2020) Microrheological characterization of covalent adaptable hydrogel degradation in response to temporal pH changes that mimic the gastrointestinal tract. <em>Soft Matter.</em> <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://dx.doi.org/10.1039/D0SM00630K\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1039/D0SM00630K</a>.</span>\r\n\r\n</div>','Rising hydrogel material could improve oral drug delivery','','inherit','closed','closed','','6629-revision-v1','','','2020-07-17 07:25:35','2020-07-17 07:25:35','',6629,'https://microbiozindia.com/uncategorized/6629-revision-v1/',0,'revision','',0),(6632,2,'2020-07-17 07:52:41','2020-07-17 07:52:41','An peer-reviewed study by researchers in NSF International and also Novateur Ventures, Vancouver, British Columbia, Canada, found significant variability within the accuracy of now available covid-19 antibody tests.1\r\n\r\nFrom the absence of experiments and effective therapeutics such as SARS-CoV-2 and also the associated covid-19 disorder, dependable antibody testing is sometimes a key section of general health plan to restrain further spread of their disorder and also gradually ease quarantine measures.\r\n\r\nThe urgent need for its growth of antibody diagnostic tests in response to this covid-19 pandemic has forced regulatory bodies to employ emergency use authorization programs to expedite the commercialization procedure for these tests. \"Granting FDA emergency usage suthorization to several organizations to accelerate the manufacturing of diagnostic tests proved to be a good movement,\" says Abdi Ghaffari, PhD, adviser in scientific events atNovateur Ventures and an adjunct associate professor at Queen\'s University. \"However, it has to be accompanied by clear and informed guidelines on preferred and acceptable profiles of their covid-19 antibody evaluations designed for a specific sign\"\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.mdpi.com/2075-4418/10/7/453\">Published independent performance statistics of five chemiluminescence immunoassays, 15 enzyme-linked immunosorbent assays, along with 42 rapid diagnostic tests that are now available on industry were reviewed to comprehend their potential and limits.</a></span>\r\n\r\nThe findings showed significant variability in the accuracy of promoted tests and highlighted several lab-based and point-of-care rapid diagnostic evaluations with high end degrees in discovering SARS-CoV-2 particular antibodies. The findings of this review highlight the significance of ongoing independent evaluations of commercialized covid-19 analytical evaluations.\r\n\r\nThe study identified 1-3 top-performing covid-19 antibody tests based on individual tests of these sensitivity (ability to accurately identify people with the disease) and specificity (ability to accurately identify individuals with no disorder ) data (&gt;95% accuracy).\r\n\r\nAntibody tests can match molecular-based tests in providing a more accurate quote of SARS-CoV-2 incidence and potentially detect people who have immunity against the disorder as these tests detect markers of their immune reaction.\r\n\r\nFor more information, visit <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.nsf.org/\">NSF International</a> </span>and <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://www.novateur.ca/\">Novateur Ventures</a>.</span>\r\n\r\n<strong>Reference</strong>\r\n\r\n1. Ghaffari A, Meurant R, Ardakani A. Covid-19 serological tests: how well do they actually perform? <em>Diagnostics.</em>2020;10(7):453; doi: <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.mdpi.com/2075-4418/10/7/453\">10.3390/diagnostics10070453</a></span>.\r\n\r\n&nbsp;','Execution of Covid-19 Antibody Tests Ranked','','publish','open','open','','execution-of-covid-19-antibody-tests-ranked','','','2020-07-17 08:06:28','2020-07-17 08:06:28','',0,'https://microbiozindia.com/?p=6632',0,'post','',0),(6633,2,'2020-07-17 07:47:17','2020-07-17 07:47:17','','85972','','inherit','open','closed','','85972','','','2020-07-17 07:47:17','2020-07-17 07:47:17','',6632,'https://microbiozindia.com/wp-content/uploads/2020/07/85972.jpg',0,'attachment','image/jpeg',0),(6634,2,'2020-07-17 07:52:41','2020-07-17 07:52:41','An peer-reviewed study by researchers in NSF International and also Novateur Ventures, Vancouver, British Columbia, Canada, found significant variability within the accuracy of now available covid-19 antibody tests.1\r\n\r\nFrom the absence of experiments and effective therapeutics such as SARS-CoV-2 and also the associated covid-19 disorder, dependable antibody testing is sometimes a key section of general health plan to restrain further spread of their disorder and also gradually ease quarantine measures.\r\n\r\nThe urgent need for its growth of antibody diagnostic tests in response to this covid-19 pandemic has forced regulatory bodies to employ emergency use authorization programs to expedite the commercialization procedure for these tests. \"Granting FDA emergency usage suthorization to several organizations to accelerate the manufacturing of diagnostic tests proved to be a good movement,\" says Abdi Ghaffari, PhD, adviser in scientific events atNovateur Ventures and an adjunct associate professor at Queen\'s University. \"However, it has to be accompanied by clear and informed guidelines on preferred and acceptable profiles of their covid-19 antibody evaluations designed for a specific sign\"\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.mdpi.com/2075-4418/10/7/453\">Published independent performance statistics of five chemiluminescence immunoassays, 15 enzyme-linked immunosorbent assays, along with 42 rapid diagnostic tests that are now available on industry were reviewed to comprehend their potential and limits.</a></span>\r\n\r\nThe findings showed significant variability in the accuracy of promoted tests and highlighted several lab-based and point-of-care rapid diagnostic evaluations with high end degrees in discovering SARS-CoV-2 particular antibodies. The findings of this review highlight the significance of ongoing independent evaluations of commercialized covid-19 analytical evaluations.\r\n\r\nThe study identified 1-3 top-performing covid-19 antibody tests based on individual tests of these sensitivity (ability to accurately identify people with the disease) and specificity (ability to accurately identify individuals with no disorder ) data (&gt;95% accuracy).\r\n\r\nAntibody tests can match molecular-based tests in providing a more accurate quote of SARS-CoV-2 incidence and potentially detect people who have immunity against the disorder as these tests detect markers of their immune reaction.\r\n\r\n<strong>Reference</strong>\r\n\r\n1. Ghaffari A, Meurant R, Ardakani A. Covid-19 serological tests: how well do they actually perform? <em>Diagnostics.</em>2020;10(7):453; doi: <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.mdpi.com/2075-4418/10/7/453\">10.3390/diagnostics10070453</a></span>.\r\n\r\n&nbsp;','Execution of Covid-19 Antibody Tests Ranked','','inherit','closed','closed','','6632-revision-v1','','','2020-07-17 07:52:41','2020-07-17 07:52:41','',6632,'https://microbiozindia.com/uncategorized/6632-revision-v1/',0,'revision','',0),(6635,2,'2020-07-17 08:06:28','2020-07-17 08:06:28','An peer-reviewed study by researchers in NSF International and also Novateur Ventures, Vancouver, British Columbia, Canada, found significant variability within the accuracy of now available covid-19 antibody tests.1\r\n\r\nFrom the absence of experiments and effective therapeutics such as SARS-CoV-2 and also the associated covid-19 disorder, dependable antibody testing is sometimes a key section of general health plan to restrain further spread of their disorder and also gradually ease quarantine measures.\r\n\r\nThe urgent need for its growth of antibody diagnostic tests in response to this covid-19 pandemic has forced regulatory bodies to employ emergency use authorization programs to expedite the commercialization procedure for these tests. \"Granting FDA emergency usage suthorization to several organizations to accelerate the manufacturing of diagnostic tests proved to be a good movement,\" says Abdi Ghaffari, PhD, adviser in scientific events atNovateur Ventures and an adjunct associate professor at Queen\'s University. \"However, it has to be accompanied by clear and informed guidelines on preferred and acceptable profiles of their covid-19 antibody evaluations designed for a specific sign\"\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.mdpi.com/2075-4418/10/7/453\">Published independent performance statistics of five chemiluminescence immunoassays, 15 enzyme-linked immunosorbent assays, along with 42 rapid diagnostic tests that are now available on industry were reviewed to comprehend their potential and limits.</a></span>\r\n\r\nThe findings showed significant variability in the accuracy of promoted tests and highlighted several lab-based and point-of-care rapid diagnostic evaluations with high end degrees in discovering SARS-CoV-2 particular antibodies. The findings of this review highlight the significance of ongoing independent evaluations of commercialized covid-19 analytical evaluations.\r\n\r\nThe study identified 1-3 top-performing covid-19 antibody tests based on individual tests of these sensitivity (ability to accurately identify people with the disease) and specificity (ability to accurately identify individuals with no disorder ) data (&gt;95% accuracy).\r\n\r\nAntibody tests can match molecular-based tests in providing a more accurate quote of SARS-CoV-2 incidence and potentially detect people who have immunity against the disorder as these tests detect markers of their immune reaction.\r\n\r\nFor more information, visit <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.nsf.org/\">NSF International</a> </span>and <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://www.novateur.ca/\">Novateur Ventures</a>.</span>\r\n\r\n<strong>Reference</strong>\r\n\r\n1. Ghaffari A, Meurant R, Ardakani A. Covid-19 serological tests: how well do they actually perform? <em>Diagnostics.</em>2020;10(7):453; doi: <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.mdpi.com/2075-4418/10/7/453\">10.3390/diagnostics10070453</a></span>.\r\n\r\n&nbsp;','Execution of Covid-19 Antibody Tests Ranked','','inherit','closed','closed','','6632-revision-v1','','','2020-07-17 08:06:28','2020-07-17 08:06:28','',6632,'https://microbiozindia.com/uncategorized/6632-revision-v1/',0,'revision','',0),(6636,2,'2020-07-17 12:11:19','2020-07-17 12:11:19','A Health Trends research from researchers in Quest Diagnostics, Secaucus, NJ, and the University of Pittsburgh Medical Center demonstrates the human papillomavirus (HPV) screening evaluation is less likely to find cervical cancer and precancer compared to cotesting, a procedure that combines HPV and Pap (Papanicolaou evaluation by liquid-based cytology) testing with the exact same specimen<sup>1</sup>\r\n\r\nThe study is the largest so far to estimate the operation of all guideline-recommended cervical cancer screening approaches at a varied population of American girls in real-world care preferences. It shows stark differences in the operation of the many suggested methods in detecting cancer and precancers in women 30 decades old and older.\r\n\r\nThe Health Trends study analyzed sensitivity levels of HPV alone, Pap independently, also cotesting in discovering cancer and precancer of the cervix in almost 19 million deidentified cotest effects achieved by Quest Diagnostics on behalf of 13.6 million girls in america by 2010 to 2018. Of those circumstances, 1,259 were diagnosed with cervical cancertwice the amount of cancer cases as the next biggest study<sup>2</sup>\r\n\r\n\"It should put to rest any thought that HPV alone accomplishes the identical pub for cancer screening\"\r\n\r\n\"Since many cervical cancers grow in the absence of standard screening, making sure women have access to the most dependable screening procedure, cotesting, when they\'re screened is a vital step in reducing mortality from the disease.\"\r\n\r\n<img class=\"alignnone wp-image-6637\" src=\"https://microbiozindia.com/wp-content/uploads/2020/07/quest-diagnostics-proposed-breach-settlement-approved-showcase_image-3-a-13305-300x181.jpg\" alt=\"\" width=\"335\" height=\"202\" />\r\n\r\n<strong>Among the key findings:</strong>\r\n\r\n1.HPV and Pap testing alone fails to detect twice as many women who develop cervical cancer as cotesting. Of 1,615 cotests taken at any time prior to a cancer diagnosis, 86.9% were positive by cotesting, a nondetection rate (also known as false negative) of about 13.1%. By comparison, Pap and HPV testing alone had nondetection rates nearly twice as high: Pap at 26.4% and HPV at 28.4%.\r\n\r\n2.Cotesting detected significantly more women who developed biopsy-confirmed adenocarcinomas, a typically aggressive form of cervical cancer, identifying 82.3% of this cancer compared to only 61.2% by HPV and 59.7% by Pap.\r\n\r\n3.HPV test fails to identify one in five women who develop cancer when performed within a year of cancer diagnosis. Among women screened within one year of a cancer diagnosis, the non-detection rate for HPV testing alone was 22.5%, nearly 1.5 times higher than Pap (14.9%) and four times higher than cotesting (5.9%).\r\n\r\n4.Cotesting detected more women who developed biopsy-confirmed precancers than HPV or Pap alone, identifying 95.6% of these precancers, compared to 92.6% by HPV and 77.9% by Pap.\r\n\r\n\"For girls who might not be screened in any way, there\'s absolutely no question which cytology or HPV main are helpful testing technologies,\" says Damian P. Alagia, III, MD, senior medical director of lady\'s wellbeing for Quest Diagnostics. \"Yet that shouldn\'t obscure the reality that cotesting is basically the better screening choice for girls and is widely accessible in the USA.\"\r\n\r\nFor more information, visit<span style=\"color: #ff6600;\"> <a style=\"color: #ff6600;\" href=\"http://www.questdiagnostics.com/HealthTrends\">Quest Diagnostics</a>.</span>\r\n\r\n<strong>References</strong>\r\n<ol>\r\n 	<li>Austin RM, Onisko A, Zhao C. Enhanced detection of cervical cancer and precancer through use of imaged liquid-based cytology in routine cytology and HPV cotesting. Am J Clin Pathol. 2018;150:385-392. doi.org/10.1093/ajcp/aqy114.</li>\r\n 	<li>Adegoke O, Kulasingam S, Virnig B. Cervical cancer trends in the United States: a 35-year population-based analysis. <em>J Woman’s Health.</em>2012;21(10):1031-1037.doi: 10.1089/jwh.2011.3385.</li>\r\n</ol>','HPV Test Misses Twice the same number of Women Who Develop Cervical Cancer as Cotesting','','publish','open','open','','hpv-test-misses-twice-the-same-number-of-women-who-develop-cervical-cancer-as-cotesting','','','2020-07-17 12:16:22','2020-07-17 12:16:22','',0,'https://microbiozindia.com/?p=6636',0,'post','',0),(6637,2,'2020-07-17 12:06:01','2020-07-17 12:06:01','','quest-diagnostics-proposed-breach-settlement-approved-showcase_image-3-a-13305','','inherit','open','closed','','quest-diagnostics-proposed-breach-settlement-approved-showcase_image-3-a-13305','','','2020-07-17 12:06:01','2020-07-17 12:06:01','',6636,'https://microbiozindia.com/wp-content/uploads/2020/07/quest-diagnostics-proposed-breach-settlement-approved-showcase_image-3-a-13305.jpg',0,'attachment','image/jpeg',0),(6638,2,'2020-07-17 12:06:36','2020-07-17 12:06:36','','Molecular_Diagnostics_September-2019','','inherit','open','closed','','molecular_diagnostics_september-2019','','','2020-07-17 12:06:36','2020-07-17 12:06:36','',6636,'https://microbiozindia.com/wp-content/uploads/2020/07/Molecular_Diagnostics_September-2019.jpg',0,'attachment','image/jpeg',0),(6639,2,'2020-07-17 12:11:19','2020-07-17 12:11:19','A Health Trends research from researchers in Quest Diagnostics, Secaucus, NJ, and the University of Pittsburgh Medical Center demonstrates the human papillomavirus (HPV) screening evaluation is less likely to find cervical cancer and precancer compared to cotesting, a procedure that combines HPV and Pap (Papanicolaou evaluation by liquid-based cytology) testing with the exact same specimen<sup>1</sup>\r\n\r\nThe study is the largest so far to estimate the operation of all guideline-recommended cervical cancer screening approaches at a varied population of American girls in real-world care preferences. It shows stark differences in the operation of the many suggested methods in detecting cancer and precancers in women 30 decades old and older.\r\n\r\nThe Health Trends study analyzed sensitivity levels of HPV alone, Pap independently, also cotesting in discovering cancer and precancer of the cervix in almost 19 million deidentified cotest effects achieved by Quest Diagnostics on behalf of 13.6 million girls in america by 2010 to 2018. Of those circumstances, 1,259 were diagnosed with cervical cancertwice the amount of cancer cases as the next biggest study<sup>2</sup>\r\n\r\n\"It should put to rest any thought that HPV alone accomplishes the identical pub for cancer screening\"\r\n\r\n\"Since many cervical cancers grow in the absence of standard screening, making sure women have access to the most dependable screening procedure, cotesting, when they\'re screened is a vital step in reducing mortality from the disease.\"\r\n\r\n<img class=\"alignnone  wp-image-6637\" src=\"https://microbiozindia.com/wp-content/uploads/2020/07/quest-diagnostics-proposed-breach-settlement-approved-showcase_image-3-a-13305-300x181.jpg\" alt=\"\" width=\"335\" height=\"202\" />\r\n\r\n<strong>Among the key findings:</strong>\r\n<ul>\r\n 	<li>HPV and Pap testing alone fails to detect twice as many women who develop cervical cancer as cotesting. Of 1,615 cotests taken at any time prior to a cancer diagnosis, 86.9% were positive by cotesting, a nondetection rate (also known as false negative) of about 13.1%. By comparison, Pap and HPV testing alone had nondetection rates nearly twice as high: Pap at 26.4% and HPV at 28.4%.</li>\r\n 	<li>Cotesting detected significantly more women who developed biopsy-confirmed adenocarcinomas, a typically aggressive form of cervical cancer, identifying 82.3% of this cancer compared to only 61.2% by HPV and 59.7% by Pap.</li>\r\n 	<li>HPV test fails to identify one in five women who develop cancer when performed within a year of cancer diagnosis. Among women screened within one year of a cancer diagnosis, the non-detection rate for HPV testing alone was 22.5%, nearly 1.5 times higher than Pap (14.9%) and four times higher than cotesting (5.9%).</li>\r\n 	<li>Cotesting detected more women who developed biopsy-confirmed precancers than HPV or Pap alone, identifying 95.6% of these precancers, compared to 92.6% by HPV and 77.9% by Pap.</li>\r\n</ul>\r\n\"For girls who might not be screened in any way, there\'s absolutely no question which cytology or HPV main are helpful testing technologies,\" says Damian P. Alagia, III, MD, senior medical director of lady\'s wellbeing for Quest Diagnostics. \"Yet that shouldn\'t obscure the reality that cotesting is basically the better screening choice for girls and is widely accessible in the USA.\"\r\n\r\nFor more information, visit<span style=\"color: #ff6600;\"> <a style=\"color: #ff6600;\" href=\"http://www.questdiagnostics.com/HealthTrends\">Quest Diagnostics</a>.</span>\r\n\r\n<strong>References</strong>\r\n<ol>\r\n 	<li>Austin RM, Onisko A, Zhao C. Enhanced detection of cervical cancer and precancer through use of imaged liquid-based cytology in routine cytology and HPV cotesting. Am J Clin Pathol. 2018;150:385-392. doi.org/10.1093/ajcp/aqy114.</li>\r\n 	<li>Adegoke O, Kulasingam S, Virnig B. Cervical cancer trends in the United States: a 35-year population-based analysis. <em>J Woman’s Health.</em>2012;21(10):1031-1037.doi: 10.1089/jwh.2011.3385.</li>\r\n</ol>','HPV Test Misses Twice the same number of Women Who Develop Cervical Cancer as Cotesting','','inherit','closed','closed','','6636-revision-v1','','','2020-07-17 12:11:19','2020-07-17 12:11:19','',6636,'https://microbiozindia.com/uncategorized/6636-revision-v1/',0,'revision','',0),(6640,2,'2020-07-17 12:16:22','2020-07-17 12:16:22','A Health Trends research from researchers in Quest Diagnostics, Secaucus, NJ, and the University of Pittsburgh Medical Center demonstrates the human papillomavirus (HPV) screening evaluation is less likely to find cervical cancer and precancer compared to cotesting, a procedure that combines HPV and Pap (Papanicolaou evaluation by liquid-based cytology) testing with the exact same specimen<sup>1</sup>\r\n\r\nThe study is the largest so far to estimate the operation of all guideline-recommended cervical cancer screening approaches at a varied population of American girls in real-world care preferences. It shows stark differences in the operation of the many suggested methods in detecting cancer and precancers in women 30 decades old and older.\r\n\r\nThe Health Trends study analyzed sensitivity levels of HPV alone, Pap independently, also cotesting in discovering cancer and precancer of the cervix in almost 19 million deidentified cotest effects achieved by Quest Diagnostics on behalf of 13.6 million girls in america by 2010 to 2018. Of those circumstances, 1,259 were diagnosed with cervical cancertwice the amount of cancer cases as the next biggest study<sup>2</sup>\r\n\r\n\"It should put to rest any thought that HPV alone accomplishes the identical pub for cancer screening\"\r\n\r\n\"Since many cervical cancers grow in the absence of standard screening, making sure women have access to the most dependable screening procedure, cotesting, when they\'re screened is a vital step in reducing mortality from the disease.\"\r\n\r\n<img class=\"alignnone wp-image-6637\" src=\"https://microbiozindia.com/wp-content/uploads/2020/07/quest-diagnostics-proposed-breach-settlement-approved-showcase_image-3-a-13305-300x181.jpg\" alt=\"\" width=\"335\" height=\"202\" />\r\n\r\n<strong>Among the key findings:</strong>\r\n\r\n1.HPV and Pap testing alone fails to detect twice as many women who develop cervical cancer as cotesting. Of 1,615 cotests taken at any time prior to a cancer diagnosis, 86.9% were positive by cotesting, a nondetection rate (also known as false negative) of about 13.1%. By comparison, Pap and HPV testing alone had nondetection rates nearly twice as high: Pap at 26.4% and HPV at 28.4%.\r\n\r\n2.Cotesting detected significantly more women who developed biopsy-confirmed adenocarcinomas, a typically aggressive form of cervical cancer, identifying 82.3% of this cancer compared to only 61.2% by HPV and 59.7% by Pap.\r\n\r\n3.HPV test fails to identify one in five women who develop cancer when performed within a year of cancer diagnosis. Among women screened within one year of a cancer diagnosis, the non-detection rate for HPV testing alone was 22.5%, nearly 1.5 times higher than Pap (14.9%) and four times higher than cotesting (5.9%).\r\n\r\n4.Cotesting detected more women who developed biopsy-confirmed precancers than HPV or Pap alone, identifying 95.6% of these precancers, compared to 92.6% by HPV and 77.9% by Pap.\r\n\r\n\"For girls who might not be screened in any way, there\'s absolutely no question which cytology or HPV main are helpful testing technologies,\" says Damian P. Alagia, III, MD, senior medical director of lady\'s wellbeing for Quest Diagnostics. \"Yet that shouldn\'t obscure the reality that cotesting is basically the better screening choice for girls and is widely accessible in the USA.\"\r\n\r\nFor more information, visit<span style=\"color: #ff6600;\"> <a style=\"color: #ff6600;\" href=\"http://www.questdiagnostics.com/HealthTrends\">Quest Diagnostics</a>.</span>\r\n\r\n<strong>References</strong>\r\n<ol>\r\n 	<li>Austin RM, Onisko A, Zhao C. Enhanced detection of cervical cancer and precancer through use of imaged liquid-based cytology in routine cytology and HPV cotesting. Am J Clin Pathol. 2018;150:385-392. doi.org/10.1093/ajcp/aqy114.</li>\r\n 	<li>Adegoke O, Kulasingam S, Virnig B. Cervical cancer trends in the United States: a 35-year population-based analysis. <em>J Woman’s Health.</em>2012;21(10):1031-1037.doi: 10.1089/jwh.2011.3385.</li>\r\n</ol>','HPV Test Misses Twice the same number of Women Who Develop Cervical Cancer as Cotesting','','inherit','closed','closed','','6636-revision-v1','','','2020-07-17 12:16:22','2020-07-17 12:16:22','',6636,'https://microbiozindia.com/uncategorized/6636-revision-v1/',0,'revision','',0),(6641,2,'2020-07-18 11:52:20','2020-07-18 11:52:20','Bharat Biotech has initiated human clinical trials for Covaxin, a vaccine candidate for COVID-19, across the nation with 375 volunteers, amid the surging numbers of coronavirus cases.\r\n\r\nIndia\'s COVID-19 caseload jumped to 10,38,716 with 34,884 people testing positive for coronavirus in the last 24 hours, based on information published by the Union Health Ministry on July 18.\r\n\r\nThe Drugs Controller General of India (DCGI) had permitted two vaccines -- one developed from the Bharat Biotech International Limited in collaboration with the Indian Council of Medical Research and a different one by ZydusCadila Healthcare Ltd to go in for the second and first phase of human clinical trials.\r\n<iframe src=\"https://www.youtube.com/embed/tATw5Zg_iiQ\" width=\"560\" height=\"315\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"></iframe>\r\n\r\n<strong>Here are all the developments about COVID-19 vaccine:</strong>\r\n\r\n&gt; The individual trial of Covaxin started at Rohtak\'s Post-Graduate Institute of Medical Sciences on July 17, Haryana Health Minister Anil Vij said.\r\n\r\n&gt; Drug firm Zydus Cadila is looking to complete clinical trials of its COVID-19 vaccine candidate ZyCoV-D in seven weeks, according to the organization\'s chairman. The organization had on Wednesday began clinical trials of its COVID-19 vaccine candidate with the first human dosing.\r\n\r\nDBT\'s Translational Health Science and Technology Institute (THSTI), Faridabad, has established that a hamster infection model for analysis of antivirals, therapeutics and vaccines, it said.\r\n\r\n&gt; India and the US are working together on combating the coronavirus and cooperation is underway for co-development of a COVID-19 vaccine, the Indian envoy has said, underlining that the partnership between the two countries in health, life sciences and technology sectors can bring benefits to the whole world.','Bharat Biotech begins human preliminaries of Covaxin','','publish','open','open','','bharat-biotech-begins-human-preliminaries-of-covaxin','','','2020-07-18 19:00:49','2020-07-18 19:00:49','',0,'https://microbiozindia.com/?p=6641',0,'post','',0),(6642,2,'2020-07-18 11:52:20','2020-07-18 11:52:20','Bharat Biotech has initiated human clinical trials for Covaxin, a vaccine candidate for COVID-19, across the nation with 375 volunteers, amid the surging numbers of coronavirus cases.\r\n\r\nIndia\'s COVID-19 caseload jumped to 10,38,716 with 34,884 people testing positive for coronavirus in the last 24 hours, based on information published by the Union Health Ministry on July 18.\r\n\r\nThe Drugs Controller General of India (DCGI) had permitted two vaccines -- one developed from the Bharat Biotech International Limited in collaboration with the Indian Council of Medical Research and a different one by ZydusCadila Healthcare Ltd to go in for the second and first phase of human clinical trials.\r\n\r\n<strong>Here are all the developments about COVID-19 vaccine:</strong>\r\n\r\n&gt; The individual trial of Covaxin started at Rohtak\'s Post-Graduate Institute of Medical Sciences on July 17, Haryana Health Minister Anil Vij said.\r\n\r\n&gt; Drug firm Zydus Cadila is looking to complete clinical trials of its COVID-19 vaccine candidate ZyCoV-D in seven weeks, according to the organization\'s chairman. The organization had on Wednesday began clinical trials of its COVID-19 vaccine candidate with the first human dosing.\r\n\r\nDBT\'s Translational Health Science and Technology Institute (THSTI), Faridabad, has established that a hamster infection model for analysis of antivirals, therapeutics and vaccines, it said.\r\n\r\n&gt; India and the US are working together on combating the coronavirus and cooperation is underway for co-development of a COVID-19 vaccine, the Indian envoy has said, underlining that the partnership between the two countries in health, life sciences and technology sectors can bring benefits to the whole world.','Bharat Biotech begins human preliminaries of Covaxin','','inherit','closed','closed','','6641-revision-v1','','','2020-07-18 11:52:20','2020-07-18 11:52:20','',6641,'https://microbiozindia.com/uncategorized/6641-revision-v1/',0,'revision','',0),(6643,2,'2020-07-18 11:57:52','2020-07-18 11:57:52','The number of confirmed cases in a new COVID-19 epidemic in China\'s far west has climbed to 17. The National Health Commission said Saturday that 16 more cases had been identified in the previous 24 hours in the Xinjiang region, in addition to a very first case.\r\n\r\nThe outbreak at the city of Urumqi is the newest to pop up since China largely contained the national spread of this virus in March. The biggest was a recent outbreak in Beijing that infected more than 330 people.\r\n\r\nGovernment in Urumqi have reduced subways, buses and taxis and shut off several residential areas, according to Chinese media reports. They also placed restrictions on individuals leaving the city, including a suspension of subway service to the airport.\r\n\r\nChina has been accused of human rights abuses in Xinjiang, the homeland of the largely Muslim Uighur ethnic community. The area has long been blanketed with extreme security, which China says is crucial to stop terrorist action.','China fights new flare-up in far west Xinjiang','','publish','open','open','','china-fights-new-flare-up-in-far-west-xinjiang','','','2020-07-18 11:57:52','2020-07-18 11:57:52','',0,'https://microbiozindia.com/?p=6643',0,'post','',0),(6644,2,'2020-07-18 11:57:52','2020-07-18 11:57:52','The number of confirmed cases in a new COVID-19 epidemic in China\'s far west has climbed to 17. The National Health Commission said Saturday that 16 more cases had been identified in the previous 24 hours in the Xinjiang region, in addition to a very first case.\r\n\r\nThe outbreak at the city of Urumqi is the newest to pop up since China largely contained the national spread of this virus in March. The biggest was a recent outbreak in Beijing that infected more than 330 people.\r\n\r\nGovernment in Urumqi have reduced subways, buses and taxis and shut off several residential areas, according to Chinese media reports. They also placed restrictions on individuals leaving the city, including a suspension of subway service to the airport.\r\n\r\nChina has been accused of human rights abuses in Xinjiang, the homeland of the largely Muslim Uighur ethnic community. The area has long been blanketed with extreme security, which China says is crucial to stop terrorist action.','China fights new flare-up in far west Xinjiang','','inherit','closed','closed','','6643-revision-v1','','','2020-07-18 11:57:52','2020-07-18 11:57:52','',6643,'https://microbiozindia.com/uncategorized/6643-revision-v1/',0,'revision','',0),(6645,2,'2020-07-18 12:36:39','2020-07-18 12:36:39','New research has identified the particular brain cells that control just how much sugar you eat and how much you crave sweet tasting meals.\r\n\r\nMost people like a candy treat every now and then. However an unchecked\"sweet tooth\" can lead to overconsumption of sugary foods and chronic health problems such as obesity and type two diabetes. Knowing the biological mechanisms that control sugar intake and taste for sweet taste could have significant implications for managing and preventing these health problems.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://medicine.uiowa.edu/content/study-pinpoints-brain-cells-trigger-sugar-cravings-and-consumption\">The new study, led by Matthew Potthoff, PhD, associate professor of neuroscience and pharmacology in the University of Iowa Carver College of Medicine, and Matthew Gillum, PhD, at the University of Copenhagen in Denmark, focuses on activities of a hormone called fibroblast growth factor 21 (FGF21). This hormone is known to play a role in energy balance, body weight control, and insulin sensitivity.</a></span>\r\n\r\n<em>This is the first study that\'s really identified where this hormone is acting in the brain and that has provided some very cool insights to how it\'s regulating sugar intake.\"-</em>Matthew Potthoff, member of the Fraternal Order of Eagles Diabetes Research Center at the UI and the Iowa Neuroscience Institute\r\n\r\nPotthoff and his coworkers previously found that FGF21 is made in the liver in response to increased levels of sugar, and acts in the brain to suppress glucose intake and the preference for sweet taste.\r\n\r\nBuilding on that finding, the team has shown, for the first time, which brain cells respond to FGF21\'s signs and how interaction helps regulate glucose intake and sweet flavor preference.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://medicine.uiowa.edu/content/study-pinpoints-brain-cells-trigger-sugar-cravings-and-consumption\">Although it was understood that FGF21 acted from the mind, identifying the precise cellular targets was complicated by the fact that the hormone\'s receptor is expressed at very low levels and is consequently hard to\"see.\"</a> </span>Using a variety of methods, the researchers were able to precisely identify which cells express the receptor for FGF21. By investigating these cells, the analysis shows that FGF21 targets glutamatergic neurons in the brain to lower sugar consumption and sweet flavor preference. The researchers also showed that FGF21\'s action on particular neurons in the ventromedial hypothalamus reduce glucose consumption by improving the neurons\' sensitivity to sugar.\r\n\r\nSeveral drugs according to a modified kind of FGF21 happen to be tested as treatments for obesity and diabetes. The new findings could lead to new drugs that precisely target different behaviours controlled by FGF21, which could help to control how much sugar a individual eats.\r\n\r\n<strong>Source:</strong>\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://medicine.uiowa.edu/content/study-pinpoints-brain-cells-trigger-sugar-cravings-and-consumption\">University of Iowa Health Care</a></span>\r\n\r\n<strong>Journal reference:</strong>\r\nJensen-Cody, S.O., et al. (2020) FGF21 Signals to Glutamatergic Neurons in the Ventromedial Hypothalamus to Suppress Carbohydrate Intake. Cell Metabolism. doi.org/10.1016/j.cmet.2020.06.008.','Examination distinguishes explicit brain cells that trigger sugar utilization and longings','','publish','open','open','','examination-distinguishes-explicit-brain-cells-that-trigger-sugar-utilization-and-longings','','','2020-07-18 12:36:39','2020-07-18 12:36:39','',0,'https://microbiozindia.com/?p=6645',0,'post','',0),(6646,2,'2020-07-18 12:35:19','2020-07-18 12:35:19','','040920_ls_review-brain_feat-1028x579','','inherit','open','closed','','040920_ls_review-brain_feat-1028x579','','','2020-07-18 12:35:19','2020-07-18 12:35:19','',6645,'https://microbiozindia.com/wp-content/uploads/2020/07/040920_ls_review-brain_feat-1028x579-1.jpg',0,'attachment','image/jpeg',0),(6647,2,'2020-07-18 12:36:39','2020-07-18 12:36:39','New research has identified the particular brain cells that control just how much sugar you eat and how much you crave sweet tasting meals.\r\n\r\nMost people like a candy treat every now and then. However an unchecked\"sweet tooth\" can lead to overconsumption of sugary foods and chronic health problems such as obesity and type two diabetes. Knowing the biological mechanisms that control sugar intake and taste for sweet taste could have significant implications for managing and preventing these health problems.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://medicine.uiowa.edu/content/study-pinpoints-brain-cells-trigger-sugar-cravings-and-consumption\">The new study, led by Matthew Potthoff, PhD, associate professor of neuroscience and pharmacology in the University of Iowa Carver College of Medicine, and Matthew Gillum, PhD, at the University of Copenhagen in Denmark, focuses on activities of a hormone called fibroblast growth factor 21 (FGF21). This hormone is known to play a role in energy balance, body weight control, and insulin sensitivity.</a></span>\r\n\r\n<em>This is the first study that\'s really identified where this hormone is acting in the brain and that has provided some very cool insights to how it\'s regulating sugar intake.\"-</em>Matthew Potthoff, member of the Fraternal Order of Eagles Diabetes Research Center at the UI and the Iowa Neuroscience Institute\r\n\r\nPotthoff and his coworkers previously found that FGF21 is made in the liver in response to increased levels of sugar, and acts in the brain to suppress glucose intake and the preference for sweet taste.\r\n\r\nBuilding on that finding, the team has shown, for the first time, which brain cells respond to FGF21\'s signs and how interaction helps regulate glucose intake and sweet flavor preference.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://medicine.uiowa.edu/content/study-pinpoints-brain-cells-trigger-sugar-cravings-and-consumption\">Although it was understood that FGF21 acted from the mind, identifying the precise cellular targets was complicated by the fact that the hormone\'s receptor is expressed at very low levels and is consequently hard to\"see.\"</a> </span>Using a variety of methods, the researchers were able to precisely identify which cells express the receptor for FGF21. By investigating these cells, the analysis shows that FGF21 targets glutamatergic neurons in the brain to lower sugar consumption and sweet flavor preference. The researchers also showed that FGF21\'s action on particular neurons in the ventromedial hypothalamus reduce glucose consumption by improving the neurons\' sensitivity to sugar.\r\n\r\nSeveral drugs according to a modified kind of FGF21 happen to be tested as treatments for obesity and diabetes. The new findings could lead to new drugs that precisely target different behaviours controlled by FGF21, which could help to control how much sugar a individual eats.\r\n\r\n<strong>Source:</strong>\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://medicine.uiowa.edu/content/study-pinpoints-brain-cells-trigger-sugar-cravings-and-consumption\">University of Iowa Health Care</a></span>\r\n\r\n<strong>Journal reference:</strong>\r\nJensen-Cody, S.O., et al. (2020) FGF21 Signals to Glutamatergic Neurons in the Ventromedial Hypothalamus to Suppress Carbohydrate Intake. Cell Metabolism. doi.org/10.1016/j.cmet.2020.06.008.','Examination distinguishes explicit brain cells that trigger sugar utilization and longings','','inherit','closed','closed','','6645-revision-v1','','','2020-07-18 12:36:39','2020-07-18 12:36:39','',6645,'https://microbiozindia.com/uncategorized/6645-revision-v1/',0,'revision','',0),(6648,2,'2020-07-18 13:39:30','2020-07-18 13:39:30','','microbioz india ad_acc_covidsafe&#x2122;_798x103[h]px_3_090620_RGB-01','','inherit','open','closed','','microbioz-india-ad_acc_covidsafe_798x103hpx_3_090620_rgb-01','','','2020-07-18 13:39:30','2020-07-18 13:39:30','',6037,'https://microbiozindia.com/wp-content/uploads/2020/06/microbioz-india-ad_acc_covidsafe™_798x103hpx_3_090620_RGB-01.jpg',0,'attachment','image/jpeg',0),(6649,2,'2020-07-18 13:39:50','2020-07-18 13:39:50','','Hi Media','','inherit','closed','closed','','6037-autosave-v1','','','2020-07-18 13:39:50','2020-07-18 13:39:50','',6037,'https://microbiozindia.com/uncategorized/6037-autosave-v1/',0,'revision','',0),(6650,2,'2020-07-18 19:00:49','2020-07-18 19:00:49','Bharat Biotech has initiated human clinical trials for Covaxin, a vaccine candidate for COVID-19, across the nation with 375 volunteers, amid the surging numbers of coronavirus cases.\r\n\r\nIndia\'s COVID-19 caseload jumped to 10,38,716 with 34,884 people testing positive for coronavirus in the last 24 hours, based on information published by the Union Health Ministry on July 18.\r\n\r\nThe Drugs Controller General of India (DCGI) had permitted two vaccines -- one developed from the Bharat Biotech International Limited in collaboration with the Indian Council of Medical Research and a different one by ZydusCadila Healthcare Ltd to go in for the second and first phase of human clinical trials.\r\n<iframe src=\"https://www.youtube.com/embed/tATw5Zg_iiQ\" width=\"560\" height=\"315\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"></iframe>\r\n\r\n<strong>Here are all the developments about COVID-19 vaccine:</strong>\r\n\r\n&gt; The individual trial of Covaxin started at Rohtak\'s Post-Graduate Institute of Medical Sciences on July 17, Haryana Health Minister Anil Vij said.\r\n\r\n&gt; Drug firm Zydus Cadila is looking to complete clinical trials of its COVID-19 vaccine candidate ZyCoV-D in seven weeks, according to the organization\'s chairman. The organization had on Wednesday began clinical trials of its COVID-19 vaccine candidate with the first human dosing.\r\n\r\nDBT\'s Translational Health Science and Technology Institute (THSTI), Faridabad, has established that a hamster infection model for analysis of antivirals, therapeutics and vaccines, it said.\r\n\r\n&gt; India and the US are working together on combating the coronavirus and cooperation is underway for co-development of a COVID-19 vaccine, the Indian envoy has said, underlining that the partnership between the two countries in health, life sciences and technology sectors can bring benefits to the whole world.','Bharat Biotech begins human preliminaries of Covaxin','','inherit','closed','closed','','6641-revision-v1','','','2020-07-18 19:00:49','2020-07-18 19:00:49','',6641,'https://microbiozindia.com/uncategorized/6641-revision-v1/',0,'revision','',0),(6651,2,'2020-07-19 08:51:04','2020-07-19 08:51:04','Curcumin, a natural compound found in the spice turmeric, could help remove specific viruses, studies have found.\r\n\r\nA study published in the Journal of General Virology revealed that curcumin can prevent Transmissible gastroenteritis virus (TGEV) - an alpha-group coronavirus that infects pigs - from infecting cells. At higher doses, the compound was also found to destroy virus particles.\r\n\r\nInfection with TGEV triggers a disorder known as transmissible gastroenteritis from piglets, which can be characterised by diarrhea, severe dehydration and death. TGEV is extremely infectious and is invariably fatal in piglets younger than fourteen days, thus posing a significant threat to the global swine industry.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://microbiologysociety.org/news/press-releases/turmeric-could-have-antiviral-properties.html\">There are currently no approved treatments for alpha-coronaviruses and although there\'s a vaccine for TGEV, it is not effective in preventing the spread of this virus</a></span>.\r\n\r\nTo ascertain the potential antiviral properties of curcumin, the research team treated experimental cells with various concentrations of this compound, before trying to infect them with TGEV. They found that high concentrations of curcumin reduced the number of virus particles from the cell culture.\r\nThe research suggests that curcumin impacts TGEV in many of ways: by directly killing the virus until it\'s ready to infect the cell, by integrating with the viral envelope to\'inactivate\' the virus, and by altering the metabolism of cells to prevent viral entry.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://microbiologysociety.org/news/press-releases/turmeric-could-have-antiviral-properties.html\">Curcumin has been shown to inhibit the replication of some kinds of virus, including dengue virus, hepatitis B and Zika virus.</a></span>\r\n\r\nThe chemical has also been discovered to have a number of important biological consequences, including antitumor, antibacterial and antifungal activities. Curcumin was picked for this study due to getting low side effects according to Dr Xie.\r\n\r\n[caption id=\"attachment_6652\" align=\"alignnone\" width=\"511\"]<img class=\"wp-image-6652 \" src=\"https://microbiozindia.com/wp-content/uploads/2020/07/GettyImages-1145055978-300x169.jpg\" alt=\"\" width=\"511\" height=\"288\" /> <span style=\"font-size: 10pt;\">Curcumin herbal supplement capsules and turmeric powder in glass bowl. Anti-inflammatory herbal medicine (Curcuma)</span>[/caption]\r\n\r\nThey said:\"There are great problems in the prevention and management of viral diseases, particularly when there are no effective vaccines. Traditional Chinese medicine and its active ingredients, are perfect screening libraries for anti inflammatory drugs due to their benefits, such as convenient acquisition and reduced side effects\"\r\n\r\nThe researchers now hope to keep their study in vivo, using an animal model to evaluate whether the inhibiting properties of curcumin would be seen in a more intricate system.\r\n\r\n\"Further research will be needed, to assess the inhibitory effect in vivo and also explore the potential mechanisms of curcumin against TGEV, which will lay a foundation for the comprehensive understanding of the antiviral mechanics and application of curcumin,\" said Dr Xie.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://microbiologysociety.org/news/press-releases/turmeric-could-have-antiviral-properties.html\" target=\"_blank\" rel=\"noopener noreferrer\">Microbiology Society</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nLi, Y., <em>et al</em>. (2020) Antiviral and virucidal effects of curcumin on transmissible gastroenteritis virus in vitro.<em> Journal of General Virology</em><span style=\"color: #ff6600;\">. <a style=\"color: #ff6600;\" href=\"https://doi.org/10.1099/jgv.0.001466\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1099/jgv.0.001466.</a></span>\r\n\r\n</div>','Study uncovers antiviral impacts of curcumin','','publish','open','open','','study-uncovers-antiviral-impacts-of-curcumin','','','2020-07-19 08:51:04','2020-07-19 08:51:04','',0,'https://microbiozindia.com/?p=6651',0,'post','',0),(6652,2,'2020-07-19 08:49:47','2020-07-19 08:49:47','','Curcumin Herbal Supplement Capsules and Turmeric Powder','Curcumin herbal supplement capsules and turmeric powder in glass bowl. Anti-inflammatory herbal medicine (Curcuma)','inherit','open','closed','','curcumin-herbal-supplement-capsules-and-turmeric-powder','','','2020-07-19 08:49:47','2020-07-19 08:49:47','',6651,'https://microbiozindia.com/wp-content/uploads/2020/07/GettyImages-1145055978.jpg',0,'attachment','image/jpeg',0),(6653,2,'2020-07-19 08:49:57','2020-07-19 08:49:57','','1050202_New Project (8)','','inherit','open','closed','','1050202_new-project-8','','','2020-07-19 08:49:57','2020-07-19 08:49:57','',6651,'https://microbiozindia.com/wp-content/uploads/2020/07/1050202_New-Project-8.png',0,'attachment','image/png',0),(6654,2,'2020-07-19 08:51:04','2020-07-19 08:51:04','Curcumin, a natural compound found in the spice turmeric, could help remove specific viruses, studies have found.\r\n\r\nA study published in the Journal of General Virology revealed that curcumin can prevent Transmissible gastroenteritis virus (TGEV) - an alpha-group coronavirus that infects pigs - from infecting cells. At higher doses, the compound was also found to destroy virus particles.\r\n\r\nInfection with TGEV triggers a disorder known as transmissible gastroenteritis from piglets, which can be characterised by diarrhea, severe dehydration and death. TGEV is extremely infectious and is invariably fatal in piglets younger than fourteen days, thus posing a significant threat to the global swine industry.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://microbiologysociety.org/news/press-releases/turmeric-could-have-antiviral-properties.html\">There are currently no approved treatments for alpha-coronaviruses and although there\'s a vaccine for TGEV, it is not effective in preventing the spread of this virus</a></span>.\r\n\r\nTo ascertain the potential antiviral properties of curcumin, the research team treated experimental cells with various concentrations of this compound, before trying to infect them with TGEV. They found that high concentrations of curcumin reduced the number of virus particles from the cell culture.\r\nThe research suggests that curcumin impacts TGEV in many of ways: by directly killing the virus until it\'s ready to infect the cell, by integrating with the viral envelope to\'inactivate\' the virus, and by altering the metabolism of cells to prevent viral entry.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://microbiologysociety.org/news/press-releases/turmeric-could-have-antiviral-properties.html\">Curcumin has been shown to inhibit the replication of some kinds of virus, including dengue virus, hepatitis B and Zika virus.</a></span>\r\n\r\nThe chemical has also been discovered to have a number of important biological consequences, including antitumor, antibacterial and antifungal activities. Curcumin was picked for this study due to getting low side effects according to Dr Xie.\r\n\r\n[caption id=\"attachment_6652\" align=\"alignnone\" width=\"511\"]<img class=\"wp-image-6652 \" src=\"https://microbiozindia.com/wp-content/uploads/2020/07/GettyImages-1145055978-300x169.jpg\" alt=\"\" width=\"511\" height=\"288\" /> <span style=\"font-size: 10pt;\">Curcumin herbal supplement capsules and turmeric powder in glass bowl. Anti-inflammatory herbal medicine (Curcuma)</span>[/caption]\r\n\r\nThey said:\"There are great problems in the prevention and management of viral diseases, particularly when there are no effective vaccines. Traditional Chinese medicine and its active ingredients, are perfect screening libraries for anti inflammatory drugs due to their benefits, such as convenient acquisition and reduced side effects\"\r\n\r\nThe researchers now hope to keep their study in vivo, using an animal model to evaluate whether the inhibiting properties of curcumin would be seen in a more intricate system.\r\n\r\n\"Further research will be needed, to assess the inhibitory effect in vivo and also explore the potential mechanisms of curcumin against TGEV, which will lay a foundation for the comprehensive understanding of the antiviral mechanics and application of curcumin,\" said Dr Xie.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://microbiologysociety.org/news/press-releases/turmeric-could-have-antiviral-properties.html\" target=\"_blank\" rel=\"noopener noreferrer\">Microbiology Society</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nLi, Y., <em>et al</em>. (2020) Antiviral and virucidal effects of curcumin on transmissible gastroenteritis virus in vitro.<em> Journal of General Virology</em><span style=\"color: #ff6600;\">. <a style=\"color: #ff6600;\" href=\"https://doi.org/10.1099/jgv.0.001466\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1099/jgv.0.001466.</a></span>\r\n\r\n</div>','Study uncovers antiviral impacts of curcumin','','inherit','closed','closed','','6651-revision-v1','','','2020-07-19 08:51:04','2020-07-19 08:51:04','',6651,'https://microbiozindia.com/uncategorized/6651-revision-v1/',0,'revision','',0),(6657,2,'2020-07-19 13:21:51','2020-07-19 13:21:51','Medication firm Zydus Cadila on Saturday said it has received final approval from the US health regulator to market generic Butalbital, Acetaminophen and Caffeine combination pills to cure symptoms of tension headaches.\r\n\r\nThe company has obtained final approval from that the United States Food and Drug Administration (USFDA) to market Butalbital, Acetaminophen and Caffeine tablets in strengths of 50mg/325mg/40 mg, Zydus Cadila said in a statement.\r\n\r\nThe drug will be manufactured in Nesher Pharma\'s manufacturing facility at St. Louis in the united states, it added.\r\n\r\nThe group now has 294 approvals and has filed over 390 abbreviated new drug applications (ANDAs) because the commencement of the filing procedure, it included.','Zydus Cadila gets final approval from USFDA to Advertise generic tension headache Pills','','publish','open','open','','zydus-cadila-gets-final-approval-from-usfda-to-advertise-generic-tension-headache-pills','','','2020-07-19 13:21:51','2020-07-19 13:21:51','',0,'https://microbiozindia.com/?p=6657',0,'post','',0),(6658,2,'2020-07-19 13:21:51','2020-07-19 13:21:51','Medication firm Zydus Cadila on Saturday said it has received final approval from the US health regulator to market generic Butalbital, Acetaminophen and Caffeine combination pills to cure symptoms of tension headaches.\r\n\r\nThe company has obtained final approval from that the United States Food and Drug Administration (USFDA) to market Butalbital, Acetaminophen and Caffeine tablets in strengths of 50mg/325mg/40 mg, Zydus Cadila said in a statement.\r\n\r\nThe drug will be manufactured in Nesher Pharma\'s manufacturing facility at St. Louis in the united states, it added.\r\n\r\nThe group now has 294 approvals and has filed over 390 abbreviated new drug applications (ANDAs) because the commencement of the filing procedure, it included.','Zydus Cadila gets final approval from USFDA to Advertise generic tension headache Pills','','inherit','closed','closed','','6657-revision-v1','','','2020-07-19 13:21:51','2020-07-19 13:21:51','',6657,'https://microbiozindia.com/uncategorized/6657-revision-v1/',0,'revision','',0),(6659,2,'2020-07-20 07:56:32','2020-07-20 07:56:32','Britain has signed deals to procure 90 million doses of 2 possible COVID-19 vaccines in the Pfizer Inc and BioNTech alliance and French group Valneva, the company ministry said on Monday.\r\n\r\nBritain had procured 30 million doses of the experimental BioNTech/Pfizer vaccine, and a deal in principle for 60 million doses of this Valneva vaccine, using an alternative of 40 million more doses if it had been demonstrated to be secure, effective and suitable, the ministry said.\r\n\r\nFinancial terms of the deals were not confirmed.\r\n\r\n\"This new venture with some of the world\'s leading pharmaceutical and vaccine companies ensure the UK has the best chance possible of securing a vaccine which protects those most at risk,\" business minister Alok Sharma said.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.moneycontrol.com/news/business/britain-signs-deals-with-pfizer-biontech-valneva-for-covid-19-vaccines-5570261.html\">The deals follow a previously announced agreement with AstraZeneca for the company to produce 100 million doses of its potential vaccine being developed in partnership with the University of Oxford.</a></span>\r\n\r\nThere\'s presently no functioning bacterium from COVID-19, the disorder caused by the novel coronavirus, and specialists say one will be necessary to control the outbreak that has infected millions of individuals around the world and killed over 600,000.\r\n\r\nBritain also said on Monday it had procured treatments containing COVID-19-neutralising antibodies from AstraZeneca to protect individuals who can\'t be vaccinated.','Britain signs manages Pfizer, BioNTech, Valneva for COVID-19 antibodies','','publish','open','open','','britain-signs-manages-pfizer-biontech-valneva-for-covid-19-antibodies','','','2020-07-20 07:56:32','2020-07-20 07:56:32','',0,'https://microbiozindia.com/?p=6659',0,'post','',0),(6660,2,'2020-07-20 07:56:32','2020-07-20 07:56:32','Britain has signed deals to procure 90 million doses of 2 possible COVID-19 vaccines in the Pfizer Inc and BioNTech alliance and French group Valneva, the company ministry said on Monday.\r\n\r\nBritain had procured 30 million doses of the experimental BioNTech/Pfizer vaccine, and a deal in principle for 60 million doses of this Valneva vaccine, using an alternative of 40 million more doses if it had been demonstrated to be secure, effective and suitable, the ministry said.\r\n\r\nFinancial terms of the deals were not confirmed.\r\n\r\n\"This new venture with some of the world\'s leading pharmaceutical and vaccine companies ensure the UK has the best chance possible of securing a vaccine which protects those most at risk,\" business minister Alok Sharma said.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.moneycontrol.com/news/business/britain-signs-deals-with-pfizer-biontech-valneva-for-covid-19-vaccines-5570261.html\">The deals follow a previously announced agreement with AstraZeneca for the company to produce 100 million doses of its potential vaccine being developed in partnership with the University of Oxford.</a></span>\r\n\r\nThere\'s presently no functioning bacterium from COVID-19, the disorder caused by the novel coronavirus, and specialists say one will be necessary to control the outbreak that has infected millions of individuals around the world and killed over 600,000.\r\n\r\nBritain also said on Monday it had procured treatments containing COVID-19-neutralising antibodies from AstraZeneca to protect individuals who can\'t be vaccinated.','Britain signs manages Pfizer, BioNTech, Valneva for COVID-19 antibodies','','inherit','closed','closed','','6659-revision-v1','','','2020-07-20 07:56:32','2020-07-20 07:56:32','',6659,'https://microbiozindia.com/uncategorized/6659-revision-v1/',0,'revision','',0),(6661,2,'2020-07-20 16:28:10','2020-07-20 16:28:10','Synchrotron InfraRed Nanospectroscopy has been used for the first time to measure biomolecular changes caused by a drug (amiodarone) in human cells (macrophages) and localized at 100 nanometre scale, i.e. two orders of magnitude smaller than the IR wavelength used as probe.\r\n\r\nThis was achieved at the <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://pubs.acs.org/doi/10.1021/acs.analchem.9b05759\">Multimode InfraRed Imaging</a></span> and <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://pubs.acs.org/doi/10.1021/acs.analchem.9b05759\">Micro-Spectroscopy (MIRIAM) beamline (B22) in Diamond Light Source, the UK\'s national synchrotron facility.</a></span>\r\n\r\nThis is a major scientific effect in Life Sciences shared by an Worldwide team, as a collaborative beamtime among the researchers from the School of Cancer and Pharmaceutical Science at Kings College London, the Department of Pharmaceutical Technology and Bio-pharmacy in University of Vienna, and the scientists of their <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://pubs.acs.org/doi/10.1021/acs.analchem.9b05759\">MIRIAM B22 beamline in Diamond.</a></span>\r\n\r\n<em>This is remarkable because the determination of lipid content in vacuoles is crucial in the study of DIPL. This will have high impacts on the development of inhaled medicines whereby DIPL is one of the key indications of adverse response from the body to foreign particles.\"-</em>Dr Andrew Chan, Principal Investigator, King\'s College London\r\n\r\nTheir latest paper, now published in Analytical Chemistry, is titled\"Synchrotron photothermal IR Nanospectroscopy of macrophages drug-induced phospholipidosis\" 10.1021/acs.analchem.9b05759 It outlinesthe use of this so-called Resonance Improved InfraRed Atomic Force Microscopy (RE AFM IR) by Synchrotron Radiation, to interrogate biological thing at the subcellular level, in this case a cellular model of drug-induced phospholipidosis (DIPL).\r\n\r\nRather than the traditional procedure to evaluate DIPL - i.e. visual affirmation by electron microscopy of these lipid bodies or the use of fluorescence labeling technique - they used IR broadband illumination by Diamond synchrotron together with AFM detection to achieve both molecular specificity and enhanced spatial resolution needed to localize metabolic alterations inside the cell.\r\n\r\nDr Andrew Chan of King\'s College London as principal researcher explains,\"The model study according to J774A-1 macrophages exposed/not subjected to amiodarone has clearly demonstrated that RE AFM IR with synchrotron radiation is effective at extracting local molecular information from small organelles inside a single cell within an label-free manner.\"\r\n\r\nAFM topography maps revealed amiodarone-treated cells had expanded cytoplasm, and sparse areas of collapsed vesicles. The Infra Red (IR) maps of the whole cell were analysed by exploiting the IR overall signal versus AFM-derived cell depth, also on lateral resolution about 100 nm. Vibrational band assignment of this nanospectra was possible too: all characteristic peaks for lipids, proteins, and DNA/RNA were also identified.\r\n\r\nAlso, both band ratio and unsupervised chemometric analysis of Synchrotron IR nanospectra in the nuclear and perinuclear regions of the cells revealed that the cytoplasm of both amiodarone-treated cells had substantially elevated group intensities in the areas corresponding to phosphate and carbonyl groups, signaling detection of phospholipid-rich inclusion bodies typical for cells using DIPL.\r\nPrinciple Beamline Scientist in the MIRIAM beamline at Diamond and one of the job\'s authors, Dr Gianfelice Cinque comments:\"Our experiment is - to my knowledge - a world first by Synchrotron photothermal IR Nano spectroscopy in life sciences, also demonstrated that photothermal IR Nano spectroscopy can successfully scan across mammalian cells and reveal the inner molecular fingerprint via the complete IR spectrum, as a result of Synchrotron IR broadband coverage.\"\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://doi.org/10.1021/acs.analchem.9b05759\">He explained that the mobile model system and the drug treatment exemplified the method capability by spatially colocalizing morphology and biochemistry in subcellular scale.</a> </span>What was notable was that the nanospectra caliber attained was such that average vibrational features observed by IR microscopy on biological cells were obviously recorded, but also for the first time in the nanoscale, supplying subcellular biochemical information in a label-free manner.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://doi.org/10.1021/acs.analchem.9b05759\">He adds;\" This achievement has been the end of a long experimental endeavor by the IR beamline B22 group of Diamond - particularly the expert work by Dr Mark Frogley and Dr Ioannis Lekkas.\"</a></span>\r\n\r\nHe proceeded to explain that the MIRIAM beamline (B22) excellence in Synchrotron IR Nano spectroscopy - i.e. Synchrotron RE-AFM-IR spectroscopy - offers exceptional chemical and morphological penetration at sub-wavelength or 100 nm resolution across a variety of real life study especially in soft matter, for example microplastic influence in living tissue, antimicrobial surface happenings, microfossil and biogeology at submicron scale, organic microelectronics analysis, microcomposite substances and mesostructures.\r\n\r\nMore research capability will be offered shortly at the MIRIAM beamline B22, as a brand new nanoIR end channel is likely from mid 2021. Past the present expertise in Synchrotron IR photothermal Nanospectroscopy, the upgrade will allow new techniques (e.g. AFM IR in tapping mode), and crucially complement them with IR scattering scanning optical microscopy (s-SNOM), pushing the spatial resolution even farther in the 10s nanometre scale.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.diamond.ac.uk/Home\" target=\"_blank\" rel=\"noopener noreferrer\">Diamond Light Source Ltd</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nChan, K. L. A., <em>et al</em>. (2020) Synchrotron Photothermal Infrared Nanospectroscopy of Drug-Induced Phospholipidosis in Macrophages. <em>American Chemical Society</em>.<span style=\"color: #ff6600;\"> <a style=\"color: #ff6600;\" href=\"https://doi.org/10.1021/acs.analchem.9b05759\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1021/acs.analchem.9b05759.</a></span>\r\n\r\n</div>','Novel nanospectroscopy measures biomolecular changes induced by drugs in human cells','','publish','open','open','','novel-nanospectroscopy-measures-biomolecular-changes-induced-by-drugs-in-human-cells','','','2020-07-20 16:28:10','2020-07-20 16:28:10','',0,'https://microbiozindia.com/?p=6661',0,'post','',0),(6662,2,'2020-07-20 16:25:58','2020-07-20 16:25:58','','internal-clock-within-live-human-cells-found-291628','','inherit','open','closed','','internal-clock-within-live-human-cells-found-291628','','','2020-07-20 16:25:58','2020-07-20 16:25:58','',6661,'https://microbiozindia.com/wp-content/uploads/2020/07/internal-clock-within-live-human-cells-found-291628.jpg',0,'attachment','image/jpeg',0),(6663,2,'2020-07-20 16:28:10','2020-07-20 16:28:10','Synchrotron InfraRed Nanospectroscopy has been used for the first time to measure biomolecular changes caused by a drug (amiodarone) in human cells (macrophages) and localized at 100 nanometre scale, i.e. two orders of magnitude smaller than the IR wavelength used as probe.\r\n\r\nThis was achieved at the <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://pubs.acs.org/doi/10.1021/acs.analchem.9b05759\">Multimode InfraRed Imaging</a></span> and <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://pubs.acs.org/doi/10.1021/acs.analchem.9b05759\">Micro-Spectroscopy (MIRIAM) beamline (B22) in Diamond Light Source, the UK\'s national synchrotron facility.</a></span>\r\n\r\nThis is a major scientific effect in Life Sciences shared by an Worldwide team, as a collaborative beamtime among the researchers from the School of Cancer and Pharmaceutical Science at Kings College London, the Department of Pharmaceutical Technology and Bio-pharmacy in University of Vienna, and the scientists of their <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://pubs.acs.org/doi/10.1021/acs.analchem.9b05759\">MIRIAM B22 beamline in Diamond.</a></span>\r\n\r\n<em>This is remarkable because the determination of lipid content in vacuoles is crucial in the study of DIPL. This will have high impacts on the development of inhaled medicines whereby DIPL is one of the key indications of adverse response from the body to foreign particles.\"-</em>Dr Andrew Chan, Principal Investigator, King\'s College London\r\n\r\nTheir latest paper, now published in Analytical Chemistry, is titled\"Synchrotron photothermal IR Nanospectroscopy of macrophages drug-induced phospholipidosis\" 10.1021/acs.analchem.9b05759 It outlinesthe use of this so-called Resonance Improved InfraRed Atomic Force Microscopy (RE AFM IR) by Synchrotron Radiation, to interrogate biological thing at the subcellular level, in this case a cellular model of drug-induced phospholipidosis (DIPL).\r\n\r\nRather than the traditional procedure to evaluate DIPL - i.e. visual affirmation by electron microscopy of these lipid bodies or the use of fluorescence labeling technique - they used IR broadband illumination by Diamond synchrotron together with AFM detection to achieve both molecular specificity and enhanced spatial resolution needed to localize metabolic alterations inside the cell.\r\n\r\nDr Andrew Chan of King\'s College London as principal researcher explains,\"The model study according to J774A-1 macrophages exposed/not subjected to amiodarone has clearly demonstrated that RE AFM IR with synchrotron radiation is effective at extracting local molecular information from small organelles inside a single cell within an label-free manner.\"\r\n\r\nAFM topography maps revealed amiodarone-treated cells had expanded cytoplasm, and sparse areas of collapsed vesicles. The Infra Red (IR) maps of the whole cell were analysed by exploiting the IR overall signal versus AFM-derived cell depth, also on lateral resolution about 100 nm. Vibrational band assignment of this nanospectra was possible too: all characteristic peaks for lipids, proteins, and DNA/RNA were also identified.\r\n\r\nAlso, both band ratio and unsupervised chemometric analysis of Synchrotron IR nanospectra in the nuclear and perinuclear regions of the cells revealed that the cytoplasm of both amiodarone-treated cells had substantially elevated group intensities in the areas corresponding to phosphate and carbonyl groups, signaling detection of phospholipid-rich inclusion bodies typical for cells using DIPL.\r\nPrinciple Beamline Scientist in the MIRIAM beamline at Diamond and one of the job\'s authors, Dr Gianfelice Cinque comments:\"Our experiment is - to my knowledge - a world first by Synchrotron photothermal IR Nano spectroscopy in life sciences, also demonstrated that photothermal IR Nano spectroscopy can successfully scan across mammalian cells and reveal the inner molecular fingerprint via the complete IR spectrum, as a result of Synchrotron IR broadband coverage.\"\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://doi.org/10.1021/acs.analchem.9b05759\">He explained that the mobile model system and the drug treatment exemplified the method capability by spatially colocalizing morphology and biochemistry in subcellular scale.</a> </span>What was notable was that the nanospectra caliber attained was such that average vibrational features observed by IR microscopy on biological cells were obviously recorded, but also for the first time in the nanoscale, supplying subcellular biochemical information in a label-free manner.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://doi.org/10.1021/acs.analchem.9b05759\">He adds;\" This achievement has been the end of a long experimental endeavor by the IR beamline B22 group of Diamond - particularly the expert work by Dr Mark Frogley and Dr Ioannis Lekkas.\"</a></span>\r\n\r\nHe proceeded to explain that the MIRIAM beamline (B22) excellence in Synchrotron IR Nano spectroscopy - i.e. Synchrotron RE-AFM-IR spectroscopy - offers exceptional chemical and morphological penetration at sub-wavelength or 100 nm resolution across a variety of real life study especially in soft matter, for example microplastic influence in living tissue, antimicrobial surface happenings, microfossil and biogeology at submicron scale, organic microelectronics analysis, microcomposite substances and mesostructures.\r\n\r\nMore research capability will be offered shortly at the MIRIAM beamline B22, as a brand new nanoIR end channel is likely from mid 2021. Past the present expertise in Synchrotron IR photothermal Nanospectroscopy, the upgrade will allow new techniques (e.g. AFM IR in tapping mode), and crucially complement them with IR scattering scanning optical microscopy (s-SNOM), pushing the spatial resolution even farther in the 10s nanometre scale.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.diamond.ac.uk/Home\" target=\"_blank\" rel=\"noopener noreferrer\">Diamond Light Source Ltd</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nChan, K. L. A., <em>et al</em>. (2020) Synchrotron Photothermal Infrared Nanospectroscopy of Drug-Induced Phospholipidosis in Macrophages. <em>American Chemical Society</em>.<span style=\"color: #ff6600;\"> <a style=\"color: #ff6600;\" href=\"https://doi.org/10.1021/acs.analchem.9b05759\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1021/acs.analchem.9b05759.</a></span>\r\n\r\n</div>','Novel nanospectroscopy measures biomolecular changes induced by drugs in human cells','','inherit','closed','closed','','6661-revision-v1','','','2020-07-20 16:28:10','2020-07-20 16:28:10','',6661,'https://microbiozindia.com/uncategorized/6661-revision-v1/',0,'revision','',0),(6664,2,'2020-07-20 16:31:55','2020-07-20 16:31:55','An exploratory COVID-19 antibody, being created by the University of Oxford, was sheltered and delivered a safe reaction in beginning phase clinical preliminaries in solid volunteers, information appeared on Monday.\r\n\r\nThe immunization, called AZD1222 and being created by pharmaceutical organization AstraZeneca and researchers at Britain\'s University of Oxford, didn\'t fast any genuine symptoms and evoked neutralizer and T-cell resistant reactions, as indicated by preliminary outcomes distributed in The Lancet clinical diary.\r\n\r\n\"We trust this implies the safe framework will recollect the infection, with the goal that our immunization will secure individuals for an all-inclusive period,\" study lead creator Andrew Pollard of the University of Oxford said.\r\n\r\n\"Be that as it may, we need more examination before we can affirm the immunization successfully secures against SARS-CoV-2 (COVID-19) disease, and for how long any assurance keeps going,\" he said.\r\n\r\nAstraZeneca\'s is among the main antibody competitors against a pandemic that has asserted in excess of 600,000 lives, close by others in mid and late-stage preliminaries.\r\n\r\nThese incorporate shots being created by China\'s Sinovac Biotech, another from state-possessed Chinese firm Sinopharm, and one from the U.S. biotech firm Moderna.\r\n\r\nAstraZeneca has consented to arrangements with governments around the globe to flexibly the immunization should it demonstrate successful and increase administrative endorsement. The organization has said it won\'t look to benefit from the antibody during the pandemic.\r\n\r\nSpecialists said the immunization caused minor reactions more as often as possible than a benchmark group, however a portion of these could be decreased by taking paracetamol, with no genuine unfriendly occasions from the antibody.','Oxford COVID-19 Vaccine Shows Promise In Early Testing: Study','','publish','open','open','','oxford-covid-19-vaccine-shows-promise-in-early-testing-study','','','2020-07-20 16:31:55','2020-07-20 16:31:55','',0,'https://microbiozindia.com/?p=6664',0,'post','',0),(6665,2,'2020-07-20 16:31:55','2020-07-20 16:31:55','An exploratory COVID-19 antibody, being created by the University of Oxford, was sheltered and delivered a safe reaction in beginning phase clinical preliminaries in solid volunteers, information appeared on Monday.\r\n\r\nThe immunization, called AZD1222 and being created by pharmaceutical organization AstraZeneca and researchers at Britain\'s University of Oxford, didn\'t fast any genuine symptoms and evoked neutralizer and T-cell resistant reactions, as indicated by preliminary outcomes distributed in The Lancet clinical diary.\r\n\r\n\"We trust this implies the safe framework will recollect the infection, with the goal that our immunization will secure individuals for an all-inclusive period,\" study lead creator Andrew Pollard of the University of Oxford said.\r\n\r\n\"Be that as it may, we need more examination before we can affirm the immunization successfully secures against SARS-CoV-2 (COVID-19) disease, and for how long any assurance keeps going,\" he said.\r\n\r\nAstraZeneca\'s is among the main antibody competitors against a pandemic that has asserted in excess of 600,000 lives, close by others in mid and late-stage preliminaries.\r\n\r\nThese incorporate shots being created by China\'s Sinovac Biotech, another from state-possessed Chinese firm Sinopharm, and one from the U.S. biotech firm Moderna.\r\n\r\nAstraZeneca has consented to arrangements with governments around the globe to flexibly the immunization should it demonstrate successful and increase administrative endorsement. The organization has said it won\'t look to benefit from the antibody during the pandemic.\r\n\r\nSpecialists said the immunization caused minor reactions more as often as possible than a benchmark group, however a portion of these could be decreased by taking paracetamol, with no genuine unfriendly occasions from the antibody.','Oxford COVID-19 Vaccine Shows Promise In Early Testing: Study','','inherit','closed','closed','','6664-revision-v1','','','2020-07-20 16:31:55','2020-07-20 16:31:55','',6664,'https://microbiozindia.com/uncategorized/6664-revision-v1/',0,'revision','',0),(6666,2,'2020-07-21 06:15:38','2020-07-21 06:15:38','\"There might be a million doses fabricated by September: that today looks like a remarkable underestimate, given the scale of what\'s happening,\" Adrian Hill of University of Oxford said, speaking to the manufacturing capacity of partner AstraZeneca.\r\n\r\n\"Surely there\'ll be a million doses round in September. What\'s less predictable compared to the production scale-up is that the incidence of disease, so when there will be an endpoint.\"\r\n\r\nHe added it was possible that there would be vaccines available at the end of the year.\r\n\r\nN-95 masks with breathing valves don\'t prevent COVID-19 spread, says health ministry\r\nN-95 masks with valved respirators don\'t help prevent the spread of the novel coronavirus, a health ministry expert has said.\r\n\r\nIn a letter dated July 20 and addressed to health authorities concerned in most states and UTs, he said:\"The use of valved respirator N-95 masks is detrimental to the measures adopted for preventing the spread of coronavirus as it doesn\'t stop the virus from escaping from the mask\"\r\n\r\nThe letter further urged the government to revisit that the advisory issued by the Ministry of Health and Family Welfare concerning the usage of homemade protective cap for the face and mouth, which will be available on the ministry\'s site.\r\n\r\nThe states and UTs have been directed to take necessary steps to prevent inappropriate use of N-95 masks.\r\n\r\nEspecially, valved respirator masks with gaskets are effective in protecting the wearer from pathogens suspended in the atmosphere but don\'t stop the virus from spreading from an infected person wearing it for his or her immediate environment. These masks have a plastic gasket embedded in the cloth, which is fundamentally a one-way valve. This means that it filters out pathogens from the air that you breathe in, but opens up while exhaling, letting the pathogen escape the mask.','Over a million dosages of Oxford/AstraZeneca COVID-19 antibody conceivable by September: Researcher','','publish','open','open','','over-a-million-dosages-of-oxford-astrazeneca-covid-19-antibody-conceivable-by-september-researcher','','','2020-07-21 06:15:38','2020-07-21 06:15:38','',0,'https://microbiozindia.com/?p=6666',0,'post','',0),(6667,2,'2020-07-21 06:15:38','2020-07-21 06:15:38','\"There might be a million doses fabricated by September: that today looks like a remarkable underestimate, given the scale of what\'s happening,\" Adrian Hill of University of Oxford said, speaking to the manufacturing capacity of partner AstraZeneca.\r\n\r\n\"Surely there\'ll be a million doses round in September. What\'s less predictable compared to the production scale-up is that the incidence of disease, so when there will be an endpoint.\"\r\n\r\nHe added it was possible that there would be vaccines available at the end of the year.\r\n\r\nN-95 masks with breathing valves don\'t prevent COVID-19 spread, says health ministry\r\nN-95 masks with valved respirators don\'t help prevent the spread of the novel coronavirus, a health ministry expert has said.\r\n\r\nIn a letter dated July 20 and addressed to health authorities concerned in most states and UTs, he said:\"The use of valved respirator N-95 masks is detrimental to the measures adopted for preventing the spread of coronavirus as it doesn\'t stop the virus from escaping from the mask\"\r\n\r\nThe letter further urged the government to revisit that the advisory issued by the Ministry of Health and Family Welfare concerning the usage of homemade protective cap for the face and mouth, which will be available on the ministry\'s site.\r\n\r\nThe states and UTs have been directed to take necessary steps to prevent inappropriate use of N-95 masks.\r\n\r\nEspecially, valved respirator masks with gaskets are effective in protecting the wearer from pathogens suspended in the atmosphere but don\'t stop the virus from spreading from an infected person wearing it for his or her immediate environment. These masks have a plastic gasket embedded in the cloth, which is fundamentally a one-way valve. This means that it filters out pathogens from the air that you breathe in, but opens up while exhaling, letting the pathogen escape the mask.','Over a million dosages of Oxford/AstraZeneca COVID-19 antibody conceivable by September: Researcher','','inherit','closed','closed','','6666-revision-v1','','','2020-07-21 06:15:38','2020-07-21 06:15:38','',6666,'https://microbiozindia.com/uncategorized/6666-revision-v1/',0,'revision','',0),(6668,2,'2020-07-21 06:58:41','2020-07-21 06:58:41','Cancer is a major cause of death and among the most complicated challenges to contemporary medication. By employing cutting-edge technologies that precisely measure the effects of candidate targets and drugs on the fundamental process of transcription, the new start-up firm QUANTRO Therapeutics tries to radically change the precision and range of cell-based drug screening.\r\n\r\nQUANTRO\'s primary focus will be on the identification and development of novel chemistry which interferes with cancer-associated transcription factors, a class of especially promising targets which have remained largely inaccessible for medication treatment.\r\n\r\nThe masterminds behind QUANTRO would be the scientists Stefan Ameres from the Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), and Johannes Zuber in the Research Institute of Molecular Pathology (IMP), which is governed mainly by the pharmaceutical firm Boehringer Ingelheim.\r\n\r\nStefan Ameres is the developer of SLAMseq, a time-resolved transcriptomics technologies that QUANTRO can use in its performance:\"SLAMseq opens up new experimental avenues to systematically measuring transcriptional activities in living cells.\r\nOur ability to solve the fingerprints of disease-causing transcriptional applications will enable us to break fresh ground in pharmaceutical research for the evolution of unprecedented healing interventions.\"\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.imba.oeaw.ac.at/about-imba/general-news-press/new-startup-quantrotherapeutics\">The foundation of QUANTRO as a spin-off firm based on technologies from the partnership between the research institutes IMP and IMBA showcases that research cooperation not only generates excellent scientific outcomes.</a></span>\r\n\r\nBut also makes a valuable contribution to the economic development of biotechnology in Vienna, according to Michael Krebs and Harald Isemann, who supported the spin-off as managing directors of IMBA and IMP. Both institutes are a part of this Vienna BioCenter, the largest life science cluster in Austria with over 1800 employees.\r\n\r\nQUANTRO was able to win two renowned investors in its seed financing round: The Boehringer Ingelheim Venture Fund and the drug-discovery and growth company Evotec.\r\n\r\nDieter Nachtigall, a chemist with over 20 decades of experience in pharmaceutical research and development and with over 10 years of responsibility at senior executive management positions at Boehringer Ingelheim, has been appointed CEO of QUANTRO Therapeutics GmbH.\r\n\r\nQUANTRO has become state-of-the-art laboratories in the new start-up labs of the Vienna Business Agency at the recently completely renovated construction VBC6 and will bring more workers on board.\r\n<div class=\"content-src-label\">Source:</div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.imba.oeaw.ac.at/about-imba/general-news-press/new-startup-quantrotherapeutics\" target=\"_blank\" rel=\"noopener noreferrer\">Institute of Molecular Biotechnology</a></span>\r\n\r\n</div>','Drug discovery pipeline to exploit transcription factors for cancer therapy','','publish','open','open','','drug-discovery-pipeline-to-exploit-transcription-factors-for-cancer-therapy','','','2020-07-21 06:58:41','2020-07-21 06:58:41','',0,'https://microbiozindia.com/?p=6668',0,'post','',0),(6669,2,'2020-07-21 06:58:07','2020-07-21 06:58:07','','drug-development-stock','','inherit','open','closed','','drug-development-stock','','','2020-07-21 06:58:07','2020-07-21 06:58:07','',6668,'https://microbiozindia.com/wp-content/uploads/2020/07/drug-development-stock.jpg',0,'attachment','image/jpeg',0),(6670,2,'2020-07-21 06:58:41','2020-07-21 06:58:41','Cancer is a major cause of death and among the most complicated challenges to contemporary medication. By employing cutting-edge technologies that precisely measure the effects of candidate targets and drugs on the fundamental process of transcription, the new start-up firm QUANTRO Therapeutics tries to radically change the precision and range of cell-based drug screening.\r\n\r\nQUANTRO\'s primary focus will be on the identification and development of novel chemistry which interferes with cancer-associated transcription factors, a class of especially promising targets which have remained largely inaccessible for medication treatment.\r\n\r\nThe masterminds behind QUANTRO would be the scientists Stefan Ameres from the Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), and Johannes Zuber in the Research Institute of Molecular Pathology (IMP), which is governed mainly by the pharmaceutical firm Boehringer Ingelheim.\r\n\r\nStefan Ameres is the developer of SLAMseq, a time-resolved transcriptomics technologies that QUANTRO can use in its performance:\"SLAMseq opens up new experimental avenues to systematically measuring transcriptional activities in living cells.\r\nOur ability to solve the fingerprints of disease-causing transcriptional applications will enable us to break fresh ground in pharmaceutical research for the evolution of unprecedented healing interventions.\"\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.imba.oeaw.ac.at/about-imba/general-news-press/new-startup-quantrotherapeutics\">The foundation of QUANTRO as a spin-off firm based on technologies from the partnership between the research institutes IMP and IMBA showcases that research cooperation not only generates excellent scientific outcomes.</a></span>\r\n\r\nBut also makes a valuable contribution to the economic development of biotechnology in Vienna, according to Michael Krebs and Harald Isemann, who supported the spin-off as managing directors of IMBA and IMP. Both institutes are a part of this Vienna BioCenter, the largest life science cluster in Austria with over 1800 employees.\r\n\r\nQUANTRO was able to win two renowned investors in its seed financing round: The Boehringer Ingelheim Venture Fund and the drug-discovery and growth company Evotec.\r\n\r\nDieter Nachtigall, a chemist with over 20 decades of experience in pharmaceutical research and development and with over 10 years of responsibility at senior executive management positions at Boehringer Ingelheim, has been appointed CEO of QUANTRO Therapeutics GmbH.\r\n\r\nQUANTRO has become state-of-the-art laboratories in the new start-up labs of the Vienna Business Agency at the recently completely renovated construction VBC6 and will bring more workers on board.\r\n<div class=\"content-src-label\">Source:</div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.imba.oeaw.ac.at/about-imba/general-news-press/new-startup-quantrotherapeutics\" target=\"_blank\" rel=\"noopener noreferrer\">Institute of Molecular Biotechnology</a></span>\r\n\r\n</div>','Drug discovery pipeline to exploit transcription factors for cancer therapy','','inherit','closed','closed','','6668-revision-v1','','','2020-07-21 06:58:41','2020-07-21 06:58:41','',6668,'https://microbiozindia.com/uncategorized/6668-revision-v1/',0,'revision','',0),(6671,2,'2020-07-21 08:13:29','2020-07-21 08:13:29','Swiss drugmaker Novartis reduced its 2020 sales outlook on Tuesday after second quarter earnings and profit fell, as hospitals which stocked up on medicines during the first-quarter on account of this COVID-19 pandemic slowed buys.\r\n\r\nNet income in the three months through June dropped 4% to $1.9 billion, compared to $2.1 billion in 2019. Earnings fell 1 percent in constant currencies to $11.35 billion, from $11.8 billion.\r\n\r\nThe Basel-based company cut its 2020 earnings outlook, saying it now expects sales to grow in the mid-single digit percent range, down from the previous expectation for a mid- to high-single-digit percentage increase.\r\n\r\nNovartis was more specific on its own profit expectations, saying it now expected core operating income to increase with a reduced double-digit percent, in comparison to its earlier view for a high-single to low-double-digit percent increase.','Novartis fixes viewpoint as second-quarter deals, benefit fall','','publish','open','open','','novartis-fixes-viewpoint-as-second-quarter-deals-benefit-fall','','','2020-07-21 08:13:29','2020-07-21 08:13:29','',0,'https://microbiozindia.com/?p=6671',0,'post','',0),(6672,2,'2020-07-21 08:13:29','2020-07-21 08:13:29','Swiss drugmaker Novartis reduced its 2020 sales outlook on Tuesday after second quarter earnings and profit fell, as hospitals which stocked up on medicines during the first-quarter on account of this COVID-19 pandemic slowed buys.\r\n\r\nNet income in the three months through June dropped 4% to $1.9 billion, compared to $2.1 billion in 2019. Earnings fell 1 percent in constant currencies to $11.35 billion, from $11.8 billion.\r\n\r\nThe Basel-based company cut its 2020 earnings outlook, saying it now expects sales to grow in the mid-single digit percent range, down from the previous expectation for a mid- to high-single-digit percentage increase.\r\n\r\nNovartis was more specific on its own profit expectations, saying it now expected core operating income to increase with a reduced double-digit percent, in comparison to its earlier view for a high-single to low-double-digit percent increase.','Novartis fixes viewpoint as second-quarter deals, benefit fall','','inherit','closed','closed','','6671-revision-v1','','','2020-07-21 08:13:29','2020-07-21 08:13:29','',6671,'https://microbiozindia.com/uncategorized/6671-revision-v1/',0,'revision','',0),(6673,2,'2020-07-21 10:36:08','2020-07-21 10:36:08','A phase II clinical trial of a COVID-19 vaccine candidate, conducted in China, has found it is safe and causes an immune reaction, a study published in The Lancet says.\r\n\r\nResearchers, for example those from the Center for Disease Control and Prevention, said the trial sought to assess the safety and immunogenicity of this vaccine candidate.\r\n\r\nThey said the results provide information from a wider group of participants than their earlier phase I trial, such as a small sub-group of participants aged over 55 years and older.\r\n\r\nHowever, the researchers cautioned that no participants at the current trial were exposed to this novel coronavirus, SARS-CoV-2, after vaccination. So they said it isn\'t possible for the present study to determine whether the vaccine candidate effectively protects against SARS-CoV-2 disease.\r\n\r\nFrom the trial, the researchers used a diminished human common cold virus (adenovirus, which infects cells easily but is incapable of causing illness ) to provide the hereditary material that codes for the novel coronavirus spike protein into the cells.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.theweek.in/news/health/2020/07/21/Phase-II-trial-finds-Chinese-COVID-19-vaccine-is-safe-induces-immune-response.html\">The scientists stated these cells then generated the coronavirus spike protein, and go to the body\'s lymph nodes where the immune system creates antibodies.</a></span>\r\n\r\nThey said these antibodies then reevaluate the spike protein and also fight off the coronavirus.\r\n\r\n\"The Beijing approach is based on the backbone of a traditional human, common-cold virus to which many people have pre-existing antibodies and they therefore make a lesser response in some people to the vaccine because people have preexisting antibodies to their vector, so may clear it before it has a opportunity to work correctly,\" explained Danny Altmann, Professor of Immunology at Imperial College London in the united kingdom, who is unrelated to the research team.\r\n\r\nAccording to the scientists, 508 participants participate in the trial of this new vaccine candidate.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.theweek.in/news/health/2020/07/21/Phase-II-trial-finds-Chinese-COVID-19-vaccine-is-safe-induces-immune-response.html\">Of these, they said 253 individuals received a higher dose of this vaccine, 129 received a very low dose, and 126 received a dummy treatment, a placebo.</a></span>\r\n\r\nThe analysis noted that about two thirds of those participants were 18-44 years old, a quarter were aged 45-54 decades, and 13 percent were 55 years or older.\r\n\r\nThe participants were monitored for immediate adverse reactions for 30 minutes following injection, and have been followed closely for any injection-site reactions in 14- and 28-days post-vaccination, the study noted.\r\n\r\nIt stated serious adverse events reported by participants during the whole study period were also documented, and blood samples have been taken from them before therapy, and 14- and 28-days post-vaccination to measure antibody responses.\r\n\r\nThe findings demonstrated that 95 percent (241/253) of those participants in the high dose group, and 91 percent (118/129) of these in the low dose group demonstrated either T cell or antibody immune reactions daily 28 post-vaccination.\r\n\r\nAccording to the researchers, the vaccine triggered a neutralising antibody response in 59 per cent (148/253) and 47 percent (61/129) of the participants, and transmitting antibody reaction in 96 per cent (244/253) and 97 percent (125/129) of participants, in the low and high dose groups, respectively, by day 28.\r\n\r\nThe analysis mentioned that the percentage of participants that had some adverse reactions such as fever, exhaustion and injection-site pain were considerably higher in vaccine recipients, compared to those who were given the placebo.\r\n\r\nThey stated the most common serious reaction was fever.\r\n\r\nThe investigators cautioned that pre-existing immunity to the human adenovirus that was used as the vector (the Ad5 vector) with this particular vaccine, and increasing age could partially hamper the specific immune responses to vaccination, especially for its antibody responses.\r\n\r\n\"Since older individuals face a higher risk of severe illness and even death connected with COVID-19 infection, they\'re an important target population for a COVID-19 vaccine. It\'s possible that an extra dose may be needed in order to cause a stronger immune response in the elderly population, but additional study is underway to evaluate this,\" said study co-author Wei Chen in the Beijing Institute of Biotechnology at China.\r\n\r\nSince the trial participants were not exposed to this coronavirus subsequent to vaccination, the scientists stated it is not possible for the present research to find out the effectiveness of the candidate vaccine.\r\n\r\nThey said it\'s also not possible to say from the present research if there are any risks linked to the antibody induced by vaccination when exposed to the novel coronavirus.','Phase 2 preliminary discovers Chinese COVID-19 antibody is sheltered, incites insusceptible reaction: Lancet study','','publish','open','open','','phase-2-preliminary-discovers-chinese-covid-19-antibody-is-sheltered-incites-insusceptible-reaction-lancet-study','','','2020-07-21 10:36:08','2020-07-21 10:36:08','',0,'https://microbiozindia.com/?p=6673',0,'post','',0),(6674,2,'2020-07-21 10:36:08','2020-07-21 10:36:08','A phase II clinical trial of a COVID-19 vaccine candidate, conducted in China, has found it is safe and causes an immune reaction, a study published in The Lancet says.\r\n\r\nResearchers, for example those from the Center for Disease Control and Prevention, said the trial sought to assess the safety and immunogenicity of this vaccine candidate.\r\n\r\nThey said the results provide information from a wider group of participants than their earlier phase I trial, such as a small sub-group of participants aged over 55 years and older.\r\n\r\nHowever, the researchers cautioned that no participants at the current trial were exposed to this novel coronavirus, SARS-CoV-2, after vaccination. So they said it isn\'t possible for the present study to determine whether the vaccine candidate effectively protects against SARS-CoV-2 disease.\r\n\r\nFrom the trial, the researchers used a diminished human common cold virus (adenovirus, which infects cells easily but is incapable of causing illness ) to provide the hereditary material that codes for the novel coronavirus spike protein into the cells.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.theweek.in/news/health/2020/07/21/Phase-II-trial-finds-Chinese-COVID-19-vaccine-is-safe-induces-immune-response.html\">The scientists stated these cells then generated the coronavirus spike protein, and go to the body\'s lymph nodes where the immune system creates antibodies.</a></span>\r\n\r\nThey said these antibodies then reevaluate the spike protein and also fight off the coronavirus.\r\n\r\n\"The Beijing approach is based on the backbone of a traditional human, common-cold virus to which many people have pre-existing antibodies and they therefore make a lesser response in some people to the vaccine because people have preexisting antibodies to their vector, so may clear it before it has a opportunity to work correctly,\" explained Danny Altmann, Professor of Immunology at Imperial College London in the united kingdom, who is unrelated to the research team.\r\n\r\nAccording to the scientists, 508 participants participate in the trial of this new vaccine candidate.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.theweek.in/news/health/2020/07/21/Phase-II-trial-finds-Chinese-COVID-19-vaccine-is-safe-induces-immune-response.html\">Of these, they said 253 individuals received a higher dose of this vaccine, 129 received a very low dose, and 126 received a dummy treatment, a placebo.</a></span>\r\n\r\nThe analysis noted that about two thirds of those participants were 18-44 years old, a quarter were aged 45-54 decades, and 13 percent were 55 years or older.\r\n\r\nThe participants were monitored for immediate adverse reactions for 30 minutes following injection, and have been followed closely for any injection-site reactions in 14- and 28-days post-vaccination, the study noted.\r\n\r\nIt stated serious adverse events reported by participants during the whole study period were also documented, and blood samples have been taken from them before therapy, and 14- and 28-days post-vaccination to measure antibody responses.\r\n\r\nThe findings demonstrated that 95 percent (241/253) of those participants in the high dose group, and 91 percent (118/129) of these in the low dose group demonstrated either T cell or antibody immune reactions daily 28 post-vaccination.\r\n\r\nAccording to the researchers, the vaccine triggered a neutralising antibody response in 59 per cent (148/253) and 47 percent (61/129) of the participants, and transmitting antibody reaction in 96 per cent (244/253) and 97 percent (125/129) of participants, in the low and high dose groups, respectively, by day 28.\r\n\r\nThe analysis mentioned that the percentage of participants that had some adverse reactions such as fever, exhaustion and injection-site pain were considerably higher in vaccine recipients, compared to those who were given the placebo.\r\n\r\nThey stated the most common serious reaction was fever.\r\n\r\nThe investigators cautioned that pre-existing immunity to the human adenovirus that was used as the vector (the Ad5 vector) with this particular vaccine, and increasing age could partially hamper the specific immune responses to vaccination, especially for its antibody responses.\r\n\r\n\"Since older individuals face a higher risk of severe illness and even death connected with COVID-19 infection, they\'re an important target population for a COVID-19 vaccine. It\'s possible that an extra dose may be needed in order to cause a stronger immune response in the elderly population, but additional study is underway to evaluate this,\" said study co-author Wei Chen in the Beijing Institute of Biotechnology at China.\r\n\r\nSince the trial participants were not exposed to this coronavirus subsequent to vaccination, the scientists stated it is not possible for the present research to find out the effectiveness of the candidate vaccine.\r\n\r\nThey said it\'s also not possible to say from the present research if there are any risks linked to the antibody induced by vaccination when exposed to the novel coronavirus.','Phase 2 preliminary discovers Chinese COVID-19 antibody is sheltered, incites insusceptible reaction: Lancet study','','inherit','closed','closed','','6673-revision-v1','','','2020-07-21 10:36:08','2020-07-21 10:36:08','',6673,'https://microbiozindia.com/uncategorized/6673-revision-v1/',0,'revision','',0),(6675,2,'2020-07-21 15:55:23','2020-07-21 15:55:23','Drugmakers racing to develop a safe and efficient coronavirus vaccine pledged on Tuesday to ensure their clinical trials could consist of varied sets of volunteers.\r\nIn prepared remarks for a U.S. congressional hearing, several companies pledged to include broad representation as they prepare to start studies with tens of thousands of volunteers from the coming months.\r\n\r\n\"Ensuring diversity in these trials, including concerning race, ethnicity, gender, age, and other elements, is a priority in our efforts,\" Menelas Pangalos, AstraZeneca Plc\'s executive vice president of biopharmaceutical development &amp; research, said in prepared remarks prior to the hearing held by the House subcommittee on oversight and investigations.\r\n\r\nA group of scientists and physicians urged the U.S. government to include Black, Latino and indigenous Americans in the design and implementation of COVID-19 vaccine trials in hopes of building confidence among those at-risk inhabitants.\r\n\r\nAgents from Johnson &amp; Johnson, Moderna Inc, Pfizer Inc, and Merck &amp; Co Inc were also set to testify later on Tuesday from the hearing, that is focused on attempts to develop a secure, successful and available COVID-19 vaccine.\r\n\r\nOver 150 vaccines are in development globally with an aim to help end the global pandemic which has claimed more than 600,000 lives. But if any will triumph remains far from apparent.\r\n\r\nHistorical data from trials of three potential COVID-19 vaccines published on Monday, including a closely watched candidate from AstraZeneca and Oxford University, higher confidence that a vaccine can train the immune system to recognize and fight the novel coronavirus without serious side effects.','Coronavirus immunization engineers promise decent variety in clinical preliminaries','','publish','open','open','','coronavirus-immunization-engineers-promise-decent-variety-in-clinical-preliminaries','','','2020-07-21 15:55:23','2020-07-21 15:55:23','',0,'https://microbiozindia.com/?p=6675',0,'post','',0),(6676,2,'2020-07-21 15:55:23','2020-07-21 15:55:23','Drugmakers racing to develop a safe and efficient coronavirus vaccine pledged on Tuesday to ensure their clinical trials could consist of varied sets of volunteers.\r\nIn prepared remarks for a U.S. congressional hearing, several companies pledged to include broad representation as they prepare to start studies with tens of thousands of volunteers from the coming months.\r\n\r\n\"Ensuring diversity in these trials, including concerning race, ethnicity, gender, age, and other elements, is a priority in our efforts,\" Menelas Pangalos, AstraZeneca Plc\'s executive vice president of biopharmaceutical development &amp; research, said in prepared remarks prior to the hearing held by the House subcommittee on oversight and investigations.\r\n\r\nA group of scientists and physicians urged the U.S. government to include Black, Latino and indigenous Americans in the design and implementation of COVID-19 vaccine trials in hopes of building confidence among those at-risk inhabitants.\r\n\r\nAgents from Johnson &amp; Johnson, Moderna Inc, Pfizer Inc, and Merck &amp; Co Inc were also set to testify later on Tuesday from the hearing, that is focused on attempts to develop a secure, successful and available COVID-19 vaccine.\r\n\r\nOver 150 vaccines are in development globally with an aim to help end the global pandemic which has claimed more than 600,000 lives. But if any will triumph remains far from apparent.\r\n\r\nHistorical data from trials of three potential COVID-19 vaccines published on Monday, including a closely watched candidate from AstraZeneca and Oxford University, higher confidence that a vaccine can train the immune system to recognize and fight the novel coronavirus without serious side effects.','Coronavirus immunization engineers promise decent variety in clinical preliminaries','','inherit','closed','closed','','6675-revision-v1','','','2020-07-21 15:55:23','2020-07-21 15:55:23','',6675,'https://microbiozindia.com/uncategorized/6675-revision-v1/',0,'revision','',0),(6677,2,'2020-07-22 07:27:04','2020-07-22 07:27:04','Serum Institute of India has said it\'ll likely be starting trials of the COVID-19 vaccine candidate developed by Oxford University and AstraZeneca at the end of August and the vaccine might get to the marketplace by first quarter of 2021.\r\n\r\nWithin an interview using CNN-News18, Poonawalla on the timeline of this vaccine reaching the marketplace stated,\"It is probably gonna be December and also for initial quarter of 2021. Because to reach all the parts of the nation, it is going to take a while. So when you create a product to get it tested yourself in your company and then it goes CDI that\'s the national release in Kasauli and after that only could a batch be published to the public. All of course has been expedited. Therefore, if you put all this together realistically massive volumes for India will be the first quarter. However a couple million doses will be available to the more immunocompromised like the healthcare employees. We are likely to have that by December.\"\r\n\r\nHe explained the size of the trials could be dependent on the statisticians afterwards but it\'s going to be approximately 5,000.\r\n\r\nSpeaking about the dosage of COVID-19 vaccine, Poonawalla explained that many vaccines require two to three doses. \"First is that the primer where you are protected 50-60 percent and the second dose provides protection beyond 70-80 per cent,\" he said.\r\n\r\n\"There aren\'t any severe side effects of the vaccine. I am very sure safety is not likely to become an issue,\" he said.\r\n\r\nThe Pune-based company\'s chief executive further said that the company, that\'s the largest vaccine maker in the entire world, can make about 700 to 800 million doses of this vaccine annually. \"We make approximately 300 million doses by December,\" he said, adding that if it is a two-dose vaccine, then it is going to take at least 3 to 4 years to vaccinate everybody on the planet.\r\n\r\nPoonawalla explained the Oxford COVID-19 vaccine is six months away from launch. \"However a couple million doses will be accessible to the immunocompromised such as the health care workers.\r\n\r\nOxford University on Monday declared satisfactory progress with the vaccine, making it one of the primary ones among the dozens of vaccine candidates being developed across the globe.\r\n\r\nThe varsity has tied up by Serum Institute of India (SII) to manufacture and provide the vaccine to India and more than 60 other nations using a combined population of 3 billion, Poonawalla explained.','Serum Institute\'s CEO Poonawalla says immunization prone to hit Indian market by Q1 2021','','publish','open','open','','serum-institutes-ceo-poonawalla-says-immunization-prone-to-hit-indian-market-by-q1-2021','','','2020-07-22 07:27:04','2020-07-22 07:27:04','',0,'https://microbiozindia.com/?p=6677',0,'post','',0),(6678,2,'2020-07-22 07:27:04','2020-07-22 07:27:04','Serum Institute of India has said it\'ll likely be starting trials of the COVID-19 vaccine candidate developed by Oxford University and AstraZeneca at the end of August and the vaccine might get to the marketplace by first quarter of 2021.\r\n\r\nWithin an interview using CNN-News18, Poonawalla on the timeline of this vaccine reaching the marketplace stated,\"It is probably gonna be December and also for initial quarter of 2021. Because to reach all the parts of the nation, it is going to take a while. So when you create a product to get it tested yourself in your company and then it goes CDI that\'s the national release in Kasauli and after that only could a batch be published to the public. All of course has been expedited. Therefore, if you put all this together realistically massive volumes for India will be the first quarter. However a couple million doses will be available to the more immunocompromised like the healthcare employees. We are likely to have that by December.\"\r\n\r\nHe explained the size of the trials could be dependent on the statisticians afterwards but it\'s going to be approximately 5,000.\r\n\r\nSpeaking about the dosage of COVID-19 vaccine, Poonawalla explained that many vaccines require two to three doses. \"First is that the primer where you are protected 50-60 percent and the second dose provides protection beyond 70-80 per cent,\" he said.\r\n\r\n\"There aren\'t any severe side effects of the vaccine. I am very sure safety is not likely to become an issue,\" he said.\r\n\r\nThe Pune-based company\'s chief executive further said that the company, that\'s the largest vaccine maker in the entire world, can make about 700 to 800 million doses of this vaccine annually. \"We make approximately 300 million doses by December,\" he said, adding that if it is a two-dose vaccine, then it is going to take at least 3 to 4 years to vaccinate everybody on the planet.\r\n\r\nPoonawalla explained the Oxford COVID-19 vaccine is six months away from launch. \"However a couple million doses will be accessible to the immunocompromised such as the health care workers.\r\n\r\nOxford University on Monday declared satisfactory progress with the vaccine, making it one of the primary ones among the dozens of vaccine candidates being developed across the globe.\r\n\r\nThe varsity has tied up by Serum Institute of India (SII) to manufacture and provide the vaccine to India and more than 60 other nations using a combined population of 3 billion, Poonawalla explained.','Serum Institute\'s CEO Poonawalla says immunization prone to hit Indian market by Q1 2021','','inherit','closed','closed','','6677-revision-v1','','','2020-07-22 07:27:04','2020-07-22 07:27:04','',6677,'https://microbiozindia.com/uncategorized/6677-revision-v1/',0,'revision','',0),(6679,2,'2020-07-22 11:22:57','2020-07-22 11:22:57','','ba73270-hplc-vanquish-core-web-ba73270-en_728x90','','inherit','open','closed','','ba73270-hplc-vanquish-core-web-ba73270-en_728x90','','','2020-07-22 11:22:57','2020-07-22 11:22:57','',3649,'https://microbiozindia.com/wp-content/uploads/2019/11/ba73270-hplc-vanquish-core-web-ba73270-en_728x90.jpg',0,'attachment','image/jpeg',0),(6680,2,'2020-07-22 11:34:47','2020-07-22 11:34:47','','Thermo Fisher','','publish','closed','closed','','thermo-fisher','','','2020-07-22 11:34:47','2020-07-22 11:34:47','',0,'https://microbiozindia.com/?post_type=ads&#038;p=6680',0,'ads','',0),(6681,2,'2020-07-22 11:39:53','2020-07-22 11:39:53','','Thermo Fisher','','publish','closed','closed','','thermo-fisher-2','','','2020-07-22 11:40:24','2020-07-22 11:40:24','',0,'https://microbiozindia.com/?post_type=ads&#038;p=6681',0,'ads','',0),(6682,2,'2020-07-22 11:37:14','2020-07-22 11:37:14','','chemical banner _798 X 103px-01','','inherit','open','closed','','chemical-banner-_798-x-103px-01','','','2020-07-22 11:37:14','2020-07-22 11:37:14','',6681,'https://microbiozindia.com/wp-content/uploads/2020/07/chemical-banner-_798-X-103px-01.jpg',0,'attachment','image/jpeg',0),(6683,2,'2020-07-22 12:25:55','2020-07-22 12:25:55','DPX Technologies, Columbia, SC, has launched a new ultra-pure tier filtration tip Together with a new program note with Hamilton Robotics, Reno, Nev, titled\"Automated Method to get High-Throughput LC-MS/MS Quantitation of Testosterone from Serum: An Improved Validated Method.\"\r\n\r\nThe method for the extraction of testosterone in serum used Low Porosity Filtration Tips-Ultra Pure (LPFT-UP) and incorporated a ZnSO4solution in addition to acetonitrile on a Hamilton Heater Shaker (HHS) for enhanced recovery and precision through protein precipitation. The LPFT-UP offer a high quality filtration media for methods with very low detection limits.\r\n\r\nPatient samples had a calculated recovery of testosterone at 99.5% without the detected matrix effects. This shows the use of ZnSO4and acetonitrile is quite effective in extracting testosterone, and also the usage of LPFT-UP resulted in negligible losses. The debut of Low Porosity Filtration tips-Ultra Pure supplies a brand new product for non detection level procedures.\r\n\r\n\"We are excited to expand our product offering for steroid testing,\" says Carmen Adamson, brand director. DPX plans to expand on the research and development to include a full panel of steroids.\r\n\r\n\"Testosterone imbalance can signal a problem in both women and men. This method gives an accurate and precise tool to aid in that decision,\" states Evan DiVirgilio, application scientist.\r\n\r\nFor more information, visit <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://dpxtechnologies.com/\">DPX Technologies</a>.</span>','DPX Technologies, Columbia, SC, has propelled another ultra-unadulterated evaluation filtration tip','','publish','open','open','','dpx-technologies-columbia-sc-has-propelled-another-ultra-unadulterated-evaluation-filtration-tip','','','2020-07-22 12:25:55','2020-07-22 12:25:55','',0,'https://microbiozindia.com/?p=6683',0,'post','',0),(6684,2,'2020-07-22 12:25:12','2020-07-22 12:25:12','','DPX-Technologies_Low-Porosity_Hamilton-cropped-466x273','','inherit','open','closed','','dpx-technologies_low-porosity_hamilton-cropped-466x273','','','2020-07-22 12:25:12','2020-07-22 12:25:12','',6683,'https://microbiozindia.com/wp-content/uploads/2020/07/DPX-Technologies_Low-Porosity_Hamilton-cropped-466x273-1.jpg',0,'attachment','image/jpeg',0),(6685,2,'2020-07-22 12:25:55','2020-07-22 12:25:55','DPX Technologies, Columbia, SC, has launched a new ultra-pure tier filtration tip Together with a new program note with Hamilton Robotics, Reno, Nev, titled\"Automated Method to get High-Throughput LC-MS/MS Quantitation of Testosterone from Serum: An Improved Validated Method.\"\r\n\r\nThe method for the extraction of testosterone in serum used Low Porosity Filtration Tips-Ultra Pure (LPFT-UP) and incorporated a ZnSO4solution in addition to acetonitrile on a Hamilton Heater Shaker (HHS) for enhanced recovery and precision through protein precipitation. The LPFT-UP offer a high quality filtration media for methods with very low detection limits.\r\n\r\nPatient samples had a calculated recovery of testosterone at 99.5% without the detected matrix effects. This shows the use of ZnSO4and acetonitrile is quite effective in extracting testosterone, and also the usage of LPFT-UP resulted in negligible losses. The debut of Low Porosity Filtration tips-Ultra Pure supplies a brand new product for non detection level procedures.\r\n\r\n\"We are excited to expand our product offering for steroid testing,\" says Carmen Adamson, brand director. DPX plans to expand on the research and development to include a full panel of steroids.\r\n\r\n\"Testosterone imbalance can signal a problem in both women and men. This method gives an accurate and precise tool to aid in that decision,\" states Evan DiVirgilio, application scientist.\r\n\r\nFor more information, visit <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://dpxtechnologies.com/\">DPX Technologies</a>.</span>','DPX Technologies, Columbia, SC, has propelled another ultra-unadulterated evaluation filtration tip','','inherit','closed','closed','','6683-revision-v1','','','2020-07-22 12:25:55','2020-07-22 12:25:55','',6683,'https://microbiozindia.com/uncategorized/6683-revision-v1/',0,'revision','',0),(6687,2,'2020-07-22 16:10:55','2020-07-22 16:10:55','Wellbeing and Human Services Secretary Alex Azar declared on Wednesday that the US has marked an agreement with Pfizer for conveyance in December of the initial 100 million dosages of a COVID-19 antibody the pharmaceutical organization is attempting to create. The US could purchase another 500 million portions under the understanding, Azar said.\r\n\r\n\"Presently those would, obviously, must be protected and powerful\" and be endorsed by the Food and Drug Administration, Azar said during an appearance on Fox News.\r\n\r\nPfizer Inc. what\'s more, BioNTech SE declared independently that the understanding is with HHS and the Defense Department for an antibody competitor the organizations are growing together.\r\n\r\nThe understanding is a piece of President Donald Trump\'s Operation Warp Speed immunization program, under which numerous COVID-19 antibodies are being grown at the same time. The program expects to convey 300 million portions of a sheltered and viable COVID-19 antibody by January 2021, as per HHS.\r\n\r\nUnder the activity, the legislature will speed improvement and purchase antibodies — before they are esteemed sheltered and powerful — with the goal that the medicine can be close by and immediately circulated once the FDA endorses or approves its crisis use.\r\n\r\nPfizer and BioNTech said the US will pay $1.95 endless supply of the initial 100 million dosages, following FDA approval or endorsement.\r\n\r\nAzar said the agreement with Pfizer and BioNTech brings to five the quantity of potential coronavirus immunizations that are being worked on.\r\n\r\nTrump said Tuesday at a preparation that \"the immunizations are coming, and they\'re coming a great deal sooner than anybody suspected conceivable, by years.\" But different nations are likewise scrambling to get their hands on an antibody for COVID-19, which has killed in excess of 617,000 individuals, as indicated by a count kept by Johns Hopkins University.\r\n\r\nAlmost 4 million Americans have been contaminated by the new coronavirus and in any event 142,000 have kicked the bucket from COVID-19, the malady it causes, as indicated by Johns Hopkins.\r\n\r\nEngland declared Monday it had tied down access to another 90 million test COVID-19 immunizations made by Pfizer and others, a move a few campaigners cautioned could intensify a worldwide scramble by rich nations to store the world\'s constrained flexibly of COVID-19 antibodies.\r\n\r\nAbout two dozen potential immunizations are in different phases of human testing around the world, with a bunch entering essential late-stage testing to demonstrate adequacy.','US signs contract with Pfizer for COVID-19 antibody dosages','','publish','open','open','','us-signs-contract-with-pfizer-for-covid-19-antibody-dosages','','','2020-07-22 16:10:55','2020-07-22 16:10:55','',0,'https://microbiozindia.com/?p=6687',0,'post','',0),(6688,2,'2020-07-22 16:10:55','2020-07-22 16:10:55','Wellbeing and Human Services Secretary Alex Azar declared on Wednesday that the US has marked an agreement with Pfizer for conveyance in December of the initial 100 million dosages of a COVID-19 antibody the pharmaceutical organization is attempting to create. The US could purchase another 500 million portions under the understanding, Azar said.\r\n\r\n\"Presently those would, obviously, must be protected and powerful\" and be endorsed by the Food and Drug Administration, Azar said during an appearance on Fox News.\r\n\r\nPfizer Inc. what\'s more, BioNTech SE declared independently that the understanding is with HHS and the Defense Department for an antibody competitor the organizations are growing together.\r\n\r\nThe understanding is a piece of President Donald Trump\'s Operation Warp Speed immunization program, under which numerous COVID-19 antibodies are being grown at the same time. The program expects to convey 300 million portions of a sheltered and viable COVID-19 antibody by January 2021, as per HHS.\r\n\r\nUnder the activity, the legislature will speed improvement and purchase antibodies — before they are esteemed sheltered and powerful — with the goal that the medicine can be close by and immediately circulated once the FDA endorses or approves its crisis use.\r\n\r\nPfizer and BioNTech said the US will pay $1.95 endless supply of the initial 100 million dosages, following FDA approval or endorsement.\r\n\r\nAzar said the agreement with Pfizer and BioNTech brings to five the quantity of potential coronavirus immunizations that are being worked on.\r\n\r\nTrump said Tuesday at a preparation that \"the immunizations are coming, and they\'re coming a great deal sooner than anybody suspected conceivable, by years.\" But different nations are likewise scrambling to get their hands on an antibody for COVID-19, which has killed in excess of 617,000 individuals, as indicated by a count kept by Johns Hopkins University.\r\n\r\nAlmost 4 million Americans have been contaminated by the new coronavirus and in any event 142,000 have kicked the bucket from COVID-19, the malady it causes, as indicated by Johns Hopkins.\r\n\r\nEngland declared Monday it had tied down access to another 90 million test COVID-19 immunizations made by Pfizer and others, a move a few campaigners cautioned could intensify a worldwide scramble by rich nations to store the world\'s constrained flexibly of COVID-19 antibodies.\r\n\r\nAbout two dozen potential immunizations are in different phases of human testing around the world, with a bunch entering essential late-stage testing to demonstrate adequacy.','US signs contract with Pfizer for COVID-19 antibody dosages','','inherit','closed','closed','','6687-revision-v1','','','2020-07-22 16:10:55','2020-07-22 16:10:55','',6687,'https://microbiozindia.com/uncategorized/6687-revision-v1/',0,'revision','',0),(6689,2,'2020-07-22 17:14:36','2020-07-22 17:14:36','AMSBIO has introduced StemFit® for Differentiation - a new chemically defined and animal component-free formulation that enables unmatched differentiation of human Induced Pluripotent Stem (hiPS) and Embryonic Stem (hES) cells.\r\n\r\nThe unique chemically defined composition of StemFit® for Differentiation minimizes lot-to-lot variation, enabling highly consistent cell differentiation. Free of animal- and human-derived components, StemFit® for Differentiation can be used to eliminate the risk of immunogenic contamination.\r\n\r\nApplications proven to benefit from StemFit® for Differentiation include: lineage-specific (endodermal, mesodermal and ectodermal) differentiation where this new product is used to replace serum-free supplements, as well as spontaneous differentiation of hiPSCs to organoids via embryoid body formation.\r\n\r\nUsed in combination with StemFit Basic feeder-free medium with iMatrix-511 laminin as extracellular matrix, StemFit® for Differentiation enables researchers to undertake clinical applications involving both expansion and differentiation of human Pluripotent Stem Cell-derived cells and tissues.\r\n\r\nSupplied as a 5X concentrate, StemFit® for Differentiation has been formulated for use with basal cell culture medium (e.g. DMEM, RPMI 1640, DMEM/F12 etc.) and a variety of different induction factors or cytokines (including Activin A and bFGF from AMSBIO).\r\n\r\nFor further information on StemFit® for Differentiation please visit <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.amsbio.com/stemfit-for-differentiation/\">https://www.amsbio.com/stemfit-for-differentiation/</a></span> or contact AMSBIO now on +44-1235-828200 / +1-617-945-5033 / info@amsbio.com.','Differentiation of Human iPS and ES Cells','','publish','open','open','','differentiation-of-human-ips-and-es-cells','','','2020-07-22 17:14:36','2020-07-22 17:14:36','',0,'https://microbiozindia.com/?p=6689',0,'post','',0),(6690,2,'2020-07-22 17:14:22','2020-07-22 17:14:22','','amsbiopr271-image','','inherit','open','closed','','amsbiopr271-image','','','2020-07-22 17:14:22','2020-07-22 17:14:22','',6689,'https://microbiozindia.com/wp-content/uploads/2020/07/amsbiopr271-image.jpg',0,'attachment','image/jpeg',0),(6691,2,'2020-07-22 17:14:36','2020-07-22 17:14:36','AMSBIO has introduced StemFit® for Differentiation - a new chemically defined and animal component-free formulation that enables unmatched differentiation of human Induced Pluripotent Stem (hiPS) and Embryonic Stem (hES) cells.\r\n\r\nThe unique chemically defined composition of StemFit® for Differentiation minimizes lot-to-lot variation, enabling highly consistent cell differentiation. Free of animal- and human-derived components, StemFit® for Differentiation can be used to eliminate the risk of immunogenic contamination.\r\n\r\nApplications proven to benefit from StemFit® for Differentiation include: lineage-specific (endodermal, mesodermal and ectodermal) differentiation where this new product is used to replace serum-free supplements, as well as spontaneous differentiation of hiPSCs to organoids via embryoid body formation.\r\n\r\nUsed in combination with StemFit Basic feeder-free medium with iMatrix-511 laminin as extracellular matrix, StemFit® for Differentiation enables researchers to undertake clinical applications involving both expansion and differentiation of human Pluripotent Stem Cell-derived cells and tissues.\r\n\r\nSupplied as a 5X concentrate, StemFit® for Differentiation has been formulated for use with basal cell culture medium (e.g. DMEM, RPMI 1640, DMEM/F12 etc.) and a variety of different induction factors or cytokines (including Activin A and bFGF from AMSBIO).\r\n\r\nFor further information on StemFit® for Differentiation please visit <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.amsbio.com/stemfit-for-differentiation/\">https://www.amsbio.com/stemfit-for-differentiation/</a></span> or contact AMSBIO now on +44-1235-828200 / +1-617-945-5033 / info@amsbio.com.','Differentiation of Human iPS and ES Cells','','inherit','closed','closed','','6689-revision-v1','','','2020-07-22 17:14:36','2020-07-22 17:14:36','',6689,'https://microbiozindia.com/uncategorized/6689-revision-v1/',0,'revision','',0),(6692,2,'2020-07-22 17:28:57','2020-07-22 17:28:57','\"The virus frequently begins in the nose prior to making its way to the lungs,\" stated Diego Restrepo, PhD, professor of developmental and cell biology in the University of Colorado School of Medicine whose lab won the $125,000 grant from the National Institutes of Health late last month. \"We believe this may spark an inflammatory response that releases cytokines which consequently silence olfactory sensory nerves in the nose\"\r\n\r\nScientists have found that the key neurological indication of Covid-19 is loss of odor without significant nasal congestion. It is frequently one of the first signs of the infection. That\'s led some to believe that the virus targets the senses in a way that other viruses don\'t.\r\n\r\n<em>There is a hypothesis that microvilli, which are protrusions on the cellular membrane, are involved in the detection of the virus and that they start an immune inflammatory response,\" Restrepo said. \"Is that good or bad?\"-</em>Diego Restrepo, PhD, Professor of Cell and Developmental Biology, University of Colorado School of Medicine\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://news.cuanschutz.edu/news-stories/cu-anschutz-researchers-win-grant-to-study-covid-19-impact-on-sense-of-smell\">Restrepo and co-investigator Maria Nagel, MD, professor of neurology and ophthalmology at the CU School of Medicine, will use human olfactory epithelium cultures to research how the novel coronavirus might change the cells and cells that detect stimuli and make perception. </a></span>\r\n\r\nThe group will explore whether manipulating a important chemosensory protein called TRPM5 can either inhibit or stimulate a virally-induced inflammatory cascade. Then they are going to test whether the FDA-approved medication flufenamic acid alters inflammation and viral infection of the olfactory epithelium.\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://news.cuanschutz.edu/news-stories/cu-anschutz-researchers-win-grant-to-study-covid-19-impact-on-sense-of-smell\">In most patients, the sense of smell contributes to about two weeks but at a subset of these infected, it persists for months due to what scientists believe is damage to the olfactory sensory neurons responsible for detecting scents.</a></span>\r\n\"A fascinating feature of this job is that we are elucidating mechanisms of SARS-CoV-2 infection of olfactory neurons that may shed light on the way the virus and associated inflammation can affect neurons inside the mind,\" Nagel said. \"This is particularly important because both neurological complications related to Covid-19 continue to emerge.\"\r\n\r\nThese insights will offer a much better window into how the virus works.\r\n\r\n\"We believe that figuring out just how the virus attacks the neurons connected with smell will help us better understand how it acts,\" Restrepo said. \"And that could finally lead to better treatments in the future\"\r\n<div class=\"content-src-label\">Source:</div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://news.cuanschutz.edu/news-stories/cu-anschutz-researchers-win-grant-to-study-covid-19-impact-on-sense-of-smell\" target=\"_blank\" rel=\"noopener noreferrer\">University of Colorado Anschutz Medical Campus</a></span>\r\n\r\n</div>','Specialists win award to examine why COVID-19 patients lose their feeling of smell','','publish','open','open','','specialists-win-award-to-examine-why-covid-19-patients-lose-their-feeling-of-smell','','','2020-07-22 17:28:57','2020-07-22 17:28:57','',0,'https://microbiozindia.com/?p=6692',0,'post','',0),(6693,2,'2020-07-22 17:27:52','2020-07-22 17:27:52','','87405','','inherit','open','closed','','87405','','','2020-07-22 17:27:52','2020-07-22 17:27:52','',6692,'https://microbiozindia.com/wp-content/uploads/2020/07/87405.jpg',0,'attachment','image/jpeg',0),(6694,2,'2020-07-22 17:28:57','2020-07-22 17:28:57','\"The virus frequently begins in the nose prior to making its way to the lungs,\" stated Diego Restrepo, PhD, professor of developmental and cell biology in the University of Colorado School of Medicine whose lab won the $125,000 grant from the National Institutes of Health late last month. \"We believe this may spark an inflammatory response that releases cytokines which consequently silence olfactory sensory nerves in the nose\"\r\n\r\nScientists have found that the key neurological indication of Covid-19 is loss of odor without significant nasal congestion. It is frequently one of the first signs of the infection. That\'s led some to believe that the virus targets the senses in a way that other viruses don\'t.\r\n\r\n<em>There is a hypothesis that microvilli, which are protrusions on the cellular membrane, are involved in the detection of the virus and that they start an immune inflammatory response,\" Restrepo said. \"Is that good or bad?\"-</em>Diego Restrepo, PhD, Professor of Cell and Developmental Biology, University of Colorado School of Medicine\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://news.cuanschutz.edu/news-stories/cu-anschutz-researchers-win-grant-to-study-covid-19-impact-on-sense-of-smell\">Restrepo and co-investigator Maria Nagel, MD, professor of neurology and ophthalmology at the CU School of Medicine, will use human olfactory epithelium cultures to research how the novel coronavirus might change the cells and cells that detect stimuli and make perception. </a></span>\r\n\r\nThe group will explore whether manipulating a important chemosensory protein called TRPM5 can either inhibit or stimulate a virally-induced inflammatory cascade. Then they are going to test whether the FDA-approved medication flufenamic acid alters inflammation and viral infection of the olfactory epithelium.\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://news.cuanschutz.edu/news-stories/cu-anschutz-researchers-win-grant-to-study-covid-19-impact-on-sense-of-smell\">In most patients, the sense of smell contributes to about two weeks but at a subset of these infected, it persists for months due to what scientists believe is damage to the olfactory sensory neurons responsible for detecting scents.</a></span>\r\n\"A fascinating feature of this job is that we are elucidating mechanisms of SARS-CoV-2 infection of olfactory neurons that may shed light on the way the virus and associated inflammation can affect neurons inside the mind,\" Nagel said. \"This is particularly important because both neurological complications related to Covid-19 continue to emerge.\"\r\n\r\nThese insights will offer a much better window into how the virus works.\r\n\r\n\"We believe that figuring out just how the virus attacks the neurons connected with smell will help us better understand how it acts,\" Restrepo said. \"And that could finally lead to better treatments in the future\"\r\n<div class=\"content-src-label\">Source:</div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://news.cuanschutz.edu/news-stories/cu-anschutz-researchers-win-grant-to-study-covid-19-impact-on-sense-of-smell\" target=\"_blank\" rel=\"noopener noreferrer\">University of Colorado Anschutz Medical Campus</a></span>\r\n\r\n</div>','Specialists win award to examine why COVID-19 patients lose their feeling of smell','','inherit','closed','closed','','6692-revision-v1','','','2020-07-22 17:28:57','2020-07-22 17:28:57','',6692,'https://microbiozindia.com/uncategorized/6692-revision-v1/',0,'revision','',0),(6695,2,'2020-07-23 08:14:02','2020-07-23 08:14:02','Researchers are making\"great progress\" in developing vaccines against COVID-19, with some in late-stage trials, but their first usage can\'t be expected until early 2021, a World Health Organization (WHO) expert said on July 22.\r\n\r\nWHO is working to guarantee fair vaccine distribution, but in the meantime it is key to suppress the virus\'s spread, said Mike Ryan, head of WHO\'s emergencies programme, as daily new instances around the world are at near-record levels.\r\n\r\n\"We are making good progress,\" Ryan said, noting that several vaccines were in phase 3 trials and not one had failed, so far, in terms of security or ability to create an immune reaction.\r\n\r\n\"Realistically it\'s going to be the very first part of next year until we begin seeing people getting vaccinated,\" he told a public event on social media.\r\n\r\nWHO was working to expand accessibility to potential vaccines and also to help scale-up production capacity, Ryan stated.\r\n\r\n\"And we need to be honest about this, since this is an international good. Vaccines for this particular outbreak are not for the wealthy, they\'re not for the bad, they\'re for everybody,\" he explained.\r\n\r\nThe United States authorities will pay $1.95 billion to purchase 100 million doses of a COVID-19 vaccine being developed by Pfizer Inc and German biotech BioNTech in case it proves safe and successful, the firms said.\r\n\r\nRyan also cautioned schools to become more careful about re-opening until neighborhood transmission of COVID-19 is in check. Debate in the United States over restarting schooling has intensified, even as the pandemic flares up in dozens of states.\r\n\r\n\"We must do all possible to bring our kids back to college, and the very best thing we could do is to stop the disease in our community,\" he explained. \"Because if you control the disease locally, you can open the colleges.\"','Try not to expect first COVID-19 immunizations until mid 2021: WHO','','publish','open','open','','try-not-to-expect-first-covid-19-immunizations-until-mid-2021-who','','','2020-07-23 08:14:02','2020-07-23 08:14:02','',0,'https://microbiozindia.com/?p=6695',0,'post','',0),(6696,2,'2020-07-23 08:14:02','2020-07-23 08:14:02','Researchers are making\"great progress\" in developing vaccines against COVID-19, with some in late-stage trials, but their first usage can\'t be expected until early 2021, a World Health Organization (WHO) expert said on July 22.\r\n\r\nWHO is working to guarantee fair vaccine distribution, but in the meantime it is key to suppress the virus\'s spread, said Mike Ryan, head of WHO\'s emergencies programme, as daily new instances around the world are at near-record levels.\r\n\r\n\"We are making good progress,\" Ryan said, noting that several vaccines were in phase 3 trials and not one had failed, so far, in terms of security or ability to create an immune reaction.\r\n\r\n\"Realistically it\'s going to be the very first part of next year until we begin seeing people getting vaccinated,\" he told a public event on social media.\r\n\r\nWHO was working to expand accessibility to potential vaccines and also to help scale-up production capacity, Ryan stated.\r\n\r\n\"And we need to be honest about this, since this is an international good. Vaccines for this particular outbreak are not for the wealthy, they\'re not for the bad, they\'re for everybody,\" he explained.\r\n\r\nThe United States authorities will pay $1.95 billion to purchase 100 million doses of a COVID-19 vaccine being developed by Pfizer Inc and German biotech BioNTech in case it proves safe and successful, the firms said.\r\n\r\nRyan also cautioned schools to become more careful about re-opening until neighborhood transmission of COVID-19 is in check. Debate in the United States over restarting schooling has intensified, even as the pandemic flares up in dozens of states.\r\n\r\n\"We must do all possible to bring our kids back to college, and the very best thing we could do is to stop the disease in our community,\" he explained. \"Because if you control the disease locally, you can open the colleges.\"','Try not to expect first COVID-19 immunizations until mid 2021: WHO','','inherit','closed','closed','','6695-revision-v1','','','2020-07-23 08:14:02','2020-07-23 08:14:02','',6695,'https://microbiozindia.com/uncategorized/6695-revision-v1/',0,'revision','',0),(6697,2,'2020-07-23 08:15:55','2020-07-23 08:15:55','Pune-based Mylab Discovery Solutions on Wednesday said it has received commercial approval from the Indian Council for Medical Research (ICMR) for its antigen testing kit for COVID-19. The product called,\'Pathocatch COVID-19 Antigen Quick testing kit\', is developed and manufactured in India, Mylab said in a statement.\r\n\r\nThe kit will be available for orders immediately and will be priced around Rs 450, it included. The evolution adds another item to the organization\'s suite of testing solutions such as COVID-19 virus, Mylab said.\r\n\r\n\"After having an inexpensive RT-PCR evaluation to decrease reliance on overseas kits, we launched Compact XL to quicken COVID-19 testing. Now, with the acceptance for an antigen testing kit, we will cover entire spectrum of COVID-19 testing and leave no rock unturned to fight this pandemic,\" Mylab Discovery Solutions MD Hasmukh Rawal said.\r\n\r\nHealth experts feel that to keep up with the pace of infections, India needs a combo of antigen and RT-PCR testing, \'\' the announcement said.','Mylab gets ICMR gesture for its antigen testing unit for COVID-19','','publish','open','open','','mylab-gets-icmr-gesture-for-its-antigen-testing-unit-for-covid-19','','','2020-07-23 08:15:55','2020-07-23 08:15:55','',0,'https://microbiozindia.com/?p=6697',0,'post','',0),(6698,2,'2020-07-23 08:15:55','2020-07-23 08:15:55','Pune-based Mylab Discovery Solutions on Wednesday said it has received commercial approval from the Indian Council for Medical Research (ICMR) for its antigen testing kit for COVID-19. The product called,\'Pathocatch COVID-19 Antigen Quick testing kit\', is developed and manufactured in India, Mylab said in a statement.\r\n\r\nThe kit will be available for orders immediately and will be priced around Rs 450, it included. The evolution adds another item to the organization\'s suite of testing solutions such as COVID-19 virus, Mylab said.\r\n\r\n\"After having an inexpensive RT-PCR evaluation to decrease reliance on overseas kits, we launched Compact XL to quicken COVID-19 testing. Now, with the acceptance for an antigen testing kit, we will cover entire spectrum of COVID-19 testing and leave no rock unturned to fight this pandemic,\" Mylab Discovery Solutions MD Hasmukh Rawal said.\r\n\r\nHealth experts feel that to keep up with the pace of infections, India needs a combo of antigen and RT-PCR testing, \'\' the announcement said.','Mylab gets ICMR gesture for its antigen testing unit for COVID-19','','inherit','closed','closed','','6697-revision-v1','','','2020-07-23 08:15:55','2020-07-23 08:15:55','',6697,'https://microbiozindia.com/uncategorized/6697-revision-v1/',0,'revision','',0),(6699,2,'2020-07-23 16:30:13','2020-07-23 16:30:13','Instead of protecting us, the immune system can sometimes go awry, as in the case of autoimmune disorders and allergies. An Ludwig-Maximilian-Universitaet (LMU) in Munich group has dissected how mast cells modulate their calcium levels to maintain the immune response under control.\r\n\r\nThe immune system defends us against attack by germs and viruses and also helps to eliminate cancer cells. The innate immune system is responsible for the initial detection and destruction of invasive pathogens.\r\n\r\nThere are situations, but in which immune responses may be misdirected, causing the machine to focus its firepower to the wrong targets - either the human body\'s own proteins (in the case of autoimmune disorders ) or on intrinsically benign foreign tissues (in the case of allergies).\r\n\r\nCurrently a team of researchers led by LMU immunopharmacologist Susanna Zierler and pharmacologist Ingrid Boekhoff in the Walther Straub Institute of Pharmacology and Toxicology has now shown that the action of certain ion-channel proteins in mast cells plays a significant role in preventing allergic and anaphylactic reactions and ensuring that immune responses don\'t overshoot.\r\n\r\nMast cells are present in almost all organs in the human body and modulate the initiation and resolution of inflammatory reactions mounted by the immune system as a means of combating infections and metabolic dysregulation.\r\n\r\nImmune reactions are highly complex procedures, which must be carefully targeted. <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.en.uni-muenchen.de/news/newsarchiv/2020/zierler_ionenkanal.html\">This usually means that immune cells have to be capable of detecting particular signals that interact with receptor proteins on the cell surface and converting them to clearly defined sets of molecular interactions that result in the activation of the proper response at the ideal time and in the right place.</a></span>\r\n\r\nAmong the reactions triggered within the cell are adjustments in the levels of positively charged ions including calcium, sodium and potassium. It ends up that rapid and transient changes in ion concentrations are essential for the activation of many types of resistant cells.\r\n\r\nIt\'s apparent that cells modulate intracellular levels of the ions principally via proteins called ion channels and ion pumps, however these flows are regulated in the context of immune reactions is not known in detail.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.en.uni-muenchen.de/news/newsarchiv/2020/zierler_ionenkanal.html\">The research groups led by Susanna Zierler and Ingrid Boekhoff have , within the framework of the Collaborative Research Center TRR-152 funded by the DFG, characterized the functions of ion channels which regulate the concentration of free calcium in mast cells.</a></span>\r\nLike most other cell types, mast cells achieve it by activating the release of calcium from intracellular stores. The endoplasmic reticulum (ER) is the greatest storage organelle for calcium .\r\n\r\nHowever, other intracellular organelles, such as the mitochondria (the cell\'s power stations) along with also the lysosomes (intracellular waste disposal units), can also supply calcium ions on demand.\r\n\r\nEvery one these intracellular compartments are delimited by membranes where technical ion channels are added.\r\n\r\n<em>These results show that perturbation of the sensitively regulated equilibrium that controls the level of intracellular calcium ions in mast cells can lead to drastic allergic and anaphylactic reactions.\"-Susanna Zierler, immunopharmacologist, Ludwig Maximilian University of Munich</em>\r\n\r\nEndolysosomal membranes, for instance, include a protein that belongs to the family called two-pore stations (TPCs). Zierler, Boekhoff and their colleagues report that among these, TPC1, plays a significant part in regulating changes in the intracellular distribution of calcium ions between endolysosomes along with the ER.\r\n\r\nThey shown that selective genetic knockout or pharmacological inhibition of TPC1 in mast cells in mice alters the equilibrium between the quantities of calcium stored within such organelles.\r\n\r\nCrucially, this change is associated with a notable increase in the secretion of histamine, which then triggers a severe allergic reaction, on both the cellular and systemic levels.\r\n\r\nThe identification of this TPC1 station protein as an important regulator of mast-cell action and histamine secretion has obvious therapeutic implications.\r\n\r\n\"The study pinpoints the TPC1 channel as a promising drug target for the treatment of allergic and mast-cell-dependent disorders,\" states Zierler. Overall, concentrated pharmacological charge of the ion stations in immune cells has great potential for the treatment of infections, allergies and maybe even leukemias.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.en.uni-muenchen.de/news/newsarchiv/2020/zierler_ionenkanal.html\" target=\"_blank\" rel=\"noopener noreferrer\">Ludwig Maximilian University of Munich</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nArlt<em>.,</em><em>E., et al. </em>(2020) TPC1 deficiency or blockade augments systemic anaphylaxis and mast cell activity. <em>Proceedings of the National Academy of Sciences</em><span style=\"color: #ff6600;\">. <a style=\"color: #ff6600;\" href=\"https://doi.org/10.1073/pnas.1920122117\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1073/pnas.1920122117</a>.</span>\r\n\r\n</div>','Study shows how mast cells manage calcium levels to control the invulnerable reaction','','publish','open','open','','study-shows-how-mast-cells-manage-calcium-levels-to-control-the-invulnerable-reaction','','','2020-07-23 16:30:43','2020-07-23 16:30:43','',0,'https://microbiozindia.com/?p=6699',0,'post','',0),(6700,2,'2020-07-23 16:28:58','2020-07-23 16:28:58','','unnamed','','inherit','open','closed','','unnamed-5','','','2020-07-23 16:28:58','2020-07-23 16:28:58','',6699,'https://microbiozindia.com/wp-content/uploads/2020/07/unnamed-1.jpg',0,'attachment','image/jpeg',0),(6701,2,'2020-07-23 16:30:13','2020-07-23 16:30:13','Instead of protecting us, the immune system can sometimes go awry, as in the case of autoimmune disorders and allergies. An Ludwig-Maximilian-Universitaet (LMU) in Munich group has dissected how mast cells modulate their calcium levels to maintain the immune response under control.\r\n\r\nThe immune system defends us against attack by germs and viruses and also helps to eliminate cancer cells. The innate immune system is responsible for the initial detection and destruction of invasive pathogens.\r\n\r\nThere are situations, but in which immune responses may be misdirected, causing the machine to focus its firepower to the wrong targets - either the human body\'s own proteins (in the case of autoimmune disorders ) or on intrinsically benign foreign tissues (in the case of allergies).\r\n\r\nCurrently a team of researchers led by LMU immunopharmacologist Susanna Zierler and pharmacologist Ingrid Boekhoff in the Walther Straub Institute of Pharmacology and Toxicology has now shown that the action of certain ion-channel proteins in mast cells plays a significant role in preventing allergic and anaphylactic reactions and ensuring that immune responses don\'t overshoot.\r\n\r\nMast cells are present in almost all organs in the human body and modulate the initiation and resolution of inflammatory reactions mounted by the immune system as a means of combating infections and metabolic dysregulation.\r\n\r\nImmune reactions are highly complex procedures, which must be carefully targeted. <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.en.uni-muenchen.de/news/newsarchiv/2020/zierler_ionenkanal.html\">This usually means that immune cells have to be capable of detecting particular signals that interact with receptor proteins on the cell surface and converting them to clearly defined sets of molecular interactions that result in the activation of the proper response at the ideal time and in the right place.</a></span>\r\n\r\nAmong the reactions triggered within the cell are adjustments in the levels of positively charged ions including calcium, sodium and potassium. It ends up that rapid and transient changes in ion concentrations are essential for the activation of many types of resistant cells.\r\n\r\nIt\'s apparent that cells modulate intracellular levels of the ions principally via proteins called ion channels and ion pumps, however these flows are regulated in the context of immune reactions is not known in detail.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.en.uni-muenchen.de/news/newsarchiv/2020/zierler_ionenkanal.html\">The research groups led by Susanna Zierler and Ingrid Boekhoff have , within the framework of the Collaborative Research Center TRR-152 funded by the DFG, characterized the functions of ion channels which regulate the concentration of free calcium in mast cells.</a></span>\r\nLike most other cell types, mast cells achieve it by activating the release of calcium from intracellular stores. The endoplasmic reticulum (ER) is the greatest storage organelle for calcium .\r\n\r\nHowever, other intracellular organelles, such as the mitochondria (the cell\'s power stations) along with also the lysosomes (intracellular waste disposal units), can also supply calcium ions on demand.\r\n\r\nEvery one these intracellular compartments are delimited by membranes where technical ion channels are added.\r\n\r\n<em>These results show that perturbation of the sensitively regulated equilibrium that controls the level of intracellular calcium ions in mast cells can lead to drastic allergic and anaphylactic reactions.\"-Susanna Zierler, immunopharmacologist, Ludwig Maximilian University of Munich</em>\r\n\r\nEndolysosomal membranes, for instance, include a protein that belongs to the family called two-pore stations (TPCs). Zierler, Boekhoff and their colleagues report that among these, TPC1, plays a significant part in regulating changes in the intracellular distribution of calcium ions between endolysosomes along with the ER.\r\n\r\nThey shown that selective genetic knockout or pharmacological inhibition of TPC1 in mast cells in mice alters the equilibrium between the quantities of calcium stored within such organelles.\r\n\r\nCrucially, this change is associated with a notable increase in the secretion of histamine, which then triggers a severe allergic reaction, on both the cellular and systemic levels.\r\n\r\nThe identification of this TPC1 station protein as an important regulator of mast-cell action and histamine secretion has obvious therapeutic implications.\r\n\r\n\"The study pinpoints the TPC1 channel as a promising drug target for the treatment of allergic and mast-cell-dependent disorders,\" states Zierler. Overall, concentrated pharmacological charge of the ion stations in immune cells has great potential for the treatment of infections, allergies and maybe even leukemias.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.en.uni-muenchen.de/news/newsarchiv/2020/zierler_ionenkanal.html\" target=\"_blank\" rel=\"noopener noreferrer\">Ludwig Maximilian University of Munich</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nArlt<em>.,</em><em>E., et al. </em>(2020) TPC1 deficiency or blockade augments systemic anaphylaxis and mast cell activity. <em>Proceedings of the National Academy of Sciences</em><span style=\"color: #ff6600;\">. <a style=\"color: #ff6600;\" href=\"https://doi.org/10.1073/pnas.1920122117\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1073/pnas.1920122117</a>.</span>\r\n\r\n</div>','Study shows how mast cells manage calcium levels to control the invulnerable reaction','','inherit','closed','closed','','6699-revision-v1','','','2020-07-23 16:30:13','2020-07-23 16:30:13','',6699,'https://microbiozindia.com/uncategorized/6699-revision-v1/',0,'revision','',0),(6702,2,'2020-07-23 16:30:43','2020-07-23 16:30:43','Instead of protecting us, the immune system can sometimes go awry, as in the case of autoimmune disorders and allergies. An Ludwig-Maximilian-Universitaet (LMU) in Munich group has dissected how mast cells modulate their calcium levels to maintain the immune response under control.\r\n\r\nThe immune system defends us against attack by germs and viruses and also helps to eliminate cancer cells. The innate immune system is responsible for the initial detection and destruction of invasive pathogens.\r\n\r\nThere are situations, but in which immune responses may be misdirected, causing the machine to focus its firepower to the wrong targets - either the human body\'s own proteins (in the case of autoimmune disorders ) or on intrinsically benign foreign tissues (in the case of allergies).\r\n\r\nCurrently a team of researchers led by LMU immunopharmacologist Susanna Zierler and pharmacologist Ingrid Boekhoff in the Walther Straub Institute of Pharmacology and Toxicology has now shown that the action of certain ion-channel proteins in mast cells plays a significant role in preventing allergic and anaphylactic reactions and ensuring that immune responses don\'t overshoot.\r\n\r\nMast cells are present in almost all organs in the human body and modulate the initiation and resolution of inflammatory reactions mounted by the immune system as a means of combating infections and metabolic dysregulation.\r\n\r\nImmune reactions are highly complex procedures, which must be carefully targeted. <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.en.uni-muenchen.de/news/newsarchiv/2020/zierler_ionenkanal.html\">This usually means that immune cells have to be capable of detecting particular signals that interact with receptor proteins on the cell surface and converting them to clearly defined sets of molecular interactions that result in the activation of the proper response at the ideal time and in the right place.</a></span>\r\n\r\nAmong the reactions triggered within the cell are adjustments in the levels of positively charged ions including calcium, sodium and potassium. It ends up that rapid and transient changes in ion concentrations are essential for the activation of many types of resistant cells.\r\n\r\nIt\'s apparent that cells modulate intracellular levels of the ions principally via proteins called ion channels and ion pumps, however these flows are regulated in the context of immune reactions is not known in detail.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.en.uni-muenchen.de/news/newsarchiv/2020/zierler_ionenkanal.html\">The research groups led by Susanna Zierler and Ingrid Boekhoff have , within the framework of the Collaborative Research Center TRR-152 funded by the DFG, characterized the functions of ion channels which regulate the concentration of free calcium in mast cells.</a></span>\r\nLike most other cell types, mast cells achieve it by activating the release of calcium from intracellular stores. The endoplasmic reticulum (ER) is the greatest storage organelle for calcium .\r\n\r\nHowever, other intracellular organelles, such as the mitochondria (the cell\'s power stations) along with also the lysosomes (intracellular waste disposal units), can also supply calcium ions on demand.\r\n\r\nEvery one these intracellular compartments are delimited by membranes where technical ion channels are added.\r\n\r\n<em>These results show that perturbation of the sensitively regulated equilibrium that controls the level of intracellular calcium ions in mast cells can lead to drastic allergic and anaphylactic reactions.\"-Susanna Zierler, immunopharmacologist, Ludwig Maximilian University of Munich</em>\r\n\r\nEndolysosomal membranes, for instance, include a protein that belongs to the family called two-pore stations (TPCs). Zierler, Boekhoff and their colleagues report that among these, TPC1, plays a significant part in regulating changes in the intracellular distribution of calcium ions between endolysosomes along with the ER.\r\n\r\nThey shown that selective genetic knockout or pharmacological inhibition of TPC1 in mast cells in mice alters the equilibrium between the quantities of calcium stored within such organelles.\r\n\r\nCrucially, this change is associated with a notable increase in the secretion of histamine, which then triggers a severe allergic reaction, on both the cellular and systemic levels.\r\n\r\nThe identification of this TPC1 station protein as an important regulator of mast-cell action and histamine secretion has obvious therapeutic implications.\r\n\r\n\"The study pinpoints the TPC1 channel as a promising drug target for the treatment of allergic and mast-cell-dependent disorders,\" states Zierler. Overall, concentrated pharmacological charge of the ion stations in immune cells has great potential for the treatment of infections, allergies and maybe even leukemias.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.en.uni-muenchen.de/news/newsarchiv/2020/zierler_ionenkanal.html\" target=\"_blank\" rel=\"noopener noreferrer\">Ludwig Maximilian University of Munich</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nArlt<em>.,</em><em>E., et al. </em>(2020) TPC1 deficiency or blockade augments systemic anaphylaxis and mast cell activity. <em>Proceedings of the National Academy of Sciences</em><span style=\"color: #ff6600;\">. <a style=\"color: #ff6600;\" href=\"https://doi.org/10.1073/pnas.1920122117\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1073/pnas.1920122117</a>.</span>\r\n\r\n</div>','Study shows how mast cells manage calcium levels to control the invulnerable reaction','','inherit','closed','closed','','6699-revision-v1','','','2020-07-23 16:30:43','2020-07-23 16:30:43','',6699,'https://microbiozindia.com/uncategorized/6699-revision-v1/',0,'revision','',0),(6703,2,'2020-07-24 05:15:56','2020-07-24 05:15:56','Airborne and potentially deadly, the virus which causes COVID-19 can only be studied safely under high level biosafety conditions. Scientists handling the virus that is infectious must wear full-body biohazard matches with pressurized respirators, and operate inside labs with multiple containment degrees and technical ventilation systems. While necessary to protect laboratory employees, these security precautions slow down efforts to find vaccines and drugs for COVID-19 since many scientists lack access to the required biosafety facilities.\r\n\r\nTo help remedy this, researchers at Washington University School of Medicine in St. Louis have developed a hybrid virus that may enable more scientists to go into the fight against the pandemic. The researchers modified a moderate virus by swapping one of its own genes for one from SARS-CoV-2, the virus that leads to COVID-19. The resulting hybrid cells and can be recognized by antibodies just like SARS-CoV-2, but can be handled under normal laboratory security requirements.\r\n\r\nThe study is available online in Mobile Host &amp; Microbe.\r\n\r\n\"I\'ve never had this many requests for a scientific material in this short time period,\" stated co-senior writer Sean Whelan, PhD, the Marvin A. Brennecke Distinguished Professor and head of the Department of Molecular Microbiology. \"We have distributed the virus to investigators in Argentina, Brazil, Mexico, Canada and, of course, throughout the U.S.. We have requests pending from the U.K. and Germany. Even before we published, people heard that we had been working on this and started asking the material.\"\r\n\r\nTo create a model of SARS-CoV-2 that will be safer to handle, Whelan and colleagues -- including co-senior writer Michael S. Diamond, MD, PhD, the Herbert S. Gasser Professor of Medicine, and co-first writers Brett Case, PhD, a postdoctoral researcher in Diamond\'s lab, and Paul W. Rothlauf, a graduate student in Whelan\'s laboratory -- began with vesicular stomatitis virus (VSV). This virus is a workhorse of virology labs because it is fairly innocuous and easy to manipulate . Primarily a virus of cattle, horses and horses, VSV occasionally infects people, causing a mild flu-like disease that lasts three to four days.\r\n\r\nThe researchers eliminated VSV\'s surface-protein gene and replaced it with the one from SARS-CoV-2, called spike. The switch produced a new virus that targets cells such as SARS-CoV-2 but lacks the other genes needed to cause acute illness. They called the hybrid VSV-SARS-CoV-2.\r\n\r\nUsing serum from COVID-19 survivors and purified antibodies, the researchers revealed that the hybrid was recognized by antibodies much like a real SARS-CoV-2 virus which came out of a COVID-19 patient. Antibodies or sera that prevented the hybrid virus from infecting cells also blocked the real SARS-CoV-2 virus from doing this; electrons or sera that failed to block the hybrid also failed to dissuade the real SARS-CoV-2. In addition, a decoy molecule was effective at misdirecting both viruses and preventing them from infecting cells.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.sciencedirect.com/science/article/pii/S1931312820303620?via%3Dihub\">\"People certainly grow antibodies against other SARS-CoV-2 proteins, but it\'s the radicals against spike that appear to be most important for protection,\" Whelan said. \"</a></span>So as long as a virus has the spike protein, then it appears to the individual immune system like SARS-CoV-2, for all intents and purposes.\"\r\n\r\nThe hybrid virus could help scientists evaluate a range of antibody-based preventives and treatments for COVID-19. The virus may be used to evaluate whether an experimental vaccine elicits neutralizing antibodies, to measure whether or not a COVID-19 survivor carries enough neutralizing antibodies to contribute plasma to COVID-19 sufferers to identify antibodies with the potential to be developed into antifungal drugs.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.sciencedirect.com/science/article/pii/S1931312820303620?via%3Dihub\">\"Among the issues in assessing neutralizing antibodies is that a good deal of these tests need a BSL-3 facility, and many clinical labs and companies don\'t have BSL-3 facilities,\" said Diamond, who is also a professor of molecular microbiology, and of pathology and immunology.</a></span> \"With this virus, you can take serum, plasma or antibodies and do high-throughput analyses at BSL-2 amounts, which each lab has, with no risk of becoming infected. And we all know that it correlates almost perfectly with all the data we get from bona fide infectious SARS-CoV-2.\"\r\n\r\nSince the hybrid virus looks like SARS-CoV-2 to the immune system but doesn\'t cause severe illness, it is a possible vaccine candidate, Diamond added. He, Whelan and colleagues have been conducting animal studies to assess the possibility.\r\n\r\n<strong>Story Source:</strong>\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.sciencedirect.com/science/article/pii/S1931312820303620?via%3Dihub\">Materials</a></span> provided by Washington University School of Medicine. Original written by Tamara Bhandari. Note: Content may be edited for style and length.\r\n\r\n<strong>Journal Reference:</strong>\r\n\r\nJames Brett Case, Paul W. Rothlauf, Rita E. Chen, Zhuoming Liu, Haiyan Zhao, Arthur S. Kim, Louis-Marie Bloyet, Qiru Zeng, Stephen Tahan, Lindsay Droit, Ma. Xenia G. Ilagan, Michael A. Tartell, Gaya Amarasinghe, Jeffrey P. Henderson, Shane Miersch, Mart Ustav, Sachdev Sidhu, Herbert W. Virgin, David Wang, Siyuan Ding, Davide Corti, Elitza S. Theel, Daved H. Fremont, Michael S. Diamond, Sean P.J. Whelan. Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2.. Cell Host &amp; Microbe, 2020; <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.sciencedirect.com/science/article/pii/S1931312820303620?via%3Dihub\">DOI: 10.1016/j.chom.2020.06.021</a></span>','Lab-made infection mirrors COVID-19 infection: Research','','publish','open','open','','lab-made-infection-mirrors-covid-19-infection-research','','','2020-07-24 05:15:56','2020-07-24 05:15:56','',0,'https://microbiozindia.com/?p=6703',0,'post','',0),(6704,2,'2020-07-24 05:15:56','2020-07-24 05:15:56','Airborne and potentially deadly, the virus which causes COVID-19 can only be studied safely under high level biosafety conditions. Scientists handling the virus that is infectious must wear full-body biohazard matches with pressurized respirators, and operate inside labs with multiple containment degrees and technical ventilation systems. While necessary to protect laboratory employees, these security precautions slow down efforts to find vaccines and drugs for COVID-19 since many scientists lack access to the required biosafety facilities.\r\n\r\nTo help remedy this, researchers at Washington University School of Medicine in St. Louis have developed a hybrid virus that may enable more scientists to go into the fight against the pandemic. The researchers modified a moderate virus by swapping one of its own genes for one from SARS-CoV-2, the virus that leads to COVID-19. The resulting hybrid cells and can be recognized by antibodies just like SARS-CoV-2, but can be handled under normal laboratory security requirements.\r\n\r\nThe study is available online in Mobile Host &amp; Microbe.\r\n\r\n\"I\'ve never had this many requests for a scientific material in this short time period,\" stated co-senior writer Sean Whelan, PhD, the Marvin A. Brennecke Distinguished Professor and head of the Department of Molecular Microbiology. \"We have distributed the virus to investigators in Argentina, Brazil, Mexico, Canada and, of course, throughout the U.S.. We have requests pending from the U.K. and Germany. Even before we published, people heard that we had been working on this and started asking the material.\"\r\n\r\nTo create a model of SARS-CoV-2 that will be safer to handle, Whelan and colleagues -- including co-senior writer Michael S. Diamond, MD, PhD, the Herbert S. Gasser Professor of Medicine, and co-first writers Brett Case, PhD, a postdoctoral researcher in Diamond\'s lab, and Paul W. Rothlauf, a graduate student in Whelan\'s laboratory -- began with vesicular stomatitis virus (VSV). This virus is a workhorse of virology labs because it is fairly innocuous and easy to manipulate . Primarily a virus of cattle, horses and horses, VSV occasionally infects people, causing a mild flu-like disease that lasts three to four days.\r\n\r\nThe researchers eliminated VSV\'s surface-protein gene and replaced it with the one from SARS-CoV-2, called spike. The switch produced a new virus that targets cells such as SARS-CoV-2 but lacks the other genes needed to cause acute illness. They called the hybrid VSV-SARS-CoV-2.\r\n\r\nUsing serum from COVID-19 survivors and purified antibodies, the researchers revealed that the hybrid was recognized by antibodies much like a real SARS-CoV-2 virus which came out of a COVID-19 patient. Antibodies or sera that prevented the hybrid virus from infecting cells also blocked the real SARS-CoV-2 virus from doing this; electrons or sera that failed to block the hybrid also failed to dissuade the real SARS-CoV-2. In addition, a decoy molecule was effective at misdirecting both viruses and preventing them from infecting cells.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.sciencedirect.com/science/article/pii/S1931312820303620?via%3Dihub\">\"People certainly grow antibodies against other SARS-CoV-2 proteins, but it\'s the radicals against spike that appear to be most important for protection,\" Whelan said. \"</a></span>So as long as a virus has the spike protein, then it appears to the individual immune system like SARS-CoV-2, for all intents and purposes.\"\r\n\r\nThe hybrid virus could help scientists evaluate a range of antibody-based preventives and treatments for COVID-19. The virus may be used to evaluate whether an experimental vaccine elicits neutralizing antibodies, to measure whether or not a COVID-19 survivor carries enough neutralizing antibodies to contribute plasma to COVID-19 sufferers to identify antibodies with the potential to be developed into antifungal drugs.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.sciencedirect.com/science/article/pii/S1931312820303620?via%3Dihub\">\"Among the issues in assessing neutralizing antibodies is that a good deal of these tests need a BSL-3 facility, and many clinical labs and companies don\'t have BSL-3 facilities,\" said Diamond, who is also a professor of molecular microbiology, and of pathology and immunology.</a></span> \"With this virus, you can take serum, plasma or antibodies and do high-throughput analyses at BSL-2 amounts, which each lab has, with no risk of becoming infected. And we all know that it correlates almost perfectly with all the data we get from bona fide infectious SARS-CoV-2.\"\r\n\r\nSince the hybrid virus looks like SARS-CoV-2 to the immune system but doesn\'t cause severe illness, it is a possible vaccine candidate, Diamond added. He, Whelan and colleagues have been conducting animal studies to assess the possibility.\r\n\r\n<strong>Story Source:</strong>\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.sciencedirect.com/science/article/pii/S1931312820303620?via%3Dihub\">Materials</a></span> provided by Washington University School of Medicine. Original written by Tamara Bhandari. Note: Content may be edited for style and length.\r\n\r\n<strong>Journal Reference:</strong>\r\n\r\nJames Brett Case, Paul W. Rothlauf, Rita E. Chen, Zhuoming Liu, Haiyan Zhao, Arthur S. Kim, Louis-Marie Bloyet, Qiru Zeng, Stephen Tahan, Lindsay Droit, Ma. Xenia G. Ilagan, Michael A. Tartell, Gaya Amarasinghe, Jeffrey P. Henderson, Shane Miersch, Mart Ustav, Sachdev Sidhu, Herbert W. Virgin, David Wang, Siyuan Ding, Davide Corti, Elitza S. Theel, Daved H. Fremont, Michael S. Diamond, Sean P.J. Whelan. Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2.. Cell Host &amp; Microbe, 2020; <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.sciencedirect.com/science/article/pii/S1931312820303620?via%3Dihub\">DOI: 10.1016/j.chom.2020.06.021</a></span>','Lab-made infection mirrors COVID-19 infection: Research','','inherit','closed','closed','','6703-revision-v1','','','2020-07-24 05:15:56','2020-07-24 05:15:56','',6703,'https://microbiozindia.com/uncategorized/6703-revision-v1/',0,'revision','',0),(6705,2,'2020-07-24 13:42:10','2020-07-24 13:42:10','The chief scientist at the World Health Organization estimates that approximately 50 percent to 60% of the population will have to be resistant to the coronavirus for there to be some protective\"herd immunity\" effect.\r\n\r\nHerd immunity is normally achieved through vaccination and occurs when most of a population is immune to a disease, obstructing its continued spread.\r\n\r\nThroughout a social media event on Friday, Dr Soumya Swaminathan said that studies done from several countries hit hard by COVID-19 reveal that about 5% to 10 percent of people now have antibodies, although in certain countries, it has been as large as 20 percent.\r\n\r\nShe states:\"As there are waves of this disease going through countries, individuals will develop antibodies and those folks will be immune for sometime so they may also act as barriers and brakes to the spread\"\r\n\r\nOther experts have estimated that as much as 70 percent to 80% of the population need to possess antibodies before there\'s a herd immunity effect.\r\n\r\nIn the pandemic\'s earlier phases, countries including Britain suggested accomplishing herd immunity as an outbreak response plan. But Swaminathan pointed out that achieving this effect with a vaccine is a lot safer than allowing the virus tear through the population.\r\n\r\nShe states that to achieve herd immunity through natural infection, you have to have several waves and you will see the morbidity and mortality that we see now.','WHO chief researcher sees no group invulnerability yet','','publish','open','open','','who-chief-researcher-sees-no-group-invulnerability-yet','','','2020-07-24 13:42:10','2020-07-24 13:42:10','',0,'https://microbiozindia.com/?p=6705',0,'post','',0),(6706,2,'2020-07-24 13:42:10','2020-07-24 13:42:10','The chief scientist at the World Health Organization estimates that approximately 50 percent to 60% of the population will have to be resistant to the coronavirus for there to be some protective\"herd immunity\" effect.\r\n\r\nHerd immunity is normally achieved through vaccination and occurs when most of a population is immune to a disease, obstructing its continued spread.\r\n\r\nThroughout a social media event on Friday, Dr Soumya Swaminathan said that studies done from several countries hit hard by COVID-19 reveal that about 5% to 10 percent of people now have antibodies, although in certain countries, it has been as large as 20 percent.\r\n\r\nShe states:\"As there are waves of this disease going through countries, individuals will develop antibodies and those folks will be immune for sometime so they may also act as barriers and brakes to the spread\"\r\n\r\nOther experts have estimated that as much as 70 percent to 80% of the population need to possess antibodies before there\'s a herd immunity effect.\r\n\r\nIn the pandemic\'s earlier phases, countries including Britain suggested accomplishing herd immunity as an outbreak response plan. But Swaminathan pointed out that achieving this effect with a vaccine is a lot safer than allowing the virus tear through the population.\r\n\r\nShe states that to achieve herd immunity through natural infection, you have to have several waves and you will see the morbidity and mortality that we see now.','WHO chief researcher sees no group invulnerability yet','','inherit','closed','closed','','6705-revision-v1','','','2020-07-24 13:42:10','2020-07-24 13:42:10','',6705,'https://microbiozindia.com/uncategorized/6705-revision-v1/',0,'revision','',0),(6707,2,'2020-07-24 13:44:00','2020-07-24 13:44:00','Animal tests of an expected COVID-19 vaccine being developed by Chinese researchers demonstrate it triggers an immune reaction against the novel coronavirus, offering some promise since it goes into early-stage human trials, according to a peer-reviewed study.\r\n\r\nARCoV is a messenger RNA vaccine which uses technology like applicants being manufactured by Moderna and BioNtech and Pfizer. It is the 2nd possible COVID-19 vaccine which China\'s military-backed research unit has transferred into clinical trials.\r\n\r\nResults of trials of ARCoV in monkeys and mice, printed in the peer-reviewed clinical journal Cell on Thursday, show both and two-dose inoculations induced strong antibody and T-cell responses against several COVID-19-causing virus strains.\r\n\r\nNevertheless, researchers conducting the trial cautioned that they were not yet able to realize the length of time the ARCoV-induced Compounds might last or how strong their defense could be to other breeds that cause COVID-19 but were not examined in the research.\r\n\r\nARCoV is secure at 25°C (77°F) for at least a week, researchers said, which might make it more attractive for possible immunisation campaigns in hard-to-reach inhabitants in places where cold-chain storage and transport aren\'t always dependable.\r\n\r\nWhile no COVID-19 vaccine was approved for sale yet, more than 150 have been in development globally with an aim to help finish the global pandemic which has claimed over 600,000 lives. But whether any will triumph remains far from clear.','Chinese COVID-19 antibody up-and-comer shows guarantee in animal tests','','publish','open','open','','chinese-covid-19-antibody-up-and-comer-shows-guarantee-in-animal-tests','','','2020-07-24 13:44:00','2020-07-24 13:44:00','',0,'https://microbiozindia.com/?p=6707',0,'post','',0),(6708,2,'2020-07-24 13:44:00','2020-07-24 13:44:00','Animal tests of an expected COVID-19 vaccine being developed by Chinese researchers demonstrate it triggers an immune reaction against the novel coronavirus, offering some promise since it goes into early-stage human trials, according to a peer-reviewed study.\r\n\r\nARCoV is a messenger RNA vaccine which uses technology like applicants being manufactured by Moderna and BioNtech and Pfizer. It is the 2nd possible COVID-19 vaccine which China\'s military-backed research unit has transferred into clinical trials.\r\n\r\nResults of trials of ARCoV in monkeys and mice, printed in the peer-reviewed clinical journal Cell on Thursday, show both and two-dose inoculations induced strong antibody and T-cell responses against several COVID-19-causing virus strains.\r\n\r\nNevertheless, researchers conducting the trial cautioned that they were not yet able to realize the length of time the ARCoV-induced Compounds might last or how strong their defense could be to other breeds that cause COVID-19 but were not examined in the research.\r\n\r\nARCoV is secure at 25°C (77°F) for at least a week, researchers said, which might make it more attractive for possible immunisation campaigns in hard-to-reach inhabitants in places where cold-chain storage and transport aren\'t always dependable.\r\n\r\nWhile no COVID-19 vaccine was approved for sale yet, more than 150 have been in development globally with an aim to help finish the global pandemic which has claimed over 600,000 lives. But whether any will triumph remains far from clear.','Chinese COVID-19 antibody up-and-comer shows guarantee in animal tests','','inherit','closed','closed','','6707-revision-v1','','','2020-07-24 13:44:00','2020-07-24 13:44:00','',6707,'https://microbiozindia.com/uncategorized/6707-revision-v1/',0,'revision','',0),(6709,2,'2020-07-24 14:37:47','2020-07-24 14:37:47','Mumbai, India; July 24, 2020: Cipla Limited (BSE: 500087; NSE: CIPLA EQ, hereinafter referred to as “Cipla”), today announced that it has been granted regulatory approval by the Drug Controller General of India (DCGI) for the launch of Favipiravir in the country under the brand name Ciplenza. The accelerated approval for manufacturing and marketing of the drug is aimed at meeting the urgent and unmet medical need for COVID-19 treatment options in the country through restricted emergency use.\r\n\r\nAs part of its efforts to enable speedy access to cater to the demand, Cipla will commercially launch Ciplenza in the first week of August priced at Rs 68 per tablet. To ensure fair and equitable distribution of the drug, supplies will be undertaken predominantly through hospital channels and via open channels, prioritised for regions with a high burden of COVID-19 cases.\r\n\r\nThe drug has been jointly developed by Cipla and CSIR-Indian Institute of Chemical Technology (IICT). As part of this partnership, CSIR-IICT has successfully developed a convenient and cost-effective synthetic process for Favipiravir. The entire process and Active Pharmaceutical Ingredient (API) of the drug has been transferred to Cipla to manufacture and market the drug at scale.\r\n\r\nFavipiravir is an off patent, oral anti-viral drug that has been shown to hasten clinical recovery in COVID -19 patients with mild to moderate symptoms.','Cipla receives regulatory approval for launch of Ciplenza in India to treat mild to moderate COVID-19','','publish','open','open','','cipla-receives-regulatory-approval-for-launch-of-ciplenza-in-india-to-treat-mild-to-moderate-covid-19','','','2020-07-24 14:37:47','2020-07-24 14:37:47','',0,'https://microbiozindia.com/?p=6709',0,'post','',0),(6710,2,'2020-07-24 14:37:47','2020-07-24 14:37:47','Mumbai, India; July 24, 2020: Cipla Limited (BSE: 500087; NSE: CIPLA EQ, hereinafter referred to as “Cipla”), today announced that it has been granted regulatory approval by the Drug Controller General of India (DCGI) for the launch of Favipiravir in the country under the brand name Ciplenza. The accelerated approval for manufacturing and marketing of the drug is aimed at meeting the urgent and unmet medical need for COVID-19 treatment options in the country through restricted emergency use.\r\n\r\nAs part of its efforts to enable speedy access to cater to the demand, Cipla will commercially launch Ciplenza in the first week of August priced at Rs 68 per tablet. To ensure fair and equitable distribution of the drug, supplies will be undertaken predominantly through hospital channels and via open channels, prioritised for regions with a high burden of COVID-19 cases.\r\n\r\nThe drug has been jointly developed by Cipla and CSIR-Indian Institute of Chemical Technology (IICT). As part of this partnership, CSIR-IICT has successfully developed a convenient and cost-effective synthetic process for Favipiravir. The entire process and Active Pharmaceutical Ingredient (API) of the drug has been transferred to Cipla to manufacture and market the drug at scale.\r\n\r\nFavipiravir is an off patent, oral anti-viral drug that has been shown to hasten clinical recovery in COVID -19 patients with mild to moderate symptoms.','Cipla receives regulatory approval for launch of Ciplenza in India to treat mild to moderate COVID-19','','inherit','closed','closed','','6709-revision-v1','','','2020-07-24 14:37:47','2020-07-24 14:37:47','',6709,'https://microbiozindia.com/uncategorized/6709-revision-v1/',0,'revision','',0),(6711,2,'2020-07-25 15:47:16','2020-07-25 15:47:16','Two injections of this vaccine were enough to induce robust immunity, completely preventing SARS-CoV-2 infection in mice.\r\n\r\nMRNA-based vaccines are all attractive options for protecting against SARS-CoV-2 because they may be quickly designed and manufactured at a huge scale within weeks. Moreover, preclinical studies have shown that mRNA-based vaccines cause potent and broadly protective immune responses against various pathogens with an acceptable safety profile.\r\n\r\nFrom the Cell analysis, Qin and his colleagues developed a vaccine comprising mRNA that encodes the receptor-binding domain (RBD) of the spike (S) protein, which is situated on the surface of SARS-CoV-2. The vaccine, called ARCoV, is encapsulated in lipid nanoparticles, which improves delivery to cells.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://linkinghub.elsevier.com/retrieve/pii/S0092867420309326\">Targeting RBD instead of the whole S protein can represent a safer option, possibly triggering the production of fewer non-neutralizing antibodies.</a></span> These antibodies could improve viral entry into cells and viral replication through a procedure called antibody-dependent enhancement of infection, which was previously reported to the associated virus SARS-CoV--that the causative agent of the SARS outbreak in 2002 to 2003.\r\n\r\n<em>The robust protection observed in the present studies and the clear immune correlates of protection pave the path forward for future COVID-19 vaccine development in humans.\"-</em>Cheng-Feng Qin, Senior Study Author, Beijing Institute of Microbiology and Epidemiology\r\n\r\nThe researchers injected ARCoV into the muscle tissue of 16 mice and provided a booster shot just two months later. The vaccine elicited the creation of elevated levels of neutralizing antibodies, which protect host cells from preventing the virus from interacting together. These antibodies were cross-reactive, offering broad protection against three different breeds of SARS-CoV-2. In addition, the vaccine raised the amount of T cells from the spleen.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://linkinghub.elsevier.com/retrieve/pii/S0092867420309326\">Mice that received two doses of ARCoV and have been exposed to SARS-CoV-2 35 days afterwards revealed no signs of viral RNA from the lungs or trachea without any lung damage or swelling.</a></span> Outcomes from 20 cynomolgus monkeys showed two ARCoV doses triggered a virus-specific T cell response and the generation of neutralizing antibodies at rates that significantly exceed those seen in most recuperated COVID-19 patients. Moreover, none of the vaccinated animals experienced negative effects.\r\nTo evaluate the thermal stability of ARCoV, the investigators stored the vaccine in different temperatures for a single, four, or seven times, injected it into mice, and visualized its tissue distribution. The results showed that the vaccine was efficiently delivered to tissues, achieving the same high level of expression after being stored at room temperature for one week, with no signs of diminished activity. \"A ready-to-use and thermostable vaccine like ARCoV is highly desirable to eliminate the need for cold-chain transport,\" Qin states.\r\n\r\nThe researchers are evaluating the long-term stability of ARCoV. \"Additionally, the term of neutralization antibody induced by ARCoV is not yet been determined, as expertise from other individual coronaviruses has signaled the potential for re-infection because of waning of this antibody reaction,\" Qin states. \"Future studies are required to assess the long-term immune response in animal models and the potency of ARCoV in people.\"\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://www.cellpress.com/\" target=\"_blank\" rel=\"noopener noreferrer\">Cell Press</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nZhang, N., <em>et al.</em> (2020) A thermostable mRNA vaccine against COVID-19. <em>Cell.</em><span style=\"color: #ff6600;\"> <a style=\"color: #ff6600;\" href=\"http://dx.doi.org/10.1016/j.cell.2020.07.024\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1016/j.cell.2020.07.024</a>.</span>\r\n\r\n</div>','Test mRNA-based COVID-19 immunization evokes defensive safe reactions in animals','','publish','open','open','','test-mrna-based-covid-19-immunization-evokes-defensive-safe-reactions-in-animals','','','2020-07-25 15:47:16','2020-07-25 15:47:16','',0,'https://microbiozindia.com/?p=6711',0,'post','',0),(6712,2,'2020-07-25 15:47:16','2020-07-25 15:47:16','Two injections of this vaccine were enough to induce robust immunity, completely preventing SARS-CoV-2 infection in mice.\r\n\r\nMRNA-based vaccines are all attractive options for protecting against SARS-CoV-2 because they may be quickly designed and manufactured at a huge scale within weeks. Moreover, preclinical studies have shown that mRNA-based vaccines cause potent and broadly protective immune responses against various pathogens with an acceptable safety profile.\r\n\r\nFrom the Cell analysis, Qin and his colleagues developed a vaccine comprising mRNA that encodes the receptor-binding domain (RBD) of the spike (S) protein, which is situated on the surface of SARS-CoV-2. The vaccine, called ARCoV, is encapsulated in lipid nanoparticles, which improves delivery to cells.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://linkinghub.elsevier.com/retrieve/pii/S0092867420309326\">Targeting RBD instead of the whole S protein can represent a safer option, possibly triggering the production of fewer non-neutralizing antibodies.</a></span> These antibodies could improve viral entry into cells and viral replication through a procedure called antibody-dependent enhancement of infection, which was previously reported to the associated virus SARS-CoV--that the causative agent of the SARS outbreak in 2002 to 2003.\r\n\r\n<em>The robust protection observed in the present studies and the clear immune correlates of protection pave the path forward for future COVID-19 vaccine development in humans.\"-</em>Cheng-Feng Qin, Senior Study Author, Beijing Institute of Microbiology and Epidemiology\r\n\r\nThe researchers injected ARCoV into the muscle tissue of 16 mice and provided a booster shot just two months later. The vaccine elicited the creation of elevated levels of neutralizing antibodies, which protect host cells from preventing the virus from interacting together. These antibodies were cross-reactive, offering broad protection against three different breeds of SARS-CoV-2. In addition, the vaccine raised the amount of T cells from the spleen.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://linkinghub.elsevier.com/retrieve/pii/S0092867420309326\">Mice that received two doses of ARCoV and have been exposed to SARS-CoV-2 35 days afterwards revealed no signs of viral RNA from the lungs or trachea without any lung damage or swelling.</a></span> Outcomes from 20 cynomolgus monkeys showed two ARCoV doses triggered a virus-specific T cell response and the generation of neutralizing antibodies at rates that significantly exceed those seen in most recuperated COVID-19 patients. Moreover, none of the vaccinated animals experienced negative effects.\r\nTo evaluate the thermal stability of ARCoV, the investigators stored the vaccine in different temperatures for a single, four, or seven times, injected it into mice, and visualized its tissue distribution. The results showed that the vaccine was efficiently delivered to tissues, achieving the same high level of expression after being stored at room temperature for one week, with no signs of diminished activity. \"A ready-to-use and thermostable vaccine like ARCoV is highly desirable to eliminate the need for cold-chain transport,\" Qin states.\r\n\r\nThe researchers are evaluating the long-term stability of ARCoV. \"Additionally, the term of neutralization antibody induced by ARCoV is not yet been determined, as expertise from other individual coronaviruses has signaled the potential for re-infection because of waning of this antibody reaction,\" Qin states. \"Future studies are required to assess the long-term immune response in animal models and the potency of ARCoV in people.\"\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://www.cellpress.com/\" target=\"_blank\" rel=\"noopener noreferrer\">Cell Press</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nZhang, N., <em>et al.</em> (2020) A thermostable mRNA vaccine against COVID-19. <em>Cell.</em><span style=\"color: #ff6600;\"> <a style=\"color: #ff6600;\" href=\"http://dx.doi.org/10.1016/j.cell.2020.07.024\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1016/j.cell.2020.07.024</a>.</span>\r\n\r\n</div>','Test mRNA-based COVID-19 immunization evokes defensive safe reactions in animals','','inherit','closed','closed','','6711-revision-v1','','','2020-07-25 15:47:16','2020-07-25 15:47:16','',6711,'https://microbiozindia.com/uncategorized/6711-revision-v1/',0,'revision','',0),(6713,2,'2020-07-25 15:49:54','2020-07-25 15:49:54','Cell division is a fundamental process that organisms need to replicate, expand, and make repairs. But when a mistake accomplishes this complex biological process, cellular abnormalities may lead to ailments, for example cancer, where cells are enabled to grow and divide out of control.\r\n\r\nTheir findings were published on April 29 at eLife, an open-access journal that is devoted to life science research.\r\n\r\nEvery individual\'parent\' cell holds two copies of each chromosome. Before cell division begins, each chromosome is duplicated so that the genetic information can be equally distributed between two\'daughter\' cells.\r\n\r\nBut if the parent cell fails to complete cell division, all four chromosomes are allocated into one daughter cell, thus producing the cell tetraploid.\r\n\r\nWhen tetraploid cells acquire twice the number of chromosomes, they also acquire twice the number of centrosomes. One of their structural and organizational roles, centrosomes are key to forming microtubules and spindle fibers, which work to pull chromosomes apart during cell division.\r\n\r\nPrevious studies had indicated that these additional centrosomes might cause tumor formation, induced by tetraploidy.\r\n\r\nBut , the Virginia Tech team came across two studies in cancer progression models, which revealed that the cells gained extra centrosomes originally, but ended up losing them over time.\r\n\r\n\"The most important goal of our study was to confirm that tetraploid cells lose the extra centrosomes, analyze the dynamics of this process, and discover the mechanism that causes this centrosome loss from tetraploid cells,\" said Daniela Cimini, a professor in the Department of Biological Sciences and the co-director of BIOTRANS.\r\n\r\nUsing live cell imaging and fixed cell evaluation within an at vitro model, the team verified that tetraploid cells failed to shed the extra centrosomes they had obtained during tetraploidization.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://vtnews.vt.edu/articles/2020/06/fralinlifesci-cell-imaging-modeling-to-understand-cancer-progression.html\">In experiments guided by mathematical modeling, they reasoned that centrosome reduction occurs when dividing tetraploid cells bunch their extra centrosomes asymmetrically.</a></span>\r\nBecause of this, among these female cells may inherit one centrosome - instead of two - that will permit the cell to endure fewer mobile division failures and create more cells at the long term.\r\n\r\nThis finding can describe how certain cancers can first gain additional centrosomes during tetraploidization, but then lose them at later stages. This implies that the causal relationship between tetraploidy and cancer requires further investigation.\r\n\r\nThe mathematical model additionally discovered that the cells that could sustain long-term survival with extra centrosomes were cells that could successfully and consistently cluster these centrosomes in two groups during cell division.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://vtnews.vt.edu/articles/2020/06/fralinlifesci-cell-imaging-modeling-to-understand-cancer-progression.html\">These predictions were tested experimentally and revealed a mechanism which explains why certain cancer cells survive despite their additional centrosome count.</a></span>\r\n\r\nAnd if cells failed to audience their extra centrosomes efficiently, another generation of daughter cells died.\r\n\r\n\"Built upon experimental measurements, the mathematical version paints a constant and detailed picture about the way the cells\' centrosome numbers change\"\r\n\r\n\"This allows us to see information that cannot be measured by experiments.\" Stated Chen, an affiliated faculty member of the Fralin Life Sciences Institute and BIOTRANS.\r\n\r\nThen, the team might like to take advantage of their model to better understand the cellular dynamics inside three-dimensional cultures and actual tumors.\r\n\r\nIn their in vitro system, the group might get a sense of what was happening within the cells by tracking and imaging them, but that cannot be completed in much more complicated systems like actual tumors.\r\n\r\nWith their latest model and previous data, the team will have the ability to make some compelling predictions.\r\n\r\nAccording to Chen, the achievement of current and prospective cancer studies could be attributed to a unique, but all significant, collaboration between researchers from the fields of biology and mathematics.\r\n\r\n\"This hand-in-hand collaboration between experimentalist and modeler is very important - and it\'s a fantastic approach for simulating biological studies\"\r\n\r\n\"The procedure requires a whole lot of intimate communication between us. When that is done properly, it can be quite powerful,\" said Chen.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://vtnews.vt.edu/articles/2020/06/fralinlifesci-cell-imaging-modeling-to-understand-cancer-progression.html\" target=\"_blank\" rel=\"noopener noreferrer\">Virginia Tech</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nBaudoin, N<em>. C., et al. </em>(2020) Asymmetric clustering of centrosomes defines the early evolution of tetraploid cells. <em>eLife</em>. <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://doi.org/10.7554/eLife.54565\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.7554/eLife.54565</a><em>.</em></span>\r\n\r\n</div>','Specialists utilize new way to deal with unwind the systems that lie behind tetraploidy','','publish','open','open','','specialists-utilize-new-way-to-deal-with-unwind-the-systems-that-lie-behind-tetraploidy','','','2020-07-25 15:49:54','2020-07-25 15:49:54','',0,'https://microbiozindia.com/?p=6713',0,'post','',0),(6714,2,'2020-07-25 15:48:20','2020-07-25 15:48:20','','researchers-crack-secret-code-to-genetic-changes-causing-our-cancer','','inherit','open','closed','','researchers-crack-secret-code-to-genetic-changes-causing-our-cancer','','','2020-07-25 15:48:20','2020-07-25 15:48:20','',6713,'https://microbiozindia.com/wp-content/uploads/2020/07/researchers-crack-secret-code-to-genetic-changes-causing-our-cancer.jpg',0,'attachment','image/jpeg',0),(6715,2,'2020-07-25 15:49:54','2020-07-25 15:49:54','Cell division is a fundamental process that organisms need to replicate, expand, and make repairs. But when a mistake accomplishes this complex biological process, cellular abnormalities may lead to ailments, for example cancer, where cells are enabled to grow and divide out of control.\r\n\r\nTheir findings were published on April 29 at eLife, an open-access journal that is devoted to life science research.\r\n\r\nEvery individual\'parent\' cell holds two copies of each chromosome. Before cell division begins, each chromosome is duplicated so that the genetic information can be equally distributed between two\'daughter\' cells.\r\n\r\nBut if the parent cell fails to complete cell division, all four chromosomes are allocated into one daughter cell, thus producing the cell tetraploid.\r\n\r\nWhen tetraploid cells acquire twice the number of chromosomes, they also acquire twice the number of centrosomes. One of their structural and organizational roles, centrosomes are key to forming microtubules and spindle fibers, which work to pull chromosomes apart during cell division.\r\n\r\nPrevious studies had indicated that these additional centrosomes might cause tumor formation, induced by tetraploidy.\r\n\r\nBut , the Virginia Tech team came across two studies in cancer progression models, which revealed that the cells gained extra centrosomes originally, but ended up losing them over time.\r\n\r\n\"The most important goal of our study was to confirm that tetraploid cells lose the extra centrosomes, analyze the dynamics of this process, and discover the mechanism that causes this centrosome loss from tetraploid cells,\" said Daniela Cimini, a professor in the Department of Biological Sciences and the co-director of BIOTRANS.\r\n\r\nUsing live cell imaging and fixed cell evaluation within an at vitro model, the team verified that tetraploid cells failed to shed the extra centrosomes they had obtained during tetraploidization.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://vtnews.vt.edu/articles/2020/06/fralinlifesci-cell-imaging-modeling-to-understand-cancer-progression.html\">In experiments guided by mathematical modeling, they reasoned that centrosome reduction occurs when dividing tetraploid cells bunch their extra centrosomes asymmetrically.</a></span>\r\nBecause of this, among these female cells may inherit one centrosome - instead of two - that will permit the cell to endure fewer mobile division failures and create more cells at the long term.\r\n\r\nThis finding can describe how certain cancers can first gain additional centrosomes during tetraploidization, but then lose them at later stages. This implies that the causal relationship between tetraploidy and cancer requires further investigation.\r\n\r\nThe mathematical model additionally discovered that the cells that could sustain long-term survival with extra centrosomes were cells that could successfully and consistently cluster these centrosomes in two groups during cell division.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://vtnews.vt.edu/articles/2020/06/fralinlifesci-cell-imaging-modeling-to-understand-cancer-progression.html\">These predictions were tested experimentally and revealed a mechanism which explains why certain cancer cells survive despite their additional centrosome count.</a></span>\r\n\r\nAnd if cells failed to audience their extra centrosomes efficiently, another generation of daughter cells died.\r\n\r\n\"Built upon experimental measurements, the mathematical version paints a constant and detailed picture about the way the cells\' centrosome numbers change\"\r\n\r\n\"This allows us to see information that cannot be measured by experiments.\" Stated Chen, an affiliated faculty member of the Fralin Life Sciences Institute and BIOTRANS.\r\n\r\nThen, the team might like to take advantage of their model to better understand the cellular dynamics inside three-dimensional cultures and actual tumors.\r\n\r\nIn their in vitro system, the group might get a sense of what was happening within the cells by tracking and imaging them, but that cannot be completed in much more complicated systems like actual tumors.\r\n\r\nWith their latest model and previous data, the team will have the ability to make some compelling predictions.\r\n\r\nAccording to Chen, the achievement of current and prospective cancer studies could be attributed to a unique, but all significant, collaboration between researchers from the fields of biology and mathematics.\r\n\r\n\"This hand-in-hand collaboration between experimentalist and modeler is very important - and it\'s a fantastic approach for simulating biological studies\"\r\n\r\n\"The procedure requires a whole lot of intimate communication between us. When that is done properly, it can be quite powerful,\" said Chen.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://vtnews.vt.edu/articles/2020/06/fralinlifesci-cell-imaging-modeling-to-understand-cancer-progression.html\" target=\"_blank\" rel=\"noopener noreferrer\">Virginia Tech</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nBaudoin, N<em>. C., et al. </em>(2020) Asymmetric clustering of centrosomes defines the early evolution of tetraploid cells. <em>eLife</em>. <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://doi.org/10.7554/eLife.54565\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.7554/eLife.54565</a><em>.</em></span>\r\n\r\n</div>','Specialists utilize new way to deal with unwind the systems that lie behind tetraploidy','','inherit','closed','closed','','6713-revision-v1','','','2020-07-25 15:49:54','2020-07-25 15:49:54','',6713,'https://microbiozindia.com/uncategorized/6713-revision-v1/',0,'revision','',0),(6717,2,'2020-07-25 16:17:19','2020-07-25 16:17:19','India\'s drug regulator has cancelled the rapid diagnostic kit import licences of 3 firms and suspended that of 15 other people saying the USFDA has eliminated the producers in their listing of coronavirus serology test kits using directions that they shouldn\'t be dispersed.\r\n\r\nThe three firms are Cadila Healthcare, MDAAC International and N W Overseas while the 15 businesses comprise Transasia Bio-Medicals, Cosmic Scientific,Inbios India, S D Biosensor, Accurex Biomedicals,Biohouse Solutions and Trivitron Healthcare among others.\r\n\r\nThe companies were issued a show cause notices on July 17 inquiring why their import licences will not be cancelled because the diagnostic kits of these producers are eliminated by USFDA with direction that it should not be distributed from the list of merchandise of serology test kits for COVID-19 disease, based on an official order by the Drug Controller General of India (DCGI).\r\n\r\nThey were directed to submit their reply from July 20, failing that it could be presumed they have nothing to say in the issue and action deemed fit will be initiated under provisions of the Drugs and Cosmetics Act.\r\n\r\n\"Your reply to the show cause notice hasn\'t yet been found satisfactory with respect to elimination of said kit, by USFDA from their list mentioning not to disperse,\" that the DCGI order issued to the 15 firms on July 21 said.\r\n\r\n\"However, it has been cited by you to not to cancel your stated import licence for the above item. Consequently, in public interest, your import licence for above product becomes inoperative and stands suspended, till further orders,\" it stated.\r\n\r\nAs for the three businesses whose licences were cancelled, the orders stated,\"Your response to the show cause notice has not been found satisfactory related to the removal of said kit, by USFDA from their listing mentioning not to disperse.\"\r\n\r\n\"Further, it has been mentioned by you that you mean to surrender your licence for the above product. Therefore, in general interest, your import licence for preceding product becomes inoperative and stands with immediate effect,\" the order issued on July 21 read.','Import licenses for rapid diagnostic units of 3 firms dropped, 15 suspended by DCGI','','publish','open','open','','import-licenses-for-rapid-diagnostic-units-of-3-firms-dropped-15-suspended-by-dcgi','','','2020-07-25 16:17:19','2020-07-25 16:17:19','',0,'https://microbiozindia.com/?p=6717',0,'post','',0),(6718,2,'2020-07-25 16:17:19','2020-07-25 16:17:19','India\'s drug regulator has cancelled the rapid diagnostic kit import licences of 3 firms and suspended that of 15 other people saying the USFDA has eliminated the producers in their listing of coronavirus serology test kits using directions that they shouldn\'t be dispersed.\r\n\r\nThe three firms are Cadila Healthcare, MDAAC International and N W Overseas while the 15 businesses comprise Transasia Bio-Medicals, Cosmic Scientific,Inbios India, S D Biosensor, Accurex Biomedicals,Biohouse Solutions and Trivitron Healthcare among others.\r\n\r\nThe companies were issued a show cause notices on July 17 inquiring why their import licences will not be cancelled because the diagnostic kits of these producers are eliminated by USFDA with direction that it should not be distributed from the list of merchandise of serology test kits for COVID-19 disease, based on an official order by the Drug Controller General of India (DCGI).\r\n\r\nThey were directed to submit their reply from July 20, failing that it could be presumed they have nothing to say in the issue and action deemed fit will be initiated under provisions of the Drugs and Cosmetics Act.\r\n\r\n\"Your reply to the show cause notice hasn\'t yet been found satisfactory with respect to elimination of said kit, by USFDA from their list mentioning not to disperse,\" that the DCGI order issued to the 15 firms on July 21 said.\r\n\r\n\"However, it has been cited by you to not to cancel your stated import licence for the above item. Consequently, in public interest, your import licence for above product becomes inoperative and stands suspended, till further orders,\" it stated.\r\n\r\nAs for the three businesses whose licences were cancelled, the orders stated,\"Your response to the show cause notice has not been found satisfactory related to the removal of said kit, by USFDA from their listing mentioning not to disperse.\"\r\n\r\n\"Further, it has been mentioned by you that you mean to surrender your licence for the above product. Therefore, in general interest, your import licence for preceding product becomes inoperative and stands with immediate effect,\" the order issued on July 21 read.','Import licenses for rapid diagnostic units of 3 firms dropped, 15 suspended by DCGI','','inherit','closed','closed','','6717-revision-v1','','','2020-07-25 16:17:19','2020-07-25 16:17:19','',6717,'https://microbiozindia.com/uncategorized/6717-revision-v1/',0,'revision','',0),(6719,2,'2020-07-26 09:37:36','2020-07-26 09:37:36','Research presented at ASM Microbe Online found that 43 percent of Staphylococcus bacteria discovered on exercise equipment in university gyms were ampicillin-resistant, with 73% of these isolates being resistant to multiple other medications.\r\n\r\nAs stated by this U.S. Centers for Disease Control and Prevention, roughly 120,000 S. aureus bacteremia cases led to 20,000 deaths in 2017. Skin abrasions are a frequent route of entry of pathogenic S. aureus strains. As emphasized by the continuing COVID-19 pandemic, there is growing public concern about temperate areas as a bastion of infectious microorganisms.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://asm.org/Press-Releases/2020/July/High-Levels-of-Antibiotic-resistant-Bacteria-Found\">Results of the analysis found 43% of 462 S. aureus isolates recovered from 45 different exercise equipment surfaces were ampicillin resistant. Of 60 representative ampicillin-resistant isolates, 73 percent were resistant to two or more additional drugs such as erythromycin and sulfisoxazole.</a></span>\r\n\r\n<em>These results suggest regularly contacted surfaces in different recreational environments can harbor multi-drug resistant S. aureus (MDRSA) and should be disinfected frequently to best maintain public health and community wellbeing.\"</em>\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://asm.org/Press-Releases/2020/July/High-Levels-of-Antibiotic-resistant-Bacteria-Found\">Chase A. Weikel, a 2018 graduate of West Chester University and current graduate student at Thomas Jefferson University in Philadelphia</a></span>\r\n\r\nSamples were collected from two university recreational centers. The surfaces fitness center patrons frequently touched, such as barbell and dumbbells grips and cable pull grips, kettlebells, elliptical and treadmill handles were swabbed and plated on Mannitol Salt Agar (MSA). This selective and differential media was utilized to isolate and presumptively identify S. aureus. Isolates were replicated to MSA plus ampicillin. Isolates additionally resistant to oxacillin or penicillin were then screened using CHROMagar&#x2122; MRSA; a sensitive and specific press used to screen for methicillin-resistant S. aureus (MRSA). Isolates that tested positive using CHROMagar&#x2122; were exposed to additional confirmatory methods including latex agglutination assay. Microscopy was used to validate Gram-positive status and cellular morphology and arrangement.\r\nThis study has been presented as an ePoster at the ASM Microbe seminar which is proceeding in an on-line format at August 2020. ASM Microbe Online brings you the lively, cutting-edge science of ASM Microbe 2020, the yearly meeting of the American Society for Microbiology. Explore the most recent study in the microbial sciences with ePosters, hear from experts in the field during live keynotes and get track-related content with a curated choice of on-demand sessions.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://asm.org/Press-Releases/2020/July/High-Levels-of-Antibiotic-resistant-Bacteria-Found\" target=\"_blank\" rel=\"noopener noreferrer\">American Society for Microbiology</a></span>\r\n\r\n</div>','Gym equipment in public rec centers have elevated levels of anti-toxin safe microbes','','publish','open','open','','gym-equipment-in-public-rec-centers-have-elevated-levels-of-anti-toxin-safe-microbes','','','2020-07-26 09:37:36','2020-07-26 09:37:36','',0,'https://microbiozindia.com/?p=6719',0,'post','',0),(6720,2,'2020-07-26 09:37:29','2020-07-26 09:37:29','','Antibiotic_Resistance','','inherit','open','closed','','antibiotic_resistance','','','2020-07-26 09:37:29','2020-07-26 09:37:29','',6719,'https://microbiozindia.com/wp-content/uploads/2020/07/Antibiotic_Resistance.jpg',0,'attachment','image/jpeg',0),(6721,2,'2020-07-26 09:37:36','2020-07-26 09:37:36','Research presented at ASM Microbe Online found that 43 percent of Staphylococcus bacteria discovered on exercise equipment in university gyms were ampicillin-resistant, with 73% of these isolates being resistant to multiple other medications.\r\n\r\nAs stated by this U.S. Centers for Disease Control and Prevention, roughly 120,000 S. aureus bacteremia cases led to 20,000 deaths in 2017. Skin abrasions are a frequent route of entry of pathogenic S. aureus strains. As emphasized by the continuing COVID-19 pandemic, there is growing public concern about temperate areas as a bastion of infectious microorganisms.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://asm.org/Press-Releases/2020/July/High-Levels-of-Antibiotic-resistant-Bacteria-Found\">Results of the analysis found 43% of 462 S. aureus isolates recovered from 45 different exercise equipment surfaces were ampicillin resistant. Of 60 representative ampicillin-resistant isolates, 73 percent were resistant to two or more additional drugs such as erythromycin and sulfisoxazole.</a></span>\r\n\r\n<em>These results suggest regularly contacted surfaces in different recreational environments can harbor multi-drug resistant S. aureus (MDRSA) and should be disinfected frequently to best maintain public health and community wellbeing.\"</em>\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://asm.org/Press-Releases/2020/July/High-Levels-of-Antibiotic-resistant-Bacteria-Found\">Chase A. Weikel, a 2018 graduate of West Chester University and current graduate student at Thomas Jefferson University in Philadelphia</a></span>\r\n\r\nSamples were collected from two university recreational centers. The surfaces fitness center patrons frequently touched, such as barbell and dumbbells grips and cable pull grips, kettlebells, elliptical and treadmill handles were swabbed and plated on Mannitol Salt Agar (MSA). This selective and differential media was utilized to isolate and presumptively identify S. aureus. Isolates were replicated to MSA plus ampicillin. Isolates additionally resistant to oxacillin or penicillin were then screened using CHROMagar&#x2122; MRSA; a sensitive and specific press used to screen for methicillin-resistant S. aureus (MRSA). Isolates that tested positive using CHROMagar&#x2122; were exposed to additional confirmatory methods including latex agglutination assay. Microscopy was used to validate Gram-positive status and cellular morphology and arrangement.\r\nThis study has been presented as an ePoster at the ASM Microbe seminar which is proceeding in an on-line format at August 2020. ASM Microbe Online brings you the lively, cutting-edge science of ASM Microbe 2020, the yearly meeting of the American Society for Microbiology. Explore the most recent study in the microbial sciences with ePosters, hear from experts in the field during live keynotes and get track-related content with a curated choice of on-demand sessions.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://asm.org/Press-Releases/2020/July/High-Levels-of-Antibiotic-resistant-Bacteria-Found\" target=\"_blank\" rel=\"noopener noreferrer\">American Society for Microbiology</a></span>\r\n\r\n</div>','Gym equipment in public rec centers have elevated levels of anti-toxin safe microbes','','inherit','closed','closed','','6719-revision-v1','','','2020-07-26 09:37:36','2020-07-26 09:37:36','',6719,'https://microbiozindia.com/uncategorized/6719-revision-v1/',0,'revision','',0),(6722,2,'2020-07-26 10:28:54','2020-07-26 10:28:54','Mailing colorectal cancer screening kits to Medicaid enrollees is a more cost-effective way to boost screening rates, according to new research from the University of North Carolina.\r\n\r\nColorectal cancer is one of the most frequently diagnosed cancers, but routine screening (such as colonoscopies and at-home feces screening ) can identify cases early, when treatment is most effective. Despite recommendations that adults undergo regular screening from ages 50 to 75 years, over one-third of qualified Americans are not up to date with screening. Strategies to enhance screening in these adults comprise mailing screening reminders and mailing fecal immunochemical test (FIT) kits, which detect blood in stool samples.\r\n\r\nTo estimate and compare the costs and effectiveness of these two approaches in low-income Medicaid-insured inhabitants, a group headed by Alison Brenner, PhD, MPH, and Stephanie Wheeler, PhD, MPH, of the University of North Carolina at Chapel Hill\'s Lineberger Comprehensive Cancer Center, developed a simulation model of 35,000 Medicaid-insured adults aged 52 to 64 years that had been overdue for colorectal cancer screening to project costs and benefits over time connected with receiving either a mailed reminder or a mailed reminder and a FIT kit.\r\n\r\nOver the span of a single year, the amount of colorectal cancer screenings, such as the two FITs and screening colonoscopies, was greater for the mailed reminder and FIT option (23.2%) than for the mailed reminder-only option (15.8percent ).\r\n\r\nThe mailed reminder also FIT alternative saved prices compared with the mailed reminder-only option from the Medicaid/state perspective because some patients that received just the reminder would program a more expensive colonoscopy, which Medicaid must reimburse, rather than a FIT.\r\n\r\nIn the health clinic/facility standpoint, the sent reminder also FIT alternative took an additional cost of just $116 per person screened within the mailed reminder-only alternate. This price falls within the assortment of what decision-makers would typically be willing to cover an extra person to be screened for esophageal cancer.\r\n\r\n\"By investing in sending the test kits with the reminder letters, health departments are expected to successfully screen more people for colorectal cancer at relatively low incremental costs, and Medicaid organizations are expected to actually save costs per extra individual screened,\" says Wheeler. \"This analysis provides strong evidence that health departments and payers like Medicaid can considerably improve colorectal cancer screening in low-income and medically underserved populations at a sensible price, even given limited funds, through the implementation of mailed FIT applications\" Wheeler notes that medically underserved populations are more likely to die from colorectal cancer in relation to other groups and extending screening to them in an efficient manner may help address this disparity.\r\n\r\nThe findings are especially timely thinking about the recent need for alternatives to confront visits with physicians throughout the covid-19 pandemic. An accompanying editorial states that\"it is time for incentives and laws that inspire payers to cover complete screening costs and evidence-based programs to boost screening toward a goal of 80% colorectal cancer screening in each area.\"\r\n\r\n<strong>Reference</strong>\r\n\r\nWheeler SB, O’Leary MC, Rhode J, et al. Comparative cost-effectiveness of mailed fecal immunochemical testing (FIT)-based interventions for increasing colorectal cancer screening in the Medicaid population. Cancer. Epub. July 6, 2020. doi: 10.1002/cncr.32992.','Sent Colorectal Cancer Kits May Increase Screening Rates','','publish','open','open','','sent-colorectal-cancer-kits-may-increase-screening-rates','','','2020-07-26 10:28:54','2020-07-26 10:28:54','',0,'https://microbiozindia.com/?p=6722',0,'post','',0),(6723,2,'2020-07-26 10:28:43','2020-07-26 10:28:43','','coronavirus-466x293','','inherit','open','closed','','coronavirus-466x293','','','2020-07-26 10:28:43','2020-07-26 10:28:43','',6722,'https://microbiozindia.com/wp-content/uploads/2020/07/coronavirus-466x293-1.jpeg',0,'attachment','image/jpeg',0),(6724,2,'2020-07-26 10:28:45','2020-07-26 10:28:45','','dreamstime_l_120022695-466x266','','inherit','open','closed','','dreamstime_l_120022695-466x266','','','2020-07-26 10:28:45','2020-07-26 10:28:45','',6722,'https://microbiozindia.com/wp-content/uploads/2020/07/dreamstime_l_120022695-466x266-1.jpg',0,'attachment','image/jpeg',0),(6725,2,'2020-07-26 10:28:54','2020-07-26 10:28:54','Mailing colorectal cancer screening kits to Medicaid enrollees is a more cost-effective way to boost screening rates, according to new research from the University of North Carolina.\r\n\r\nColorectal cancer is one of the most frequently diagnosed cancers, but routine screening (such as colonoscopies and at-home feces screening ) can identify cases early, when treatment is most effective. Despite recommendations that adults undergo regular screening from ages 50 to 75 years, over one-third of qualified Americans are not up to date with screening. Strategies to enhance screening in these adults comprise mailing screening reminders and mailing fecal immunochemical test (FIT) kits, which detect blood in stool samples.\r\n\r\nTo estimate and compare the costs and effectiveness of these two approaches in low-income Medicaid-insured inhabitants, a group headed by Alison Brenner, PhD, MPH, and Stephanie Wheeler, PhD, MPH, of the University of North Carolina at Chapel Hill\'s Lineberger Comprehensive Cancer Center, developed a simulation model of 35,000 Medicaid-insured adults aged 52 to 64 years that had been overdue for colorectal cancer screening to project costs and benefits over time connected with receiving either a mailed reminder or a mailed reminder and a FIT kit.\r\n\r\nOver the span of a single year, the amount of colorectal cancer screenings, such as the two FITs and screening colonoscopies, was greater for the mailed reminder and FIT option (23.2%) than for the mailed reminder-only option (15.8percent ).\r\n\r\nThe mailed reminder also FIT alternative saved prices compared with the mailed reminder-only option from the Medicaid/state perspective because some patients that received just the reminder would program a more expensive colonoscopy, which Medicaid must reimburse, rather than a FIT.\r\n\r\nIn the health clinic/facility standpoint, the sent reminder also FIT alternative took an additional cost of just $116 per person screened within the mailed reminder-only alternate. This price falls within the assortment of what decision-makers would typically be willing to cover an extra person to be screened for esophageal cancer.\r\n\r\n\"By investing in sending the test kits with the reminder letters, health departments are expected to successfully screen more people for colorectal cancer at relatively low incremental costs, and Medicaid organizations are expected to actually save costs per extra individual screened,\" says Wheeler. \"This analysis provides strong evidence that health departments and payers like Medicaid can considerably improve colorectal cancer screening in low-income and medically underserved populations at a sensible price, even given limited funds, through the implementation of mailed FIT applications\" Wheeler notes that medically underserved populations are more likely to die from colorectal cancer in relation to other groups and extending screening to them in an efficient manner may help address this disparity.\r\n\r\nThe findings are especially timely thinking about the recent need for alternatives to confront visits with physicians throughout the covid-19 pandemic. An accompanying editorial states that\"it is time for incentives and laws that inspire payers to cover complete screening costs and evidence-based programs to boost screening toward a goal of 80% colorectal cancer screening in each area.\"\r\n\r\n<strong>Reference</strong>\r\n\r\nWheeler SB, O’Leary MC, Rhode J, et al. Comparative cost-effectiveness of mailed fecal immunochemical testing (FIT)-based interventions for increasing colorectal cancer screening in the Medicaid population. Cancer. Epub. July 6, 2020. doi: 10.1002/cncr.32992.','Sent Colorectal Cancer Kits May Increase Screening Rates','','inherit','closed','closed','','6722-revision-v1','','','2020-07-26 10:28:54','2020-07-26 10:28:54','',6722,'https://microbiozindia.com/uncategorized/6722-revision-v1/',0,'revision','',0),(6726,2,'2020-07-26 10:28:58','2020-07-26 10:28:58','Mailing colorectal cancer screening kits to Medicaid enrollees is a more cost-effective way to boost screening rates, according to new research from the University of North Carolina.\n\nColorectal cancer is one of the most frequently diagnosed cancers, but routine screening (such as colonoscopies and at-home feces screening ) can identify cases early, when treatment is most effective. Despite recommendations that adults undergo regular screening from ages 50 to 75 years, over one-third of qualified Americans are not up to date with screening. Strategies to enhance screening in these adults comprise mailing screening reminders and mailing fecal immunochemical test (FIT) kits, which detect blood in stool samples.\n\nTo estimate and compare the costs and effectiveness of these two approaches in low-income Medicaid-insured inhabitants, a group headed by Alison Brenner, PhD, MPH, and Stephanie Wheeler, PhD, MPH, of the University of North Carolina at Chapel Hill\'s Lineberger Comprehensive Cancer Center, developed a simulation model of 35,000 Medicaid-insured adults aged 52 to 64 years that had been overdue for colorectal cancer screening to project costs and benefits over time connected with receiving either a mailed reminder or a mailed reminder and a FIT kit.\n\nOver the span of a single year, the amount of colorectal cancer screenings, such as the two FITs and screening colonoscopies, was greater for the mailed reminder and FIT option (23.2%) than for the mailed reminder-only option (15.8percent ).\n\nThe mailed reminder also FIT alternative saved prices compared with the mailed reminder-only option from the Medicaid/state perspective because some patients that received just the reminder would program a more expensive colonoscopy, which Medicaid must reimburse, rather than a FIT.\n\nIn the health clinic/facility standpoint, the sent reminder also FIT alternative took an additional cost of just $116 per person screened within the mailed reminder-only alternate. This price falls within the assortment of what decision-makers would typically be willing to cover an extra person to be screened for esophageal cancer.\n\n\"By investing in sending the test kits with the reminder letters, health departments are expected to successfully screen more people for colorectal cancer at relatively low incremental costs, and Medicaid organizations are expected to actually save costs per extra individual screened,\" says Wheeler. \"This analysis provides strong evidence that health departments and payers like Medicaid can considerably improve colorectal cancer screening in low-income and medically underserved populations at a sensible price, even given limited funds, through the implementation of mailed FIT applications\" Wheeler notes that medically underserved populations are more likely to die from colorectal cancer in relation to other groups and extending screening to them in an efficient manner may help address this disparity.\n\nThe findings are especially timely thinking about the recent need for alternatives to confront visits with physicians throughout the covid-19 pandemic. An accompanying editorial states that\"it is time for incentives and laws that inspire payers to cover complete screening costs and evidence-based programs to boost screening toward a goal of 80% colorectal cancer screening in each area.\"\n\n<strong>Reference</strong>\n\nWheeler SB, O’Leary MC, Rhode J, et al. Comparative cost-effectiveness of mailed fecal immunochemical testing (FIT)-based interventions for increasing colorectal cancer screening in the Medicaid population. Cancer. Epub. July 6, 2020. doi: 10.1002/cncr.32992.','Sent Colorectal Cancer Kits May Increase Screening Rates','','inherit','closed','closed','','6722-autosave-v1','','','2020-07-26 10:28:58','2020-07-26 10:28:58','',6722,'https://microbiozindia.com/uncategorized/6722-autosave-v1/',0,'revision','',0),(6727,2,'2020-07-26 10:30:34','2020-07-26 10:30:34','The Advanced Medical Technology Association (AdvaMed) has made a detailed, nationwide covid-19 diagnostic supply registry to assist state and federal governments in their own wing responses. The national registry has been launched in partnership with 13 commercial diagnostics makers: Abbott, BD, bioMérieux, Bio-Rad, Beckman Coulter, Cepheid, Hologic, Ortho Clinical Diagnostics, Qiagen, Roche Diagnostics, Sekisui Diagnostics, Siemens Healthineers, along with Thermo Fisher Scientific.\r\nThe registry\'s first publicly published data set demonstrates that since the beginning of the pandemic, more than 65 million tests are manufactured and shipped nationwide, with evaluation shipments currently topping 800,000 daily.\r\n\r\n\"It is absolutely crucial to our country\'s health and financial recovery that we have sufficient supplies to examine everybody who needs it, and, as important, to know where these supplies are so we can get them where they\'re most needed,\" says Scott Whitaker, president and CEO of AdvaMed. \"This national registry is going to be a crucial instrument for national and state authorities as they work to protect both the patients and health care providers and move to reopen the US economy\"\r\n\r\nThe registry will compile information from diagnostic companies along with publicly accessible data on daily tests performed to make a centralized and standardized covid-19 diagnostic distribution registry. The registry will provide weekly say - and - national-level updates on the number of molecular, antigen, and serology (antibody) tests shipped in america.\r\n\r\nAdvaMed\'s registry can help streamline communications and information sharing between diagnostic businesses and federal and state authorities in addition to standardize test supply reporting. It is going to also facilitate cooperation with labs and other public health stakeholders to optimize access to all platforms of covid-19 testing so that any prospective shortages are identified and handled quickly.\r\n\r\nFor more information, visit <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://www.advamed.org/\">AdvaMed</a>.</span>\r\n\r\n<strong>Featured image: </strong>Colorized scanning electron micrograph of an apoptotic cell (purple) heavily infected with SARS-COV-2 virus particles (yellow), isolated from a patient sample. Image captured at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: NIAID.','AdvaMed Unveils National Covid-19 Testing Registry','','publish','open','open','','advamed-unveils-national-covid-19-testing-registry','','','2020-07-26 10:30:34','2020-07-26 10:30:34','',0,'https://microbiozindia.com/?p=6727',0,'post','',0),(6728,2,'2020-07-26 10:30:34','2020-07-26 10:30:34','The Advanced Medical Technology Association (AdvaMed) has made a detailed, nationwide covid-19 diagnostic supply registry to assist state and federal governments in their own wing responses. The national registry has been launched in partnership with 13 commercial diagnostics makers: Abbott, BD, bioMérieux, Bio-Rad, Beckman Coulter, Cepheid, Hologic, Ortho Clinical Diagnostics, Qiagen, Roche Diagnostics, Sekisui Diagnostics, Siemens Healthineers, along with Thermo Fisher Scientific.\r\nThe registry\'s first publicly published data set demonstrates that since the beginning of the pandemic, more than 65 million tests are manufactured and shipped nationwide, with evaluation shipments currently topping 800,000 daily.\r\n\r\n\"It is absolutely crucial to our country\'s health and financial recovery that we have sufficient supplies to examine everybody who needs it, and, as important, to know where these supplies are so we can get them where they\'re most needed,\" says Scott Whitaker, president and CEO of AdvaMed. \"This national registry is going to be a crucial instrument for national and state authorities as they work to protect both the patients and health care providers and move to reopen the US economy\"\r\n\r\nThe registry will compile information from diagnostic companies along with publicly accessible data on daily tests performed to make a centralized and standardized covid-19 diagnostic distribution registry. The registry will provide weekly say - and - national-level updates on the number of molecular, antigen, and serology (antibody) tests shipped in america.\r\n\r\nAdvaMed\'s registry can help streamline communications and information sharing between diagnostic businesses and federal and state authorities in addition to standardize test supply reporting. It is going to also facilitate cooperation with labs and other public health stakeholders to optimize access to all platforms of covid-19 testing so that any prospective shortages are identified and handled quickly.\r\n\r\nFor more information, visit <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"http://www.advamed.org/\">AdvaMed</a>.</span>\r\n\r\n<strong>Featured image: </strong>Colorized scanning electron micrograph of an apoptotic cell (purple) heavily infected with SARS-COV-2 virus particles (yellow), isolated from a patient sample. Image captured at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: NIAID.','AdvaMed Unveils National Covid-19 Testing Registry','','inherit','closed','closed','','6727-revision-v1','','','2020-07-26 10:30:34','2020-07-26 10:30:34','',6727,'https://microbiozindia.com/uncategorized/6727-revision-v1/',0,'revision','',0),(6729,2,'2020-07-26 13:11:43','2020-07-26 13:11:43','The National Task Force on COVID-19 has ruled against incorporating Itolizumab medicate in clinical administration conventions for rewarding the malady despite the fact that the DCGI has affirmed its \"confined crisis use\" in contaminated patients, official sources said. Considering the neglected clinical needs in COVID-19, Itolizumab, a previously endorsed medication of Biocon, utilized for rewarding psoriasis - a skin condition - was affirmed for \"confined crisis use\" in the treatment of coronavirus by the Drugs Controller General of India (DCGI) as of late.\r\n\r\nThe consent to showcase the medication was allowed for the treatment of cytokine discharge condition in \'moderate\' to \'serious\' Acute Respiratory Distress Syndrome patients due to COVID-19.\r\n\r\n\"The issue of remembering the medication for the clinical conventions was talked about in a gathering hung on Friday. A dominant part of the individuals from the team opined that there was insufficient proof right now to get the medication remembered for the clinical administration conventions for COVID-19,\" said an official source.\r\n\r\nA residential biopharmaceutical organization, Biocon, has been assembling and promoting Itolizumab, a monoclonal counter acting agent, for the treatment of patients with moderate to extreme constant plaque psoriasis since 2013, under the brand name ALZUMAb, the Union wellbeing service had before said.','Minitsry of Health rules against incorporating Itolizumab in clinical administration convention for COVID-19','','publish','open','open','','minitsry-of-health-rules-against-incorporating-itolizumab-in-clinical-administration-convention-for-covid-19','','','2020-07-26 13:11:43','2020-07-26 13:11:43','',0,'https://microbiozindia.com/?p=6729',0,'post','',0),(6730,2,'2020-07-26 13:11:43','2020-07-26 13:11:43','The National Task Force on COVID-19 has ruled against incorporating Itolizumab medicate in clinical administration conventions for rewarding the malady despite the fact that the DCGI has affirmed its \"confined crisis use\" in contaminated patients, official sources said. Considering the neglected clinical needs in COVID-19, Itolizumab, a previously endorsed medication of Biocon, utilized for rewarding psoriasis - a skin condition - was affirmed for \"confined crisis use\" in the treatment of coronavirus by the Drugs Controller General of India (DCGI) as of late.\r\n\r\nThe consent to showcase the medication was allowed for the treatment of cytokine discharge condition in \'moderate\' to \'serious\' Acute Respiratory Distress Syndrome patients due to COVID-19.\r\n\r\n\"The issue of remembering the medication for the clinical conventions was talked about in a gathering hung on Friday. A dominant part of the individuals from the team opined that there was insufficient proof right now to get the medication remembered for the clinical administration conventions for COVID-19,\" said an official source.\r\n\r\nA residential biopharmaceutical organization, Biocon, has been assembling and promoting Itolizumab, a monoclonal counter acting agent, for the treatment of patients with moderate to extreme constant plaque psoriasis since 2013, under the brand name ALZUMAb, the Union wellbeing service had before said.','Minitsry of Health rules against incorporating Itolizumab in clinical administration convention for COVID-19','','inherit','closed','closed','','6729-revision-v1','','','2020-07-26 13:11:43','2020-07-26 13:11:43','',6729,'https://microbiozindia.com/uncategorized/6729-revision-v1/',0,'revision','',0),(6731,2,'2020-07-27 08:55:32','2020-07-27 08:55:32','Effective antivirals with secure clinical profile are urgently needed to improve the overall prognosis. In an analysis of a randomly collected cohort of 124 patients using COVID-19, the authors discovered that hypercoagulability according to elevated levels of D-dimers was associated with illness severity.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.sciencedirect.com/science/article/pii/S2211383520305529?via%3Dihub\">By calculating of a U.S. FDA approved drug library, the authors identified that an anticoagulation agent dipyridamole (DIP) at silico, which suppressed SARS-CoV-2 replication invitro.</a></span>\r\n\r\nAt a proof-of-concept trial between 31 patients using COVID-19, DIP supplementation has been associated with significantly decreased concentrations of D-dimers (P&lt;0.05), greater lymphocyte and platelet recovery in the flow, and markedly enhanced clinical outcomes for the severely ill patients compared with the control patients.\r\n\r\nTo sum up, DIP could be used for the treatment of seriously ill patients using COVID-19 through antibacterial and anticoagulation consequences.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.apsb.org/\" target=\"_blank\" rel=\"noopener noreferrer\">Ascension Parish School Board</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nLiu, X<em>., et al. </em>(2020) Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19. <em>Elsevier</em>. <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://doi.org/10.1016/j.apsb.2020.04.008\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1016/j.apsb.2020.04.008</a><em>.</em></span>\r\n\r\n</div>','Analysts recognize anticoagulation operator that stifles SARS-CoV-2 replication in vitro','','publish','open','open','','analysts-recognize-anticoagulation-operator-that-stifles-sars-cov-2-replication-in-vitro','','','2020-07-27 08:55:32','2020-07-27 08:55:32','',0,'https://microbiozindia.com/?p=6731',0,'post','',0),(6732,2,'2020-07-27 08:55:32','2020-07-27 08:55:32','Effective antivirals with secure clinical profile are urgently needed to improve the overall prognosis. In an analysis of a randomly collected cohort of 124 patients using COVID-19, the authors discovered that hypercoagulability according to elevated levels of D-dimers was associated with illness severity.\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.sciencedirect.com/science/article/pii/S2211383520305529?via%3Dihub\">By calculating of a U.S. FDA approved drug library, the authors identified that an anticoagulation agent dipyridamole (DIP) at silico, which suppressed SARS-CoV-2 replication invitro.</a></span>\r\n\r\nAt a proof-of-concept trial between 31 patients using COVID-19, DIP supplementation has been associated with significantly decreased concentrations of D-dimers (P&lt;0.05), greater lymphocyte and platelet recovery in the flow, and markedly enhanced clinical outcomes for the severely ill patients compared with the control patients.\r\n\r\nTo sum up, DIP could be used for the treatment of seriously ill patients using COVID-19 through antibacterial and anticoagulation consequences.\r\n<div class=\"content-src-label\"><strong>Source:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\n<span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://www.apsb.org/\" target=\"_blank\" rel=\"noopener noreferrer\">Ascension Parish School Board</a></span>\r\n\r\n</div>\r\n<div class=\"content-src-label\"><strong>Journal reference:</strong></div>\r\n<div class=\"content-src-value\">\r\n\r\nLiu, X<em>., et al. </em>(2020) Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19. <em>Elsevier</em>. <span style=\"color: #ff6600;\"><a style=\"color: #ff6600;\" href=\"https://doi.org/10.1016/j.apsb.2020.04.008\" target=\"_blank\" rel=\"noopener noreferrer\">doi.org/10.1016/j.apsb.2020.04.008</a><em>.</em></span>\r\n\r\n</div>','Analysts recognize anticoagulation operator that stifles SARS-CoV-2 replication in vitro','','inherit','closed','closed','','6731-revision-v1','','','2020-07-27 08:55:32','2020-07-27 08:55:32','',6731,'https://microbiozindia.com/uncategorized/6731-revision-v1/',0,'revision','',0);
